Pipeline Prospector | Drug Development Pipelines & Deals

[{"orgOrder":0,"company":"Biora Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BT-600","moa":"JAK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Biora Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Biora Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Resolution Therapeutics Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"RTX001","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Resolution Therapeutics Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Resolution Therapeutics Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Resolution Therapeutics Limited \/ Undisclosed"},{"orgOrder":0,"company":"Rise Therapeutics LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"R-2487","moa":"T-cell receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Rise Therapeutics LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rise Therapeutics LLC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rise Therapeutics LLC \/ Undisclosed"},{"orgOrder":0,"company":"Rise Therapeutics LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"R-2487","moa":"T-cell receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Rise Therapeutics LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rise Therapeutics LLC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rise Therapeutics LLC \/ Undisclosed"},{"orgOrder":0,"company":"Rise Therapeutics LLC","sponsor":"Mayo Clinic | University of Colorado, Denver","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"R-3750","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Rise Therapeutics LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rise Therapeutics LLC \/ Mayo Clinic | University of Colorado, Denver","highestDevelopmentStatusID":"6","companyTruncated":"Rise Therapeutics LLC \/ Mayo Clinic | University of Colorado, Denver"},{"orgOrder":0,"company":"Rise Therapeutics LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"R-3750","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Rise Therapeutics LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rise Therapeutics LLC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rise Therapeutics LLC \/ Undisclosed"},{"orgOrder":0,"company":"Rise Therapeutics LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"R-5280","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Rise Therapeutics LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rise Therapeutics LLC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rise Therapeutics LLC \/ Undisclosed"},{"orgOrder":0,"company":"Rise Therapeutics LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"R-5780","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Rise Therapeutics LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rise Therapeutics LLC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rise Therapeutics LLC \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharma Biotherapeutics USA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SPH3127","moa":"Renin","graph1":"Immunology","graph2":"Phase II","graph3":"Shanghai Pharma Biotherapeutics USA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Pharma Biotherapeutics USA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Pharma Biotherapeutics USA \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharma Biotherapeutics USA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SPH4336","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Pharma Biotherapeutics USA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Pharma Biotherapeutics USA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Pharma Biotherapeutics USA \/ Undisclosed"},{"orgOrder":0,"company":"Visirna Therapeutics HK Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"HONG KONG","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VSA001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Visirna Therapeutics HK Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Visirna Therapeutics HK Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Visirna Therapeutics HK Limited \/ Undisclosed"},{"orgOrder":0,"company":"Visirna Therapeutics HK Limited","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VSA001","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Visirna Therapeutics HK Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Visirna Therapeutics HK Limited \/ Arrowhead Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Visirna Therapeutics HK Limited \/ Arrowhead Pharmaceuticals"},{"orgOrder":0,"company":"Visirna Therapeutics HK Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"HONG KONG","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"VSA003","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Visirna Therapeutics HK Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Visirna Therapeutics HK Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Visirna Therapeutics HK Limited \/ Undisclosed"},{"orgOrder":0,"company":"Visirna Therapeutics HK Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"HONG KONG","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VSA003","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Visirna Therapeutics HK Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Visirna Therapeutics HK Limited \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Visirna Therapeutics HK Limited \/ Undisclosed"},{"orgOrder":0,"company":"Visirna Therapeutics HK Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"HONG KONG","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"VSA006","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Visirna Therapeutics HK Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Visirna Therapeutics HK Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Visirna Therapeutics HK Limited \/ Undisclosed"},{"orgOrder":0,"company":"Visirna Therapeutics HK Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"VSA012","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Visirna Therapeutics HK Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Visirna Therapeutics HK Limited \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Visirna Therapeutics HK Limited \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"S-Pindolol Benzoate","moa":"\n5-HT1A receptor\/Beta-adrenoceptors\/Beta2-adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"S-Pindolol Benzoate","moa":"\n5-HT1A receptor\/Beta-adrenoceptors\/Beta2-adrenergic receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Series A Financing","leadProduct":"S-Pindolol Benzoate","moa":"\n5-HT1A receptor\/Beta-adrenoceptors\/Beta2-adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Mankind Pharma"},{"orgOrder":0,"company":"MetaboMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MTB-9655","moa":"\nACSS2","graph1":"Oncology","graph2":"Phase I","graph3":"MetaboMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MetaboMed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MetaboMed \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"INCB000928","moa":"\nALK2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"INCB000928","moa":"\nALK2","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"INCB000928","moa":"\nALK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"INCB000928","moa":"\nALK2","graph1":"Nephrology","graph2":"Phase I","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu YaYao Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"YY2201","moa":"ATR","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu YaYao Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu YaYao Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu YaYao Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Miracogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"MRG001","moa":"\nBMPR2\/CXCR4\/CaN\/Cytokines\/FKBP1A","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Miracogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Miracogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Miracogen \/ Undisclosed"},{"orgOrder":0,"company":"Medreg","sponsor":"Icon Plc | Johns Hopkins University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"MRG-001","moa":"\nBMPR2\/CXCR4\/CaN\/Cytokines\/FKBP1A","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Medreg","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medreg \/ Icon Plc | Johns Hopkins University","highestDevelopmentStatusID":"8","companyTruncated":"Medreg \/ Icon Plc | Johns Hopkins University"},{"orgOrder":0,"company":"Medreg","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"MRG-001","moa":"\nBMPR2\/CXCR4\/CaN\/Cytokines\/FKBP1A","graph1":"Neurology","graph2":"Phase II","graph3":"Medreg","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medreg \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medreg \/ Undisclosed"},{"orgOrder":0,"company":"Medreg","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MRG-001","moa":"\nBMPR2\/CXCR4\/CaN\/Cytokines\/FKBP1A","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Medreg","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medreg \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medreg \/ Undisclosed"},{"orgOrder":0,"company":"Medreg","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"MRG-001","moa":"\nBMPR2\/CXCR4\/CaN\/Cytokines\/FKBP1A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medreg","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medreg \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medreg \/ Undisclosed"},{"orgOrder":0,"company":"Medreg","sponsor":"Vanderbilt University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"MRG-001","moa":"\nBMPR2\/CXCR4\/CaN\/Cytokines\/FKBP1A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medreg","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medreg \/ Vanderbilt University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Medreg \/ Vanderbilt University Medical Center"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"MVT-2163","moa":"\nCA19.9","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ BioNTech"},{"orgOrder":0,"company":"Qiagen","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"INCA033989","moa":"\nCALR||","graph1":"Oncology","graph2":"Phase I","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qiagen \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Qiagen \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"INCA033989","moa":"\nCALR","graph1":"Oncology","graph2":"Phase I","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"INCA033989","moa":"\nCALR","graph1":"Oncology","graph2":"Phase I","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MT-2111","moa":"\nCD19\/DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innolake Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"ILB-3101","moa":"\nCD276\/Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Innolake Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innolake Biopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innolake Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"INCA00186","moa":"\nCD73","graph1":"Oncology","graph2":"Phase I","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cofrogliptin","moa":"DPP-4","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Drogsan Pharmaceuticals","sponsor":"Rockwell Medical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"TURKEY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"\nFe","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Drogsan Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Drogsan Pharmaceuticals \/ Rockwell Medical","highestDevelopmentStatusID":"15","companyTruncated":"Drogsan Pharmaceuticals \/ Rockwell Medical"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"\nFe","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rockwell Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Rockwell Medical \/ Undisclosed"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Licensing Agreement","leadProduct":"Ferric Pyrophosphate Citrate","moa":"\nFe","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rockwell Medical \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Rockwell Medical \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"\nFe","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rockwell Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Rockwell Medical \/ Undisclosed"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"\nFe","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rockwell Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Rockwell Medical \/ Undisclosed"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"\nFe","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rockwell Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Rockwell Medical \/ Undisclosed"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"\nFe||","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rockwell Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rockwell Medical \/ Undisclosed"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Drogsan Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Licensing Agreement","leadProduct":"Ferric Pyrophosphate Citrate","moa":"\nFe","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rockwell Medical \/ Drogsan Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Rockwell Medical \/ Drogsan Pharmaceuticals"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"\nFe","graph1":"Nephrology","graph2":"Phase IV","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rockwell Medical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Rockwell Medical \/ Undisclosed"},{"orgOrder":0,"company":"Xi'An Aolitai Pharmaceutical Technology Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MT2004","moa":"\nFXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Xi'An Aolitai Pharmaceutical Technology Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xi'An Aolitai Pharmaceutical Technology Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xi'An Aolitai Pharmaceutical Technology Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Xi'an Biocare Pharma Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MT2004","moa":"\nFXR","graph1":"Undisclosed","graph2":"Phase I","graph3":"Xi'an Biocare Pharma Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xi'an Biocare Pharma Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xi'an Biocare Pharma Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Biomed Industries","sponsor":"Bioneurals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NA-931","moa":"\nGCGR\/GIPR\/GLP-1R\/IGF-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biomed Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomed Industries \/ Bioneurals","highestDevelopmentStatusID":"8","companyTruncated":"Biomed Industries \/ Bioneurals"},{"orgOrder":0,"company":"Biomed Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NA-931","moa":"\nGCGR\/GIPR\/GLP-1R\/IGF-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biomed Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomed Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomed Industries \/ Undisclosed"},{"orgOrder":0,"company":"Biomed Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NA-931","moa":"\nGCGR\/GIPR\/GLP-1R\/IGF-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biomed Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomed Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomed Industries \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GZR102","moa":"GLP-1R | INSR","graph1":"Endocrinology","graph2":"Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GZR102","moa":"GLP-1R | INSR","graph1":"Endocrinology","graph2":"Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Bio-Targeting Therapeutics","sponsor":"Xiaorong Wu","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Ad-TD-nsIL12","moa":"IL-12R","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Bio-Targeting Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Bio-Targeting Therapeutics \/ Xiaorong Wu","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Bio-Targeting Therapeutics \/ Xiaorong Wu"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MT-2990","moa":"\nIL-33","graph1":"Undisclosed","graph2":"Phase I","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Y-mAbs Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2022","type":"Agreement","leadProduct":"177-Lu DOTA","moa":"\nIonising radiation||","graph1":"Oncology","graph2":"Phase I","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Isotope Technologies Munich \/ Y-mAbs Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Isotope Technologies Munich \/ Y-mAbs Therapeutics"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"GD2-SADA","moa":"\nIonising radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"177-Lu DOTA","moa":"\nIonising radiation||","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"177-Lu DOTA","moa":"\nIonising radiation||","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"GD2-SADA","moa":"\nIonising radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MT-921","moa":"\nLipid","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Saisei Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Saisei Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saisei Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Saisei Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Chemi-Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ESTONIA","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Chemi-Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Chemi-Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chemi-Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Ateria Health","sponsor":"Immuron","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2022","type":"Financing","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ateria Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ateria Health \/ Immuron","highestDevelopmentStatusID":"15","companyTruncated":"Ateria Health \/ Immuron"},{"orgOrder":0,"company":"Ateria Health","sponsor":"Immuron","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2022","type":"Financing","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ateria Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ateria Health \/ Immuron","highestDevelopmentStatusID":"15","companyTruncated":"Ateria Health \/ Immuron"},{"orgOrder":0,"company":"Milky Way Life Sciences LLC","sponsor":"Beth Israel Deaconess Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Milky Way Life Sciences LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Milky Way Life Sciences LLC \/ Beth Israel Deaconess Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Milky Way Life Sciences LLC \/ Beth Israel Deaconess Medical Center"},{"orgOrder":0,"company":"Immuron","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2024","type":"Funding","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ US Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ US Department of Defense"},{"orgOrder":0,"company":"Immuron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Undisclosed"},{"orgOrder":0,"company":"Immuron","sponsor":"Pharmaron","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2022","type":"Agreement","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Pharmaron","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Pharmaron"},{"orgOrder":0,"company":"Immuron","sponsor":"Medical Technology Enterprise Consortium","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2022","type":"Funding","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Medical Technology Enterprise Consortium","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Medical Technology Enterprise Consortium"},{"orgOrder":0,"company":"Immuron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Undisclosed"},{"orgOrder":0,"company":"Immuron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Undisclosed"},{"orgOrder":0,"company":"Immuron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Undisclosed"},{"orgOrder":0,"company":"Immuron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Undisclosed"},{"orgOrder":0,"company":"Immuron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Undisclosed"},{"orgOrder":0,"company":"Immuron","sponsor":"NMRC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2024","type":"Agreement","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ NMRC","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ NMRC"},{"orgOrder":0,"company":"Immuron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Undisclosed"},{"orgOrder":0,"company":"Immuron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Immuron \/ Undisclosed"},{"orgOrder":0,"company":"Immuron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Immuron \/ Undisclosed"},{"orgOrder":0,"company":"Immuron","sponsor":"Monash University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2020","type":"Agreement","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Monash University","highestDevelopmentStatusID":"4","companyTruncated":"Immuron \/ Monash University"},{"orgOrder":0,"company":"Armra","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Armra","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Armra \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Armra \/ Citruslabs"},{"orgOrder":0,"company":"Immuron","sponsor":"US Department of Defense | Naval Medical Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Travelan","moa":"\nLPS","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ US Department of Defense | Naval Medical Research Center","highestDevelopmentStatusID":"8","companyTruncated":"Immuron \/ US Department of Defense | Naval Medical Research Center"},{"orgOrder":0,"company":"Neurokine Therapeutics","sponsor":"Columbia University | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MW150","moa":"\np38-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"Neurokine Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurokine Therapeutics \/ Columbia University | National Institute on Aging","highestDevelopmentStatusID":"8","companyTruncated":"Neurokine Therapeutics \/ Columbia University | National Institute on Aging"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"NBP2001","moa":"\nSARS-CoV-2 antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SK Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Medicago","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"MT-2766","moa":"\nSARS-CoV-2 S protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicago \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Medicago \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"MW33","moa":"\nSARS-CoV-2 S protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Shanghai Public Health Clinical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"MW33","moa":"\nSARS-CoV-2 S protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Shanghai Public Health Clinical Center","highestDevelopmentStatusID":"8","companyTruncated":"Mabwell \/ Shanghai Public Health Clinical Center"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"EdiGene","sponsor":"Haihe Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EdiGene \/ Haihe Laboratory","highestDevelopmentStatusID":"6","companyTruncated":"EdiGene \/ Haihe Laboratory"},{"orgOrder":0,"company":"EdiGene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EdiGene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EdiGene \/ Undisclosed"},{"orgOrder":0,"company":"EdiGene","sponsor":"3H Health Investment","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"EdiGene","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"EdiGene \/ 3H Health Investment","highestDevelopmentStatusID":"6","companyTruncated":"EdiGene \/ 3H Health Investment"},{"orgOrder":0,"company":"Medytox","sponsor":"Bloomage Biotechnology Corp., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Termination","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Medytox","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medytox \/ Bloomage Biotechnology Corp., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Medytox \/ Bloomage Biotechnology Corp., Ltd"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"MingMed Biotechnology","sponsor":"Claruvis Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"MingMed Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MingMed Biotechnology \/ Claruvis Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"MingMed Biotechnology \/ Claruvis Pharmaceutical"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Urology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Galderma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2023","type":"Termination","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Galderma"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Allergan Aesthetics","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Allergan Aesthetics"},{"orgOrder":0,"company":"HTL Biotechnology","sponsor":"Eirion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase II","graph3":"HTL Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liniment","sponsorNew":"HTL Biotechnology \/ Eirion Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"HTL Biotechnology \/ Eirion Therapeutics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Healis Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Healis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Healis Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Healis Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Shanghai Haohai Biological Technology","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series A Financing","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase II","graph3":"Eirion Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Liniment","sponsorNew":"Eirion Therapeutics \/ Shanghai Haohai Biological Technology","highestDevelopmentStatusID":"8","companyTruncated":"Eirion Therapeutics \/ Shanghai Haohai Biological Technology"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MTPS9579A","moa":"\nTryptase","graph1":"Immunology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CSJ117","moa":"\nTSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CSJ117","moa":"\nTSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CSJ117","moa":"\nTSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KUR-101","moa":"? opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KUR-101","moa":"? opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Kures","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"KUR-101","moa":"? opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Kures","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kures \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kures \/ Undisclosed"},{"orgOrder":0,"company":"Kures","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"KUR-101","moa":"? opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Kures","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kures \/ ATAI Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Kures \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"SLS-004","moa":"?-synuclein","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"SLS-004","moa":"?-synuclein","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SLS-004","moa":"?-synuclein","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Funding","leadProduct":"SLS-004","moa":"?-synuclein","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seelos Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PF-07328948","moa":"[3-methyl-2-oxobutanoate dehydrogenase] kinase (BCKDK)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"PF-07328948","moa":"[3-methyl-2-oxobutanoate dehydrogenase] kinase (BCKDK)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PF-07328948","moa":"[3-methyl-2-oxobutanoate dehydrogenase] kinase (BCKDK)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PF-07328948","moa":"[3-methyl-2-oxobutanoate dehydrogenase] kinase (BCKDK)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inncelerex","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"14-C Ibrexafungerp","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scynexis \/ Inncelerex","highestDevelopmentStatusID":"6","companyTruncated":"Scynexis \/ Inncelerex"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Napp Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Napp Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Napp Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Hartford Hospital","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hartford Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hartford Hospital \/ Melinta Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Hartford Hospital \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0.56999999999999995,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.56999999999999995,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Mundipharma"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0.56999999999999995,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.56999999999999995,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Mundipharma"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Divestment","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Mundipharma"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"Candida","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0.46000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Mundipharma"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Mundipharma"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"CorMedix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0.33000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.33000000000000002,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ CorMedix","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ CorMedix"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"CorMedix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0.33000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.33000000000000002,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ CorMedix","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ CorMedix"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Tours","sponsor":"University Hospital, Angers | Centre Hospitalier Universitaire de Besancon | University Hospital, Bordeaux | University Hospital, Brest | Centre Hospitalier Universitaire Dijon | University Hospital, Grenoble | University Hospital, Lille | University Hosp","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Caspofungin","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"University Hospital, Tours","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"University Hospital, Tours \/ University Hospital, Angers | Centre Hospitalier Universitaire de Besancon | University Hospital, Bordeaux | University Hospital, Brest | Centre Hospitalier Universitaire Dijon | University Hospital, Grenoble | University Hospital, Lille | University Hosp","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital, Tours \/ University Hospital, Angers | Centre Hospitalier Universitaire de Besancon | University Hospital, Bordeaux | University Hospital, Brest | Centre Hospitalier Universitaire Dijon | University Hospital, Grenoble | University Hospital, Lille | University Hosp"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0.58999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.58999999999999997,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"FDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ FDA","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ FDA"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"||1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0.40000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.58999999999999997,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.58999999999999997,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Scynexis","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Hansoh Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Hansoh Pharma"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0.12,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Hansoh Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Hansoh Pharma"},{"orgOrder":0,"company":"Scynexis","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Hercules Capital"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"||1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0.58999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.58999999999999997,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0.58999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.58999999999999997,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Micafungin","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Micafungin","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Sandoz B2B"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Micafungin","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Sandoz B2B"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Micafungin","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Yung Shin Pharm Industrial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Micafungin","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Yung Shin Pharm Industrial","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yung Shin Pharm Industrial \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yung Shin Pharm Industrial \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Micafungin","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Bionorica SE","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BX-1","moa":"11-beta-HSD1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Charite University, Berlin, Germany \/ Bionorica SE","highestDevelopmentStatusID":"8","companyTruncated":"Charite University, Berlin, Germany \/ Bionorica SE"},{"orgOrder":0,"company":"Catalysis","sponsor":"Atika Pharma S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Dipotassium Glycyrrhizinate","moa":"11-beta-hydroxysteroid dehydrogenase 1; Tumor necrosis factor; Caspase-3; Nuclear factor NF-kappa-B; Lipoprotein lipase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Catalysis \/ Atika Pharma S.L.","highestDevelopmentStatusID":"11","companyTruncated":"Catalysis \/ Atika Pharma S.L."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RTX-1688","moa":"15-hydroxyprostaglandin dehydrogenase","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TAS-205","moa":"15-LOX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TAS-205","moa":"15-LOX","graph1":"Undisclosed","graph2":"Phase I","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taiho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Epirium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MF-300","moa":"15-PGDH","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Epirium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epirium \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ Undisclosed"},{"orgOrder":0,"company":"Epirium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MF-300","moa":"15-PGDH","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Epirium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epirium \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"GSK4532990","moa":"17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"GSK4532990","moa":"17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"GSK4532990","moa":"17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Licensing Agreement","leadProduct":"GSK4532990","moa":"17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":1.03,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":1.03,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ GSK"},{"orgOrder":0,"company":"PathAI, inc","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"GSK4532990","moa":"17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"PathAI, inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PathAI, inc \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"PathAI, inc \/ GSK"},{"orgOrder":0,"company":"OrphAI Therapeutics","sponsor":"Yale University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Apilimod mesylate","moa":"1-phosphatidylinositol 3-phosphate 5-kinase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OrphAI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OrphAI Therapeutics \/ Yale University","highestDevelopmentStatusID":"8","companyTruncated":"OrphAI Therapeutics \/ Yale University"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Apilimod mesylate","moa":"1-phosphatidylinositol 3-phosphate 5-kinase","graph1":"Neurology","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AI Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OrphAI Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Apilimod mesylate","moa":"1-phosphatidylinositol 3-phosphate 5-kinase","graph1":"Neurology","graph2":"Phase II","graph3":"OrphAI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OrphAI Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrphAI Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Apilimod mesylate","moa":"1-phosphatidylinositol 3-phosphate 5-kinase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AI Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kintai Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Apilimod mesylate","moa":"||1-phosphatidylinositol 3-phosphate 5-kinase","graph1":"Neurology","graph2":"Preclinical","graph3":"Kintai Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kintai Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Kintai Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Marizomib","moa":"20S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb | Secura Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Marizomib","moa":"20S proteasome","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Secura Bio","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Secura Bio"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Marizomib","moa":"20S proteasome","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chinese SLE Treatment And Research Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chinese SLE Treatment And Research Group \/ Undisclosed"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Undisclosed"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Venus Remedies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"PETHEMA Foundation","sponsor":"Bristol Myers Squibb | Sanofi | Adknoma | Start from Scratch","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase III","graph3":"PETHEMA Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PETHEMA Foundation \/ Bristol Myers Squibb | Sanofi | Adknoma | Start from Scratch","highestDevelopmentStatusID":"10","companyTruncated":"PETHEMA Foundation \/ Bristol Myers Squibb | Sanofi | Adknoma | Start from Scratch"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"Amgen Inc | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ Amgen Inc | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"University of Miami \/ Amgen Inc | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Eastern Cooperative Oncology Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Eastern Cooperative Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eastern Cooperative Oncology Group \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Eastern Cooperative Oncology Group \/ National Cancer Institute"},{"orgOrder":0,"company":"ECOG-ACRIN Cancer Research Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase III","graph3":"ECOG-ACRIN Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Shilpa Medicare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amneal Pharmaceuticals \/ Shilpa Medicare","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Shilpa Medicare"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amneal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Instituto do Cancer do Estado de S\u00e3o Paulo","sponsor":"Libbs Farmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BRAZIL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Instituto do Cancer do Estado de S\u00e3o Paulo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Instituto do Cancer do Estado de S\u00e3o Paulo \/ Libbs Farmaceutica","highestDevelopmentStatusID":"8","companyTruncated":"Instituto do Cancer do Estado de S\u00e3o Paulo \/ Libbs Farmaceutica"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Johnson & Johnson Innovative Medicine | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Johnson & Johnson Innovative Medicine | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Gabrail Cancer Center Research \/ Johnson & Johnson Innovative Medicine | National Cancer Institute"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Sanofi | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Sanofi | National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Gabrail Cancer Center Research \/ Sanofi | National Cancer Institute"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Amgen Inc | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Forest University Health Sciences \/ Amgen Inc | GSK","highestDevelopmentStatusID":"8","companyTruncated":"Wake Forest University Health Sciences \/ Amgen Inc | GSK"},{"orgOrder":0,"company":"OHSU Knight Cancer Institute","sponsor":"Oregon Health and Science University | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"OHSU Knight Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OHSU Knight Cancer Institute \/ Oregon Health and Science University | Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"OHSU Knight Cancer Institute \/ Oregon Health and Science University | Sanofi"},{"orgOrder":0,"company":"University of Washington","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"University of Washington \/ Sanofi"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | Bristol Myers Squibb | PPD | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"26S proteasome","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Insert","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | Bristol Myers Squibb | PPD | Rho, Inc","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | Bristol Myers Squibb | PPD | Rho, Inc"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Amgen Inc | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Amgen Inc | Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Amgen Inc | Sanofi"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"European Myeloma Network","sponsor":"EMN Trial Office | Sanofi | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase III","graph3":"European Myeloma Network","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"European Myeloma Network \/ EMN Trial Office | Sanofi | Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"European Myeloma Network \/ EMN Trial Office | Sanofi | Amgen Inc"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Cantero Therapeutics","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BBP-711","moa":"2-Hydroxyacid oxidase 1 (HAO1)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Cantero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Cantero Therapeutics \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Cantero Therapeutics \/ Celerion"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Biolexa","moa":"30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Raynovent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Leritrelvir","moa":"3CL protease (SARS-CoV-2)","graph1":"Nephrology","graph2":"Phase I","graph3":"Raynovent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raynovent Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Raynovent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Raynovent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Leritrelvir","moa":"3CL protease (SARS-CoV-2)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Raynovent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raynovent Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Raynovent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Raynovent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Leritrelvir","moa":"3CL protease (SARS-CoV-2)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Raynovent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raynovent Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Raynovent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang ACEA Pharmaceutical Co. Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"14-C STI-1558","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Zhejiang ACEA Pharmaceutical Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zhejiang ACEA Pharmaceutical Co. Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang ACEA Pharmaceutical Co. Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ALG-097558","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aligos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALG-097558","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aligos Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALG-097558","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aligos Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"ALG-097558","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Aligos Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ALG-097558","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aligos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ALG-097558","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aligos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ALG-097558","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aligos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ASC11","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ASC11","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ASC11","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ASC11","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ASC11","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"CDI-873","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cocrystal Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"COR803","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quince Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Quince Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Hematology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Hematology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"University of Chicago","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ University of Chicago","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ University of Chicago"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ European Investment Bank","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ European Investment Bank"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Oncology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Oncology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Oncology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NLC-001","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ Undisclosed"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NLC-001","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ Undisclosed"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NLC-001","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ Undisclosed"},{"orgOrder":0,"company":"Todos Medical","sponsor":"T-Cell Protect","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Termination","leadProduct":"NLC-001","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ T-Cell Protect","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ T-Cell Protect"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NLC-001","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ Undisclosed"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NLC-001","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ Undisclosed"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NLC-001","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ Undisclosed"},{"orgOrder":0,"company":"Todos Medical","sponsor":"NLC Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"NLC-001","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ NLC Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ NLC Pharma"},{"orgOrder":0,"company":"NLC Pharma","sponsor":"Todos Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"NLC-V-01","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NLC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NLC Pharma \/ Todos Medical","highestDevelopmentStatusID":"8","companyTruncated":"NLC Pharma \/ Todos Medical"},{"orgOrder":0,"company":"NLC Pharma","sponsor":"Todos Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"NLC-V-01","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NLC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NLC Pharma \/ Todos Medical","highestDevelopmentStatusID":"8","companyTruncated":"NLC Pharma \/ Todos Medical"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NLC-V-01","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medical \/ Undisclosed"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NLC-V-01","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medical \/ Undisclosed"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NLC-V-01","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medical \/ Undisclosed"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NLC-V-01","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medical \/ Undisclosed"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NLC-V-01","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medical \/ Undisclosed"},{"orgOrder":0,"company":"Todos Medical","sponsor":"NLC Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NLC-V-01","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ NLC Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medical \/ NLC Pharma"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PF-07329640","moa":"3CLpro","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Undisclosed","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Undisclosed","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Undisclosed","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Nephrology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Shanghai Institute of Materia Medica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Shanghai Institute of Materia Medica","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Shanghai Institute of Materia Medica"},{"orgOrder":0,"company":"IMBiologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IMB-101","moa":"3-ketoacyl-CoA thiolase, mitochondrial (ACAA2)","graph1":"Immunology","graph2":"Phase I","graph3":"IMBiologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMBiologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IMBiologics \/ Undisclosed"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AR-12","moa":"3-phosphoinositide dependent protein kinase-1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Commonwealth University \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Virginia Commonwealth University \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Aptevo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Aptevo Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Aptevo Therapeutics"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alligator Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Alligator Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Alligator Bioscience"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alligator Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Alligator Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Alligator Bioscience"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alligator Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Alligator Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1017","moa":"||4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1017","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1017","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1017","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AVA-001","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avalon GloboCare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Avalon GloboCare \/ Undisclosed"},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AVA-001","moa":"||4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avalon GloboCare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Avalon GloboCare \/ Undisclosed"},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AVA-001","moa":"||4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avalon GloboCare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Avalon GloboCare \/ Undisclosed"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Cinrebafusp Alpha","moa":"||4-1BB","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pieris Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||4-1BB","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pieris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||4-1BB","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pieris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Cinrebafusp Alpha","moa":"4-1BB","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pieris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Seagen","sponsor":"Pieris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Cinrebafusp Alpha","moa":"||4-1BB","graph1":"Oncology","graph2":"Preclinical","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seagen \/ Pieris Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Seagen \/ Pieris Pharmaceuticals"},{"orgOrder":0,"company":"Eutilex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"EU101","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eutilex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eutilex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eutilex \/ Undisclosed"},{"orgOrder":0,"company":"Eutilex","sponsor":"Samsung Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"EU101","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eutilex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eutilex \/ Samsung Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Eutilex \/ Samsung Biologics"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"National OncoVenture","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"EU101","moa":"4-1BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ National OncoVenture","highestDevelopmentStatusID":"5","companyTruncated":"Samsung Biologics \/ National OncoVenture"},{"orgOrder":0,"company":"Sunshine Guojian","sponsor":"Numab Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Partnership","leadProduct":"ND021","moa":"4-1BB","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Guojian","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Guojian \/ Numab Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Guojian \/ Numab Therapeutics"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"3S Bio Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Series B Financing","leadProduct":"ND021","moa":"4-1BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Numab Therapeutics","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ 3S Bio Inc","highestDevelopmentStatusID":"5","companyTruncated":"Numab Therapeutics \/ 3S Bio Inc"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Boston Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"PRS-342","moa":"4-1BB","graph1":"Oncology","graph2":"Preclinical","graph3":"Pieris Pharmaceuticals","amount2":0.35999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.35999999999999999,"dosageForm":"Injection","sponsorNew":"Pieris Pharmaceuticals \/ Boston Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Pieris Pharmaceuticals \/ Boston Pharmaceuticals"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TJ-C64B","moa":"4-1BB","graph1":"Oncology","graph2":"Preclinical","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"IBD0333","moa":"4-1BB \/ CD24","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Clesitamig","moa":"4-1BB | CD3 | DLL3","graph1":"Oncology","graph2":"Phase I","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Cabaletta Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"IASO Bio","amount2":0.16,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Cabaletta Bio","highestDevelopmentStatusID":"4","companyTruncated":"IASO Bio \/ Cabaletta Bio"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||4-1BB\/CD19","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||4-1BB\/CD19","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Public Offering","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ TD Cowen","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ TD Cowen"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Public Offering","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ TD Cowen","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ TD Cowen"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Cabaletta Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"WuXi Advanced Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"WuXi Advanced Therapies \/ Cabaletta Bio","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Advanced Therapies \/ Cabaletta Bio"},{"orgOrder":0,"company":"Beijing Immunoah Pharma Tech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IMB071703","moa":"4-1BB\/CD40","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Immunoah Pharma Tech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Immunoah Pharma Tech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Immunoah Pharma Tech \/ Undisclosed"},{"orgOrder":0,"company":"NovaRock Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"NBL-028","moa":"4-1BB\/CLDN6","graph1":"Oncology","graph2":"Phase I","graph3":"NovaRock Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NovaRock Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NovaRock Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Binacea Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BNA035","moa":"4-1BB\/EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Binacea Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Binacea Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Binacea Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"YH32364","moa":"4-1BB|EFGR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"BNT314","moa":"4-1BB\/EpCAM","graph1":"Oncology","graph2":"Phase I","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Genmab","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/ Genmab"},{"orgOrder":0,"company":"BioNTech","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"BNT314","moa":"4-1BB|EpCAM","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ Merck & Co"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"||4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"||4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"BioNTech","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Termination","leadProduct":"Acasunlimab","moa":"||4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Genmab","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"4-1BB|PDL1","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Sun Yat-sen University | Mianyang Central Hospital | Xiangyang Central Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Sun Yat-sen University | Mianyang Central Hospital | Xiangyang Central Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Leads Biolabs \/ Sun Yat-sen University | Mianyang Central Hospital | Xiangyang Central Hospital"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Etoposide","moa":"||4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB|PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Shanghai Zhongshan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB|PDL1","graph1":"Oncology","graph2":"Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Shanghai Zhongshan Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Leads Biolabs \/ Shanghai Zhongshan Hospital"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"LBL-024","moa":"4-1BB|PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Undisclosed"},{"orgOrder":0,"company":"Sound Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"FTL008.16","moa":"4-1BBL\/5T4","graph1":"Oncology","graph2":"Phase I","graph3":"Sound Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sound Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sound Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitisinone","moa":"4-hydroxyphenylpyruvate dioxygenase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitisinone","moa":"4-hydroxyphenylpyruvate dioxygenase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cycle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cycle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Oakrum Pharma, LLC","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Nitisinone","moa":"4-hydroxyphenylpyruvate dioxygenase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Oakrum Pharma, LLC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oakrum Pharma, LLC \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Oakrum Pharma, LLC \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Analog Pharma","sponsor":"Dipharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nitisinone","moa":"4-hydroxyphenylpyruvate dioxygenase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Analog Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Analog Pharma \/ Dipharma","highestDevelopmentStatusID":"15","companyTruncated":"Analog Pharma \/ Dipharma"},{"orgOrder":0,"company":"RS Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Thiostrepton","moa":"50S","graph1":"Oncology","graph2":"Phase II","graph3":"RS Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RS Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RS Oncology \/ Undisclosed"},{"orgOrder":0,"company":"RS Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Thiostrepton","moa":"50S","graph1":"Oncology","graph2":"Phase II","graph3":"RS Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RS Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RS Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"IDP-126","moa":"50S ribosomal protein L1","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"IDP-126","moa":"50S ribosomal protein L1","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"IDP-126","moa":"50S ribosomal protein L1","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"BV300","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BioVersys AG","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"BioVersys AG \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"BioVersys AG \/ CARB-X"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"RHB-204","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Givosiran","moa":"5-aminolevulinate synthase mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Givosiran","moa":"5-aminolevulinate synthase mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Givosiran","moa":"5-aminolevulinate synthase mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Givosiran","moa":"5-aminolevulinate synthase mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2023","type":"Expanded Collaboration","leadProduct":"Givosiran Sodium","moa":"5-aminolevulinate synthase mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medison Pharma \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Journey Colab","sponsor":"MBX Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"Mescaline","moa":"5-HT 2A receptor (HTR2A)","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Journey Colab","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Journey Colab \/ MBX Capital","highestDevelopmentStatusID":"4","companyTruncated":"Journey Colab \/ MBX Capital"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mescaline","moa":"5-HT 2A receptor (HTR2A)","graph1":"Immunology","graph2":"IND Enabling","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"HaEmek Medical Center, Israel","sponsor":"MAPS Public Benefit Corporation (MAPS PBC) 3141 Stevens Creek Blvd, #40547 San Jose, CA 95117 USA","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT 2A receptor (HTR2A)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HaEmek Medical Center, Israel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaEmek Medical Center, Israel \/ MAPS Public Benefit Corporation (MAPS PBC) 3141 Stevens Creek Blvd, #40547 San Jose, CA 95117 USA","highestDevelopmentStatusID":"8","companyTruncated":"HaEmek Medical Center, Israel \/ MAPS Public Benefit Corporation (MAPS PBC) 3141 Stevens Creek Blvd, #40547 San Jose, CA 95117 USA"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT 2A receptor (HTR2A)","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Eleusis","sponsor":"Beckley Psytech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Psilocin","moa":"5-HT 2A receptor (HTR2A)","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Eleusis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eleusis \/ Beckley Psytech","highestDevelopmentStatusID":"6","companyTruncated":"Eleusis \/ Beckley Psytech"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT 2A receptor (HTR2A)","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Filament Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT 2A receptor (HTR2A)","graph1":"Undisclosed","graph2":"Phase I","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Filament Health","highestDevelopmentStatusID":"6","companyTruncated":"University of California, San Francisco \/ Filament Health"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Alto Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocin","moa":"5-HT 2A receptor (HTR2A)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tryp Therapeutics \/ Alto Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Alto Capital Limited"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Pharmaceutical Research Unit, Jordan","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT 2A receptor (HTR2A)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Lobe Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lobe Sciences \/ Pharmaceutical Research Unit, Jordan","highestDevelopmentStatusID":"6","companyTruncated":"Lobe Sciences \/ Pharmaceutical Research Unit, Jordan"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT 2A receptor (HTR2A)","graph1":"Neurology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mydecine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT 2A receptor (HTR2A)","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mydecine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Mydecine \/ Undisclosed"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT 2A receptor (HTR2A)","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UMass Dartmouth","sponsor":"Caamtech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Expanded Collaboration","leadProduct":"Tryptamine","moa":"5-HT 2A receptor (HTR2A)","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"UMass Dartmouth","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UMass Dartmouth \/ Caamtech","highestDevelopmentStatusID":"2","companyTruncated":"UMass Dartmouth \/ Caamtech"},{"orgOrder":0,"company":"Mydecine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Tryptamine","moa":"5-HT 2A receptor (HTR2A)","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Mydecine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Mydecine \/ Undisclosed"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AD04","moa":"5-HT 3 receptor (5HT3R)","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ADvantage Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Institute of Materia Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bilobalide","moa":"5-HT 3A receptor (HTR3A)","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Institute of Materia Medica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Materia Medica \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Institute of Materia Medica \/ Undisclosed"},{"orgOrder":0,"company":"Mydecine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"MYCO-003","moa":"5-HT receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mydecine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Mydecine \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"||5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"||5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"||5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATX01","moa":"5-HT transporter","graph1":"Neurology","graph2":"Phase II","graph3":"AlgoTherapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"AlgoTherapeutix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AlgoTherapeutix \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"EmpathBio","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"EMP-01","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ATAI Life Sciences \/ EmpathBio","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ EmpathBio"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ammoxetine","moa":"5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ammoxetine","moa":"5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EVX-301","moa":"5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Evecxia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Series C Financing","leadProduct":"HSDB 4295","moa":"5-HT\/norepinephrine reuptake","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Evox Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Evox Therapeutics \/ Redmile Group","highestDevelopmentStatusID":"4","companyTruncated":"Evox Therapeutics \/ Redmile Group"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Evecxia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Evecxia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Quotient Sciences"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ansofaxine HCl","moa":"5-HT\/norepinephrine\/dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"CMND-100","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aragen Life Sciences \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Aragen Life Sciences \/ Clearmind Medicine"},{"orgOrder":0,"company":"BIRAD","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BIRAD","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BIRAD \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"BIRAD \/ Clearmind Medicine"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Johns Hopkins University","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Johns Hopkins University"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"IMP Clinical Supply Services","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ IMP Clinical Supply Services","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ IMP Clinical Supply Services"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University Of Jerusalem","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Hebrew University Of Jerusalem","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Hebrew University Of Jerusalem"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Hebrew University of Jerusalem","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Hebrew University of Jerusalem"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Exscientia","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"DSP-0038","moa":"5-HT1A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Sumitomo Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Sumitomo Pharma"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"DSP-1181","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"DSP-1181","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor||5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRELAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor||5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A","graph1":"Undisclosed","graph2":"Phase I","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor||5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A","graph1":"Undisclosed","graph2":"Phase I","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRELAND","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor||5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A","graph1":"Undisclosed","graph2":"Phase I","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor||5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A","graph1":"Undisclosed","graph2":"Phase I","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Cat\u00f3lica de Cuyo","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Cat\u00f3lica de Cuyo","highestDevelopmentStatusID":"7","companyTruncated":"Biomind Labs \/ Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Cat\u00f3lica de Cuyo"},{"orgOrder":0,"company":"GH Research","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Cantor Fitzgerald","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"GH Research","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Cantor Fitzgerald","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Series B Financing","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.13,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ RA Capital Management"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Lusaris Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Series A Financing","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lusaris Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Lusaris Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Lusaris Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"SCIRENT Clinical Research and Science d.o.o.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"(S)-Pindolol Benzoate","moa":"5-HT1A receptor | beta-adrenoceptors | beta 2-adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Actimed Therapeutics \/ SCIRENT Clinical Research and Science d.o.o.","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ SCIRENT Clinical Research and Science d.o.o."},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BGP-014","moa":"5-HT1A\/2A receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"ZonMw | Canisius-Wilhelmina Hospital | Leiden University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ ZonMw | Canisius-Wilhelmina Hospital | Leiden University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Radboud University Medical Center \/ ZonMw | Canisius-Wilhelmina Hospital | Leiden University Medical Center"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Mind Medicine"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Leerink Partners"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"University Hospital Basel","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ University Hospital Basel","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ University Hospital Basel"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"MM-120","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"K\u00fcleon Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KB-128","moa":"5-HT1A\/2A\/2B receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"K\u00fcleon Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"K\u00fcleon Bioscience \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"K\u00fcleon Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole Fumarate","moa":"5-HT1A\/2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole Fumarate","moa":"5-HT1A\/2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole Fumarate","moa":"5-HT1A\/2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Kanghong Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Chengdu Kanghong Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chengdu Kanghong Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chengdu Kanghong Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Whanin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Whanin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Whanin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Whanin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"The Medical Research Network","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"The Medical Research Network","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Medical Research Network \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"The Medical Research Network \/ AbbVie Inc"},{"orgOrder":0,"company":"Aya Mohammed Abdel Magid Abdel Hamid","sponsor":"Advanced Research Network | Atco Pharma for Pharmaceutical Ind.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"5-HT1A|5-HT2A|D2 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Aya Mohammed Abdel Magid Abdel Hamid","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aya Mohammed Abdel Magid Abdel Hamid \/ Advanced Research Network | Atco Pharma for Pharmaceutical Ind.","highestDevelopmentStatusID":"6","companyTruncated":"Aya Mohammed Abdel Magid Abdel Hamid \/ Advanced Research Network | Atco Pharma for Pharmaceutical Ind."},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"14-C RE104","moa":"5-HT2A receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Reunion Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Carleton University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Carleton University","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Carleton University"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Negev Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Private Placement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Negev Capital","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Negev Capital"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UC San Diego","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"UC San Diego","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"UC San Diego \/ BetterLife Pharma","highestDevelopmentStatusID":"4","companyTruncated":"UC San Diego \/ BetterLife Pharma"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Carleton University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Carleton University","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Carleton University"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Nucro-Technics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Nucro-Technics","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Nucro-Technics"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"HAVN Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"||5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bolt Biotherapeutics \/ HAVN Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Bolt Biotherapeutics \/ HAVN Life Sciences"},{"orgOrder":0,"company":"Ceruvia Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Ceruvia Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ceruvia Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ceruvia Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Ceruvia Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Ceruvia Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ceruvia Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ceruvia Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Wisconsin Medical Cyclotron & Radiopharmacy","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BetterLife Pharma \/ Wisconsin Medical Cyclotron & Radiopharmacy","highestDevelopmentStatusID":"4","companyTruncated":"BetterLife Pharma \/ Wisconsin Medical Cyclotron & Radiopharmacy"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"UC San Diego School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BetterLife Pharma \/ UC San Diego School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"BetterLife Pharma \/ UC San Diego School of Medicine"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"HAVN Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"||5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bolt Biotherapeutics \/ HAVN Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Bolt Biotherapeutics \/ HAVN Life Sciences"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BMND07","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Cat\u00f3lica de Cuyo","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"BMND08","moa":"5-HT2A receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biomind Labs \/ Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Cat\u00f3lica de Cuyo","highestDevelopmentStatusID":"7","companyTruncated":"Biomind Labs \/ Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Cat\u00f3lica de Cuyo"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"BPL-003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"BPL-003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"BPL-003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"BPL-003","moa":"5-HT2A receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Bretisilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gilgamesh Pharmaceuticals","amount2":1.2,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":1.2,"dosageForm":"Undisclosed","sponsorNew":"Gilgamesh Pharmaceuticals \/ Abbvie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Gilgamesh Pharmaceuticals \/ Abbvie Inc"},{"orgOrder":0,"company":"Cybin","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CYB003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cybin \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Cybin","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CYB003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cybin \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Cybin","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CYB003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cybin \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs Drug Development | Drug Safety Navigator","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CYB003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cybin \/ Clinilabs Drug Development | Drug Safety Navigator","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Clinilabs Drug Development | Drug Safety Navigator"},{"orgOrder":0,"company":"Cybin","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CYB004","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cybin \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Entheon Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entheon Biomedical \/ Cybin","highestDevelopmentStatusID":"6","companyTruncated":"Entheon Biomedical \/ Cybin"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Entheon Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entheon Biomedical \/ Cybin","highestDevelopmentStatusID":"6","companyTruncated":"Entheon Biomedical \/ Cybin"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated N,N-dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated N,N-dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Alliance Global Partners"},{"orgOrder":0,"company":"Cybin","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Clinilabs","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Clinilabs"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Thermo Fisher Scientific \/ Cybin","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fisher Scientific \/ Cybin"},{"orgOrder":0,"company":"Cybin","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Bloom Burton Securities","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Cybin","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Clinilabs","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Clinilabs"},{"orgOrder":0,"company":"Cybin","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Deep Track Capital","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Deep Track Capital"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Worldwide Clinical Trials \/ Cybin","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Clinical Trials \/ Cybin"},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Clinilabs","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Clinilabs"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Cybin","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Cybin"},{"orgOrder":0,"company":"Facet Life Sciences","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Facet Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Facet Life Sciences \/ Cybin","highestDevelopmentStatusID":"10","companyTruncated":"Facet Life Sciences \/ Cybin"},{"orgOrder":0,"company":"Fluence","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Fluence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fluence \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Fluence \/ Cybin"},{"orgOrder":0,"company":"Blumentech S.L.","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Blumentech S.L.","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blumentech S.L. \/ Terran Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Blumentech S.L. \/ Terran Biosciences"},{"orgOrder":0,"company":"Hammersmith Medicines Research","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Hammersmith Medicines Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hammersmith Medicines Research \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hammersmith Medicines Research \/ Algernon Pharmaceuticals"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Film, Soluble","sponsorNew":"ATAI Life Sciences \/ Berenberg","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Berenberg"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Film, Soluble","sponsorNew":"ATAI Life Sciences \/ Berenberg","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Berenberg"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Film, Soluble","sponsorNew":"ATAI Life Sciences \/ Berenberg","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Berenberg"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Cybin"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Cybin"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Reconnect Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Reconnect Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reconnect Labs \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Reconnect Labs \/ Undisclosed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ ATAI Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"IntelGenx \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Algernon NeuroScience","sponsor":"Dalmore Group","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon NeuroScience","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Algernon NeuroScience \/ Dalmore Group","highestDevelopmentStatusID":"6","companyTruncated":"Algernon NeuroScience \/ Dalmore Group"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Charles River Laboratories, Inc \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ Algernon Pharmaceuticals"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Laboratorium Ofichem B.V","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Entheon Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entheon Biomedical \/ Laboratorium Ofichem B.V","highestDevelopmentStatusID":"7","companyTruncated":"Entheon Biomedical \/ Laboratorium Ofichem B.V"},{"orgOrder":0,"company":"Algernon NeuroScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon NeuroScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon NeuroScience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon NeuroScience \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Validcare","sponsor":"Algernon NeuroScience","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Partnership","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Validcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Validcare \/ Algernon NeuroScience","highestDevelopmentStatusID":"6","companyTruncated":"Validcare \/ Algernon NeuroScience"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Dalton Pharma Services","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dalton Pharma Services \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Dalton Pharma Services \/ Algernon Pharmaceuticals"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Sairiyo Therapeutics \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Sairiyo Therapeutics \/ PharmaTher"},{"orgOrder":0,"company":"Psilera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Psilera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Psilera \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Psilera \/ Undisclosed"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Terran Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terran Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Terran Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Psilera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Psilera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psilera \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Psilera \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Unlimited Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Unlimited Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unlimited Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Unlimited Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Yale University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Yale University","highestDevelopmentStatusID":"4","companyTruncated":"Algernon Pharmaceuticals \/ Yale University"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Akome Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Akome Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akome Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Akome Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Eleusis","sponsor":"Beckley Psytech","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"ELE-101","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Eleusis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eleusis \/ Beckley Psytech","highestDevelopmentStatusID":"7","companyTruncated":"Eleusis \/ Beckley Psytech"},{"orgOrder":0,"company":"Field Trip Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FT-104","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Field Trip Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Field Trip Health \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Field Trip Health \/ Undisclosed"},{"orgOrder":0,"company":"Field Trip Psychedelics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"FT-104","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Field Trip Psychedelics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Field Trip Psychedelics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Field Trip Psychedelics \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"GH001","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"GH001","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"GH001","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"Isoprocin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ MPM BioImpact","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ MPM BioImpact"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Seleni Institute","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"Isoprocin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ Seleni Institute","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ Seleni Institute"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Isoprocin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ MPM BioImpact","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ MPM BioImpact"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Isoprocin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LYN-005","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lyndra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LYN-005","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lyndra Therapeutics \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Ksana Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Ksana Health","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Ksana Health"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0.059999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"McQuade Center for Strategic Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ McQuade Center for Strategic Research and Development","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ McQuade Center for Strategic Research and Development"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Cybin","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Cybin"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Centre for Addiction and Mental Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Centre for Addiction and Mental Health","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Centre for Addiction and Mental Health"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"PharmAla Biotech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ PharmAla Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Mindset Pharma \/ PharmAla Biotech"},{"orgOrder":0,"company":"PsyBio Therapeutics","sponsor":"Advanced Biofuels","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Norbaeocystin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PsyBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PsyBio Therapeutics \/ Advanced Biofuels","highestDevelopmentStatusID":"6","companyTruncated":"PsyBio Therapeutics \/ Advanced Biofuels"},{"orgOrder":0,"company":"Filament Health","sponsor":"University of British Columbia","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"PEX010","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Filament Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Filament Health \/ University of British Columbia","highestDevelopmentStatusID":"8","companyTruncated":"Filament Health \/ University of British Columbia"},{"orgOrder":0,"company":"Filament Health","sponsor":"University of British Columbia","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"PEX010","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Filament Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Filament Health \/ University of British Columbia","highestDevelopmentStatusID":"8","companyTruncated":"Filament Health \/ University of British Columbia"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocin Analog","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Lobe Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lobe Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lobe Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocin Analog","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Lobe Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lobe Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lobe Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Empyrean Neuroscience","sponsor":"Veteran biotech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series A Financing","leadProduct":"Psilocybin Derivative","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Empyrean Neuroscience","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Empyrean Neuroscience \/ Veteran biotech","highestDevelopmentStatusID":"5","companyTruncated":"Empyrean Neuroscience \/ Veteran biotech"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"MycoMedica Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ MycoMedica Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ MycoMedica Life Sciences"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Avance Clinical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Avance Clinical","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Avance Clinical"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"MindBio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ MindBio Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ MindBio Therapeutics"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RE104","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RE104","moa":"5-HT2A receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Reunion Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RE104","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"SPL026","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"SPL026","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"SPL026","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"TRYP-0082","moa":"5-HT2A receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tryp Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"TRYP-0082","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tryp Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Integrative Research Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"PHILIPPINES","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT2A receptor\/5-HT2C receptor\/5-HT7 receptor\/?2A-AR","graph1":"Neurology","graph2":"Phase II","graph3":"Integrative Research Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integrative Research Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Integrative Research Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"IRLAB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT2A receptor\/5-HT2C receptor\/5-HT7 receptor\/?2A-AR","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Undisclosed"},{"orgOrder":0,"company":"IRLAB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT2A receptor\/5-HT2C receptor\/5-HT7 receptor\/?2A-AR","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Undisclosed"},{"orgOrder":0,"company":"IRLAB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT2A receptor\/5-HT2C receptor\/5-HT7 receptor\/?2A-AR","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IRLAB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Undisclosed"},{"orgOrder":0,"company":"IRLAB","sponsor":"Integrative Research Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT2A receptor\/5-HT2C receptor\/5-HT7 receptor\/?2A-AR","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IRLAB \/ Integrative Research Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Integrative Research Laboratories"},{"orgOrder":0,"company":"IRLAB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT2A receptor\/5-HT2C receptor\/5-HT7 receptor\/?2A-AR","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IRLAB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Undisclosed"},{"orgOrder":0,"company":"IRLAB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT2A receptor\/5-HT2C receptor\/5-HT7 receptor\/?2A-AR","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IRLAB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Undisclosed"},{"orgOrder":0,"company":"IRLAB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT2A receptor\/5-HT2C receptor\/5-HT7 receptor\/?2A-AR","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IRLAB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Undisclosed"},{"orgOrder":0,"company":"IRLAB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT2A receptor\/5-HT2C receptor\/5-HT7 receptor\/?2A-AR","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IRLAB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Undisclosed"},{"orgOrder":0,"company":"IRLAB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT2A receptor\/5-HT2C receptor\/5-HT7 receptor\/?2A-AR","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IRLAB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Undisclosed"},{"orgOrder":0,"company":"Exscientia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"DSP-2342","moa":"5-HT2A\/5-HT7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Undisclosed"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"INP105","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Impel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Impel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"LY03010","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Divestment","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EB-003","moa":"5-HT2A|5-HT1B","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"AnaMar","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AM1476","moa":"5-HT2B receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"AnaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnaMar \/ Covance","highestDevelopmentStatusID":"6","companyTruncated":"AnaMar \/ Covance"},{"orgOrder":0,"company":"AnaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AM1476","moa":"5-HT2B receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AnaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnaMar \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnaMar \/ Undisclosed"},{"orgOrder":0,"company":"AnaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AM1476","moa":"5-HT2B receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AnaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnaMar \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnaMar \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bright Minds Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Liquid","sponsorNew":"Bright Minds Biosciences \/ Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"Bright Minds Biosciences \/ Asset Management"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bright Minds Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Liquid","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Private Placement","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Eight Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Eight Capital","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Eight Capital"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Private Placement","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Firefly Neuroscience","sponsor":"Bright Minds Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Firefly Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Firefly Neuroscience \/ Bright Minds Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Firefly Neuroscience \/ Bright Minds Biosciences"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LP352","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longboard Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"LP352","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longboard Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LP352","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longboard Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LP352","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longboard Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LP352","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longboard Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Association for Research in Otolaryngology","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Association for Research in Otolaryngology","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Association for Research in Otolaryngology"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Cochlear Limited","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Cochlear Limited","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Cochlear Limited"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu SciMount Pharmatech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SMP-100","moa":"5-HT3 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Chengdu SciMount Pharmatech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu SciMount Pharmatech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chengdu SciMount Pharmatech \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu SciMount Pharmatech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SMP-100","moa":"5-HT3 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Chengdu SciMount Pharmatech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu SciMount Pharmatech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chengdu SciMount Pharmatech \/ Undisclosed"},{"orgOrder":0,"company":"Xiling Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SMP-100","moa":"5-HT3 receptor","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Xiling Lab","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Xiling Lab \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Xiling Lab \/ Undisclosed"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Mosapride Citrate","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lunan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lunan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Eunpyeong St. Mary's Hospital","sponsor":"Dong-A ST Co., Ltd. | Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Mosapride Citrate","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Eunpyeong St. Mary's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eunpyeong St. Mary's Hospital \/ Dong-A ST Co., Ltd. | Daewoong Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Eunpyeong St. Mary's Hospital \/ Dong-A ST Co., Ltd. | Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PCS12852","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Processa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Intact Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"PCS12852","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0.46000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.46000000000000002,"dosageForm":"Tablet","sponsorNew":"Processa Pharmaceuticals \/ Intact Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Intact Therapeutics"},{"orgOrder":0,"company":"Rose Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ROSE-010","moa":"5-HT4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rose Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rose Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rose Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SPC-15","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Silo Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Silo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Resyca","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"SPC-15","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Silo Pharma \/ Resyca","highestDevelopmentStatusID":"5","companyTruncated":"Silo Pharma \/ Resyca"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SPC-15","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Silo Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Silo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SPC-15","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silo Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Silo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Frontage Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"SPC-15","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silo Pharma \/ Frontage Laboratories, Inc","highestDevelopmentStatusID":"5","companyTruncated":"Silo Pharma \/ Frontage Laboratories, Inc"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Resyca BV Partner","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"SPC-15","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silo Pharma \/ Resyca BV Partner","highestDevelopmentStatusID":"5","companyTruncated":"Silo Pharma \/ Resyca BV Partner"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SPC-15","moa":"5-HT4 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silo Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Silo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ACM-001.1","moa":"5-HTA1a\/beta-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Actimed Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Actimed Therapeutics \/ Quotient Sciences"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Centre for Human Drug Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-hydroxytryptamine receptor 6; Sigma non-opioid intracellular receptor 1; 5-hydroxytryptamine receptor 2A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Centre for Human Drug Research","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Centre for Human Drug Research"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Universidade Federal do Rio Grande do Norte","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-hydroxytryptamine receptor 6; Sigma non-opioid intracellular receptor 1; 5-hydroxytryptamine receptor 2A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Universidade Federal do Rio Grande do Norte","highestDevelopmentStatusID":"6","companyTruncated":"Biomind Labs \/ Universidade Federal do Rio Grande do Norte"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Atuliflapon","moa":"5-LOX","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Oleclumab","moa":"5'-nucleotidase","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||5'-nucleotidase","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Chiome Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CBA-1535","moa":"5T4","graph1":"Oncology","graph2":"Phase I","graph3":"Chiome Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiome Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chiome Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Imbioray Biomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"IBR854","moa":"5T4","graph1":"Oncology","graph2":"Phase I","graph3":"Imbioray Biomedicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imbioray Biomedicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Imbioray Biomedicine \/ Undisclosed"},{"orgOrder":0,"company":"Imbioray Biomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"IBR854","moa":"5T4","graph1":"Oncology","graph2":"Phase II","graph3":"Imbioray Biomedicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imbioray Biomedicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imbioray Biomedicine \/ Undisclosed"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ASN004","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Asana BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Asana BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Kirilys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"ASN004","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I","graph3":"Kirilys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kirilys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kirilys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"DF7001","moa":"5T4 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dragonfly Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Dragonfly Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"JK06","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"JK06","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Byondis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"SYD1875","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ Undisclosed"},{"orgOrder":0,"company":"Tubulis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"TUB-030","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tubulis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Undisclosed"},{"orgOrder":0,"company":"Tubulis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"TUB-030","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tubulis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Undisclosed"},{"orgOrder":0,"company":"Exelixis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"XB010","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exelixis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Undisclosed"},{"orgOrder":0,"company":"Invenra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||5T4 protein","graph1":"Oncology","graph2":"Phase I","graph3":"Invenra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invenra \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Invenra \/ Undisclosed"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"XB010","moa":"5T4 protein","graph1":"Oncology","graph2":"Discovery","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Exelixis","highestDevelopmentStatusID":"2","companyTruncated":"Catalent Pharma Solutions \/ Exelixis"},{"orgOrder":0,"company":"The Aurum Institute NPC","sponsor":"Ludwig Maximilian University of Munich | Stichting Katholieke Universiteit | Wits Health Consortium | Instituto Nacional de Sa\u00fade, Mozambique | National Institute for Medical Research, Tanzania | University of Stellenbosch | Sequella, Inc. | TB Alliance","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sutezolid","moa":"70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"The Aurum Institute NPC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Aurum Institute NPC \/ Ludwig Maximilian University of Munich | Stichting Katholieke Universiteit | Wits Health Consortium | Instituto Nacional de Sa\u00fade, Mozambique | National Institute for Medical Research, Tanzania | University of Stellenbosch | Sequella, Inc. | TB Alliance","highestDevelopmentStatusID":"9","companyTruncated":"The Aurum Institute NPC \/ Ludwig Maximilian University of Munich | Stichting Katholieke Universiteit | Wits Health Consortium | Instituto Nacional de Sa\u00fade, Mozambique | National Institute for Medical Research, Tanzania | University of Stellenbosch | Sequella, Inc. | TB Alliance"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tobramycin","moa":"||70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tobramycin","moa":"||70S ribosome","graph1":"Immunology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Sonoran Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tobramycin","moa":"||70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sonoran Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoran Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sonoran Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"NICE","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ NICE","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ NICE"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ELX-02","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eloxx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Korro Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Undisclosed"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Korro Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Undisclosed"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Korro Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Undisclosed"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Korro Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Undisclosed"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Korro Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Undisclosed"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Korro Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Undisclosed"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Private Placement","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"Korro Bio \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Deep Track Capital"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Korro Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VX-634","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VX-634","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"VX-814","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Z Factor Limited","sponsor":"Hammersmith Medicines Research | Centessa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ZF874","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Z Factor Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Z Factor Limited \/ Hammersmith Medicines Research | Centessa Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Z Factor Limited \/ Hammersmith Medicines Research | Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Z Factor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ZF874","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Z Factor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Z Factor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Z Factor \/ Undisclosed"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ZF874","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Centessa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"DZD2269","moa":"A2A receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dizal Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dizal Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"DZD2269","moa":"A2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dizal Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dizal Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series B Financing","leadProduct":"EOS-850","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"EOS-850","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"EOS-850","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Minister Of Economy And Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"EOS-850","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ Minister Of Economy And Research","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ Minister Of Economy And Research"},{"orgOrder":0,"company":"Exscientia","sponsor":"Biotrial","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EXS21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Exscientia \/ Biotrial","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Biotrial"},{"orgOrder":0,"company":"Exscientia","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"EXS21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Exscientia \/ Quotient Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Quotient Sciences"},{"orgOrder":0,"company":"Exscientia","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"EXS21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Suspension","sponsorNew":"Exscientia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Undisclosed"},{"orgOrder":0,"company":"Exscientia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EXS21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Exscientia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Undisclosed"},{"orgOrder":0,"company":"Exscientia","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EXS21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Exscientia \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Evotec"},{"orgOrder":0,"company":"Exscientia","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EXS21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Exscientia \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Evotec"},{"orgOrder":0,"company":"Innolake Biopharm","sponsor":"Shanghai East Hospital | Shandong Cancer Hospital and Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ILB2109","moa":"A2aR","graph1":"Oncology","graph2":"Phase I","graph3":"Innolake Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innolake Biopharm \/ Shanghai East Hospital | Shandong Cancer Hospital and Institute","highestDevelopmentStatusID":"6","companyTruncated":"Innolake Biopharm \/ Shanghai East Hospital | Shandong Cancer Hospital and Institute"},{"orgOrder":0,"company":"Innolake Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ILB-2109","moa":"A2aR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innolake Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innolake Biopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innolake Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2021","type":"Licensing Agreement","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.28999999999999998,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Radboud University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Radboud University Medical Center"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Radboud University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Radboud University Medical Center"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AM-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2020","type":"Funding","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Cowen","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Cowen"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AM-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"AM-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Agreement","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"KBI Biopharma \/ AM-Pharma","highestDevelopmentStatusID":"10","companyTruncated":"KBI Biopharma \/ AM-Pharma"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"KW-6356","moa":"A2AR","graph1":"Neurology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KW-6356","moa":"||A2AR","graph1":"Neurology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Recap","moa":"A2AR","graph1":"Undisclosed","graph2":"Phase I","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AM-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Portage Biotech \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Merck & Co"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Portage Biotech \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Portage Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Portage Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Tarus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Portage Biotech \/ Tarus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Tarus Therapeutics"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Portage Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarus Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Tarus Therapeutics \/ Portage Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Tarus Therapeutics \/ Portage Biotech"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TT-10","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Portage Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"5-Methyltetrazole","moa":"A2AR\/BR","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.26000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Domain Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"5-Methyltetrazole","moa":"A2AR\/BR","graph1":"Oncology","graph2":"Phase I","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Adovate","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"ADO-5030","moa":"A2BR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Adial Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Adial Pharmaceuticals \/ Adovate","highestDevelopmentStatusID":"6","companyTruncated":"Adial Pharmaceuticals \/ Adovate"},{"orgOrder":0,"company":"Cancer Research UK","sponsor":"Teon Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research UK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Research UK \/ Teon Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Research UK \/ Teon Therapeutics"},{"orgOrder":0,"company":"Teon Therapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Teon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teon Therapeutics \/ Cancer Research","highestDevelopmentStatusID":"5","companyTruncated":"Teon Therapeutics \/ Cancer Research"},{"orgOrder":0,"company":"Teon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Teon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Teon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Oceanpine Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Oceanpine Capital","highestDevelopmentStatusID":"5","companyTruncated":"Mateon Therapeutics \/ Oceanpine Capital"},{"orgOrder":0,"company":"Cytonics Corporation","sponsor":"Southern Star Research","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"CYT-108","moa":"A2M protease","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Cytonics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytonics Corporation \/ Southern Star Research","highestDevelopmentStatusID":"6","companyTruncated":"Cytonics Corporation \/ Southern Star Research"},{"orgOrder":0,"company":"Cytonics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"CYT-108","moa":"A2M protease","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Cytonics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cytonics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cytonics \/ Undisclosed"},{"orgOrder":0,"company":"Cytonics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"CYT-108","moa":"A2M protease","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Cytonics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cytonics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cytonics \/ Undisclosed"},{"orgOrder":0,"company":"Cytonics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"CYT-108","moa":"A2M protease","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Cytonics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cytonics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cytonics \/ Undisclosed"},{"orgOrder":0,"company":"BioIntervene","sponsor":"MPM Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series A Financing","leadProduct":"BIO-205","moa":"A3AR","graph1":"Neurology","graph2":"Preclinical","graph3":"BioIntervene","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"BioIntervene \/ MPM Capital","highestDevelopmentStatusID":"4","companyTruncated":"BioIntervene \/ MPM Capital"},{"orgOrder":0,"company":"Neumentum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NTM-006","moa":"A3AR","graph1":"Neurology","graph2":"Phase II","graph3":"Neumentum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumentum \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neumentum \/ Undisclosed"},{"orgOrder":0,"company":"Neumentum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NTM-006","moa":"A3AR","graph1":"Neurology","graph2":"Phase II","graph3":"Neumentum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumentum \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neumentum \/ Undisclosed"},{"orgOrder":0,"company":"Jalon Therapeutics","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Financing","leadProduct":"JRT39","moa":"AAC-11","graph1":"Oncology","graph2":"Preclinical","graph3":"Jalon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jalon Therapeutics \/ Bpifrance","highestDevelopmentStatusID":"4","companyTruncated":"Jalon Therapeutics \/ Bpifrance"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adrenas Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AAV BBP-631","moa":"AAV","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Adrenas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adrenas Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adrenas Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Ixo-Vec","moa":"AAV2\/VEGF gene","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"EDIT-103","moa":"AAV5","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Editas Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Editas Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"EDIT-103","moa":"AAV5","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Editas Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Editas Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"EDIT-103","moa":"AAV5","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Editas Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Editas Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Aspa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AAV9 BBP-812","moa":"AAV9","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Aspa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aspa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aspa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Rebisufligene Etisparvovec","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Rebisufligene Etisparvovec","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Rebisufligene Etisparvovec","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Rebisufligene Etisparvovec","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Rebisufligene Etisparvovec","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"UX111","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abeona Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Abeona Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"UX111","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abeona Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Abeona Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Acquisition","leadProduct":"UX111","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abeona Therapeutics \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Abeona Therapeutics \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Lantu Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Vesemnogene Lantuparvovec","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lantu Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantu Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lantu Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Artery Therapeutics, Inc.","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CS6253","moa":"ABCA1","graph1":"Neurology","graph2":"Phase I","graph3":"Artery Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Artery Therapeutics, Inc. \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Artery Therapeutics, Inc. \/ National Institute on Aging"},{"orgOrder":0,"company":"Character Biosciences","sponsor":"aMoon","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Series B Financing","leadProduct":"CTX203","moa":"ABCA1","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Character Biosciences","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Character Biosciences \/ aMoon","highestDevelopmentStatusID":"5","companyTruncated":"Character Biosciences \/ aMoon"},{"orgOrder":0,"company":"AAVantgarde Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"AAVB-039","moa":"ABCA4 protein","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AAVantgarde Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AAVantgarde Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AAVantgarde Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ABCD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ABCD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ABCD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ABCD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ABCD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ABCD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ABCD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ABCD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Undisclosed"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Licensing Agreement","leadProduct":"SAR422459","moa":"ABCR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biomedica \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Biomedica \/ Sanofi"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Soleus Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0.11,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.11,"dosageForm":"Tablet, Film Coated","sponsorNew":"Inhibikase Therapeutics \/ Soleus Capital","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ Soleus Capital"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.28000000000000003,"dosageForm":"Tablet, Film Coated","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ABLi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IKT-001PRO","moa":"ABL\/PDGFR?\/PDGFR?\/c-Kit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ABLi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABLi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABLi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AER-901","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aerami Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ABLi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Risvodetinib","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"ABLi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABLi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABLi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ABLi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Risvodetinib","moa":"ABL1","graph1":"Undisclosed","graph2":"Phase I","graph3":"ABLi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ABLi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ABLi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Thinkequity"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Risvodetinib Succinate","moa":"ABL1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Shionogi","sponsor":"OrsoBio","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"TLC-3595","moa":"ACC2","graph1":"Endocrinology","graph2":"Phase I","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ OrsoBio","highestDevelopmentStatusID":"6","companyTruncated":"Shionogi \/ OrsoBio"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TLC-3595","moa":"ACC2","graph1":"Endocrinology","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Longitude Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series A Financing","leadProduct":"TLC-3595","moa":"ACC2","graph1":"Endocrinology","graph2":"Phase II","graph3":"OrsoBio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"OrsoBio \/ Longitude Capital","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Longitude Capital"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TLC-3595","moa":"ACC2","graph1":"Endocrinology","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TLC-3595","moa":"ACC2","graph1":"Endocrinology","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Alunacedase Alpha","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apeiron Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alunacedase Alpha","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apeiron Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Alunacedase Alpha","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apeiron Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alunacedase Alpha","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apeiron Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alunacedase Alpha","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apeiron Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai IxCell Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Shanghai IxCell Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai IxCell Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai IxCell Biotech \/ Undisclosed"},{"orgOrder":0,"company":"ARTBIO","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Radiolabeled Compound","year":"2023","type":"Series A Financing","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ARTBIO","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"ARTBIO \/ Third Rock Ventures","highestDevelopmentStatusID":"6","companyTruncated":"ARTBIO \/ Third Rock Ventures"},{"orgOrder":0,"company":"ARTBIO","sponsor":"F-Prime Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Radiolabeled Compound","year":"2023","type":"Financing","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ARTBIO","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"ARTBIO \/ F-Prime Capital","highestDevelopmentStatusID":"6","companyTruncated":"ARTBIO \/ F-Prime Capital"},{"orgOrder":0,"company":"ARTBIO","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ARTBIO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARTBIO \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ARTBIO \/ Undisclosed"},{"orgOrder":0,"company":"SpectronRx","sponsor":"ARTBIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Partnership","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"SpectronRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpectronRx \/ ARTBIO","highestDevelopmentStatusID":"6","companyTruncated":"SpectronRx \/ ARTBIO"},{"orgOrder":0,"company":"PharmaLogic","sponsor":"ARTBIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Agreement","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaLogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaLogic \/ ARTBIO","highestDevelopmentStatusID":"6","companyTruncated":"PharmaLogic \/ ARTBIO"},{"orgOrder":0,"company":"Nucleus RadioPharma","sponsor":"ARTBIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Collaboration","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Nucleus RadioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nucleus RadioPharma \/ ARTBIO","highestDevelopmentStatusID":"6","companyTruncated":"Nucleus RadioPharma \/ ARTBIO"},{"orgOrder":0,"company":"Agastiya Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Agastiya Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agastiya Biotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Agastiya Biotech \/ Undisclosed"},{"orgOrder":0,"company":"AKSO Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"AKSO Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AKSO Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"AKSO Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Mabpharm","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"ACE-MAB","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mabpharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabpharm \/ Sorrento Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Mabpharm \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Sinclair Research","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"AnQlar","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sinclair Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinclair Research \/ Virpax Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Sinclair Research \/ Virpax Pharmaceuticals"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"DARPin","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Partners \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Molecular Partners \/ Undisclosed"},{"orgOrder":0,"company":"Asia Cell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Asia Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asia Cell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Asia Cell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Asia Cell Therapeutics","sponsor":"RenJi Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Asia Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asia Cell Therapeutics \/ RenJi Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Asia Cell Therapeutics \/ RenJi Hospital"},{"orgOrder":0,"company":"Asia Cell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Asia Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asia Cell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Asia Cell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LifeCell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"LifeCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LifeCell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LifeCell \/ Undisclosed"},{"orgOrder":0,"company":"CellResearch Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Podiatry","graph2":"Phase I","graph3":"CellResearch Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellResearch Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CellResearch Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Signature Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Signature Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Signature Biologics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Signature Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Sotira","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"KEPTIDE COVID","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sotira","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sotira \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sotira \/ Undisclosed"},{"orgOrder":0,"company":"Yiling Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KT07","moa":"ACE2 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Yiling Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yiling Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Yiling Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Xiamen University","sponsor":"Yiling Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Lianhua Qingwen","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Xiamen University","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xiamen University \/ Yiling Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Xiamen University \/ Yiling Pharmaceutical"},{"orgOrder":0,"company":"Yiling Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Lianhua Qingwen","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Yiling Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yiling Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Yiling Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"LMN-301","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Lumen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lumen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"USAMRDC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Funding","leadProduct":"LMN-301","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lumen Bioscience \/ USAMRDC","highestDevelopmentStatusID":"5","companyTruncated":"Lumen Bioscience \/ USAMRDC"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Carbohydrate","year":"2022","type":"Licensing Agreement","leadProduct":"Quaternary Ammonium Palmitoyl Glycol Chitosan","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nanomerics \/ Virpax Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Nanomerics \/ Virpax Pharmaceuticals"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Carbohydrate","year":"2023","type":"Inapplicable","leadProduct":"Quaternary Ammonium Palmitoyl Glycol Chitosan","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altasciences Company Inc \/ Virpax Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Altasciences Company Inc \/ Virpax Pharmaceuticals"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"STI-1499","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sorrento Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"STI-1499","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sorrento Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"STI-1499","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sorrento Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"STI-1499","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sorrento Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SmartPharm Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"STI-1499","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SmartPharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SmartPharm Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SmartPharm Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Azitra","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series B Financing","leadProduct":"ATR-01","moa":"Acetoacetyl-CoA thiolase (ACAT1)","graph1":"Dermatology","graph2":"Preclinical","graph3":"Azitra","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Azitra \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Azitra \/ Leaps by Bayer"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Acotiamide HCl Hydrate","moa":"Acetylcholinesterase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bright Cloud International","sponsor":"National Institute on Aging | Rutgers, The State University of New Jersey","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Bright Cloud International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bright Cloud International \/ National Institute on Aging | Rutgers, The State University of New Jersey","highestDevelopmentStatusID":"1","companyTruncated":"Bright Cloud International \/ National Institute on Aging | Rutgers, The State University of New Jersey"},{"orgOrder":0,"company":"ICURE PHARM, INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Approved FDF","graph3":"ICURE PHARM, INC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"ICURE PHARM, INC \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ICURE PHARM, INC \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Theranexus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Donepezil","moa":"||Acetylcholinesterase","graph1":"Neurology","graph2":"Phase I","graph3":"Theranexus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theranexus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theranexus \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Donepezil","moa":"||Acetylcholinesterase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VA Connecticut Healthcare System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"VA Connecticut Healthcare System","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Connecticut Healthcare System \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"VA Connecticut Healthcare System \/ Undisclosed"},{"orgOrder":0,"company":"VA Connecticut Healthcare System","sponsor":"Yale University | National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"VA Connecticut Healthcare System","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Connecticut Healthcare System \/ Yale University | National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"9","companyTruncated":"VA Connecticut Healthcare System \/ Yale University | National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Corium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Corium \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Undisclosed"},{"orgOrder":0,"company":"Corium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Corium \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Undisclosed"},{"orgOrder":0,"company":"Corium","sponsor":"Lotus Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Corium \/ Lotus Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Lotus Pharmaceutical"},{"orgOrder":0,"company":"KemPharm","sponsor":"Corium","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"KemPharm \/ Corium","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Corium"},{"orgOrder":0,"company":"Corium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Corium \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Undisclosed"},{"orgOrder":0,"company":"Corium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Corium \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Undisclosed"},{"orgOrder":0,"company":"Corium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corium \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Corium \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Synergy Pharmaceutical Sciences Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Donepezil Dihydroxynaphthalate","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Phase I","graph3":"Shanghai Synergy Pharmaceutical Sciences Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Synergy Pharmaceutical Sciences Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Synergy Pharmaceutical Sciences Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Galantamine Hydrobromide","moa":"Acetylcholinesterase","graph1":"Undisclosed","graph2":"Phase III","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Famous Medical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fordine","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Phase IV","graph3":"Jiangsu Famous Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Famous Medical Technology \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Famous Medical Technology \/ Undisclosed"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"Second Affiliated Hospital, Zhejiang University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fordine","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Phase IV","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"WanBangDe Pharmaceutical \/ Second Affiliated Hospital, Zhejiang University","highestDevelopmentStatusID":"11","companyTruncated":"WanBangDe Pharmaceutical \/ Second Affiliated Hospital, Zhejiang University"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"Ganzhou City People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fordine","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Phase IV","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"WanBangDe Pharmaceutical \/ Ganzhou City People's Hospital","highestDevelopmentStatusID":"11","companyTruncated":"WanBangDe Pharmaceutical \/ Ganzhou City People's Hospital"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"Zhejiang Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fordine","moa":"Acetylcholinesterase","graph1":"Undisclosed","graph2":"Phase I","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"WanBangDe Pharmaceutical \/ Zhejiang Hospital","highestDevelopmentStatusID":"6","companyTruncated":"WanBangDe Pharmaceutical \/ Zhejiang Hospital"},{"orgOrder":0,"company":"WanBangDe Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fordine","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"WanBangDe Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Controlled Release","sponsorNew":"WanBangDe Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"WanBangDe Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University of California, Irvine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Neostigmine","moa":"Acetylcholinesterase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of California, Irvine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of California, Irvine \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Irvine \/ Merck & Co"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Exela Pharma Sciences, LLC.","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Divestment","leadProduct":"Neostigmine Methylsulfate","moa":"Acetylcholinesterase","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Avadel Pharmaceuticals \/ Exela Pharma Sciences, LLC.","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Exela Pharma Sciences, LLC."},{"orgOrder":0,"company":"Endo International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Neostigmine Methylsulfate","moa":"||Acetylcholinesterase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Endo International \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Undisclosed"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"NMD PHARMA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"Acetylcholinesterase","graph1":"Immunology","graph2":"Phase III","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leiden University Medical Center \/ NMD PHARMA","highestDevelopmentStatusID":"10","companyTruncated":"Leiden University Medical Center \/ NMD PHARMA"},{"orgOrder":0,"company":"Acella Pharmaceuticals","sponsor":"Milla Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"Acetylcholinesterase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Acella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Acella Pharmaceuticals \/ Milla Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acella Pharmaceuticals \/ Milla Pharmaceuticals"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Alter Pharma group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"Acetylcholinesterase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Milla Pharmaceuticals \/ Alter Pharma group","highestDevelopmentStatusID":"15","companyTruncated":"Milla Pharmaceuticals \/ Alter Pharma group"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"Acetylcholinesterase","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clesacostat","moa":"Acetyl-CoA carboxylase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Columbia University \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Columbia University \/ Pfizer Inc"},{"orgOrder":0,"company":"Temple University","sponsor":"National Center for Complementary and Integrative Health | Quercegen Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Quercetin","moa":"Acetyl-CoA:lyso-PAF acetyltransferase (PCAT)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Temple University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Temple University \/ National Center for Complementary and Integrative Health | Quercegen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Temple University \/ National Center for Complementary and Integrative Health | Quercegen Pharmaceuticals"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Hugel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Croma-Pharma \/ Hugel","highestDevelopmentStatusID":"8","companyTruncated":"Croma-Pharma \/ Hugel"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":63,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":63,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Urology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Urology","graph2":"Phase II","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"\nSNAP25||ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"\nSNAP25||ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"\nSNAP25||ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"\nSNAP25||ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"\nSNAP25||ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Ipsen"},{"orgOrder":0,"company":"SYMATESE FR 69630 Chaponost","sponsor":"Evolus","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Botulinum toxin type A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SYMATESE FR 69630 Chaponost","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SYMATESE FR 69630 Chaponost \/ Evolus","highestDevelopmentStatusID":"15","companyTruncated":"SYMATESE FR 69630 Chaponost \/ Evolus"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Clinical Testing of Beverly Hills","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Clinical Testing of Beverly Hills","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clinical Testing of Beverly Hills \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"Clinical Testing of Beverly Hills \/ Galderma"},{"orgOrder":0,"company":"Clinical Testing of Beverly Hills","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I","graph3":"Clinical Testing of Beverly Hills","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clinical Testing of Beverly Hills \/ Allergan","highestDevelopmentStatusID":"6","companyTruncated":"Clinical Testing of Beverly Hills \/ Allergan"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Revision Skincare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Revision Skincare","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revision Skincare \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Revision Skincare \/ Undisclosed"},{"orgOrder":0,"company":"RMW Testing","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"RMW Testing","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"RMW Testing \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RMW Testing \/ Undisclosed"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Ipsen","highestDevelopmentStatusID":"11","companyTruncated":"Gabrail Cancer Center Research \/ Ipsen"},{"orgOrder":0,"company":"Chongqing Claruvis Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Chongqing Claruvis Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chongqing Claruvis Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chongqing Claruvis Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Claruvis Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase II","graph3":"Chongqing Claruvis Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chongqing Claruvis Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chongqing Claruvis Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Claruvis Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Chongqing Claruvis Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chongqing Claruvis Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chongqing Claruvis Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Protox Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Protox Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protox Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Protox Inc \/ Undisclosed"},{"orgOrder":0,"company":"Protox Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Protox Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protox Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Protox Inc \/ Undisclosed"},{"orgOrder":0,"company":"Protox Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Protox Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protox Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Protox Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hugel","sponsor":"Sihuan Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Sihuan Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Hugel \/ Sihuan Pharmaceutical"},{"orgOrder":0,"company":"Hugel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hugel \/ Undisclosed"},{"orgOrder":0,"company":"Hugel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hugel \/ Undisclosed"},{"orgOrder":0,"company":"Hugel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hugel \/ Undisclosed"},{"orgOrder":0,"company":"Medytox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Medytox","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medytox \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medytox \/ Undisclosed"},{"orgOrder":0,"company":"Huons Global","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Huons Global","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huons Global \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huons Global \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Merz Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Merz Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase II","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Western University, Canada","sponsor":"Manjog Enterprises Limited","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase IV","graph3":"Western University, Canada","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Western University, Canada \/ Manjog Enterprises Limited","highestDevelopmentStatusID":"11","companyTruncated":"Western University, Canada \/ Manjog Enterprises Limited"},{"orgOrder":0,"company":"University of Calgary","sponsor":"Canadian Academy of Sport and Exercise Medicine (CASEM) | Kinesis Medical Centre Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Calgary \/ Canadian Academy of Sport and Exercise Medicine (CASEM) | Kinesis Medical Centre Inc.","highestDevelopmentStatusID":"1","companyTruncated":"University of Calgary \/ Canadian Academy of Sport and Exercise Medicine (CASEM) | Kinesis Medical Centre Inc."},{"orgOrder":0,"company":"University of Calgary","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ Allergan","highestDevelopmentStatusID":"9","companyTruncated":"University of Calgary \/ Allergan"},{"orgOrder":0,"company":"SUNY Downstate Medical Center","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"SUNY Downstate Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SUNY Downstate Medical Center \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"SUNY Downstate Medical Center \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Dalhousie University","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nova Scotia Health Authority \/ Dalhousie University","highestDevelopmentStatusID":"8","companyTruncated":"Nova Scotia Health Authority \/ Dalhousie University"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Eirion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liniment","sponsorNew":"Eirion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eirion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Merz Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merz Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Immunology","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Allergan","highestDevelopmentStatusID":"6","companyTruncated":"Massachusetts General Hospital \/ Allergan"},{"orgOrder":0,"company":"Espad Pharmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Espad Pharmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Espad Pharmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Espad Pharmed \/ Undisclosed"},{"orgOrder":0,"company":"Vitality Institute Medical Products","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Vitality Institute Medical Products","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vitality Institute Medical Products \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Vitality Institute Medical Products \/ Undisclosed"},{"orgOrder":0,"company":"ATGC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"ATGC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATGC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ATGC \/ Undisclosed"},{"orgOrder":0,"company":"Innopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Innopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innopharm \/ Undisclosed"},{"orgOrder":0,"company":"LKGS_277","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase II","graph3":"LKGS_277","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LKGS_277 \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LKGS_277 \/ Undisclosed"},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"AqubotulinumtoxinA","moa":"ACh receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Aquavit Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aquavit Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Aquavit Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AqubotulinumtoxinA","moa":"ACh receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Aquavit Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aquavit Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Aquavit Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"AqubotulinumtoxinA","moa":"ACh receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Aquavit Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aquavit Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Aquavit Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"EdiGene | The Affiliated Hospital Of Guizhou Medical University | Zunyi Medical College","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ET-01","moa":"ACh receptor","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ EdiGene | The Affiliated Hospital Of Guizhou Medical University | Zunyi Medical College","highestDevelopmentStatusID":"1","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ EdiGene | The Affiliated Hospital Of Guizhou Medical University | Zunyi Medical College"},{"orgOrder":0,"company":"EdiGene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ET-01","moa":"ACh receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EdiGene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EdiGene \/ Undisclosed"},{"orgOrder":0,"company":"EdiGene","sponsor":"923rd Hospital of Joint Logistics Support Force of PLA","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"ET-01","moa":"ACh receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EdiGene \/ 923rd Hospital of Joint Logistics Support Force of PLA","highestDevelopmentStatusID":"6","companyTruncated":"EdiGene \/ 923rd Hospital of Joint Logistics Support Force of PLA"},{"orgOrder":0,"company":"Hugel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Letibotulinumtoxina","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Undisclosed"},{"orgOrder":0,"company":"Hugel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Letibotulinumtoxina","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Undisclosed"},{"orgOrder":0,"company":"Hugel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Letibotulinumtoxina","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Undisclosed"},{"orgOrder":0,"company":"Hugel","sponsor":"Sihuan Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Letibotulinumtoxina","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Sihuan Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Sihuan Pharmaceutical"},{"orgOrder":0,"company":"Chongqing Claruvis Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"YY003","moa":"ACh receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Chongqing Claruvis Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chongqing Claruvis Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chongqing Claruvis Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Urology","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northwell Health \/ Allergan","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ Allergan"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Revance Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Viatris","highestDevelopmentStatusID":"1","companyTruncated":"Revance Therapeutics \/ Viatris"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Neurology","graph2":"Phase IV","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"Beth Israel Deaconess Medical Center \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase I","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IPN59011","moa":"ACh-alpha-1\/beta-1\/delta\/gamma receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE||Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Parexel"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ TFS Trial Form Support","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ TFS Trial Form Support"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Prevail Infoworks","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Prevail Infoworks","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Prevail Infoworks"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ TFS Trial Form Support","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ TFS Trial Form Support"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Thinkequity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Thinkequity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Thinkequity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Canaccord Genuity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ National Institutes of Health"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Thinkequity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Neurology","graph2":"Preclinical","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"ACHE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Annovis Bio \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Annovis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bigespas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dimebon","moa":"ACHE","graph1":"Neurology","graph2":"Phase II","graph3":"Bigespas","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bigespas \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bigespas \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Titan Partners Group LLC","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"China Medical System Holdings Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ China Medical System Holdings Limited","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ China Medical System Holdings Limited"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ The Benchmark Company","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ The Benchmark Company"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Linical","sponsor":"Alpha Cognition","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase I","graph3":"Linical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Linical \/ Alpha Cognition","highestDevelopmentStatusID":"6","companyTruncated":"Linical \/ Alpha Cognition"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"AMRMC","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Cognition \/ AMRMC","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cognition \/ AMRMC"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"NB-02","moa":"AChE","graph1":"Neurology","graph2":"Preclinical","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SipNose","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase I","graph3":"SipNose","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SipNose \/ Noveome Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"SipNose \/ Noveome Biotherapeutics"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Noveome Biotherapeutics \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ IQVIA"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Noveome Biotherapeutics \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ IQVIA"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Noveome Biotherapeutics \/ Parexel","highestDevelopmentStatusID":"7","companyTruncated":"Noveome Biotherapeutics \/ Parexel"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ IQVIA"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Walter Reed Army Institute","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"ST266","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Walter Reed Army Institute","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Biotherapeutics \/ Walter Reed Army Institute"},{"orgOrder":0,"company":"Singota Solutions","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"ST266","moa":"AChE","graph1":"Immunology","graph2":"Preclinical","graph3":"Singota Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Singota Solutions \/ Noveome Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Singota Solutions \/ Noveome Biotherapeutics"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Commonwealth Of Pennsylvania","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"ST266","moa":"AChE","graph1":"Immunology","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Commonwealth Of Pennsylvania","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Biotherapeutics \/ Commonwealth Of Pennsylvania"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Immunology","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stellate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"STL-101","moa":"AChE","graph1":"Neurology","graph2":"Preclinical","graph3":"Stellate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stellate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Stellate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"StrideBio","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Series B Financing","leadProduct":"STRX-310","moa":"AChE","graph1":"Neurology","graph2":"Discovery","graph3":"StrideBio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"StrideBio \/ Northpond Ventures","highestDevelopmentStatusID":"2","companyTruncated":"StrideBio \/ Northpond Ventures"},{"orgOrder":0,"company":"Progreso y Salud Foundation","sponsor":"Amarna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"SVec","moa":"AChE","graph1":"Neurology","graph2":"Undisclosed","graph3":"Progreso y Salud Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Progreso y Salud Foundation \/ Amarna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Progreso y Salud Foundation \/ Amarna Therapeutics"},{"orgOrder":0,"company":"MimiVax","sponsor":"Brain Trust Accelerator Fund Ii","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"Montanide","moa":"||AChE","graph1":"Oncology","graph2":"Phase II","graph3":"MimiVax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MimiVax \/ Brain Trust Accelerator Fund Ii","highestDevelopmentStatusID":"8","companyTruncated":"MimiVax \/ Brain Trust Accelerator Fund Ii"},{"orgOrder":0,"company":"MimiVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"M57-KLH","moa":"||AChE","graph1":"Oncology","graph2":"Phase II","graph3":"MimiVax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MimiVax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MimiVax \/ Undisclosed"},{"orgOrder":0,"company":"MimiVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Montanide","moa":"||AChE","graph1":"Oncology","graph2":"Phase II","graph3":"MimiVax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MimiVax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MimiVax \/ Undisclosed"},{"orgOrder":0,"company":"MimiVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Montanide","moa":"||AChE","graph1":"Oncology","graph2":"Phase II","graph3":"MimiVax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MimiVax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MimiVax \/ Undisclosed"},{"orgOrder":0,"company":"MimiVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Montanide","moa":"||AChE","graph1":"Oncology","graph2":"Phase II","graph3":"MimiVax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MimiVax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MimiVax \/ Undisclosed"},{"orgOrder":0,"company":"MimiVax","sponsor":"UI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Partnership","leadProduct":"SurVaxM","moa":"AChE||Hemocyanin 1 | Baculoviral IAP repeat-containing protein 5","graph1":"Oncology","graph2":"Phase II","graph3":"MimiVax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MimiVax \/ UI Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MimiVax \/ UI Pharmaceuticals"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"T20K","moa":"AChE","graph1":"Neurology","graph2":"Phase I","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyxone AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cyxone AB \/ Undisclosed"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Professor Rikard Holmdahl","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2020","type":"Agreement","leadProduct":"T20K","moa":"AChE","graph1":"Neurology","graph2":"Phase I","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyxone AB \/ Professor Rikard Holmdahl","highestDevelopmentStatusID":"6","companyTruncated":"Cyxone AB \/ Professor Rikard Holmdahl"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"TSHA-105","moa":"AChE","graph1":"Neurology","graph2":"Preclinical","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taysha Gene Therapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Taysha Gene Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"TSHA-105","moa":"AChE","graph1":"Neurology","graph2":"Preclinical","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taysha Gene Therapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Taysha Gene Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Enzyvant","sponsor":"Aceragen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Acquisition","leadProduct":"Recombinant Human Acid Ceramidase","moa":"Acid ceramidase","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Enzyvant","amount2":0.23000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Enzyvant \/ Aceragen","highestDevelopmentStatusID":"5","companyTruncated":"Enzyvant \/ Aceragen"},{"orgOrder":0,"company":"Rediscovery Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Nephrology","graph2":"Phase II","graph3":"Rediscovery Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rediscovery Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rediscovery Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PaxMedica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PaxMedica \/ Undisclosed"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PaxMedica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PaxMedica \/ Undisclosed"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PaxMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Undisclosed"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PaxMedica \/ Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Lind Partners"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Vox Nova","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PaxMedica \/ Vox Nova","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Vox Nova"},{"orgOrder":0,"company":"Rediscovery Life Sciences","sponsor":"PaxMedica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rediscovery Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rediscovery Life Sciences \/ PaxMedica","highestDevelopmentStatusID":"10","companyTruncated":"Rediscovery Life Sciences \/ PaxMedica"},{"orgOrder":0,"company":"Rediscovery Life Sciences","sponsor":"Rex Health Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series B Financing","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Nephrology","graph2":"Phase II","graph3":"Rediscovery Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rediscovery Life Sciences \/ Rex Health Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Rediscovery Life Sciences \/ Rex Health Ventures"},{"orgOrder":0,"company":"PaxMedica","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"PaxMedica \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PaxMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Undisclosed"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PaxMedica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PaxMedica \/ Undisclosed"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PaxMedica \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"PaxMedica \/ Undisclosed"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PaxMedica \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"PaxMedica \/ Undisclosed"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PaxMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Undisclosed"},{"orgOrder":0,"company":"Mitobridge","sponsor":"OrsoBio","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Acquisition","leadProduct":"TLC-065","moa":"ACMSD","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Mitobridge","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitobridge \/ OrsoBio","highestDevelopmentStatusID":"4","companyTruncated":"Mitobridge \/ OrsoBio"},{"orgOrder":0,"company":"Philogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"68-Ga OncoACP3","moa":"ACP3","graph1":"Oncology","graph2":"Phase I","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Philogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Philogen \/ Undisclosed"},{"orgOrder":0,"company":"Philochem","sponsor":"RayzeBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabeled Compound","year":"2025","type":"Licensing Agreement","leadProduct":"68-Ga OncoACP3","moa":"ACP3","graph1":"Oncology","graph2":"Phase I","graph3":"Philochem","amount2":1.3500000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.3500000000000001,"dosageForm":"Injection","sponsorNew":"Philochem \/ RayzeBio","highestDevelopmentStatusID":"6","companyTruncated":"Philochem \/ RayzeBio"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"LX9851","moa":"ACSL5","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Lexicon pharmaceuticals","amount2":1,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"Lexicon pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Lexicon pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lu AG13909","moa":"ACTH receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lu AG13909","moa":"ACTH receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Funding","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Funding","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ BARDA"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Funding","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ BARDA"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Recombinant HUman Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Undisclosed","graph2":"Phase I","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAegis Therapeutics \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Locate Bio","sponsor":"Mercia Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Funding","leadProduct":"rhBMP-2","moa":"Activin receptor type-1 | Bone morphogenetic protein receptor type-1A | Activin receptor type-2B | Bone morphogenetic protein receptor type-2 | Bone morphogenetic protein receptor type-1B | Activin receptor type-2A","graph1":"Neurology","graph2":"Undisclosed","graph3":"Locate Bio","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Locate Bio \/ Mercia Asset Management","highestDevelopmentStatusID":"1","companyTruncated":"Locate Bio \/ Mercia Asset Management"},{"orgOrder":0,"company":"Locate Bio","sponsor":"Mercia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Protein","year":"2024","type":"Funding","leadProduct":"rhBMP-2","moa":"Activin receptor type-1 | Bone morphogenetic protein receptor type-1A | Activin receptor type-2B | Bone morphogenetic protein receptor type-2 | Bone morphogenetic protein receptor type-1B | Activin receptor type-2A","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Preclinical","graph3":"Locate Bio","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Locate Bio \/ Mercia Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Locate Bio \/ Mercia Ventures"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TP-0184","moa":"Activin receptor-like kinase 2 (ALK-2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Supercede Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SPCD-4-79","moa":"Activin type-2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Supercede Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supercede Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Supercede Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"PSI CRO","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"KER-050","moa":"Activin type-2A receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ PSI CRO","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ PSI CRO"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"KER-050","moa":"Activin type-2A receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"KER-050","moa":"Activin type-2A receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"LAE102","moa":"Activin type-2A receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Laekna Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Laekna Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LAE102","moa":"Activin type-2A receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Laekna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LAE102","moa":"Activin type-2A receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Laekna Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ARO-ALK7","moa":"ACVR1C","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-ALK7","moa":"ACVR1C","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ARO-ALK7","moa":"ACVR1C","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Licensing Agreement","leadProduct":"Elritercept","moa":"ACVR2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":1.3,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Elritercept","moa":"ACVR2A","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Elritercept","moa":"ACVR2A","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Elritercept","moa":"ACVR2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Elritercept","moa":"ACVR2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Elritercept","moa":"ACVR2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Elritercept","moa":"ACVR2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Elritercept","moa":"ACVR2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"Elritercept","moa":"ACVR2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":1.3,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Partnership","leadProduct":"Elritercept","moa":"ACVR2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Hansoh Pharma"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Elritercept","moa":"ACVR2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Elritercept","moa":"ACVR2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"KER-012","moa":"ACVR2A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Endocrinology","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"||Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"||Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"Bimagrumab","moa":"||Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":1.9299999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1.9299999999999999,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"Bimagrumab","moa":"||Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":1.9299999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1.9299999999999999,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Versanis Bio","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Versanis Bio","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Versanis Bio"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"ACVR2A | ACVR2B","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Hematology","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase (SCD)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Quotient Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Quotient Sciences"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase (SCD)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Galmed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Virginia Commonwealth University","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Virginia Commonwealth University","highestDevelopmentStatusID":"8","companyTruncated":"Galmed Pharmaceuticals \/ Virginia Commonwealth University"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Virginia Commonwealth University","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Virginia Commonwealth University","highestDevelopmentStatusID":"8","companyTruncated":"Galmed Pharmaceuticals \/ Virginia Commonwealth University"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galmed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galmed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Galmed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Virginia Commonwealth University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galmed Pharmaceuticals \/ Virginia Commonwealth University","highestDevelopmentStatusID":"4","companyTruncated":"Galmed Pharmaceuticals \/ Virginia Commonwealth University"},{"orgOrder":0,"company":"OnKai","sponsor":"Galmed Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Partnership","leadProduct":"Aramchol meglumine","moa":"Acyl-CoA desaturase-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"OnKai","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OnKai \/ Galmed Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"OnKai \/ Galmed Pharmaceuticals"},{"orgOrder":0,"company":"Adanate","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ADA-011","moa":"ADA","graph1":"Oncology","graph2":"Phase I","graph3":"Adanate","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adanate \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adanate \/ Undisclosed"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"DB-1317","moa":"ADAM9","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"M6495","moa":"ADAMTS5","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Merck & Co","amount2":0.53000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.53000000000000003,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LX9211","moa":"Adaptor-associated kinase 1 (AAK1)","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LX9211","moa":"Adaptor-associated kinase 1 (AAK1)","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LX9211","moa":"Adaptor-associated kinase 1 (AAK1)","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SPA - Antibiotic Products","sponsor":"Pharmaceutical Development and Services","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ITALY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clodronic Acid Disodium Salt","moa":"Adenine nucleotide translocator 1 (SLC25A4)","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"SPA - Antibiotic Products","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SPA - Antibiotic Products \/ Pharmaceutical Development and Services","highestDevelopmentStatusID":"9","companyTruncated":"SPA - Antibiotic Products \/ Pharmaceutical Development and Services"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"CYR-064","moa":"Adenosine A1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cyrano Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Neladenoson Bialanate","moa":"Adenosine A1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Neladenoson Bialanate","moa":"Adenosine A1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Palo Biofarma","sponsor":"Scope International AG","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PBF-2897","moa":"Adenosine A1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Palo Biofarma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palo Biofarma \/ Scope International AG","highestDevelopmentStatusID":"8","companyTruncated":"Palo Biofarma \/ Scope International AG"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PNV-5030","moa":"Adenosine A1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AST-004","moa":"Adenosine A1 receptor (ADORA1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Astrocyte Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astrocyte Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Astrocyte Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AST-004","moa":"Adenosine A1 receptor (ADORA1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Astrocyte Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astrocyte Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Astrocyte Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AST-004","moa":"Adenosine A1 receptor (ADORA1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Astrocyte Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astrocyte Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Astrocyte Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Alzheimers Drug Discovery Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"AST-004","moa":"Adenosine A1 receptor (ADORA1)","graph1":"Neurology","graph2":"Preclinical","graph3":"Astrocyte Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Astrocyte Pharmaceuticals \/ Alzheimers Drug Discovery Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Astrocyte Pharmaceuticals \/ Alzheimers Drug Discovery Foundation"},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AST-004","moa":"Adenosine A1 receptor (ADORA1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Astrocyte Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astrocyte Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Astrocyte Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of Virginia School of Medicine","sponsor":"Adial Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"Adenosine A2A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"University of Virginia School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Virginia School of Medicine \/ Adial Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Virginia School of Medicine \/ Adial Pharmaceuticals"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"Adenosine A2A receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adial Pharmaceuticals \/ University of California","highestDevelopmentStatusID":"1","companyTruncated":"Adial Pharmaceuticals \/ University of California"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Wisconsin Medical Cyclotron & Radiopharmacy","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"Adenosine A2A receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adial Pharmaceuticals \/ Wisconsin Medical Cyclotron & Radiopharmacy","highestDevelopmentStatusID":"4","companyTruncated":"Adial Pharmaceuticals \/ Wisconsin Medical Cyclotron & Radiopharmacy"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AZD4635","moa":"Adenosine A2a receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AZD4635","moa":"Adenosine A2a receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Angel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Ciforadenant","moa":"||Adenosine A2a receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"||Adenosine A2a receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"||Adenosine A2a receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"||Adenosine A2a receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"Adenosine A2a receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"||Adenosine A2a receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"Adenosine A2a receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Circadian Therapeutics","sponsor":"Neuroscience Trials Australia","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CT-1500","moa":"Adenosine A2a receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Circadian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Circadian Therapeutics \/ Neuroscience Trials Australia","highestDevelopmentStatusID":"6","companyTruncated":"Circadian Therapeutics \/ Neuroscience Trials Australia"},{"orgOrder":0,"company":"Convalife","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CVL006","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convalife","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Convalife \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Convalife \/ Undisclosed"},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Dutch Government","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Funding","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InteRNA Technologies \/ Dutch Government","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Technologies \/ Dutch Government"},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InteRNA Technologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Technologies \/ Undisclosed"},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InteRNA Technologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Technologies \/ Undisclosed"},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InteRNA Technologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Technologies \/ Undisclosed"},{"orgOrder":0,"company":"InteRNA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InteRNA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA \/ Undisclosed"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Istradefylline","moa":"Adenosine A2a receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Georgetown University \/ Kyowa Kirin","highestDevelopmentStatusID":"11","companyTruncated":"Georgetown University \/ Kyowa Kirin"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Istradefylline","moa":"Adenosine A2a receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Commonwealth University \/ Kyowa Kirin","highestDevelopmentStatusID":"8","companyTruncated":"Virginia Commonwealth University \/ Kyowa Kirin"},{"orgOrder":0,"company":"Marvel Biosciences","sponsor":"iBraiN Institute","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Istradefylline","moa":"Adenosine A2a receptor","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Marvel Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marvel Biosciences \/ iBraiN Institute","highestDevelopmentStatusID":"4","companyTruncated":"Marvel Biosciences \/ iBraiN Institute"},{"orgOrder":0,"company":"GE Healthcare","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"GE Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GE Healthcare \/ Covance","highestDevelopmentStatusID":"7","companyTruncated":"GE Healthcare \/ Covance"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Etrumadenant","moa":"Adenosine A2a receptor | Adenosine A2b receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ Arcus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Weill Medical College of Cornell University \/ Arcus Biosciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Etrumadenant","moa":"Adenosine A2a receptor | Adenosine A2b receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arcus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arcus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Etrumadenant","moa":"Adenosine A2a receptor | Adenosine A2b receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Etrumadenant","moa":"Adenosine A2a receptor | Adenosine A2b receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Etrumadenant","moa":"Adenosine A2a receptor | Adenosine A2b receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TT-4","moa":"Adenosine A2B receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TT-4","moa":"Adenosine A2B receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TT-4","moa":"Adenosine A2B receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Namodenoson","moa":"||Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Chong Kun Dang Pharm","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Chong Kun Dang Pharm","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Chong Kun Dang Pharm"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Ewopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Ewopharma","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Ewopharma"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Namodenoson","moa":"||Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"||Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Ewopharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Ewopharma","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Ewopharma"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Fondazione Telethon","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Fondazione Telethon","highestDevelopmentStatusID":"6","companyTruncated":"Can-Fite BioPharma \/ Fondazione Telethon"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Rabin Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Rabin Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Rabin Medical Center"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Lewis Katz School of Medicine","sponsor":"Can-Fite BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lewis Katz School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lewis Katz School of Medicine \/ Can-Fite BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Lewis Katz School of Medicine \/ Can-Fite BioPharma"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CF602","moa":"Adenosine A3 receptor (ADORA3)","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-101","moa":"Adenosine deaminase (ADA)","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"OTL-101","moa":"Adenosine deaminase (ADA)","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PEGASUS LABORATORIES INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Potassium Bromide","moa":"Adenosine kinase","graph1":"Neurology","graph2":"Approved FDF","graph3":"PEGASUS LABORATORIES INC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"PEGASUS LABORATORIES INC \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PEGASUS LABORATORIES INC \/ Undisclosed"},{"orgOrder":0,"company":"TheiaLife","sponsor":"LifeSci Consulting","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.A.E","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"7-Methylxanthine","moa":"Adenosine receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"TheiaLife","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TheiaLife \/ LifeSci Consulting","highestDevelopmentStatusID":"8","companyTruncated":"TheiaLife \/ LifeSci Consulting"},{"orgOrder":0,"company":"Rashid Latif Medical College","sponsor":"Punjab Institute of Cardology | Himmel Pharmaceutical private limited, Pakistan","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"PAKISTAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Adenosine","moa":"Adenosine receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Rashid Latif Medical College","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rashid Latif Medical College \/ Punjab Institute of Cardology | Himmel Pharmaceutical private limited, Pakistan","highestDevelopmentStatusID":"10","companyTruncated":"Rashid Latif Medical College \/ Punjab Institute of Cardology | Himmel Pharmaceutical private limited, Pakistan"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AK131","moa":"Adenosine receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK131","moa":"Adenosine receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Dietary Supplement","year":"2020","type":"Divestment","leadProduct":"Caffeine","moa":"||Adenosine receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0.82999999999999996,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Hypera Pharma"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Dietary Supplement","year":"2021","type":"Divestment","leadProduct":"Caffeine","moa":"||Adenosine receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0.82999999999999996,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Hypera Pharma"},{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"Groupement Interr\u00e9gional de Recherche Clinique et d'Innovation | Laboratory of excellence DISTALZ | R\u00e9gion Nord-Pas de Calais, France | Meo coffee","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University Hospital, Lille \/ Groupement Interr\u00e9gional de Recherche Clinique et d'Innovation | Laboratory of excellence DISTALZ | R\u00e9gion Nord-Pas de Calais, France | Meo coffee","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Lille \/ Groupement Interr\u00e9gional de Recherche Clinique et d'Innovation | Laboratory of excellence DISTALZ | R\u00e9gion Nord-Pas de Calais, France | Meo coffee"},{"orgOrder":0,"company":"University of Zurich","sponsor":"Lokman Hekim \u00dcniversitesi | Elixir Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Sleep","graph2":"Undisclosed","graph3":"University of Zurich","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Zurich \/ Lokman Hekim \u00dcniversitesi | Elixir Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Zurich \/ Lokman Hekim \u00dcniversitesi | Elixir Pharmaceuticals"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Applied Science & Performance Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Applied Science & Performance Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Science & Performance Institute \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Applied Science & Performance Institute \/ Undisclosed"},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Caffeine","moa":"||Adenosine receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Comera Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Comera Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Comera Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Loxo Oncology Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NICHD Global Network for Women's and Children's Health","sponsor":"KLE Academy of Higher Education and Research, Jawaharlal Nehru Medical College, Belagavi, India | Gates Foundation | University of Virginia | University of Alabama at Birmingham | Thomas Jefferson University | Columbia University | University of Colorado,","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Caffeine Citrate","moa":"Adenosine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"NICHD Global Network for Women's and Children's Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NICHD Global Network for Women's and Children's Health \/ KLE Academy of Higher Education and Research, Jawaharlal Nehru Medical College, Belagavi, India | Gates Foundation | University of Virginia | University of Alabama at Birmingham | Thomas Jefferson University | Columbia University | University of Colorado,","highestDevelopmentStatusID":"10","companyTruncated":"NICHD Global Network for Women's and Children's Health \/ KLE Academy of Higher Education and Research, Jawaharlal Nehru Medical College, Belagavi, India | Gates Foundation | University of Virginia | University of Alabama at Birmingham | Thomas Jefferson University | Columbia University | University of Colorado,"},{"orgOrder":0,"company":"Inspyr Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RT-AR001","moa":"Adenosine receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Inspyr Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inspyr Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Inspyr Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Iteos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Inupadenant","moa":"adenosine receptor antagonists","graph1":"Oncology","graph2":"Phase I","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ iTeos Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Iteos Therapeutics \/ iTeos Therapeutics"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Iteos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Inupadenant","moa":"adenosine receptor antagonists","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ iTeos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Therapeutics \/ iTeos Therapeutics"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Linezolid","moa":"||Adenosine triphosphatase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TB Alliance \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TB Alliance \/ Undisclosed"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Australian Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"Linezolid","moa":"||Adenosine triphosphatase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TB Alliance","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"TB Alliance \/ Australian Government","highestDevelopmentStatusID":"8","companyTruncated":"TB Alliance \/ Australian Government"},{"orgOrder":0,"company":"Allysta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ALY688","moa":"Adiponectin receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Allysta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allysta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Allysta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allysta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ALY688","moa":"Adiponectin receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Allysta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allysta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Allysta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allysta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ALY688","moa":"Adiponectin receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Allysta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allysta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Allysta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"ADM","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adrenomed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed \/ Undisclosed"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"ADM","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adrenomed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed \/ Undisclosed"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"ADM","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adrenomed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed \/ Undisclosed"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"ADM","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adrenomed \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Adrenomed \/ Undisclosed"},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"PENAO Pty Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"PENAO","moa":"||AdNT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aurigene Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aurigene Pharmaceutical Services \/ PENAO Pty Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Aurigene Pharmaceutical Services \/ PENAO Pty Ltd"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PNV-6005","moa":"ADORA2A","graph1":"Immunology","graph2":"Preclinical","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adial Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Adial Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Cell Therapy Group Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Cell Therapy Group Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Cell Therapy Group Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Cell Therapy Group Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Sunkaky Medical Cooperation","sponsor":"Abinopharm Inc | Aba Chemicals Co Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Sunkaky Medical Cooperation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunkaky Medical Cooperation \/ Abinopharm Inc | Aba Chemicals Co Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Sunkaky Medical Cooperation \/ Abinopharm Inc | Aba Chemicals Co Ltd"},{"orgOrder":0,"company":"Seneque SA","sponsor":"CEN Nutriment | Centre d'Expertise de la Performance | LGD","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Seneque SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seneque SA \/ CEN Nutriment | Centre d'Expertise de la Performance | LGD","highestDevelopmentStatusID":"1","companyTruncated":"Seneque SA \/ CEN Nutriment | Centre d'Expertise de la Performance | LGD"},{"orgOrder":0,"company":"Seneque SA","sponsor":"CEN Biotech | LGD","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Seneque SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seneque SA \/ CEN Biotech | LGD","highestDevelopmentStatusID":"1","companyTruncated":"Seneque SA \/ CEN Biotech | LGD"},{"orgOrder":0,"company":"Seneque SA","sponsor":"Dicentra Inc. | LGD","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Seneque SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seneque SA \/ Dicentra Inc. | LGD","highestDevelopmentStatusID":"1","companyTruncated":"Seneque SA \/ Dicentra Inc. | LGD"},{"orgOrder":0,"company":"Abinopharm Inc","sponsor":"Prorelix Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Abinopharm Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abinopharm Inc \/ Prorelix Research","highestDevelopmentStatusID":"1","companyTruncated":"Abinopharm Inc \/ Prorelix Research"},{"orgOrder":0,"company":"TriHealth","sponsor":"DoNotAge.org","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TriHealth","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TriHealth \/ DoNotAge.org","highestDevelopmentStatusID":"1","companyTruncated":"TriHealth \/ DoNotAge.org"},{"orgOrder":0,"company":"Metro International Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Metro International Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metro International Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Metro International Biotech \/ Undisclosed"},{"orgOrder":0,"company":"New York State Psychiatric Institute","sponsor":"BioXcel Therapeutics | Yale University | Clinilabs | National Institute on Drug Abuse | CenExel HRI","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BXCL501","moa":"ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"New York State Psychiatric Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New York State Psychiatric Institute \/ BioXcel Therapeutics | Yale University | Clinilabs | National Institute on Drug Abuse | CenExel HRI","highestDevelopmentStatusID":"7","companyTruncated":"New York State Psychiatric Institute \/ BioXcel Therapeutics | Yale University | Clinilabs | National Institute on Drug Abuse | CenExel HRI"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BXCL501","moa":"ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BXCL501","moa":"ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BXCL501","moa":"ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BXCL501","moa":"ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BXCL501","moa":"ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"6","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BXCL501","moa":"ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BXCL501","moa":"ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Premier Research Group","highestDevelopmentStatusID":"8","companyTruncated":"BioXcel Therapeutics \/ Premier Research Group"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GB-401","moa":"ADRB","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GB-401","moa":"ADRB","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CST-103","moa":"ADRB2","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CuraSen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CST-103","moa":"||ADRB2","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CuraSen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CST-103","moa":"ADRB2","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CuraSen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CST-2032","moa":"ADRB2","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CuraSen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CST-2032","moa":"ADRB2","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CuraSen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CST-107","moa":"||ADRB2","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CuraSen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Sosei Heptares \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Undisclosed"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Sosei Heptares \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Undisclosed"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"University Medical Center Groningen \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Propeller Health","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Propeller Health","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Propeller Health"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Valeo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Valeo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Valeo Pharma"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Vectura Ltd \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Vectura Ltd \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Propeller Health","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Propeller Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule, Powder for Inhalation","sponsorNew":"Propeller Health \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Propeller Health \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Nefecon","moa":"ADRB2","graph1":"Nephrology","graph2":"Phase III","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calliditas Therapeutics AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Calliditas Therapeutics AB \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PT027","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dipivefrin","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Nevakar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ephedrine","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nevakar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nevakar \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nevakar \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nexus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nexus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Nevakar","sponsor":"Par Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nevakar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Nevakar \/ Par Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Nevakar \/ Par Pharmaceutical"},{"orgOrder":0,"company":"Nevakar","sponsor":"Endo International","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nevakar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Nevakar \/ Endo International","highestDevelopmentStatusID":"15","companyTruncated":"Nevakar \/ Endo International"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Endo International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Endo International \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius SE & Co. KGaA \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Undisclosed"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Schreiner MediPharm","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Hormone","year":"2020","type":"Partnership","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Schreiner MediPharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Schreiner MediPharm \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Schreiner MediPharm \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Recordati","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ITALY","productType":"Hormone","year":"2023","type":"Acquisition","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Recordati \/ ARS Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ ARS Pharmaceuticals"},{"orgOrder":0,"company":"Orexo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orexo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Hadassah Medical Organization | Medis | Pharma Medica Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nasus Pharma \/ Hadassah Medical Organization | Medis | Pharma Medica Research","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Hadassah Medical Organization | Medis | Pharma Medica Research"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2025","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Nasus Pharma \/ Laidlaw & Company","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Laidlaw & Company"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Lovelace Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Belhaven Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Belhaven Biopharma \/ Lovelace Biomedical","highestDevelopmentStatusID":"10","companyTruncated":"Belhaven Biopharma \/ Lovelace Biomedical"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Belhaven Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Belhaven Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belhaven Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Belhaven Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Powder","sponsorNew":"Belhaven Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belhaven Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Termination","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adamis Pharmaceuticals \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Sandoz B2B"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"US WorldMeds","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Adamis Pharmaceuticals \/ US WorldMeds","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ US WorldMeds"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"KALEO INC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Hormone","year":"2022","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valeo Pharma \/ KALEO INC","highestDevelopmentStatusID":"15","companyTruncated":"Valeo Pharma \/ KALEO INC"},{"orgOrder":0,"company":"KALEO INC","sponsor":"Pan Canadian Pharmaceutical Alliance","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"KALEO INC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"KALEO INC \/ Pan Canadian Pharmaceutical Alliance","highestDevelopmentStatusID":"15","companyTruncated":"KALEO INC \/ Pan Canadian Pharmaceutical Alliance"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"HLK Pharmacin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ HLK Pharmacin","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ HLK Pharmacin"},{"orgOrder":0,"company":"Windgap Medical","sponsor":"Taiwania Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Series B Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Windgap Medical","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Windgap Medical \/ Taiwania Capital","highestDevelopmentStatusID":"1","companyTruncated":"Windgap Medical \/ Taiwania Capital"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Merger","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Silverback Therapeutics \/ ARS Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Silverback Therapeutics \/ ARS Pharmaceuticals"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"ALK-ABELLO INC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0.46999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.46999999999999997,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ ALK-ABELLO INC","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ ALK-ABELLO INC"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"ALK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ ALK","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ ALK"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurelis","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.20999999999999999,"dosageForm":"Spray","sponsorNew":"Neurelis \/ OrbiMed Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ OrbiMed Advisors"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Series D Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ RA Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ RA Capital Management"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Merger","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Silverback Therapeutics \/ ARS Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Silverback Therapeutics \/ ARS Pharmaceuticals"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"ALK-ABELLO INC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ ALK-ABELLO INC","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ ALK-ABELLO INC"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Seqirus","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharmaceuticals \/ Seqirus"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aptar Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aptar Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptar Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aptar Pharma \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ RTW Investments"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ RTW Investments"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Series A Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Belhaven Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Powder","sponsorNew":"Belhaven Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belhaven Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Signet","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Hormone","year":"2022","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Juno Pharmaceuticals Pty Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Pharmaceuticals Pty Ltd \/ Signet","highestDevelopmentStatusID":"15","companyTruncated":"Juno Pharmaceuticals Pty Ltd \/ Signet"},{"orgOrder":0,"company":"De Motu Cordis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"De Motu Cordis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"De Motu Cordis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"De Motu Cordis \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Grandpharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Epinephrine Bitartrate","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Injection, Pre-Filled","sponsorNew":"ALK \/ Grandpharma","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Grandpharma"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Labetalol Hydrochloride","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"University Hospital Basel","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lys-MDA","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ University Hospital Basel","highestDevelopmentStatusID":"6","companyTruncated":"Mind Medicine \/ University Hospital Basel"},{"orgOrder":0,"company":"NuLiv Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Norepinephrine","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"NuLiv Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NuLiv Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NuLiv Science \/ Undisclosed"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Norepinephrine Bitartrate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GLAND PHARMA LIMITED \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Norepinephrine Bitartrate","moa":"||Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Norepinephrine Bitartrate","moa":"||Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nevakar","sponsor":"Long Grove Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Hormone","year":"2023","type":"Licensing Agreement","leadProduct":"Norepinephrine Bitartrate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nevakar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nevakar \/ Long Grove Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Nevakar \/ Long Grove Pharmaceuticals"},{"orgOrder":0,"company":"Laboratorios Sophia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"MEXICO","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Naphazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Laboratorios Sophia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Sophia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Laboratorios Sophia \/ Undisclosed"},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"APR Applied Pharma Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"APR Applied Pharma Research \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"APR Applied Pharma Research \/ Undisclosed"},{"orgOrder":0,"company":"Centurion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TURKEY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Centurion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centurion Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centurion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | US Department of Veterans Affairs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | US Department of Veterans Affairs","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | US Department of Veterans Affairs"},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophore India Pharmaceuticals Pvt Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophore India Pharmaceuticals Pvt Ltd \/ Undisclosed"},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"APR Applied Pharma Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"APR Applied Pharma Research \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"APR Applied Pharma Research \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Advita","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Advita","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Advita"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"APR Applied Pharma Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"APR Applied Pharma Research \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"APR Applied Pharma Research \/ Undisclosed"},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"APR Applied Pharma Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"APR Applied Pharma Research \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"APR Applied Pharma Research \/ Undisclosed"},{"orgOrder":0,"company":"UCI Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"UCI Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCI Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"UCI Health \/ Undisclosed"},{"orgOrder":0,"company":"Senator Richard Lugar Research Institute","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Senator Richard Lugar Research Institute","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Senator Richard Lugar Research Institute \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Senator Richard Lugar Research Institute \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Neurorx","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Neurorx","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Neurorx"},{"orgOrder":0,"company":"Mannkind","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Partnership","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mannkind \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Mannkind \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ University of California","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ University of California"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"||Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"||Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"||Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"ALS Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ ALS Foundation","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ ALS Foundation"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"IQVIA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ IQVIA"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"||Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"||Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Denk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Denk Pharma","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Denk Pharma"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"||Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Quantum Leap Healthcare \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Advita","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Advita","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.050000000000000003,"dosageForm":"Inhalation","sponsorNew":"Advita \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Advita \/ Relief Therapeutics"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"RVL Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.089999999999999997,"dosageForm":"Solution","sponsorNew":"Santen Pharmaceutical \/ RVL Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ RVL Pharmaceuticals"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Haleon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Haleon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haleon \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Haleon \/ Undisclosed"},{"orgOrder":0,"company":"Levation Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Levation Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Levation Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Levation Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Undisclosed","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"EPI Health","sponsor":"Novan","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Cream","sponsorNew":"EPI Health \/ Novan","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ Novan"},{"orgOrder":0,"company":"EPI Health","sponsor":"Sato Yakuhin Kogyo Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"EPI Health \/ Sato Yakuhin Kogyo Co., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ Sato Yakuhin Kogyo Co., Ltd"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Athyrium Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Athyrium Capital","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Athyrium Capital"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RVL Pharmaceuticals","sponsor":"Athyrium Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Private Placement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"RVL Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"RVL Pharmaceuticals \/ Athyrium Capital","highestDevelopmentStatusID":"15","companyTruncated":"RVL Pharmaceuticals \/ Athyrium Capital"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Alora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Divestment","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.17000000000000001,"dosageForm":"Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Alora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Alora Pharmaceuticals"},{"orgOrder":0,"company":"Revision Skincare","sponsor":"RVL Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Revision Skincare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Revision Skincare \/ RVL Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Revision Skincare \/ RVL Pharmaceuticals"},{"orgOrder":0,"company":"Telethon Kids Institute","sponsor":"Child and Adolescent Health Service - Perth | Sao Paulo Clinical Hospital - SP | Rigshospitalet","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Telethon Kids Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Telethon Kids Institute \/ Child and Adolescent Health Service - Perth | Sao Paulo Clinical Hospital - SP | Rigshospitalet","highestDevelopmentStatusID":"11","companyTruncated":"Telethon Kids Institute \/ Child and Adolescent Health Service - Perth | Sao Paulo Clinical Hospital - SP | Rigshospitalet"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Viatris"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"FamyGen Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ FamyGen Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ FamyGen Life Sciences"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"American Society of Ophthalmic Administrator","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ American Society of Ophthalmic Administrator","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ American Society of Ophthalmic Administrator"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"||Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"||Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"||Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Viatris"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Opus Genetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Opus Genetics \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Oculos Development Services","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Oculos Development Services","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Oculos Development Services"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Opus Genetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Opus Genetics \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Rexahn Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Rexahn Pharmaceuticals Inc","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Rexahn Pharmaceuticals Inc"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"||Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"||Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"||Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Pharma Nueva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"THAILAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Alfuzosin HCl","moa":"Adrenergic receptor alpha-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharma Nueva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharma Nueva \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharma Nueva \/ Undisclosed"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Alzheimers Drug Discovery Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"CST-3056","moa":"Adrenergic-alpha-1A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"CuraSen Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"CuraSen Therapeutics \/ Alzheimers Drug Discovery Foundation","highestDevelopmentStatusID":"4","companyTruncated":"CuraSen Therapeutics \/ Alzheimers Drug Discovery Foundation"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CST-3056","moa":"Adrenergic-alpha-1A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CuraSen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CuraSen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CST-3056","moa":"Adrenergic receptor alpha-1","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CuraSen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Midodrine","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Midodrine","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"University of Alberta","sponsor":"Alberta Health services | Institute of Health Economics, Canada","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Midodrine","moa":"Adrenergic receptor alpha-1","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alberta \/ Alberta Health services | Institute of Health Economics, Canada","highestDevelopmentStatusID":"11","companyTruncated":"University of Alberta \/ Alberta Health services | Institute of Health Economics, Canada"},{"orgOrder":0,"company":"University of Alberta","sponsor":"University Hospital Foundation | Institute of Health Economics, Canada | Alberta Health services","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Midodrine","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alberta \/ University Hospital Foundation | Institute of Health Economics, Canada | Alberta Health services","highestDevelopmentStatusID":"11","companyTruncated":"University of Alberta \/ University Hospital Foundation | Institute of Health Economics, Canada | Alberta Health services"},{"orgOrder":0,"company":"University of Florida","sponsor":"Omeros","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Neurology","graph2":"Phase IV","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Florida \/ Omeros","highestDevelopmentStatusID":"11","companyTruncated":"University of Florida \/ Omeros"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Texas Health Resources","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UT Southwestern Medical Center \/ Texas Health Resources","highestDevelopmentStatusID":"6","companyTruncated":"UT Southwestern Medical Center \/ Texas Health Resources"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Immunology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Xellia Pharmaceuticals ApS","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Xellia Pharmaceuticals ApS","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Xellia Pharmaceuticals ApS"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner Surgical Group Limited","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor alpha-1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Omeros","amount2":1,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":1,"dosageForm":"Solution","sponsorNew":"Omeros \/ Rayner Surgical Group Limited","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner Surgical Group Limited"},{"orgOrder":0,"company":"Omeros","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor alpha-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Omeros","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.19,"dosageForm":"Solution","sponsorNew":"Omeros \/ DRI Healthcare Trust","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor alpha-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eyenovia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Undisclosed"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor alpha-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eyenovia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Undisclosed"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor alpha-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eyenovia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Undisclosed"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Chardan Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor alpha-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eyenovia \/ Chardan Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Chardan Healthcare"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor alpha-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eyenovia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Undisclosed"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor alpha-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eyenovia \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Avenue Venture Opportunities Fund"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor alpha-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eyenovia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Undisclosed"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor alpha-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eyenovia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor alpha-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Omeros","amount2":1.3300000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":1.3300000000000001,"dosageForm":"Solution\/Drops","sponsorNew":"Omeros \/ Rayner","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor alpha-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Omeros","amount2":1.3300000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":1.3300000000000001,"dosageForm":"Solution\/Drops","sponsorNew":"Omeros \/ Rayner","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor alpha-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Omeros","amount2":1.3300000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":1.3300000000000001,"dosageForm":"Solution\/Drops","sponsorNew":"Omeros \/ Rayner","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Undisclosed"},{"orgOrder":0,"company":"VA Puget Sound Health Care System","sponsor":"University of Washington | VA Mental Illness Research, Education and Clinical Centers","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"VA Puget Sound Health Care System","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Puget Sound Health Care System \/ University of Washington | VA Mental Illness Research, Education and Clinical Centers","highestDevelopmentStatusID":"11","companyTruncated":"VA Puget Sound Health Care System \/ University of Washington | VA Mental Illness Research, Education and Clinical Centers"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Xintian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Silodosin","moa":"Alpha-1a adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Xintian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xintian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Xintian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Silodosin","moa":"||Alpha-1a adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Huilun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Silodosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Shanghai Huilun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Huilun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Huilun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"PAKISTAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cipla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"||Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cipla \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Undisclosed"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"||Adrenergic receptor alpha-1","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Berlin Chemie \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Berlin Chemie \/ Undisclosed"},{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Berlin Chemie \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Berlin Chemie \/ Undisclosed"},{"orgOrder":0,"company":"TriHealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Undisclosed","graph2":"Phase III","graph3":"TriHealth","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"TriHealth \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TriHealth \/ Undisclosed"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase III","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Endeavor Health \/ Undisclosed"},{"orgOrder":0,"company":"NeoTract, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase IV","graph3":"NeoTract, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeoTract, Inc. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NeoTract, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"University of Massachusetts, Worcester","sponsor":"UMass Memorial Health","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"University of Massachusetts, Worcester","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Massachusetts, Worcester \/ UMass Memorial Health","highestDevelopmentStatusID":"11","companyTruncated":"University of Massachusetts, Worcester \/ UMass Memorial Health"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Apraclonidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tarian Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase II","graph3":"Tarian Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Tarian Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tarian Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CHA University","sponsor":"Hanlim Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"CHA University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CHA University \/ Hanlim Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"CHA University \/ Hanlim Pharmaceutical"},{"orgOrder":0,"company":"CHA University","sponsor":"Hanlim Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"CHA University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CHA University \/ Hanlim Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"CHA University \/ Hanlim Pharmaceutical"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Zhaoke Ophthalmology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zhaoke Ophthalmology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhaoke Ophthalmology \/ Undisclosed"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"||Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"||Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tenpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Tenpoint Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tenpoint Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tarian Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Dermatology","graph2":"Phase II","graph3":"Tarian Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Tarian Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tarian Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"||Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Visiox Pharma","sponsor":"Founding Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visiox Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Visiox Pharma \/ Founding Partners","highestDevelopmentStatusID":"10","companyTruncated":"Visiox Pharma \/ Founding Partners"},{"orgOrder":0,"company":"Visiox Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visiox Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Visiox Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Visiox Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocugen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Immunology","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocugen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Undisclosed"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Slayback Pharma \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Slayback Pharma \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Slayback Pharma \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Slayback Pharma \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"||Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Apotex Fermentation Inc. \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Fermentation Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Visus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Visus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Visus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"Clonidine","moa":"||Adrenergic receptor alpha-2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ European Investment Bank"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Clonidine","moa":"||Adrenergic receptor alpha-2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioSenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clonidine","moa":"||Adrenergic receptor alpha-2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioSenic \/ Undisclosed"},{"orgOrder":0,"company":"BioSenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioSenic \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sollis Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"Sollis Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sollis Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sollis Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Sabal Therapeutics","sponsor":"Athena Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sabal Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Sabal Therapeutics \/ Athena Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"Sabal Therapeutics \/ Athena Bioscience"},{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Athena Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Athena Bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Athena Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Undisclosed"},{"orgOrder":0,"company":"Las Vegas Medical Research, LLC DBA Vector Clinical Trials","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Las Vegas Medical Research, LLC DBA Vector Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Las Vegas Medical Research, LLC DBA Vector Clinical Trials \/ Tris Pharma Inc","highestDevelopmentStatusID":"11","companyTruncated":"Las Vegas Medical Research, LLC DBA Vector Clinical Trials \/ Tris Pharma Inc"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Monopar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Harbin Medical University","sponsor":"Yangtze River Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Harbin Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Harbin Medical University \/ Yangtze River Pharmaceutical Group","highestDevelopmentStatusID":"1","companyTruncated":"Harbin Medical University \/ Yangtze River Pharmaceutical Group"},{"orgOrder":0,"company":"Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.","sponsor":"Shenzhen People's Hospital | Dongyuan People's Hospital | Kunming Children's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Undisclosed","graph3":"Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd. \/ Shenzhen People's Hospital | Dongyuan People's Hospital | Kunming Children's Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd. \/ Shenzhen People's Hospital | Dongyuan People's Hospital | Kunming Children's Hospital"},{"orgOrder":0,"company":"Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.","sponsor":"Zhongshan Hospital of Traditional Chinese Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Undisclosed","graph3":"Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd. \/ Zhongshan Hospital of Traditional Chinese Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd. \/ Zhongshan Hospital of Traditional Chinese Medicine"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"GCS Ramsay Sant\u00e9","sponsor":"Euraxi Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase IV","graph3":"GCS Ramsay Sant\u00e9","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GCS Ramsay Sant\u00e9 \/ Euraxi Pharma","highestDevelopmentStatusID":"11","companyTruncated":"GCS Ramsay Sant\u00e9 \/ Euraxi Pharma"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Undisclosed"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Undisclosed"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Undisclosed","graph2":"Phase III","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Undisclosed"},{"orgOrder":0,"company":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","sponsor":"Canadian Critical Care Trials Group","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal \/ Canadian Critical Care Trials Group","highestDevelopmentStatusID":"9","companyTruncated":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal \/ Canadian Critical Care Trials Group"},{"orgOrder":0,"company":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","sponsor":"US Department of Defense | Congressionally Directed Medical Research Programs | RTI International | VA Connecticut Healthcare System | BioXcel Therapeutics | Yale University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance \/ US Department of Defense | Congressionally Directed Medical Research Programs | RTI International | VA Connecticut Healthcare System | BioXcel Therapeutics | Yale University","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance \/ US Department of Defense | Congressionally Directed Medical Research Programs | RTI International | VA Connecticut Healthcare System | BioXcel Therapeutics | Yale University"},{"orgOrder":0,"company":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","sponsor":"US Department of Defense | Congressionally Directed Medical Research Programs | VA Connecticut Healthcare System | BioXcel Therapeutics | Yale University | RTI International","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance \/ US Department of Defense | Congressionally Directed Medical Research Programs | VA Connecticut Healthcare System | BioXcel Therapeutics | Yale University | RTI International","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance \/ US Department of Defense | Congressionally Directed Medical Research Programs | VA Connecticut Healthcare System | BioXcel Therapeutics | Yale University | RTI International"},{"orgOrder":0,"company":"Temple University","sponsor":"BioXcel Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Temple University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Temple University \/ BioXcel Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Temple University \/ BioXcel Therapeutics"},{"orgOrder":0,"company":"Vanderbilt University Medical Center","sponsor":"Pfizer Inc | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"Vanderbilt University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vanderbilt University Medical Center \/ Pfizer Inc | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"10","companyTruncated":"Vanderbilt University Medical Center \/ Pfizer Inc | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Lotus Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Lotus Clinical Research","highestDevelopmentStatusID":"11","companyTruncated":"BioXcel Therapeutics \/ Lotus Clinical Research"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Lone Baandrup","sponsor":"Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital | Capital Region Pharmacy, Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Lone Baandrup","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lone Baandrup \/ Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital | Capital Region Pharmacy, Denmark","highestDevelopmentStatusID":"9","companyTruncated":"Lone Baandrup \/ Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital | Capital Region Pharmacy, Denmark"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Egymedicalpedia \/ Undisclosed"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Egymedicalpedia \/ Undisclosed"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Undisclosed","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aurobindo Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Undisclosed","graph2":"Phase III","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"A.forall","sponsor":"Sagent Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"A.forall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"A.forall \/ Sagent Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"A.forall \/ Sagent Pharmaceuticals"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"London Health Sciences Centre | University Health Network, Toronto | McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase IV","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sunnybrook Health Sciences Centre \/ London Health Sciences Centre | University Health Network, Toronto | McMaster University","highestDevelopmentStatusID":"11","companyTruncated":"Sunnybrook Health Sciences Centre \/ London Health Sciences Centre | University Health Network, Toronto | McMaster University"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Rodman & Renshaw LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Rodman & Renshaw LLC","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Rodman & Renshaw LLC"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Termination","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Oaktree Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.13,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Oaktree Capital","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Oaktree Capital"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Milla Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Milla Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioXcel Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Avenacy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avenacy \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Undisclosed"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Azurity Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Slayback Pharma \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Slayback Pharma \/ Azurity Pharma"},{"orgOrder":0,"company":"Vizient","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Undisclosed","graph3":"Vizient","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vizient \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Vizient \/ Pfizer Inc"},{"orgOrder":0,"company":"Teikoku Pharma USA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase II","graph3":"Teikoku Pharma USA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Teikoku Pharma USA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Teikoku Pharma USA \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Xinchen Wang","sponsor":"Tibet Autonomous Region People\u2019s Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Xinchen Wang","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xinchen Wang \/ Tibet Autonomous Region People\u2019s Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Xinchen Wang \/ Tibet Autonomous Region People\u2019s Hospital"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Idazoxan","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Terran Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Terran Biosciences"},{"orgOrder":0,"company":"ImmuneMed, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ImmuneMed, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneMed, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ImmuneMed, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indoco Remedies Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Undisclosed"},{"orgOrder":0,"company":"Federal Emergency Management Agency","sponsor":"US WorldMeds","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Federal Emergency Management Agency","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Federal Emergency Management Agency \/ US WorldMeds","highestDevelopmentStatusID":"15","companyTruncated":"Federal Emergency Management Agency \/ US WorldMeds"},{"orgOrder":0,"company":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","sponsor":"US Department of Defense | RTI International | Michael E. DeBakey VA Medical Center | US WorldMeds | Foundation for Advancing Veterans' Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance \/ US Department of Defense | RTI International | Michael E. DeBakey VA Medical Center | US WorldMeds | Foundation for Advancing Veterans' Health Research","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance \/ US Department of Defense | RTI International | Michael E. DeBakey VA Medical Center | US WorldMeds | Foundation for Advancing Veterans' Health Research"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"US WorldMeds \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"US WorldMeds \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"US WorldMeds \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"US WorldMeds \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"IM Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Methyldopa","moa":"Adrenergic receptor alpha-2","graph1":"Endocrinology","graph2":"Phase I","graph3":"IM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IM Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IM Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"IM Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Methyldopa","moa":"Adrenergic receptor alpha-2","graph1":"Endocrinology","graph2":"Phase I","graph3":"IM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IM Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IM Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImmunoMolecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Methyldopa","moa":"Adrenergic receptor alpha-2","graph1":"Endocrinology","graph2":"Phase I","graph3":"ImmunoMolecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ImmunoMolecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoMolecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tizanidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Urology","graph2":"Phase III","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Endeavor Health \/ Undisclosed"},{"orgOrder":0,"company":"Second Affiliated Hospital, Zhejiang University","sponsor":"Credit Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tizanidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase III","graph3":"Second Affiliated Hospital, Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Second Affiliated Hospital, Zhejiang University \/ Credit Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Second Affiliated Hospital, Zhejiang University \/ Credit Pharmaceutical"},{"orgOrder":0,"company":"Delpor","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Tizanidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Delpor","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Implant","sponsorNew":"Delpor \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Delpor \/ National Institutes of Health"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"GCS Ramsay Sant\u00e9","sponsor":"Euraxi Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Neurology","graph2":"Phase II","graph3":"GCS Ramsay Sant\u00e9","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GCS Ramsay Sant\u00e9 \/ Euraxi Pharma","highestDevelopmentStatusID":"8","companyTruncated":"GCS Ramsay Sant\u00e9 \/ Euraxi Pharma"},{"orgOrder":0,"company":"University of Galway","sponsor":"Health Research Board, Ireland","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Galway","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Galway \/ Health Research Board, Ireland","highestDevelopmentStatusID":"8","companyTruncated":"University of Galway \/ Health Research Board, Ireland"},{"orgOrder":0,"company":"Cambridge University Hospitals NHS Foundation Trust","sponsor":"Antaros Medical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Cambridge University Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cambridge University Hospitals NHS Foundation Trust \/ Antaros Medical","highestDevelopmentStatusID":"11","companyTruncated":"Cambridge University Hospitals NHS Foundation Trust \/ Antaros Medical"},{"orgOrder":0,"company":"Norgine","sponsor":"Goldman Sachs Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Financing","leadProduct":"Sodium Chloride","moa":"||Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Norgine \/ Goldman Sachs Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Goldman Sachs Asset Management"},{"orgOrder":0,"company":"Attgeno","sponsor":"Vinnova","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Attgeno","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Attgeno \/ Vinnova","highestDevelopmentStatusID":"7","companyTruncated":"Attgeno \/ Vinnova"},{"orgOrder":0,"company":"Agitated Solutions","sponsor":"Bright Research Partners","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Undisclosed","graph2":"Phase III","graph3":"Agitated Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agitated Solutions \/ Bright Research Partners","highestDevelopmentStatusID":"10","companyTruncated":"Agitated Solutions \/ Bright Research Partners"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Entrinsic bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"||Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Entrinsic bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Entrinsic bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Entrinsic bioscience \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jeffrey Alan Klein","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Jeffrey Alan Klein","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jeffrey Alan Klein \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jeffrey Alan Klein \/ Undisclosed"},{"orgOrder":0,"company":"Suzana Erico Tanni Minamoto","sponsor":"Liita Care ApS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Suzana Erico Tanni Minamoto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Suzana Erico Tanni Minamoto \/ Liita Care ApS","highestDevelopmentStatusID":"8","companyTruncated":"Suzana Erico Tanni Minamoto \/ Liita Care ApS"},{"orgOrder":0,"company":"Avenacy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Isoproterenol HCl","moa":"Adrenergic receptor beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenacy \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Undisclosed"},{"orgOrder":0,"company":"Asan Medical Center","sponsor":"Chong Kun Dang Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Carvedilol","moa":"Adrenergic receptor beta | Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Asan Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asan Medical Center \/ Chong Kun Dang Pharm","highestDevelopmentStatusID":"10","companyTruncated":"Asan Medical Center \/ Chong Kun Dang Pharm"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"APD418","moa":"Adrenergic receptor beta-3 (ADRB3)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"APD418","moa":"Adrenergic receptor beta-3 (ADRB3)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"McQuade Center","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"BRAZIL","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"ACH000029","moa":"Adrenergic-alpha-1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ McQuade Center","highestDevelopmentStatusID":"4","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ McQuade Center"},{"orgOrder":0,"company":"Levation Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LEV102","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Levation Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Levation Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Levation Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Whitecap Biosciences","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"WB007","moa":"Adrenergic-alpha-1 receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Whitecap Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Whitecap Biosciences \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"7","companyTruncated":"Whitecap Biosciences \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BR9006-1","moa":"Adrenergic-alpha-1A receptor","graph1":"Urology","graph2":"Phase I","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"FELIQS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"FLQ-101","moa":"ADRA2","graph1":"Ophthalmology","graph2":"Phase I","graph3":"FELIQS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FELIQS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"FELIQS \/ Undisclosed"},{"orgOrder":0,"company":"FELIQS","sponsor":"Beyond Next Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"FLQ-101","moa":"Adrenergic-alpha-2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"FELIQS","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"FELIQS \/ Beyond Next Ventures","highestDevelopmentStatusID":"6","companyTruncated":"FELIQS \/ Beyond Next Ventures"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Nordic Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"JTA-004","moa":"Adrenergic-alpha-2 receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Nordic Bioscience","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Nordic Bioscience"},{"orgOrder":0,"company":"ImmunoMolecular Therapeutics","sponsor":"WCCT Global","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IMT-002","moa":"Adrenergic-alpha-2A receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"ImmunoMolecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ImmunoMolecular Therapeutics \/ WCCT Global","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoMolecular Therapeutics \/ WCCT Global"},{"orgOrder":0,"company":"Genuine Research Center, Egypt","sponsor":"Nerhadou International","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"EGYPT","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nerkardou","moa":"Adrenergic-beta-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Genuine Research Center, Egypt","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Genuine Research Center, Egypt \/ Nerhadou International","highestDevelopmentStatusID":"11","companyTruncated":"Genuine Research Center, Egypt \/ Nerhadou International"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BAY1097761","moa":"Adrenomedullin (ADM)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Georgetown University \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Georgetown University \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"||Advanced glycosylation end product-specific receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Georgetown University \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Baptist Health","sponsor":"Miami Cancer Institute | Cantex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baptist Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baptist Health \/ Miami Cancer Institute | Cantex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Baptist Health \/ Miami Cancer Institute | Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Medpace, Inc"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Miami Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Miami Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Miami Cancer Institute"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Michigan Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Michigan Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Cantex Pharmaceuticals \/ Michigan Medicine"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Michigan Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Michigan Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Cantex Pharmaceuticals \/ Michigan Medicine"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Lenox Hill Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Lenox Hill Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Lenox Hill Hospital"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"vTv Therapeutics \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"vTv Therapeutics \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Harvard University","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cantex Pharmaceuticals \/ Harvard University","highestDevelopmentStatusID":"6","companyTruncated":"Cantex Pharmaceuticals \/ Harvard University"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Aro-Rage","moa":"Advanced glycosylation end product-specific receptor messenger RNA (AGER mRNA)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Aro-Rage","moa":"Advanced glycosylation end product-specific receptor messenger RNA (AGER mRNA)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-RAGE","moa":"Advanced glycosylation end product-specific receptor messenger RNA (AGER mRNA)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARO-RAGE","moa":"Advanced glycosylation end product-specific receptor messenger RNA (AGER mRNA)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-RAGE","moa":"Advanced glycosylation end product-specific receptor messenger RNA (AGER mRNA)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"HRS-9563","moa":"AGT","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1||Angiotensin II type-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Orphan Reach","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1||Angiotensin II type-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Orphan Reach","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Orphan Reach"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"SGS Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1||Angiotensin II type-2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vicore Pharma \/ SGS Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ SGS Life Sciences"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Orphan Reach","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1||Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vicore Pharma \/ Orphan Reach","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Orphan Reach"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1||Angiotensin II type-2 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vicore Pharma \/ CTC Clinical Trial Consultants","highestDevelopmentStatusID":"6","companyTruncated":"Vicore Pharma \/ CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1||Angiotensin II type-2 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Population Services International","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Population Services International","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Population Services International"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Orphan Reach","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Orphan Reach","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Orphan Reach"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Talfirastide","moa":"AGTR1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Constant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Constant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Talfirastide","moa":"AGTR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Constant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Constant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"AllianThera Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"YUQA-1007","moa":"AHR","graph1":"Immunology","graph2":"Phase I","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Falk Pharma \/ AllianThera Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Falk Pharma \/ AllianThera Biopharma"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IDE-161","moa":"AKR1C3","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"DermBiont","sponsor":"Zepeda Dermatologia","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SM-020","moa":"AKT","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Zepeda Dermatologia","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Zepeda Dermatologia"},{"orgOrder":0,"company":"DermBiont","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SM-020","moa":"AKT","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Undisclosed"},{"orgOrder":0,"company":"DermBiont","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SM-020","moa":"AKT","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Undisclosed"},{"orgOrder":0,"company":"DermBiont","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SM-020","moa":"AKT","graph1":"Oncology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Undisclosed"},{"orgOrder":0,"company":"DermBiont","sponsor":"Double Point Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"SM-020","moa":"AKT","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Double Point Ventures","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Double Point Ventures"},{"orgOrder":0,"company":"DermBiont","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SM-020","moa":"AKT","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Undisclosed"},{"orgOrder":0,"company":"DermBiont","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SM-020","moa":"AKT","graph1":"Oncology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DermBiont \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Undisclosed"},{"orgOrder":0,"company":"Vaderis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VAD044","moa":"AKT kinase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vaderis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vaderis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vaderis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vaderis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VAD044","moa":"AKT kinase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vaderis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vaderis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vaderis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vaderis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VAD044","moa":"AKT kinase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vaderis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vaderis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vaderis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vaderis Therapeutics","sponsor":"Medicxi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VAD044","moa":"AKT kinase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vaderis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vaderis Therapeutics \/ Medicxi","highestDevelopmentStatusID":"7","companyTruncated":"Vaderis Therapeutics \/ Medicxi"},{"orgOrder":0,"company":"Almac Group","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"VAD044","moa":"AKT kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Almac Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almac Group \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Almac Group \/ Undisclosed"},{"orgOrder":0,"company":"Immunity Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IPL344","moa":"AKT signaling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Immunity Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunity Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunity Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Immunity Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IPL344","moa":"AKT signaling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Immunity Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunity Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunity Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Rose Research Center","sponsor":"Foundation for a Smoke Free World","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"Alanine racemase | D-alanylalanine synthetase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Rose Research Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rose Research Center \/ Foundation for a Smoke Free World","highestDevelopmentStatusID":"8","companyTruncated":"Rose Research Center \/ Foundation for a Smoke Free World"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"Alanine racemase | D-alanylalanine synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"The Alfred","sponsor":"Blue Bell Health, Australia | Gold Coast Hospital and Health Service","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Cycloserine","moa":"Alanine racemase | D-alanylalanine synthetase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"The Alfred","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Alfred \/ Blue Bell Health, Australia | Gold Coast Hospital and Health Service","highestDevelopmentStatusID":"8","companyTruncated":"The Alfred \/ Blue Bell Health, Australia | Gold Coast Hospital and Health Service"},{"orgOrder":0,"company":"COD Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Curcumin","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"COD Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"COD Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"COD Research \/ Undisclosed"},{"orgOrder":0,"company":"Addis Ababa University","sponsor":"Akay Natural Ingredients Private Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ETHIOPIA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Addis Ababa University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Addis Ababa University \/ Akay Natural Ingredients Private Limited","highestDevelopmentStatusID":"1","companyTruncated":"Addis Ababa University \/ Akay Natural Ingredients Private Limited"},{"orgOrder":0,"company":"Hempstreet","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2022","type":"Partnership","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hempstreet","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Hempstreet \/ MGC Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Hempstreet \/ MGC Pharmaceuticals"},{"orgOrder":0,"company":"Meru Health, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Meru Health, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meru Health, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Meru Health, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"NovoBliss Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"NovoBliss Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovoBliss Research \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NovoBliss Research \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Cancerolog\u00eda","sponsor":"Sabinsa","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"MEXICO","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Institute of Cancerolog\u00eda","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institute of Cancerolog\u00eda \/ Sabinsa","highestDevelopmentStatusID":"1","companyTruncated":"National Institute of Cancerolog\u00eda \/ Sabinsa"},{"orgOrder":0,"company":"Vascarta","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Vascarta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Gel","sponsorNew":"Vascarta \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vascarta \/ Undisclosed"},{"orgOrder":0,"company":"Vascarta","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vascarta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Vascarta \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vascarta \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Bridgewest Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Public Offering","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Immix Biopharma \/ Bridgewest Group","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Bridgewest Group"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"SignPath Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SignPath Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SignPath Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SignPath Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PLT Health Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"PLT Health Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PLT Health Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PLT Health Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeiGene"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeiGene"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeiGene"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeiGene"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeiGene"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Johnson & Johnson"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"MGC Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MGC Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Epiceutical Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Immunology","graph2":"Undisclosed","graph3":"Epiceutical Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epiceutical Labs \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Epiceutical Labs \/ Undisclosed"},{"orgOrder":0,"company":"Medinutra LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Immunology","graph2":"Undisclosed","graph3":"Medinutra LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medinutra LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Medinutra LLC \/ Undisclosed"},{"orgOrder":0,"company":"Vascarta","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vascarta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vascarta \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vascarta \/ Undisclosed"},{"orgOrder":0,"company":"Vascarta","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Agreement","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vascarta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Vascarta \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"6","companyTruncated":"Vascarta \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Wageningen University and Research","sponsor":"Ministry of Economic Affairs | Givaudan France Naturals | Nexira | Wecare | Roquette Freres | Ingredion Pharma Solutions | Ingredia S.A. | Darling | Winclove Probiotics B.V. | Bioiberica","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Curcumin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Wageningen University and Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wageningen University and Research \/ Ministry of Economic Affairs | Givaudan France Naturals | Nexira | Wecare | Roquette Freres | Ingredion Pharma Solutions | Ingredia S.A. | Darling | Winclove Probiotics B.V. | Bioiberica","highestDevelopmentStatusID":"1","companyTruncated":"Wageningen University and Research \/ Ministry of Economic Affairs | Givaudan France Naturals | Nexira | Wecare | Roquette Freres | Ingredion Pharma Solutions | Ingredia S.A. | Darling | Winclove Probiotics B.V. | Bioiberica"},{"orgOrder":0,"company":"Northumbria University","sponsor":"Pukka Herbs Limited","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Northumbria University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northumbria University \/ Pukka Herbs Limited","highestDevelopmentStatusID":"1","companyTruncated":"Northumbria University \/ Pukka Herbs Limited"},{"orgOrder":0,"company":"Gaia Herbs Inc.","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Gaia Herbs Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gaia Herbs Inc. \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Gaia Herbs Inc. \/ Nutrasource"},{"orgOrder":0,"company":"Tonghua Anrate Biopharmaceutical","sponsor":"The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Recombinant Human Albumin","moa":"Albumin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Tonghua Anrate Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Anrate Biopharmaceutical \/ The First Hospital of Jilin University","highestDevelopmentStatusID":"10","companyTruncated":"Tonghua Anrate Biopharmaceutical \/ The First Hospital of Jilin University"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"BTG International Inc | Embolx","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"68-Ga Macro-aggregated Albumin","moa":"Albumin","graph1":"Urology","graph2":"Phase I","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ BTG International Inc | Embolx","highestDevelopmentStatusID":"6","companyTruncated":"University of North Carolina \/ BTG International Inc | Embolx"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"INDIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Albumin","moa":"Albumin||Bilirubin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shilpa Medicare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shilpa Medicare \/ Undisclosed"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"INDIA","productType":"Protein","year":"2025","type":"Agreement","leadProduct":"Recombinant Human Albumin","moa":"Albumin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shilpa Medicare \/ Orion Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Shilpa Medicare \/ Orion Corporation"},{"orgOrder":0,"company":"Eisbach Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EIS-12656","moa":"ALC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisbach Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisbach Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisbach Bio \/ Undisclosed"},{"orgOrder":0,"company":"Eisbach Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EIS-12656","moa":"ALC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisbach Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisbach Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisbach Bio \/ Undisclosed"},{"orgOrder":0,"company":"Eisbach Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EIS-12656","moa":"||ALC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisbach Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisbach Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eisbach Bio \/ Undisclosed"},{"orgOrder":0,"company":"Eisbach Bio","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"EIS-12656","moa":"||ALC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisbach Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisbach Bio \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"Eisbach Bio \/ CPRIT"},{"orgOrder":0,"company":"GSNOR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cavosonstat","moa":"Alcohol dehydrogenase class III","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GSNOR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSNOR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSNOR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Utah","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sulfiram","moa":"Aldehyde dehydrogenase","graph1":"Oncology","graph2":"Phase I","graph3":"University of Utah","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Utah \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"University of Utah \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sulfiram","moa":"Aldehyde dehydrogenase","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"National Institute on Aging","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Aging \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Aging \/ Undisclosed"},{"orgOrder":0,"company":"Aldena Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Aldena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aldena Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aldena Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.5,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"US Food & Drug Administration","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ US Food & Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ US Food & Drug Administration"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tetraphase Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tetraphase Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Advanced BioDesign","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABD-3001","moa":"ALDH1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Advanced BioDesign","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Advanced BioDesign \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Advanced BioDesign \/ Undisclosed"},{"orgOrder":0,"company":"Advanced BioDesign","sponsor":"Xerys Funds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"ABD-3001","moa":"ALDH1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Advanced BioDesign","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Advanced BioDesign \/ Xerys Funds","highestDevelopmentStatusID":"7","companyTruncated":"Advanced BioDesign \/ Xerys Funds"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"DCR-A1203","moa":"ALDH2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dicerna Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"DCR-AUD","moa":"ALDH2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dicerna Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"DCR-AUD","moa":"ALDH2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dicerna Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Mirivadelgat","moa":"ALDH2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Foresee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Foresee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"QPS-Qualitix Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Mirivadelgat","moa":"ALDH2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foresee Pharmaceuticals \/ QPS-Qualitix Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Foresee Pharmaceuticals \/ QPS-Qualitix Clinical Research"},{"orgOrder":0,"company":"Quercis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Isoquercitrin","moa":"Aldo-keto reductase family 1 member B1; Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quercis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quercis Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Quercis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Institut de Recherches Cliniques de Montreal","sponsor":"Pharmascience Inc. | SciAN Services | Quercis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Isoquercitrin","moa":"Aldo-keto reductase family 1 member B1; Angiotensin-converting enzyme","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Institut de Recherches Cliniques de Montreal","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut de Recherches Cliniques de Montreal \/ Pharmascience Inc. | SciAN Services | Quercis Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Institut de Recherches Cliniques de Montreal \/ Pharmascience Inc. | SciAN Services | Quercis Pharma"},{"orgOrder":0,"company":"National Heart, Lung, and Blood Institute","sponsor":"Quercis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Isoquercitrin","moa":"Aldo-keto reductase family 1 member B1; Angiotensin-converting enzyme","graph1":"Genetic Disease","graph2":"Phase II","graph3":"National Heart, Lung, and Blood Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Heart, Lung, and Blood Institute \/ Quercis Pharma","highestDevelopmentStatusID":"8","companyTruncated":"National Heart, Lung, and Blood Institute \/ Quercis Pharma"},{"orgOrder":0,"company":"Jeffrey Zwicker","sponsor":"Quercegen Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Isoquercitrin","moa":"Aldo-keto reductase family 1 member B1; Angiotensin-converting enzyme","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jeffrey Zwicker","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jeffrey Zwicker \/ Quercegen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Jeffrey Zwicker \/ Quercegen Pharmaceuticals"},{"orgOrder":0,"company":"Factors Group of Nutritional Companies Inc.","sponsor":"Isura","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Liposomal Glutathione","moa":"Aldo-keto reductase family 1 member B1; Matrix metalloproteinase-9; Cytochrome P450 3A4; Glutathione peroxidase; Glutathione reductase, mitochondrial; Glutathione synthetase; Glutathione S-transferase Mu 1; Glutathione S-transferase kappa 1; Glutathione S-transferase A3; Glutathione S-transferase Mu 3; Glutathione S-transferase A4; Glutathione S-transferase Mu 4; Glutathione S-transferase A5; Glutathione S-transferase P; Glutathione S-transferase omega-1; Glutathione peroxidase 1; Glutathione peroxidase 2; Glutathione S-transferase theta-1; Maleylacetoacetate isomerase; Epididymal secretory glutathione peroxidase; Glutathione peroxidase 3; Lactoylglutathione lyase; Leukotriene C4 synthase; Glutathione S-transferase 3, mitochondrial; Hematopoietic prostaglandin D synthase; Glutathione S-transferase A1; Glutathione S-transferase A2; Microsomal glutathione S-transferase 1; S-formylglutathione hydrolase; Glutathione hydrolase 1 proenzyme; Glutathione S-transferase Mu 2; Glutaredoxin-1; Pho","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Factors Group of Nutritional Companies Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Factors Group of Nutritional Companies Inc. \/ Isura","highestDevelopmentStatusID":"1","companyTruncated":"Factors Group of Nutritional Companies Inc. \/ Isura"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BI690517","moa":"ALDOS","graph1":"Nephrology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BI690517","moa":"ALDOS","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ IQVIA"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vicadrostat","moa":"ALDOS","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vicadrostat","moa":"ALDOS","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vicadrostat","moa":"ALDOS","graph1":"Nephrology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vicadrostat","moa":"ALDOS","graph1":"Endocrinology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vicadrostat","moa":"ALDOS","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vicadrostat","moa":"ALDOS","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Caficrestat","moa":"Aldose reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Applied Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Caficrestat","moa":"Aldose reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Applied Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Caficrestat","moa":"Aldose reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Applied Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Maggie's Pearl","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Epalrestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Maggie's Pearl","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maggie's Pearl \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maggie's Pearl \/ Undisclosed"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SAL0140","moa":"Aldosterone","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed"},{"orgOrder":0,"company":"BPGbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"aldosterone antagonists (spironolactone type)","graph1":"Oncology","graph2":"Phase II","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BPGbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BPGbio \/ Undisclosed"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||aldosterone antagonists (spironolactone type)","graph1":"Oncology","graph2":"Phase I","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BerGenBio ASA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BerGenBio ASA \/ Undisclosed"},{"orgOrder":0,"company":"Berg Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||aldosterone antagonists (spironolactone type)","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Berg Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Undisclosed"},{"orgOrder":0,"company":"Berg Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||aldosterone antagonists (spironolactone type)","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Berg Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Undisclosed"},{"orgOrder":0,"company":"BPGbio","sponsor":"Berg Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||aldosterone antagonists (spironolactone type)","graph1":"Oncology","graph2":"Phase II","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BPGbio \/ Berg Health","highestDevelopmentStatusID":"8","companyTruncated":"BPGbio \/ Berg Health"},{"orgOrder":0,"company":"Berg Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||aldosterone antagonists (spironolactone type)","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Berg Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Undisclosed"},{"orgOrder":0,"company":"Berg Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||aldosterone antagonists (spironolactone type)","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Berg Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Undisclosed"},{"orgOrder":0,"company":"Berg Health","sponsor":"AdventHealth","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Collaboration","leadProduct":"Ubidecarenone","moa":"aldosterone antagonists (spironolactone type)","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Berg Health \/ AdventHealth","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ AdventHealth"},{"orgOrder":0,"company":"BPGbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"aldosterone antagonists (spironolactone type)","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BPGbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BPGbio \/ Undisclosed"},{"orgOrder":0,"company":"BPGbio","sponsor":"Debra of America","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Partnership","leadProduct":"Ubidecarenone","moa":"aldosterone antagonists (spironolactone type)","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BPGbio \/ Debra of America","highestDevelopmentStatusID":"8","companyTruncated":"BPGbio \/ Debra of America"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BI 690517","moa":"||Aldosterone synthase","graph1":"Nephrology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BI 690517","moa":"Aldosterone synthase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Endocrinology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MLS-101","moa":"Aldosterone synthase (CYP11B2)","graph1":"Nephrology","graph2":"Phase II","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mineralys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mineralys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spur Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SwanBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SwanBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SwanBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SwanBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SwanBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Series B Financing","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"SwanBio Therapeutics \/ Syncona Limited","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Syncona Limited"},{"orgOrder":0,"company":"Sichuan University","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ensatinib","moa":"ALK","graph1":"Oncology","graph2":"Phase II","graph3":"Sichuan University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan University \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sichuan University \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Neladalkib","moa":"ALK","graph1":"Oncology","graph2":"Phase III","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nuvalent \/ Undisclosed"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NMS-01940153E","moa":"ALK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Nerviano Medical Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nerviano Medical Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Shouyao Holdings (Beijing) Co. LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CT-707","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shouyao Holdings (Beijing) Co. LTD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shouyao Holdings (Beijing) Co. LTD \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shouyao Holdings (Beijing) Co. LTD \/ Undisclosed"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Reprocell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Dimesna","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Reprocell","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Reprocell"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dimesna","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"LP-300","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"LP-300","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ Undisclosed"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Undisclosed"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Undisclosed"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Undisclosed"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Undisclosed"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Undisclosed"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ Undisclosed"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Undisclosed"},{"orgOrder":0,"company":"Peking University Cancer Hospital & Institute","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Peking University Cancer Hospital & Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University Cancer Hospital & Institute \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Peking University Cancer Hospital & Institute \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Fudan University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Betta Pharmaceuticals \/ Fudan University","highestDevelopmentStatusID":"10","companyTruncated":"Betta Pharmaceuticals \/ Fudan University"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Xcovery","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Xcovery","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xcovery \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Xcovery \/ Undisclosed"},{"orgOrder":0,"company":"Xcovery","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Xcovery","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xcovery \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Xcovery \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Xcovery","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Xcovery","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xcovery \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Xcovery \/ Undisclosed"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Phase II","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CStone Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"CStone Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Intergroupe Francophone de Cancerologie Thoracique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Phase II","graph3":"Intergroupe Francophone de Cancerologie Thoracique","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intergroupe Francophone de Cancerologie Thoracique \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Intergroupe Francophone de Cancerologie Thoracique \/ Undisclosed"},{"orgOrder":0,"company":"Nationwide Children\u2019s Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Phase I","graph3":"Nationwide Children\u2019s Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nationwide Children\u2019s Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Nationwide Children\u2019s Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"SCRI Development Innovations, LLC","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Phase II","graph3":"SCRI Development Innovations, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCRI Development Innovations, LLC \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"SCRI Development Innovations, LLC \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Massachusetts General Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Eli Lilly"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Strata Oncology","sponsor":"Merck & Co | Pfizer Inc | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor | EML4-ALK","graph1":"Oncology","graph2":"Phase II","graph3":"Strata Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Strata Oncology \/ Merck & Co | Pfizer Inc | Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Strata Oncology \/ Merck & Co | Pfizer Inc | Gilead Sciences"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor | Epidermal growth factor receptor erbB1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Intergroupe Francophone de Cancerologie Thoracique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Intergroupe Francophone de Cancerologie Thoracique","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intergroupe Francophone de Cancerologie Thoracique \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Intergroupe Francophone de Cancerologie Thoracique \/ Undisclosed"},{"orgOrder":0,"company":"Princess Maxima Center for Pediatric Oncology","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Princess Maxima Center for Pediatric Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Princess Maxima Center for Pediatric Oncology \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Princess Maxima Center for Pediatric Oncology \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"ETOP IBCSG Partners Foundation","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"ETOP IBCSG Partners Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ETOP IBCSG Partners Foundation \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"ETOP IBCSG Partners Foundation \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Foundation Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Undisclosed"},{"orgOrder":0,"company":"PharmaBlock Sciences","sponsor":"Shouyao","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"SY-707","moa":"ALK\/FAK\/IGF1R multi-target kinase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"PharmaBlock Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaBlock Sciences \/ Shouyao","highestDevelopmentStatusID":"9","companyTruncated":"PharmaBlock Sciences \/ Shouyao"},{"orgOrder":0,"company":"Diagonal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"DIAG723","moa":"ALK-1 receptor","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Diagonal Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diagonal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Diagonal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BCX9250","moa":"ALK-2 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCryst Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BCX9250","moa":"ALK-2 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCryst Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clementia Pharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"IPN60130","moa":"ALK-2 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Clementia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clementia Pharmaceuticals \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Clementia Pharmaceuticals \/ Ipsen"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KER-047","moa":"ALK-2 receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KER-047","moa":"ALK-2 receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KER-047","moa":"ALK-2 receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"KER-047","moa":"ALK-2 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TD-1058","moa":"ALK5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Series C Financing","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ EQT Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ EQT Life Sciences"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Series D Financing","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Sanofi"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Series B Financing","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Pfizer Inc"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgomAb Therapeutics N.V \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Undisclosed"},{"orgOrder":0,"company":"Thirona Bio","sponsor":"Mannkind","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"FBM5712","moa":"ALK-5 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Thirona Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Thirona Bio \/ Mannkind","highestDevelopmentStatusID":"4","companyTruncated":"Thirona Bio \/ Mannkind"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Alkaline Phosphatase","moa":"Alkaline phosphatase","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"ALXN1850","moa":"Alkaline phosphatase tissue-nonspecific (ALPL)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"ALXN1850","moa":"Alkaline phosphatase tissue-nonspecific (ALPL)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"ALXN1850","moa":"Alkaline phosphatase tissue-nonspecific (ALPL)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"ALXN1850","moa":"Alkaline phosphatase tissue-nonspecific (ALPL)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"ALXN1910","moa":"Alkaline phosphatase tissue-nonspecific (ALPL)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sanford Burnham Prebys","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"N-Acetyl-D-Leucine","moa":"Alkaline phosphatase, tissue-nonspecific isozyme","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Sanford Burnham Prebys","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Sanford Burnham Prebys"},{"orgOrder":0,"company":"Labo'Life","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"2LEBV","moa":"Allergen cell","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Labo'Life","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Labo'Life \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Labo'Life \/ Undisclosed"},{"orgOrder":0,"company":"Labo'Life","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"2LPAPI","moa":"Allergen cell","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Labo'Life","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Labo'Life \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Labo'Life \/ Undisclosed"},{"orgOrder":0,"company":"ALK","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"5-grass Mix Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"ALK \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Syneos Health"},{"orgOrder":0,"company":"Inmunotek","sponsor":"BioClever 2005 | NTS Hub S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ BioClever 2005 | NTS Hub S.L.","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ BioClever 2005 | NTS Hub S.L."},{"orgOrder":0,"company":"Inmunotek","sponsor":"BioClever 2005 | NTS Hub S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ BioClever 2005 | NTS Hub S.L.","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ BioClever 2005 | NTS Hub S.L."},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Inimmune","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Inimmune","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Inimmune"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Circuit Clinical","sponsor":"Intrommune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"IND Enabling","graph3":"Circuit Clinical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Paste","sponsorNew":"Circuit Clinical \/ Intrommune Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Circuit Clinical \/ Intrommune Therapeutics"},{"orgOrder":0,"company":"Inventprise","sponsor":"University of the Philippines National Health Institute | Health Index Clinic | Grand Centennial Homes Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PCV-25","moa":"Allergen cell","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inventprise","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inventprise \/ University of the Philippines National Health Institute | Health Index Clinic | Grand Centennial Homes Clinic","highestDevelopmentStatusID":"8","companyTruncated":"Inventprise \/ University of the Philippines National Health Institute | Health Index Clinic | Grand Centennial Homes Clinic"},{"orgOrder":0,"company":"Inventprise","sponsor":"Canadian Center for Vaccinology | Vaccine Evaluation Center, Canada | PATH","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PCV-25","moa":"Allergen cell","graph1":"Undisclosed","graph2":"Phase I","graph3":"Inventprise","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inventprise \/ Canadian Center for Vaccinology | Vaccine Evaluation Center, Canada | PATH","highestDevelopmentStatusID":"6","companyTruncated":"Inventprise \/ Canadian Center for Vaccinology | Vaccine Evaluation Center, Canada | PATH"},{"orgOrder":0,"company":"ALK","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Peanut Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Parexel","highestDevelopmentStatusID":"7","companyTruncated":"ALK \/ Parexel"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Ergomed | ClinCompetence Cologne GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Purethal Mites","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HAL Allergy \/ Ergomed | ClinCompetence Cologne GmbH","highestDevelopmentStatusID":"10","companyTruncated":"HAL Allergy \/ Ergomed | ClinCompetence Cologne GmbH"},{"orgOrder":0,"company":"ALK","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Tree Slit","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Parexel"},{"orgOrder":0,"company":"Mesoblast International S\u00e0rl","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mesoblast International S\u00e0rl","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast International S\u00e0rl \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Mesoblast International S\u00e0rl \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast International S\u00e0rl","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mesoblast International S\u00e0rl","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast International S\u00e0rl \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Mesoblast International S\u00e0rl \/ Undisclosed"},{"orgOrder":0,"company":"Cardiothoracic Surgical Trials Network","sponsor":"Mesoblast","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Partnership","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiothoracic Surgical Trials Network","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardiothoracic Surgical Trials Network \/ Mesoblast","highestDevelopmentStatusID":"9","companyTruncated":"Cardiothoracic Surgical Trials Network \/ Mesoblast"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Mesoblast | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Mesoblast | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"10","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Mesoblast | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Mesoblast","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Mesoblast","highestDevelopmentStatusID":"7","companyTruncated":"Cleveland Clinic \/ Mesoblast"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Mesoblast","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Mesoblast","highestDevelopmentStatusID":"7","companyTruncated":"Cleveland Clinic \/ Mesoblast"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"BMT CTN","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ BMT CTN","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ BMT CTN"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Private Placement","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Gregory George","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Gregory George","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Gregory George"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":1.3600000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":1.3600000000000001,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2021","type":"Termination","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":1.3600000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":1.3600000000000001,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Financing","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Cleveland Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Mesoblast \/ Cleveland Clinic"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FHD-286","moa":"Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foghorn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FHD-286","moa":"Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foghorn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foghorn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foghorn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foghorn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foghorn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foghorn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FHD-286","moa":"Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foghorn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foghorn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foghorn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Foghorn Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foghorn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"FHD-286","moa":"Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Foghorn Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"St. Joseph's Hospital and Medical Center, Phoenix","sponsor":"Ivy Brain Tumor Center | Barrow Neurological Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"St. Joseph's Hospital and Medical Center, Phoenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Joseph's Hospital and Medical Center, Phoenix \/ Ivy Brain Tumor Center | Barrow Neurological Institute","highestDevelopmentStatusID":"6","companyTruncated":"St. Joseph's Hospital and Medical Center, Phoenix \/ Ivy Brain Tumor Center | Barrow Neurological Institute"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series A Financing","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Black Diamond Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"QTX3034","moa":"Allosteric KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quanta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"QTX3034","moa":"Allosteric KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quanta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Avidity Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series D Financing","leadProduct":"QTX3034","moa":"Allosteric KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Quanta Therapeutics \/ Avidity Partners","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Avidity Partners"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"QTX3034","moa":"Allosteric KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quanta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Nephrology","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AdipoPharma","sponsor":"Newton Biocapital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2023","type":"Series A Financing","leadProduct":"PATAS","moa":"ALMS1","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AdipoPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AdipoPharma \/ Newton Biocapital","highestDevelopmentStatusID":"4","companyTruncated":"AdipoPharma \/ Newton Biocapital"},{"orgOrder":0,"company":"AdipoPharma","sponsor":"Newton Biocapital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2024","type":"Funding","leadProduct":"PATAS","moa":"ALMS1","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AdipoPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AdipoPharma \/ Newton Biocapital","highestDevelopmentStatusID":"4","companyTruncated":"AdipoPharma \/ Newton Biocapital"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Utreloxastat","moa":"15-LOX||ALOX15","graph1":"Neurology","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Utreloxastat","moa":"ALOX15","graph1":"Neurology","graph2":"Phase I","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Utreloxastat","moa":"ALOX15","graph1":"Neurology","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Plex Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"CAP4196","moa":"Alpha A crystallin","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Plex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Plex Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Plex Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"MST Financial Services","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ MST Financial Services","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ MST Financial Services"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alterity Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"MST Financial Services","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Alterity Therapeutics \/ MST Financial Services","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ MST Financial Services"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NRL001","moa":"Alpha-1 adrenoceptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NRL001","moa":"Alpha-1 adrenoceptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Alpha-1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin||Leukocyte elastase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Alpha-1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin||Leukocyte elastase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Alpha-1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin||Leukocyte elastase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Alpha-1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin||Leukocyte elastase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Blessing Corporate Services","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Alpha-1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin||Leukocyte elastase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Blessing Corporate Services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blessing Corporate Services \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Blessing Corporate Services \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Alpha-1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Children's Hospital Medical Center, Cincinnati","sponsor":"CSL Behring | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Alpha-1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Children's Hospital Medical Center, Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital Medical Center, Cincinnati \/ CSL Behring | National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Children's Hospital Medical Center, Cincinnati \/ CSL Behring | National Institutes of Health"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"DCR-A1AT","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Undisclosed"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Undisclosed"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Undisclosed"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Undisclosed"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":2.2000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":2.2000000000000002,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Sanofi"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":2.2000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":2.2000000000000002,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Sanofi"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Undisclosed"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Undisclosed"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Undisclosed"},{"orgOrder":0,"company":"Healthgen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"OsrhAAT","moa":"Alpha-1 antitrypsin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Healthgen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Healthgen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Healthgen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"VX-864","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"VX-864","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Collaboration","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Molnlycke Health Care AB \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"Molnlycke Health Care AB \/ MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dressing","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Public Offering","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Gel","sponsorNew":"MediWound \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Funding","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"MediWound \/ EIC Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ EIC Accelerator"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Molnlycke Health Care","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Private Placement","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.029999999999999999,"dosageForm":"Gel","sponsorNew":"MediWound \/ Molnlycke Health Care","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Molnlycke Health Care"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Private Placement","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"MediWound \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"MediWound","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediWound \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Undisclosed"},{"orgOrder":0,"company":"3M Health Care","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Collaboration","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"3M Health Care","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"3M Health Care \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"3M Health Care \/ MediWound"},{"orgOrder":0,"company":"MiMedx","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Collaboration","leadProduct":"Anacaulase","moa":"||Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MiMedx \/ MediWound","highestDevelopmentStatusID":"4","companyTruncated":"MiMedx \/ MediWound"},{"orgOrder":0,"company":"Translational Sciences, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TS23","moa":"Alpha-2 plasmin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Translational Sciences, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Sciences, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Translational Sciences, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Translational Sciences, Inc.","sponsor":"University of Cincinnati | National Institute of Neurological Disorders and Stroke | Medical University of South Carolina | University of Arizona","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"TS23","moa":"Alpha-2 plasmin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Translational Sciences, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Sciences, Inc. \/ University of Cincinnati | National Institute of Neurological Disorders and Stroke | Medical University of South Carolina | University of Arizona","highestDevelopmentStatusID":"8","companyTruncated":"Translational Sciences, Inc. \/ University of Cincinnati | National Institute of Neurological Disorders and Stroke | Medical University of South Carolina | University of Arizona"},{"orgOrder":0,"company":"CSL","sponsor":"Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"TS23","moa":"Alpha-2 plasmin","graph1":"Hematology","graph2":"Phase I","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL \/ Translational Sciences","highestDevelopmentStatusID":"6","companyTruncated":"CSL \/ Translational Sciences"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"FINLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tasipimidine","moa":"Alpha-2A adrenergic receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution","sponsorNew":"Orion Corporation \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Orion Corporation \/ Icon Plc"},{"orgOrder":0,"company":"Xgene Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"XG005","moa":"Alpha-2-beta-subunit","graph1":"Neurology","graph2":"Phase I","graph3":"Xgene Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xgene Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xgene Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Xgene Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"XG005","moa":"Alpha-2-beta-subunit","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Xgene Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xgene Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Xgene Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SPY001","moa":"Alpha-4-beta-7 integrin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spyre Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Aeglea BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"SPY001","moa":"Alpha-4-beta-7 integrin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Aeglea BioTherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Spyre Therapeutics \/ Aeglea BioTherapeutics"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Fairmount Funds Management LLC","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"SPY001","moa":"Alpha-4-beta-7 integrin","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Aeglea BioTherapeutics","amount2":0.20999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.20999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Aeglea BioTherapeutics \/ Fairmount Funds Management LLC","highestDevelopmentStatusID":"4","companyTruncated":"Aeglea BioTherapeutics \/ Fairmount Funds Management LLC"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SPY001","moa":"Alpha-4-beta-7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spyre Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Earendil Labs","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"HXN-1002","moa":"Alpha-4-beta-7\/TL1A","graph1":"Immunology","graph2":"Preclinical","graph3":"Earendil Labs","amount2":1.8500000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.8500000000000001,"dosageForm":"Undisclosed","sponsorNew":"Earendil Labs \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Earendil Labs \/ Sanofi"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CEND-1","moa":"Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CEND-1","moa":"Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Lisata Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Qilu Pharmaceutical \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Anup Kasi","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CEND-1","moa":"Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anup Kasi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anup Kasi \/ Lisata Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Anup Kasi \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Lisata Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Qilu Pharmaceutical \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Preclinical","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valo Therapeutics \/ Lisata Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Valo Therapeutics \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Caladrius Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Caladrius Biosciences"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"GATC Health","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"GATC Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GATC Health \/ Lisata Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"GATC Health \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"WARPNINE","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ WARPNINE","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ WARPNINE"},{"orgOrder":0,"company":"Haystack Oncology","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Haystack Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Haystack Oncology \/ Lisata Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Haystack Oncology \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Cend Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Cend Therapeutics"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"University of Sydney","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ University of Sydney","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ University of Sydney"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Merger","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Caladrius Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Caladrius Biosciences"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"University of Cincinnati","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Discovery","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ University of Cincinnati","highestDevelopmentStatusID":"2","companyTruncated":"Lisata Therapeutics \/ University of Cincinnati"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"LSTA1","moa":"Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"LSTA1","moa":"Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Australasian Gastro-Intestinal Trials Group","sponsor":"University of Sydney","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LSTA1","moa":"Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Australasian Gastro-Intestinal Trials Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Australasian Gastro-Intestinal Trials Group \/ University of Sydney","highestDevelopmentStatusID":"8","companyTruncated":"Australasian Gastro-Intestinal Trials Group \/ University of Sydney"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Alpha-5 integrin","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Funding","leadProduct":"PAT 103","moa":"Alpha-5\/beta-1 integrin","graph1":"Neurology","graph2":"Preclinical","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Alpha-5 integrin","highestDevelopmentStatusID":"4","companyTruncated":"Pasithea Therapeutics \/ Alpha-5 integrin"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PLN-101095","moa":"Alpha-5-beta-1\/Alpha-5-beta-8","graph1":"Oncology","graph2":"Phase I","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Alpha-5-beta-1\/Alpha-5-beta-8","graph1":"Oncology","graph2":"Phase I","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"PLN-101095","moa":"Alpha-5-beta-1\/Alpha-5-beta-8","graph1":"Oncology","graph2":"Phase I","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pliant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pliant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Damona Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"DPX-101","moa":"Alpha-5-GABAA-R","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Damona Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Damona Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Damona Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Damona Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"DPX-101","moa":"Alpha-5-GABAA-R","graph1":"Neurology","graph2":"Preclinical","graph3":"Damona Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Damona Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Damona Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ADP\u2011A2AFP","moa":"Alpha-fetoprotein","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ADP\u2011A2AFP","moa":"Alpha-fetoprotein","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"HRYZ Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Afp Specific T Cell Receptor T Cell","moa":"Alpha-fetoprotein","graph1":"Oncology","graph2":"Phase I","graph3":"HRYZ Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HRYZ Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HRYZ Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series E Financing","leadProduct":"ET140202","moa":"Alpha-fetoprotein (AFP)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Eureka Therapeutics \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eureka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eureka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eureka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eureka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Cirm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Funding","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Eureka Therapeutics \/ Cirm","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Cirm"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eureka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha-fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eureka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AbSci","sponsor":"Alpha Cancer Technologies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Recombinant Human Alpha-Fetoprotein","moa":"Alpha-fetoprotein receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AbSci","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbSci \/ Alpha Cancer Technologies","highestDevelopmentStatusID":"6","companyTruncated":"AbSci \/ Alpha Cancer Technologies"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AGI-134","moa":"Alpha-galactosidase A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Partnership","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orsini Specialty Pharmacy \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Sanofi"},{"orgOrder":0,"company":"Avrobio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-03","moa":"Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avrobio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Avrobio \/ Undisclosed"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Amicus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Agreement","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orsini Specialty Pharmacy \/ Amicus Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Amicus Therapeutics"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Financing","leadProduct":"Cipaglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0.40000000000000002,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Amicus Therapeutics \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"ARYA Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0.59999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.59999999999999998,"dosageForm":"Capsule","sponsorNew":"Amicus Therapeutics \/ ARYA Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ ARYA Sciences"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chiesi Group \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Protalix BioTherapeutics"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chiesi Group \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Protalix BioTherapeutics"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chiesi Group \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Protalix BioTherapeutics"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Psagot Investment House","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Financing","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Psagot Investment House","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Psagot Investment House"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"4D-310","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"4D-310","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"4D-310","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"4D-310","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"4D-310","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"4D-310","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"4D-310","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series C Financing","leadProduct":"4D-310","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"4D Molecular Therapeutics \/ Viking Global Investors","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Viking Global Investors"},{"orgOrder":0,"company":"Avrobio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Undisclosed"},{"orgOrder":0,"company":"Avrobio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Undisclosed"},{"orgOrder":0,"company":"Avrobio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Undisclosed"},{"orgOrder":0,"company":"Avrobio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Undisclosed"},{"orgOrder":0,"company":"Avrobio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Undisclosed"},{"orgOrder":0,"company":"Avrobio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Undisclosed"},{"orgOrder":0,"company":"Avrobio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Undisclosed"},{"orgOrder":0,"company":"Avrobio","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Morgan Stanley"},{"orgOrder":0,"company":"Avrobio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Undisclosed"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Boston Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"PAZ320","moa":"Alpha-glucosidase","graph1":"Endocrinology","graph2":"Phase II","graph3":"Boston Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boston Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boston Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Aridis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"Suvratoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Aridis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Aridis Pharmaceuticals"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Suvratoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Termination","leadProduct":"Suvratoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Aridis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Public Offering","leadProduct":"Tosatoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"German Center for Infection Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RHCDS-13b","moa":"Alpha-ketoamide protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"German Center for Infection Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"German Center for Infection Research \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"German Center for Infection Research \/ Undisclosed"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"GB-501","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"San Raffaele-Telethon Institute for Gene Therapy","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ San Raffaele-Telethon Institute for Gene Therapy","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ San Raffaele-Telethon Institute for Gene Therapy"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biomedica \/ Orchard Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Biomedica \/ Orchard Therapeutics"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Generium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Antibody-protein Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Verenafusp Alfa","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generium \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Generium \/ Undisclosed"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"RGX-111","moa":"Alpha-L-iduronidase (IDUA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio \/ Undisclosed"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-111","moa":"Alpha-L-iduronidase (IDUA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio \/ Undisclosed"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"RGX-111","moa":"Alpha-L-iduronidase (IDUA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio \/ Undisclosed"},{"orgOrder":0,"company":"TargEDys","sponsor":"Inoliva","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Hafnia alvei HA4597","moa":"Alpha-MSH","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"TargEDys","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TargEDys \/ Inoliva","highestDevelopmentStatusID":"15","companyTruncated":"TargEDys \/ Inoliva"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Portland Investment Counsel Inc.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Series A Financing","leadProduct":"212-Pb Dotamtate","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"RadioMedix \/ Portland Investment Counsel Inc.","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Portland Investment Counsel Inc."},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"212-Pb Dotamtate","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RadioMedix \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Oranomed"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"212-Pb Dotamtate","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RadioMedix \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Oranomed"},{"orgOrder":0,"company":"Oranomed","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"212-Pb Dotamtate","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oranomed","amount2":0.35999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.35999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Oranomed \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Oranomed \/ Sanofi"},{"orgOrder":0,"company":"Ablaze Pharma","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"225-Ac","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ablaze Pharma","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Ablaze Pharma \/ Vivo Capital","highestDevelopmentStatusID":"15","companyTruncated":"Ablaze Pharma \/ Vivo Capital"},{"orgOrder":0,"company":"Ablaze Pharma","sponsor":"Yonghe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"225-Ac","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ablaze Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ablaze Pharma \/ Yonghe Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ablaze Pharma \/ Yonghe Pharma"},{"orgOrder":0,"company":"Bayer AG","sponsor":"BWXT Medical Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"225-Ac","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ BWXT Medical Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/ BWXT Medical Ltd."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"225-Ac","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"BWX Technologies","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"225-Ac","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"BWX Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BWX Technologies \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"BWX Technologies \/ Bayer AG"},{"orgOrder":0,"company":"BWX Technologies","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Expanded Collaboration","leadProduct":"225-Ac","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"BWX Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BWX Technologies \/ Fusion Pharma","highestDevelopmentStatusID":"1","companyTruncated":"BWX Technologies \/ Fusion Pharma"},{"orgOrder":0,"company":"Ratio Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Financing","leadProduct":"225-Ac Conjugated PSMA","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Ratio Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Ratio Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Ratio Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"225-Ac FPI-2068","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nihon Medi-Physics","sponsor":"Cyclotron","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"225-Ac PET","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nihon Medi-Physics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nihon Medi-Physics \/ Cyclotron","highestDevelopmentStatusID":"1","companyTruncated":"Nihon Medi-Physics \/ Cyclotron"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"ABD-147","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"ABD-147","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"ABD-147","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Financing","leadProduct":"ABD-147","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"BWX Technologies","sponsor":"TRIUMF","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"n.c.a 225-Ac","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"BWX Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BWX Technologies \/ TRIUMF","highestDevelopmentStatusID":"1","companyTruncated":"BWX Technologies \/ TRIUMF"},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2023","type":"Agreement","leadProduct":"PNT2001","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eckert & Ziegler Strahlen \/ Point Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Eckert & Ziegler Strahlen \/ Point Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Ionetix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Agreement","leadProduct":"225-Ac","moa":"||Alpha-radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Point Biopharma \/ Ionetix","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Ionetix"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Agreement","leadProduct":"225-Ac","moa":"||Alpha-radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NorthStar Medical Radioisotopes \/ Point Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"NorthStar Medical Radioisotopes \/ Point Biopharma"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"PNT2001","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Point Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Radium-223","moa":"||Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Linc AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Oncoinvent \/ Linc AB","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Linc AB"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"||Alpha-radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alpha Tau Medical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Tau Medical \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Alpha Tau Medical \/ Medison Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Medison Pharma"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alpha Tau Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alpha Tau Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alpha Tau Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Tau Medical \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Radspherin","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Radspherin","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Radspherin","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Oncoinvent \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Undisclosed"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Oncoinvent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2025","type":"Merger","leadProduct":"Radspherin","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BerGenBio ASA \/ Oncoinvent","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Oncoinvent"},{"orgOrder":0,"company":"Affiris","sponsor":"AC Immune","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRIA","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"PD01","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Affiris","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Affiris \/ AC Immune","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ AC Immune"},{"orgOrder":0,"company":"Affiris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PD01","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Affiris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Affiris \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Licensing Agreement","leadProduct":"ARO-SNCA","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Preclinical","graph3":"Arrowhead Pharmaceuticals","amount2":2.2000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":2.2000000000000002,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Arrowhead Pharmaceuticals \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CDNF","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Herantis Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Herantis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Nanoform","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FINLAND","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"CDNF","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Herantis Pharma \/ Nanoform","highestDevelopmentStatusID":"7","companyTruncated":"Herantis Pharma \/ Nanoform"},{"orgOrder":0,"company":"Convalife","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CVL237","moa":"Alpha-synuclein","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Convalife","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Convalife \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Convalife \/ Undisclosed"},{"orgOrder":0,"company":"Convalife","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CVL237","moa":"Alpha-synuclein","graph1":"Oncology","graph2":"Phase II","graph3":"Convalife","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Convalife \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Convalife \/ Undisclosed"},{"orgOrder":0,"company":"Enterin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ENT-01","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Enterin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enterin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enterin \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Innosuisse","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Innosuisse","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Innosuisse"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Titan Partners Group LLC","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lu AF82422","moa":"Alpha-synuclein","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lu AF82422","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lu AF82422","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Prothena","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Prasinezumab","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Prothena","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Prothena"},{"orgOrder":0,"company":"Prothena","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Prasinezumab","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Prothena \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Prasinezumab","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Prasinezumab","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Prothena","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Prasinezumab","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Prasinezumab","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Prasinezumab","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Prasinezumab","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Prasinezumab","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Enterin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Squalamine phosphate","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Enterin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enterin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enterin \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer CentreOne","sponsor":"Enterin","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Squalamine phosphate","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Pfizer CentreOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer CentreOne \/ Enterin","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer CentreOne \/ Enterin"},{"orgOrder":0,"company":"Enterin","sponsor":"Parkinson\u2019s Virtual Biotech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Squalamine phosphate","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Enterin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enterin \/ Parkinson\u2019s Virtual Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Enterin \/ Parkinson\u2019s Virtual Biotech"},{"orgOrder":0,"company":"Enterin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Squalamine phosphate","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"IND Enabling","graph3":"Enterin","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enterin \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Enterin \/ Undisclosed"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-312","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Undisclosed"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"UB-312","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-312","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Undisclosed"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"UB-312","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-312","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid, Suspension","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Exidavnemab","moa":"Alpha-synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"BioArctic AB \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Exidavnemab","moa":"Alpha-synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioArctic AB \/ Undisclosed"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Exidavnemab","moa":"Alpha-synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioArctic AB \/ Undisclosed"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Exidavnemab","moa":"Alpha-synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioArctic AB \/ Undisclosed"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Exidavnemab","moa":"Alpha-synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioArctic AB \/ Undisclosed"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Exidavnemab","moa":"Alpha-synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioArctic AB \/ Undisclosed"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Termination","leadProduct":"Exidavnemab","moa":"Alpha-synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"BioArctic AB","amount2":0.76000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.76000000000000001,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"BioArctic AB \/ AbbVie Inc"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Parkinson Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"UCB0599","moa":"Alpha-synuclein misfolding","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"UCB Pharma S.A \/ Parkinson Study Group","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Parkinson Study Group"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"UCB0599","moa":"Alpha-synuclein misfolding","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"UCB0599","moa":"Alpha-synuclein misfolding","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"SLS-007","moa":"Alpha-synuclein non-amyloid component","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"SLS-007","moa":"Alpha-synuclein non-amyloid component","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"SLS-007","moa":"Alpha-synuclein non-amyloid component","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"SLS-007","moa":"Alpha-synuclein non-amyloid component","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SLS-007","moa":"Alpha-synuclein non-amyloid component","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VIP236","moa":"Alpha-V-beta-3 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vincerx Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VIP236","moa":"Alpha-V-beta-3 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vincerx Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"VIP236","moa":"Alpha-V-beta-3 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vincerx Pharma \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Leerink Partners"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VIP236","moa":"Alpha-V-beta-3 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vincerx Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VIP236","moa":"Alpha-V-beta-3 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vincerx Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ImaginAb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IAB56","moa":"Alpha-V-beta-6 integrin","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImaginAb \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"ImaginAb \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"MORF-720","moa":"Alpha-V-beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Morphic Therapeutic","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Morphic Therapeutic \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Morphic Therapeutic \/ AbbVie Inc"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CRB-601","moa":"Alpha-V-beta-8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CRB-601","moa":"Alpha-V-beta-8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CRB-601","moa":"Alpha-V-beta-8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CRB-601","moa":"||Alpha-V-beta-8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CRB-601","moa":"Alpha-V-beta-8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CRB-601","moa":"||Alpha-V-beta-8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CRB-601","moa":"Alpha-V-beta-8 integrin","graph1":"Oncology","graph2":"Preclinical","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Heidelberg University","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2024","type":"Licensing Agreement","leadProduct":"225-Ac PSMA","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II","graph3":"Heidelberg University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Heidelberg University \/ Fusion Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Heidelberg University \/ Fusion Pharma"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2024","type":"Acquisition","leadProduct":"225-Ac PSMA","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":2.3999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":2.3999999999999999,"dosageForm":"Infusion","sponsorNew":"Fusion Pharma \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"225-Ac PSMA","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"225-Ac PSMA","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"225-Ac PSMA","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2024","type":"Acquisition","leadProduct":"225-Ac PSMA","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II","graph3":"Fusion Pharma","amount2":2.3999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":2.3999999999999999,"dosageForm":"Infusion","sponsorNew":"Fusion Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Fusion Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Acquisition","leadProduct":"225-Ac PSMA","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RadioMedix \/ Fusion Pharma","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Fusion Pharma"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"FPI-2265","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"FPI-2265","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"FPI-2265","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ilofotase Alfa","moa":"ALPI","graph1":"Undisclosed","graph2":"Phase II","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"AM-Pharma \/ FGK Clinical Research"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ilofotase Alfa","moa":"ALPI","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AM-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"ALPK1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Drug Farm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Undisclosed"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"ALPK1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Drug Farm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Undisclosed"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DF-006","moa":"ALPK1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Drug Farm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Undisclosed"},{"orgOrder":0,"company":"Drug Farm","sponsor":"YD Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Series C Financing","leadProduct":"DF-006","moa":"ALPK1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Drug Farm","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Liquid","sponsorNew":"Drug Farm \/ YD Capital","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ YD Capital"},{"orgOrder":0,"company":"Drug Farm","sponsor":"BioVeda China Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"DF-006","moa":"ALPK1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Drug Farm","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Drug Farm \/ BioVeda China Fund","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ BioVeda China Fund"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Xiamen Amoytop Biotech Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"DF-006","moa":"ALPK1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Drug Farm \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Xiamen Amoytop Biotech Co., Ltd"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"ALPK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Drug Farm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Undisclosed"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"ALPK1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Drug Farm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Undisclosed"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"ALPK1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Drug Farm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Undisclosed"},{"orgOrder":0,"company":"Drug Farm","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"ALPK1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Drug Farm \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"ALPK1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Drug Farm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"SGN-ALPV","moa":"ALPPL2","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Molecure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Molecure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Undisclosed"},{"orgOrder":0,"company":"Molecure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Molecure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Undisclosed"},{"orgOrder":0,"company":"Molecure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Molecure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Undisclosed"},{"orgOrder":0,"company":"Molecure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Molecure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Undisclosed"},{"orgOrder":0,"company":"Molecure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Molecure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Undisclosed"},{"orgOrder":0,"company":"OncoArendi Therapeutics","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"OncoArendi Therapeutics","amount2":0.38,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.38,"dosageForm":"Undisclosed","sponsorNew":"OncoArendi Therapeutics \/ Galapagos","highestDevelopmentStatusID":"8","companyTruncated":"OncoArendi Therapeutics \/ Galapagos"},{"orgOrder":0,"company":"Molecure","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecure \/ Galapagos","highestDevelopmentStatusID":"4","companyTruncated":"Molecure \/ Galapagos"},{"orgOrder":0,"company":"GamaMabs Pharma","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Murlentamab","moa":"AMHR2","graph1":"Oncology","graph2":"Preclinical","graph3":"GamaMabs Pharma","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"GamaMabs Pharma \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"GamaMabs Pharma \/ Exelixis"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Mercaptopurine","moa":"Amidophosphoribosyltransferase | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Children's Oncology Group \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ION-827359","moa":"Amiloride-sensitive sodium channel, ENaC mRNA","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vedic Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Vedic Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedic Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vedic Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Qingshan Likang Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Nephrology","graph2":"Phase IV","graph3":"Chengdu Qingshan Likang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Chengdu Qingshan Likang Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chengdu Qingshan Likang Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"DoubleGood AB","sponsor":"starScience GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"DoubleGood AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DoubleGood AB \/ starScience GmbH","highestDevelopmentStatusID":"1","companyTruncated":"DoubleGood AB \/ starScience GmbH"},{"orgOrder":0,"company":"ZandA Technologies, llc","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Undisclosed","graph2":"Phase II","graph3":"ZandA Technologies, llc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ZandA Technologies, llc \/ KGK Science","highestDevelopmentStatusID":"8","companyTruncated":"ZandA Technologies, llc \/ KGK Science"},{"orgOrder":0,"company":"UConn Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Neurology","graph2":"Phase I","graph3":"UConn Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UConn Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"UConn Health \/ Undisclosed"},{"orgOrder":0,"company":"Mead Johnson Nutrition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mead Johnson Nutrition","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mead Johnson Nutrition \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Mead Johnson Nutrition \/ Undisclosed"},{"orgOrder":0,"company":"The People's Hospital of Gaozhou","sponsor":"Chengdu Qingshan Likang Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"The People's Hospital of Gaozhou","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The People's Hospital of Gaozhou \/ Chengdu Qingshan Likang Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"The People's Hospital of Gaozhou \/ Chengdu Qingshan Likang Pharmaceutical"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Precision For Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Precision For Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Precision For Medicine"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Precision For Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Precision For Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Precision For Medicine"},{"orgOrder":0,"company":"VA Greater Los Angeles Healthcare System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase IV","graph3":"VA Greater Los Angeles Healthcare System","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Greater Los Angeles Healthcare System \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"VA Greater Los Angeles Healthcare System \/ Undisclosed"},{"orgOrder":0,"company":"Baptist Health","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Baptist Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baptist Health \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Baptist Health \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Baptist Health","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Baptist Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baptist Health \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Baptist Health \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Baptist Health","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Baptist Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baptist Health \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Baptist Health \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase I","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"6","companyTruncated":"Brigham and Women's Hospital \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"ECOG-ACRIN Cancer Research Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"ECOG-ACRIN Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Blue Earth Diagnostics | Dragon Master Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase I","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Philadelphia \/ Blue Earth Diagnostics | Dragon Master Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Children's Hospital of Philadelphia \/ Blue Earth Diagnostics | Dragon Master Foundation"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Blue Earth Diagnostics | Dragon Master Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase I","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Philadelphia \/ Blue Earth Diagnostics | Dragon Master Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Children's Hospital of Philadelphia \/ Blue Earth Diagnostics | Dragon Master Foundation"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Firibastat","moa":"Aminopeptidase A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Firibastat","moa":"Aminopeptidase A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ PRA Health Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ PRA Health Sciences"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Firibastat","moa":"Aminopeptidase A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Firibastat","moa":"Aminopeptidase A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Firibastat","moa":"Aminopeptidase A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Firibastat","moa":"Aminopeptidase A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Firibastat","moa":"Aminopeptidase A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Xediton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Firibastat","moa":"Aminopeptidase A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Xediton Pharmaceuticals"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Faran","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Firibastat","moa":"Aminopeptidase A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Faran","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Faran"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Eurofins CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Firibastat","moa":"Aminopeptidase A","graph1":"Nephrology","graph2":"Phase I","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum Genomics \/ Eurofins CDMO","highestDevelopmentStatusID":"6","companyTruncated":"Quantum Genomics \/ Eurofins CDMO"},{"orgOrder":0,"company":"Conmed Pharmaceutical","sponsor":"Tri-Service General Hospital | Tungs\u2019 Taichung Metroharbour Hospital | Chang Gung Memorial Hospital | Taichung Veterans General Hospital | Kaohsiung Medical University | Taichung Tzu Chi Hospital | Fu Jen Catholic University","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AST-120","moa":"Ammonia","graph1":"Dermatology","graph2":"Phase IV","graph3":"Conmed Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Conmed Pharmaceutical \/ Tri-Service General Hospital | Tungs\u2019 Taichung Metroharbour Hospital | Chang Gung Memorial Hospital | Taichung Veterans General Hospital | Kaohsiung Medical University | Taichung Tzu Chi Hospital | Fu Jen Catholic University","highestDevelopmentStatusID":"11","companyTruncated":"Conmed Pharmaceutical \/ Tri-Service General Hospital | Tungs\u2019 Taichung Metroharbour Hospital | Chang Gung Memorial Hospital | Taichung Veterans General Hospital | Kaohsiung Medical University | Taichung Tzu Chi Hospital | Fu Jen Catholic University"},{"orgOrder":0,"company":"Genfit","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genfit","amount2":0.19,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Genfit \/ HealthCare Royalty","highestDevelopmentStatusID":"8","companyTruncated":"Genfit \/ HealthCare Royalty"},{"orgOrder":0,"company":"Versantis","sponsor":"Genfit","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Versantis","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"Versantis \/ Genfit","highestDevelopmentStatusID":"8","companyTruncated":"Versantis \/ Genfit"},{"orgOrder":0,"company":"Versantis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versantis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Versantis \/ Undisclosed"},{"orgOrder":0,"company":"Versantis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versantis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Versantis \/ Undisclosed"},{"orgOrder":0,"company":"Versantis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Versantis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Versantis \/ Undisclosed"},{"orgOrder":0,"company":"Genfit","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genfit","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Genfit \/ HealthCare Royalty","highestDevelopmentStatusID":"8","companyTruncated":"Genfit \/ HealthCare Royalty"},{"orgOrder":0,"company":"Versantis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Versantis \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Versantis \/ Undisclosed"},{"orgOrder":0,"company":"Versantis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hematology","graph2":"Preclinical","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Versantis \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Versantis \/ Undisclosed"},{"orgOrder":0,"company":"Versantis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Neurology","graph2":"Phase II","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Versantis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Versantis \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Hong Kong Winhealth Pharma Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Amino Acid","year":"2021","type":"Collaboration","leadProduct":"L-Ornithine L-aspartate","moa":"Ammonia detoxification","graph1":"Neurology","graph2":"Approved FDF","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merz Pharma \/ Hong Kong Winhealth Pharma Group","highestDevelopmentStatusID":"15","companyTruncated":"Merz Pharma \/ Hong Kong Winhealth Pharma Group"},{"orgOrder":0,"company":"Hexaell Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"L-Ornithine L-aspartate","moa":"Ammonia detoxification","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Hexaell Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hexaell Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hexaell Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axcella Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Undisclosed"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axcella Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Axcella Health \/ Undisclosed"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axcella Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Undisclosed"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axcella Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Undisclosed"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axcella Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Undisclosed"},{"orgOrder":0,"company":"Axcella Health","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Axcella Health","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Axcella Health \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ J.P. Morgan"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axcella Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Axcella Health \/ Undisclosed"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axcella Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Axcella Health \/ Undisclosed"},{"orgOrder":0,"company":"Neuracle Science","sponsor":"Samsung Medical Center | Severance Hospital | Korea University Anam Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NS101","moa":"AMPA receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Neuracle Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuracle Science \/ Samsung Medical Center | Severance Hospital | Korea University Anam Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Neuracle Science \/ Samsung Medical Center | Severance Hospital | Korea University Anam Hospital"},{"orgOrder":0,"company":"Neuracle Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NS101","moa":"AMPA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Neuracle Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuracle Science \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Neuracle Science \/ Undisclosed"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RAP-219","moa":"AMPA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapport Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"RAP-219","moa":"AMPA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.17000000000000001,"dosageForm":"Tablet","sponsorNew":"Rapport Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RAP-219","moa":"AMPA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapport Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"RAP-219","moa":"AMPA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.17000000000000001,"dosageForm":"Tablet","sponsorNew":"Rapport Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RAP-219","moa":"AMPA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapport Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RAP-219","moa":"AMPA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapport Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NBI-1065846","moa":"AMPA receptor\/GPR139","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Inotiv","sponsor":"Sea Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"SPM-0404","moa":"AMPA receptor\/GRIK","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Inotiv","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inotiv \/ Sea Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Inotiv \/ Sea Pharmaceuticals"},{"orgOrder":0,"company":"Sea Pharmaceuticals","sponsor":"TCG Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"SPM-0404","moa":"AMPA receptor\/GRIK","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sea Pharmaceuticals \/ TCG Lifesciences","highestDevelopmentStatusID":"5","companyTruncated":"Sea Pharmaceuticals \/ TCG Lifesciences"},{"orgOrder":0,"company":"ImmunoMet","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"IM156","moa":"AMP-activated protein kinase (AMPK)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"ImmunoMet","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoMet \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"ImmunoMet \/ Undisclosed"},{"orgOrder":0,"company":"ImmunoMet","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"IM156","moa":"AMP-activated protein kinase (AMPK)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"ImmunoMet","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoMet \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"ImmunoMet \/ Undisclosed"},{"orgOrder":0,"company":"ImmunoMet","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IM156","moa":"||AMP-activated protein kinase (AMPK)","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoMet","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoMet \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoMet \/ Undisclosed"},{"orgOrder":0,"company":"National Center for Global Health and Medicine, Japan","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Imeglimin Hydrochloride","moa":"AMP-activated protein kinase (AMPK)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"National Center for Global Health and Medicine, Japan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Center for Global Health and Medicine, Japan \/ Sumitomo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"National Center for Global Health and Medicine, Japan \/ Sumitomo Pharma"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BLX-0871","moa":"AMPK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biolexis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biolexis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Neurology","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Neurology","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Neurology","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Clarke Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series A Financing","leadProduct":"MLX0800","moa":"AMPK","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biolexis Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Biolexis Therapeutics \/ Clarke Capital","highestDevelopmentStatusID":"4","companyTruncated":"Biolexis Therapeutics \/ Clarke Capital"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NBI-1065845","moa":"AMPK","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NBI-1065845","moa":"AMPK","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NBI-1065845","moa":"AMPK","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NBI-1065845","moa":"AMPK","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NBI-1065845","moa":"AMPK","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NBI-1065845","moa":"AMPK","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"NephroDI Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"NDI-5033","moa":"AMPK","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"NephroDI Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NephroDI Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"NephroDI Therapeutics \/ Xontogeny, LLC"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PXL065","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PXL065","moa":"AMPK","graph1":"Neurology","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PXL770","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PXL770","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PXL770","moa":"AMPK","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PXL770","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PXL770","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PXL770","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"JMP Securities","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"PXL770","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Poxel \/ JMP Securities","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ JMP Securities"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PXL770","moa":"AMPK","graph1":"Neurology","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"Poxel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"PXL770","moa":"AMPK","graph1":"Neurology","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"Solution","sponsorNew":"OrsoBio \/ Ascenta Capital","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Ascenta Capital"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"OrsoBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Samsara BioCapital","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Dermatology","graph2":"IND Enabling","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OrsoBio \/ Samsara BioCapital","highestDevelopmentStatusID":"5","companyTruncated":"OrsoBio \/ Samsara BioCapital"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pramlintide","moa":"||Amylin receptor AMY1, CALCR\/RAMP1","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pramlintide","moa":"||Amylin receptor AMY1, CALCR\/RAMP1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AbViro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Florbetaben","moa":"Amyloid||Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"AbViro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbViro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbViro \/ Undisclosed"},{"orgOrder":0,"company":"AbViro","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Florbetaben","moa":"Amyloid||Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"AbViro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbViro \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"AbViro \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"pharmtrace","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Florbetaben","moa":"Amyloid","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ pharmtrace","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ pharmtrace"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Remternetug","moa":"Amyloid","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Remternetug","moa":"Amyloid","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Alzheimer's Association | Eli Lilly | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Remternetug","moa":"Amyloid","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Alzheimer's Association | Eli Lilly | National Institute on Aging","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ Alzheimer's Association | Eli Lilly | National Institute on Aging"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Alzheimer's Association | Eli Lilly | National Institute on Aging | GHR Foundation | Private Donors","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Remternetug","moa":"Amyloid","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Alzheimer's Association | Eli Lilly | National Institute on Aging | GHR Foundation | Private Donors","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ Alzheimer's Association | Eli Lilly | National Institute on Aging | GHR Foundation | Private Donors"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Remternetug","moa":"Amyloid","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Trontinemab","moa":"Amyloid","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ABBV-916","moa":"Amyloid beta A4 protein (APP)","graph1":"Neurology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AC Immune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ACI-24","moa":"Amyloid beta A4 protein (APP)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AC Immune \/ Undisclosed"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ACU193","moa":"Amyloid beta A4 protein (APP)","graph1":"Neurology","graph2":"Phase I","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acumen Pharmaceuticals \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Acumen Pharmaceuticals \/ National Institute on Aging"},{"orgOrder":0,"company":"BeyondBio Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BEY2153","moa":"Amyloid beta A4 protein (APP)","graph1":"Neurology","graph2":"Phase II","graph3":"BeyondBio Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeyondBio Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BeyondBio Inc \/ Undisclosed"},{"orgOrder":0,"company":"BeyondBio Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BEY2153","moa":"Amyloid beta A4 protein (APP)","graph1":"Neurology","graph2":"Phase II","graph3":"BeyondBio Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeyondBio Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BeyondBio Inc \/ Undisclosed"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"EB-101","moa":"Amyloid beta A4 protein (APP)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Sheet","sponsorNew":"Abeona Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"EB-101","moa":"Amyloid beta A4 protein (APP)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Sheet","sponsorNew":"Abeona Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GV-971","moa":"Amyloid beta A4 protein (APP)","graph1":"Neurology","graph2":"Phase IV","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Valley Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Green Valley Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GV-971","moa":"Amyloid beta A4 protein (APP)","graph1":"Neurology","graph2":"Phase IV","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Valley Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Green Valley Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LY3372993","moa":"Amyloid beta A4 protein (APP)","graph1":"Neurology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"Gedeon Richter | University Hospital Antwerp | AZ Jan Palfijn Gent | Our Lady of Lourdes Hospital Waregem","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Inositol","moa":"Amyloid beta A4 protein (APP)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Ghent \/ Gedeon Richter | University Hospital Antwerp | AZ Jan Palfijn Gent | Our Lady of Lourdes Hospital Waregem","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital Ghent \/ Gedeon Richter | University Hospital Antwerp | AZ Jan Palfijn Gent | Our Lady of Lourdes Hospital Waregem"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Inositol","moa":"Amyloid beta A4 protein (APP)","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lo.Li.Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Inositol","moa":"Amyloid beta A4 protein (APP)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Lo.Li.Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Inositol","moa":"Amyloid beta A4 protein (APP)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Lo.Li.Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Inositol","moa":"Amyloid beta A4 protein (APP)","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw","highestDevelopmentStatusID":"1","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-311","moa":"Amyloid beta A4 protein (APP)","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ Undisclosed"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-311","moa":"Amyloid beta A4 protein (APP)","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ Undisclosed"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Public Offering","leadProduct":"UB-311","moa":"Amyloid beta A4 protein (APP)","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ BofA Securities"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"University of Florida","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"UB-311","moa":"Amyloid beta A4 protein (APP)","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ University of Florida","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ University of Florida"},{"orgOrder":0,"company":"AnaCardio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AC01","moa":"Amyloid-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"AnaCardio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AnaCardio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AnaCardio \/ Undisclosed"},{"orgOrder":0,"company":"Mitosynergy LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cunermuspir","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Mitosynergy LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mitosynergy LLC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mitosynergy LLC \/ Undisclosed"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GAL-201","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galimedix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galimedix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GAL-201","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galimedix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galimedix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GT316","moa":"Amyloid-beta","graph1":"Oncology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GT316","moa":"Amyloid-beta","graph1":"Oncology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Charsire Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Multiglycan Complex","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Charsire Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Charsire Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Charsire Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Undisclosed","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"BTIG","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ BTIG","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ BTIG"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Fenway Sports Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Fenway Sports Group","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Fenway Sports Group"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Great Point Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.12,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Great Point Partners","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Great Point Partners"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Affinity Asset Advisors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Affinity Asset Advisors","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Affinity Asset Advisors"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Fenway Sports Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2021","type":"Financing","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Fenway Sports Group","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Fenway Sports Group"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Leede Jones Gable","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2021","type":"Public Offering","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Leede Jones Gable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Leede Jones Gable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2021","type":"Public Offering","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"PRInnovation GmbH","sponsor":"Priavoid | SPRIN-D | Julius Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"PRI-002","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"PRInnovation GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PRInnovation GmbH \/ Priavoid | SPRIN-D | Julius Clinical","highestDevelopmentStatusID":"8","companyTruncated":"PRInnovation GmbH \/ Priavoid | SPRIN-D | Julius Clinical"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"Walgreens","sponsor":"Prothena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Walgreens","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Walgreens \/ Prothena","highestDevelopmentStatusID":"6","companyTruncated":"Walgreens \/ Prothena"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SLS-005","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SLS-005","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurimmune","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurimmune \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Neurimmune \/ Undisclosed"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Termination","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurimmune","amount2":0.38,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.38,"dosageForm":"Infusion","sponsorNew":"Neurimmune \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Neurimmune \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta A4 protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune \/ Genentech"},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Termination","leadProduct":"Crenezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0.41999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.41999999999999998,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune \/ Genentech"},{"orgOrder":0,"company":"AC Immune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"AC Immune","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ AC Immune","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ AC Immune"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Banner Alzheimer\u2019s Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Banner Alzheimer\u2019s Institute","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Banner Alzheimer\u2019s Institute"},{"orgOrder":0,"company":"Genentech","sponsor":"AC Immune","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ AC Immune","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ AC Immune"},{"orgOrder":0,"company":"Banner Alzheimer's Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Banner Alzheimer's Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Banner Alzheimer's Institute \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Banner Alzheimer's Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Banner Health","sponsor":"National Institute on Aging | Universidad de Antioquia","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Banner Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Banner Health \/ National Institute on Aging | Universidad de Antioquia","highestDevelopmentStatusID":"9","companyTruncated":"Banner Health \/ National Institute on Aging | Universidad de Antioquia"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Quanterix","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Quanterix","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Quanterix \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Quanterix \/ Eli Lilly"},{"orgOrder":0,"company":"Quanterix","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Quanterix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Quanterix \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Quanterix \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Donanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"MorphoSys","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MorphoSys \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly | F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly | F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ Eli Lilly | F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"C2N Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ C2N Diagnostics","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ C2N Diagnostics"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Undisclosed"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Undisclosed"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Undisclosed"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Undisclosed"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioArctic AB \/ Eisai Inc","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai Inc"},{"orgOrder":0,"company":"CareMed","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Partnership","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"CareMed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CareMed \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"CareMed \/ Eisai"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Alzheimer's Clinical Trials Consortium | Biogen | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai Inc \/ Alzheimer's Clinical Trials Consortium | Biogen | National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Eisai Inc \/ Alzheimer's Clinical Trials Consortium | Biogen | National Institute on Aging"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai Inc \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Eisai Inc \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Partnership","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Frontage Laboratories, Inc \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Frontage Laboratories, Inc \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Alzheimer's Association | Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Alzheimer's Association | Eisai Inc","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ Alzheimer's Association | Eisai Inc"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Solanezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Solanezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Solanezumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"||Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ National Institute on Aging"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Quotient Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Quotient Sciences"},{"orgOrder":0,"company":"Alzheon","sponsor":"Alerce Medical Technology Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series E Financing","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Alerce Medical Technology Partners","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Alerce Medical Technology Partners"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ National Institute on Aging"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series D Financing","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"CooperSurgical Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Copper","moa":"Amyloid-beta precursor protein; Adenosylhomocysteinase; Histone H2B type 1-C\/E\/F\/G\/I; Glyceraldehyde-3-phosphate dehydrogenase; Nucleoside diphosphate kinase A; Histone H1.4; Peroxiredoxin-1; Protein S100-A8; Small ribosomal subunit protein uS2; Actin, cytoplasmic 2; Alpha-enolase; Elongation factor 1-alpha 1; Keratin, type II cytoskeletal 8; Protein disulfide-isomerase; Protein disulfide-isomerase A3; 60 kDa heat shock protein, mitochondrial; Heat shock 70 kDa protein 13; Endoplasmic reticulum chaperone BiP; Endoplasmin; Serotransferrin; Cell growth-regulating nucleolar protein; Small ribosomal subunit protein uS5; Serine\/arginine-rich splicing factor 1; Heterogeneous nuclear ribonucleoproteins A2\/B1; Heterogeneous nuclear ribonucleoprotein H; Heterogeneous nuclear ribonucleoprotein H3; Cobalt-precorrin-5B C(1)-methyltransferase; Heterogeneous nuclear ribonucleoprotein L; Splicing factor, proline- and glutamine-rich; Splicing factor 3A subunit 2; Small ribosomal subunit protein RACK1;","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"CooperSurgical Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"CooperSurgical Inc. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"CooperSurgical Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Israelita Albert Einstein","sponsor":"Essity","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Copper","moa":"Amyloid-beta precursor protein; Adenosylhomocysteinase; Histone H2B type 1-C\/E\/F\/G\/I; Glyceraldehyde-3-phosphate dehydrogenase; Nucleoside diphosphate kinase A; Histone H1.4; Peroxiredoxin-1; Protein S100-A8; Small ribosomal subunit protein uS2; Actin, cytoplasmic 2; Alpha-enolase; Elongation factor 1-alpha 1; Keratin, type II cytoskeletal 8; Protein disulfide-isomerase; Protein disulfide-isomerase A3; 60 kDa heat shock protein, mitochondrial; Heat shock 70 kDa protein 13; Endoplasmic reticulum chaperone BiP; Endoplasmin; Serotransferrin; Cell growth-regulating nucleolar protein; Small ribosomal subunit protein uS5; Serine\/arginine-rich splicing factor 1; Heterogeneous nuclear ribonucleoproteins A2\/B1; Heterogeneous nuclear ribonucleoprotein H; Heterogeneous nuclear ribonucleoprotein H3; Cobalt-precorrin-5B C(1)-methyltransferase; Heterogeneous nuclear ribonucleoprotein L; Splicing factor, proline- and glutamine-rich; Splicing factor 3A subunit 2; Small ribosomal subunit protein RACK1;","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Hospital Israelita Albert Einstein","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Israelita Albert Einstein \/ Essity","highestDevelopmentStatusID":"9","companyTruncated":"Hospital Israelita Albert Einstein \/ Essity"},{"orgOrder":0,"company":"The Institute for Molecular Medicine","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FINLAND","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"AV-1959R","moa":"Amyloid-beta-plaque||Amyloid-beta\/Tau","graph1":"Neurology","graph2":"Preclinical","graph3":"The Institute for Molecular Medicine","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"The Institute for Molecular Medicine \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"The Institute for Molecular Medicine \/ National Institute on Aging"},{"orgOrder":0,"company":"Nuravax","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"AV-1959R","moa":"||Amyloid-beta\/Tau","graph1":"Neurology","graph2":"Phase I","graph3":"Nuravax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuravax \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Nuravax \/ National Institutes of Health"},{"orgOrder":0,"company":"Nuravax","sponsor":"Arvax","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"AV-1959R","moa":"Amyloid-beta\/Tau","graph1":"Neurology","graph2":"Phase I","graph3":"Nuravax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuravax \/ Arvax","highestDevelopmentStatusID":"6","companyTruncated":"Nuravax \/ Arvax"},{"orgOrder":0,"company":"Alzinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ALZ-201","moa":"Amyloid-beta-42 aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alzinova \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Alzinova \/ Undisclosed"},{"orgOrder":0,"company":"Alzinova","sponsor":"CRST Oy","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta-oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alzinova \/ CRST Oy","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ CRST Oy"},{"orgOrder":0,"company":"Alzinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta-oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alzinova \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Undisclosed"},{"orgOrder":0,"company":"Alzinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta-oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alzinova \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Undisclosed"},{"orgOrder":0,"company":"Alzinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta-oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alzinova \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Undisclosed"},{"orgOrder":0,"company":"Alzinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta-oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alzinova \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Undisclosed"},{"orgOrder":0,"company":"Alzinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta-oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alzinova \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Undisclosed"},{"orgOrder":0,"company":"Sinotau Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F Florbetaben","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"Undisclosed","graph3":"Sinotau Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinotau Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sinotau Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"pharmtrace klinische Entwicklung","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F Florbetaben","moa":"Amyloid-beta-plaque","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ pharmtrace klinische Entwicklung","highestDevelopmentStatusID":"10","companyTruncated":"Life Molecular Imaging \/ pharmtrace klinische Entwicklung"},{"orgOrder":0,"company":"Brain Health Alliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F Florbetapir","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"Phase I","graph3":"Brain Health Alliance","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brain Health Alliance \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Brain Health Alliance \/ Undisclosed"},{"orgOrder":0,"company":"HTA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"18-F Florbetazine","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"Phase I","graph3":"HTA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HTA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HTA \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F Flutemetamol","moa":"Amyloid-beta-plaque","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Yale University \/ Pfizer Inc"},{"orgOrder":0,"company":"Nuravax","sponsor":"National Institute on Aging | Institute for Molecular Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"DUVAX","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"Phase I","graph3":"Nuravax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuravax \/ National Institute on Aging | Institute for Molecular Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Nuravax \/ National Institute on Aging | Institute for Molecular Medicine"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ALZN002","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alzamend Neuro \/ Biorasi","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Biorasi"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ALZN002","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Biorasi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"ALZN002","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alzamend Neuro \/ Biorasi","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Biorasi"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"BitNile Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ALZN002","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alzamend Neuro \/ BitNile Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ BitNile Holdings"},{"orgOrder":0,"company":"The Institute for Molecular Medicine","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FINLAND","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"AV-1959D","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"The Institute for Molecular Medicine","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"The Institute for Molecular Medicine \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"The Institute for Molecular Medicine \/ National Institute on Aging"},{"orgOrder":0,"company":"Institute for Molecular Medicine","sponsor":"National Institute on Aging | Clinartis","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AV-1959D","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase I","graph3":"Institute for Molecular Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Institute for Molecular Medicine \/ National Institute on Aging | Clinartis","highestDevelopmentStatusID":"6","companyTruncated":"Institute for Molecular Medicine \/ National Institute on Aging | Clinartis"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"The Department Of Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ The Department Of Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ The Department Of Biotechnology"},{"orgOrder":0,"company":"The Institute for Molecular Medicine","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FINLAND","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"The Institute for Molecular Medicine","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"The Institute for Molecular Medicine \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"The Institute for Molecular Medicine \/ National Institute on Aging"},{"orgOrder":0,"company":"Touchlight","sponsor":"University of Nottingham","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Touchlight \/ University of Nottingham","highestDevelopmentStatusID":"4","companyTruncated":"Touchlight \/ University of Nottingham"},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takis Biotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"Karolinska Institutet","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cobra Biologics \/ Karolinska Institutet","highestDevelopmentStatusID":"4","companyTruncated":"Cobra Biologics \/ Karolinska Institutet"},{"orgOrder":0,"company":"Scancell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scancell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scancell \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Scancell \/ Undisclosed"},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Applied DNA Sciences Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Applied DNA Sciences Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Applied DNA Sciences Inc \/ Undisclosed"},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Applied DNA Sciences Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Applied DNA Sciences Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Applied DNA Sciences Inc \/ Undisclosed"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"7HP349","moa":"||Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"7 Hills Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"7 Hills Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"AnGes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnGes \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AnGes \/ Undisclosed"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ology Bioservices","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"City of Hope","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ Undisclosed"},{"orgOrder":0,"company":"University of Adelaide","sponsor":"Enesi Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Adelaide","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Adelaide \/ Enesi Pharma Limited","highestDevelopmentStatusID":"1","companyTruncated":"University of Adelaide \/ Enesi Pharma Limited"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Hoth Therapeutics \/ Washington University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Hoth Therapeutics \/ Washington University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase IV","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Green Valley Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase IV","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Green Valley Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase IV","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Green Valley Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase IV","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Green Valley Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase IV","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Green Valley Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jawaharlal Nehru Centre for Advanced Scientific Research","sponsor":"IGC Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"TGR-63","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Jawaharlal Nehru Centre for Advanced Scientific Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jawaharlal Nehru Centre for Advanced Scientific Research \/ IGC Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Jawaharlal Nehru Centre for Advanced Scientific Research \/ IGC Pharma"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TGR-63","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TGR-63","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TGR-63","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TGR-63","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGC Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AccurEdit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ART001","moa":"Amyloidogenic TTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AccurEdit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AccurEdit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AccurEdit Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AccurEdit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ART001","moa":"Amyloidogenic TTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AccurEdit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AccurEdit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AccurEdit Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AccurEdit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ART001","moa":"Amyloidogenic TTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AccurEdit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AccurEdit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AccurEdit Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Amycretin","moa":"GLP-1\/Amylin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Amycretin","moa":"GLP-1\/Amylin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Amycretin","moa":"GLP-1\/Amylin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Amycretin","moa":"AMYR","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AZD6234","moa":"AMYR","graph1":"Undisclosed","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AZD6234","moa":"AMYR","graph1":"Undisclosed","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AZD6234","moa":"AMYR","graph1":"Endocrinology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AZD6234","moa":"AMYR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AZD6234","moa":"AMYR","graph1":"Nephrology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AZD6234","moa":"AMYR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AZD6234","moa":"AMYR","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Spirig Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Tibolone","moa":"anabolic steroids; steroids (not prednisolone derivatives)","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mithra Pharmaceuticals \/ Spirig Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Spirig Healthcare"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"BIOSYENT PHARMA INC","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Tibolone","moa":"anabolic steroids; steroids (not prednisolone derivatives)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mithra Pharmaceuticals \/ BIOSYENT PHARMA INC","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ BIOSYENT PHARMA INC"},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Celerion | National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Desmetramadol","moa":"analgesics (mixed opiate receptor agonists\/antagonists)","graph1":"Neurology","graph2":"Phase I","graph3":"Syntrix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syntrix Pharmaceuticals \/ Celerion | National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Syntrix Pharmaceuticals \/ Celerion | National Institute on Drug Abuse"},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Desmetramadol","moa":"analgesics (mixed opiate receptor agonists\/antagonists)","graph1":"Neurology","graph2":"Phase I","graph3":"Syntrix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syntrix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Syntrix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"PF-04457845","moa":"Anandamide amidohydrolase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.40999999999999998,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TPX-0131","moa":"Anaplastic lymphoma kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Turning Point Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Turning Point Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TPX-0131","moa":"Anaplastic lymphoma kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Turning Point Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Turning Point Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Physiomics","sponsor":"ValiRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"VAL201","moa":"Androgen activated SRC kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Physiomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Physiomics \/ ValiRx","highestDevelopmentStatusID":"7","companyTruncated":"Physiomics \/ ValiRx"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Center for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Center for Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Center for Cancer Research"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"AUSTRIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Enanthate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"AUSTRIA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Sunshine Mandi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Zhejiang Sunshine Mandi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Zhejiang Sunshine Mandi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Sunshine Mandi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Sunshine Mandi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Zhejiang Sunshine Mandi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Zhejiang Sunshine Mandi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Sunshine Mandi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AnHorn Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AH 001","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"AnHorn Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnHorn Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnHorn Medicines \/ Undisclosed"},{"orgOrder":0,"company":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Chinese University of Hong Kong","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Chinese University of Hong Kong","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese University of Hong Kong \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Chinese University of Hong Kong \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Kindai University","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Kindai University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kindai University \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Kindai University \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BDR Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Cambridge University Hospitals NHS Foundation Trust","sponsor":"University of Cambridge | Janssen-Cilag","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cambridge University Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cambridge University Hospitals NHS Foundation Trust \/ University of Cambridge | Janssen-Cilag","highestDevelopmentStatusID":"8","companyTruncated":"Cambridge University Hospitals NHS Foundation Trust \/ University of Cambridge | Janssen-Cilag"},{"orgOrder":0,"company":"Universit\u00e4t M\u00fcnster","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Universit\u00e4t M\u00fcnster","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e4t M\u00fcnster \/ Janssen Pharmaceutica","highestDevelopmentStatusID":"8","companyTruncated":"Universit\u00e4t M\u00fcnster \/ Janssen Pharmaceutica"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Jonsson Comprehensive Cancer Center \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Johnson & Johnson Innovative Medicine | University Health Network, Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of British Columbia \/ Johnson & Johnson Innovative Medicine | University Health Network, Toronto","highestDevelopmentStatusID":"8","companyTruncated":"University of British Columbia \/ Johnson & Johnson Innovative Medicine | University Health Network, Toronto"},{"orgOrder":0,"company":"ECOG-ACRIN Cancer Research Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ECOG-ACRIN Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute"},{"orgOrder":0,"company":"University of Washington","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"University of Washington \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Aragon Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Aragon Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Aragon Pharmaceuticals"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Veracyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veracyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Veracyte \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veracyte \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Edwin Posadas","sponsor":"Kairos Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Edwin Posadas","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Edwin Posadas \/ Kairos Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Edwin Posadas \/ Kairos Pharma"},{"orgOrder":0,"company":"University of Southern California","sponsor":"National Cancer Institute | Auransa","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AU-409","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"University of Southern California","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Southern California \/ National Cancer Institute | Auransa","highestDevelopmentStatusID":"6","companyTruncated":"University of Southern California \/ National Cancer Institute | Auransa"},{"orgOrder":0,"company":"Alessa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bicalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Alessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alessa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alessa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alessa Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bicalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Alessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alessa Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Alessa Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2025","type":"Inapplicable","leadProduct":"BMS-986365","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"BMS-986365","moa":"Androgen receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"BMS-986365","moa":"Androgen receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CB03-154","moa":"Androgen receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Zhimeng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Zhimeng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CB03-154","moa":"Androgen receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Zhimeng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Zhimeng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CB03-154","moa":"Androgen receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Zhimeng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Zhimeng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CB03-154","moa":"Androgen receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Zhimeng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Zhimeng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Cassiopea","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Cassiopea","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Cassiopea"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Glenmark Pharmaceuticals \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"InfectoPharm Drugs and Consilium","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cosmo Pharmaceuticals \/ InfectoPharm Drugs and Consilium","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ InfectoPharm Drugs and Consilium"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"3S Bio Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.070000000000000007,"dosageForm":"Cream","sponsorNew":"Cosmo Pharmaceuticals \/ 3S Bio Inc","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ 3S Bio Inc"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hyphens Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Hyphens Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Hyphens Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hyundai Pharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Hyundai Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Hyundai Pharm"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0.23999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.23999999999999999,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.23999999999999999,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Undisclosed"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Ergomed | Pharmapace | Canfield Scientific | Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cassiopea \/ Ergomed | Pharmapace | Canfield Scientific | Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Cassiopea \/ Ergomed | Pharmapace | Canfield Scientific | Icon Plc"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Ergomed | Pharmapace | Canfield Scientific | Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cassiopea \/ Ergomed | Pharmapace | Canfield Scientific | Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Cassiopea \/ Ergomed | Pharmapace | Canfield Scientific | Icon Plc"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cosmo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cosmo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Narrows Institute for Biomedical Research","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Narrows Institute for Biomedical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Narrows Institute for Biomedical Research \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"8","companyTruncated":"Narrows Institute for Biomedical Research \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Curia","sponsor":"Cassiopea","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Curia \/ Cassiopea","highestDevelopmentStatusID":"15","companyTruncated":"Curia \/ Cassiopea"},{"orgOrder":0,"company":"National Cancer Center Hospital East","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Center Hospital East","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Cancer Center Hospital East \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Center Hospital East \/ Bayer AG"},{"orgOrder":0,"company":"Cancer Research Antwerp","sponsor":"Bayer AG | Veracyte","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Cancer Research Antwerp","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cancer Research Antwerp \/ Bayer AG | Veracyte","highestDevelopmentStatusID":"9","companyTruncated":"Cancer Research Antwerp \/ Bayer AG | Veracyte"},{"orgOrder":0,"company":"UNICANCER","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"UNICANCER","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UNICANCER \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"UNICANCER \/ Bayer AG"},{"orgOrder":0,"company":"UNICANCER","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"UNICANCER","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UNICANCER \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"UNICANCER \/ Bayer AG"},{"orgOrder":0,"company":"Association Pour La Recherche des Th\u00e9rapeutiques Innovantes en Canc\u00e9rologie","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Association Pour La Recherche des Th\u00e9rapeutiques Innovantes en Canc\u00e9rologie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Association Pour La Recherche des Th\u00e9rapeutiques Innovantes en Canc\u00e9rologie \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Association Pour La Recherche des Th\u00e9rapeutiques Innovantes en Canc\u00e9rologie \/ Bayer AG"},{"orgOrder":0,"company":"UNICANCER","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"UNICANCER","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UNICANCER \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"UNICANCER \/ Bayer AG"},{"orgOrder":0,"company":"Institut Claudius Regaud","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Institut Claudius Regaud","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Institut Claudius Regaud \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Institut Claudius Regaud \/ Bayer AG"},{"orgOrder":0,"company":"Institut Bergoni\u00e9","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Institut Bergoni\u00e9","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Bergoni\u00e9 \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Institut Bergoni\u00e9 \/ Bayer AG"},{"orgOrder":0,"company":"Jena University Hospital","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Jena University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jena University Hospital \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Jena University Hospital \/ Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"IQWiG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"IQWiG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IQWiG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"IQWiG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2023","type":"Agreement","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"AdventHealth","sponsor":"Bayer AG | Sumitomo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AdventHealth","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AdventHealth \/ Bayer AG | Sumitomo Pharma","highestDevelopmentStatusID":"6","companyTruncated":"AdventHealth \/ Bayer AG | Sumitomo Pharma"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Merck & Co | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Merck & Co | Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Merck & Co | Bayer AG"},{"orgOrder":0,"company":"ECOG-ACRIN Cancer Research Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ECOG-ACRIN Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute"},{"orgOrder":0,"company":"Alliance Foundation Trials","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Alliance Foundation Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alliance Foundation Trials \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Alliance Foundation Trials \/ Bayer AG"},{"orgOrder":0,"company":"GenesisCare USA","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"GenesisCare USA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenesisCare USA \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"GenesisCare USA \/ Bayer AG"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Biotechnology \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Biotechnology \/ Bayer AG"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orion Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orion Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orion Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Agreement","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Biotechnology","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Orion Biotechnology \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Biotechnology \/ Bayer AG"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Collaboration","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Thermo Fisher Scientific \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fisher Scientific \/ Bayer AG"},{"orgOrder":0,"company":"D'Or Institute for Research and Education","sponsor":"Bayer AG | RPH Central Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BRAZIL","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"D'Or Institute for Research and Education","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"D'Or Institute for Research and Education \/ Bayer AG | RPH Central Pharma","highestDevelopmentStatusID":"8","companyTruncated":"D'Or Institute for Research and Education \/ Bayer AG | RPH Central Pharma"},{"orgOrder":0,"company":"Brazilian Clinical Research Institute","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BRAZIL","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Brazilian Clinical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Brazilian Clinical Research Institute \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Brazilian Clinical Research Institute \/ Bayer AG"},{"orgOrder":0,"company":"Trans Tasman Radiation Oncology Group","sponsor":"Bayer AG | Peter MacCallum Cancer Centre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Trans Tasman Radiation Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trans Tasman Radiation Oncology Group \/ Bayer AG | Peter MacCallum Cancer Centre","highestDevelopmentStatusID":"8","companyTruncated":"Trans Tasman Radiation Oncology Group \/ Bayer AG | Peter MacCallum Cancer Centre"},{"orgOrder":0,"company":"University of Tennessee Health Science Center","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"University of Tennessee Health Science Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Tennessee Health Science Center \/ US Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"University of Tennessee Health Science Center \/ US Department of Defense"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Veru \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Veru \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen Receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli Lilly"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"University of Adelaide","sponsor":"Veru","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"University of Adelaide","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Adelaide \/ Veru","highestDevelopmentStatusID":"8","companyTruncated":"University of Adelaide \/ Veru"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Hinova","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor||AR","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Hinova","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Hinova"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"BDR Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ume\u00e5 University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ume\u00e5 University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ume\u00e5 University \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ume\u00e5 University \/ Undisclosed"},{"orgOrder":0,"company":"MEDSIR","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"MEDSIR","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEDSIR \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"MEDSIR \/ Pfizer Inc"},{"orgOrder":0,"company":"Nanoform","sponsor":"ONConcept Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Nanoform \/ ONConcept Consortium","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/ ONConcept Consortium"},{"orgOrder":0,"company":"CHU de Quebec-Universite Laval","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"CHU de Quebec-Universite Laval","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CHU de Quebec-Universite Laval \/ Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"CHU de Quebec-Universite Laval \/ Astellas Pharma"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University Health Network, Toronto \/ Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ Astellas Pharma"},{"orgOrder":0,"company":"University of Michigan Rogel Cancer Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Michigan Rogel Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan Rogel Cancer Center \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"University of Michigan Rogel Cancer Center \/ Incyte Corporation"},{"orgOrder":0,"company":"MANA RBM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"MANA RBM","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MANA RBM \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MANA RBM \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Astellas Pharma"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alessa Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Alessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alessa Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Alessa Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Astellas Pharma | Breast Cancer Research Foundation | Corcept Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Astellas Pharma | Breast Cancer Research Foundation | Corcept Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Astellas Pharma | Breast Cancer Research Foundation | Corcept Therapeutics"},{"orgOrder":0,"company":"MANA RBM","sponsor":"Bayer AG | Carolina Urologic Research Center | Tulane University | Barbara Ann Karmanos Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"MANA RBM","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MANA RBM \/ Bayer AG | Carolina Urologic Research Center | Tulane University | Barbara Ann Karmanos Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"MANA RBM \/ Bayer AG | Carolina Urologic Research Center | Tulane University | Barbara Ann Karmanos Cancer Institute"},{"orgOrder":0,"company":"Hinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hinova \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hinova \/ Undisclosed"},{"orgOrder":0,"company":"Hinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hinova \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hinova \/ Undisclosed"},{"orgOrder":0,"company":"Hinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hinova \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hinova \/ Undisclosed"},{"orgOrder":0,"company":"Hinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hinova \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hinova \/ Undisclosed"},{"orgOrder":0,"company":"Hinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hinova \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Hinova \/ Undisclosed"},{"orgOrder":0,"company":"Jemincare","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"JMKX002992","moa":"Androgen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0.65000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.65000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Jemincare \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Genentech"},{"orgOrder":0,"company":"Suzhou Koshine Biomedica, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KX-826","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Suzhou Koshine Biomedica, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Koshine Biomedica, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Koshine Biomedica, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KX-826","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Suzhou Koshine Biomedica, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KX-826","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Suzhou Koshine Biomedica, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Suzhou Koshine Biomedica, Inc."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Suzhou Koshine Biomedica, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KX-826","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Suzhou Koshine Biomedica, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Suzhou Koshine Biomedica, Inc."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KX-826","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"LPCN 1148","moa":"Androgen receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"PROTACs","year":"2021","type":"Inapplicable","leadProduct":"Luxdegalutamide","moa":"Androgen receptor||Androgen receptor (AR)","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"PROTACs","year":"2025","type":"Inapplicable","leadProduct":"Luxdegalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"PROTACs","year":"2025","type":"Inapplicable","leadProduct":"Luxdegalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Arvinas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"Luxdegalutamide","moa":"NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Undisclosed"},{"orgOrder":0,"company":"Arvinas","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2024","type":"Licensing Agreement","leadProduct":"Luxdegalutamide","moa":"||NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":1.1599999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.1599999999999999,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Nido Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NIDO-361","moa":"Androgen receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Nido Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nido Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nido Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Nido Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NIDO-361","moa":"Androgen receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Nido Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nido Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nido Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Nido Biosciences","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"NIDO-361","moa":"Androgen receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Nido Biosciences","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0.11,"dosageForm":"Tablet","sponsorNew":"Nido Biosciences \/ 5Am Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Nido Biosciences \/ 5Am Ventures"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"US Department of Defense | Walter Reed National Military Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Oxandrolone","moa":"Androgen Receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ US Department of Defense | Walter Reed National Military Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ US Department of Defense | Walter Reed National Military Medical Center"},{"orgOrder":0,"company":"Science Valley Research Institute","sponsor":"Stin Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Oxandrolone","moa":"Androgen Receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Science Valley Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Science Valley Research Institute \/ Stin Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Science Valley Research Institute \/ Stin Pharma"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Applied Biology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Applied Biology","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Applied Biology"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Applied Biology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Applied Biology","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Applied Biology"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"||Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Undisclosed","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Gree Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Gree Group","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Gree Group"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.23999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Corpometria Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"||Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Biology \/ Corpometria Institute","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Corpometria Institute"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Corpometria Institute","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Corpometria Institute","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Corpometria Institute"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ IQVIA"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Peking University First Hospital","sponsor":"Jiangsu Hengrui Pharmaceutical | Beijing Biote Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rezvilutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Peking University First Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Peking University First Hospital \/ Jiangsu Hengrui Pharmaceutical | Beijing Biote Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Peking University First Hospital \/ Jiangsu Hengrui Pharmaceutical | Beijing Biote Pharmaceutical"},{"orgOrder":0,"company":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rezvilutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"8","companyTruncated":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SHR3680","moa":"Androgen Receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SHR3680","moa":"Androgen Receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SHR3680","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SHR3680","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SHR3680","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SHR3680","moa":"Androgen Receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"University of Utah","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"University of Utah","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"University of Utah \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Utah \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Aleor Dermaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aleor Dermaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Canisius-Wilhelmina Hospital","sponsor":"Besins Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Canisius-Wilhelmina Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Canisius-Wilhelmina Hospital \/ Besins Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Canisius-Wilhelmina Hospital \/ Besins Healthcare"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"QuantumLeap Healthcare Collaborative","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"QuantumLeap Healthcare Collaborative","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QuantumLeap Healthcare Collaborative \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"QuantumLeap Healthcare Collaborative \/ Undisclosed"},{"orgOrder":0,"company":"Qualia Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Qualia Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualia Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Qualia Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"Empower Research","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"University of Miami \/ Empower Research","highestDevelopmentStatusID":"10","companyTruncated":"University of Miami \/ Empower Research"},{"orgOrder":0,"company":"Sports Medicine Research and Testing Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Sports Medicine Research and Testing Laboratory","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sports Medicine Research and Testing Laboratory \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sports Medicine Research and Testing Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Acerus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Acerus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Upsher-Smith Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Upsher-Smith Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Divestment","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Aytu BioPharma \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2022","type":"Agreement","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Verity Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Verity Pharmaceuticals Inc \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Verity Pharmaceuticals Inc \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Agreement","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"HavaH Therapeutics","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Hormone","year":"2021","type":"Licensing Agreement","leadProduct":"Testosterone","moa":"||Androgen Receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"HavaH Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"HavaH Therapeutics \/ Clarus Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"HavaH Therapeutics \/ Clarus Therapeutics"},{"orgOrder":0,"company":"Lars M\u00f8ller Pedersen","sponsor":"Besins Healthcare | Copenhagen University Hospital at Herlev | Zealand University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lars M\u00f8ller Pedersen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Lars M\u00f8ller Pedersen \/ Besins Healthcare | Copenhagen University Hospital at Herlev | Zealand University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Lars M\u00f8ller Pedersen \/ Besins Healthcare | Copenhagen University Hospital at Herlev | Zealand University Hospital"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"Dendreon","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Testosterone Cypionate","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Dendreon","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ Dendreon"},{"orgOrder":0,"company":"University of Miami","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Cypionate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Miami \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Miami \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Latin American Cooperative Oncology Group","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Cypionate","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Latin American Cooperative Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Latin American Cooperative Oncology Group \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Latin American Cooperative Oncology Group \/ Bayer AG"},{"orgOrder":0,"company":"North Florida Foundation for Research and Education","sponsor":"North Florida\/South Georgia Veterans Health System | Brooks Rehabilitation | University of Florida | VA Eastern Colorado Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Enanthate","moa":"Androgen Receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"North Florida Foundation for Research and Education","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"North Florida Foundation for Research and Education \/ North Florida\/South Georgia Veterans Health System | Brooks Rehabilitation | University of Florida | VA Eastern Colorado Health Care System","highestDevelopmentStatusID":"8","companyTruncated":"North Florida Foundation for Research and Education \/ North Florida\/South Georgia Veterans Health System | Brooks Rehabilitation | University of Florida | VA Eastern Colorado Health Care System"},{"orgOrder":0,"company":"Tulane University","sponsor":"LSU Health Sciences Center New Orleans | Antares Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Enanthate","moa":"Androgen Receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Tulane University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tulane University \/ LSU Health Sciences Center New Orleans | Antares Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Tulane University \/ LSU Health Sciences Center New Orleans | Antares Pharma"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Enanthate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Halozyme Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Halozyme Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","sponsor":"Bayer AG | The George Institute | HMRI","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Enanthate","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group \/ Bayer AG | The George Institute | HMRI","highestDevelopmentStatusID":"8","companyTruncated":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group \/ Bayer AG | The George Institute | HMRI"},{"orgOrder":0,"company":"Smartway Pharmaceuticals","sponsor":"Marinus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2023","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Smartway Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Smartway Pharmaceuticals \/ Marinus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Smartway Pharmaceuticals \/ Marinus Pharmaceuticals"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0.5,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.51000000000000001,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ Grunenthal","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Grunenthal"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0.51000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.51000000000000001,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ Grunenthal","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Grunenthal"},{"orgOrder":0,"company":"nuBioAge","sponsor":"Marius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2024","type":"Collaboration","leadProduct":"Testosterone Undecanoate","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"nuBioAge","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"nuBioAge \/ Marius Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"nuBioAge \/ Marius Pharmaceuticals"},{"orgOrder":0,"company":"University of Miami","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Miami \/ Clarus Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"University of Miami \/ Clarus Therapeutics"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Clarus Therapeutics | Allegheny Health Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Clarus Therapeutics | Allegheny Health Network","highestDevelopmentStatusID":"8","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Clarus Therapeutics | Allegheny Health Network"},{"orgOrder":0,"company":"St. Louis University","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"St. Louis University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"St. Louis University \/ Clarus Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"St. Louis University \/ Clarus Therapeutics"},{"orgOrder":0,"company":"Blue Water Acquisition Corporation","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Merger","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Blue Water Acquisition Corporation","amount2":0.38,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.38,"dosageForm":"Capsule","sponsorNew":"Blue Water Acquisition Corporation \/ Clarus Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Blue Water Acquisition Corporation \/ Clarus Therapeutics"},{"orgOrder":0,"company":"Tolmar","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tolmar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tolmar \/ Icon Plc","highestDevelopmentStatusID":"15","companyTruncated":"Tolmar \/ Icon Plc"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Gameday Men\u2019s Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Gameday Men\u2019s Health","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Gameday Men\u2019s Health"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Private Placement","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Private Placement","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mangoceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Halozyme Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Pharmalink, S.L.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Agreement","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Pharmalink, S.L.","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Pharmalink, S.L."},{"orgOrder":0,"company":"Lipocine","sponsor":"SPC Pharm","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ SPC Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ SPC Pharm"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Tolmar","sponsor":"UpScriptHealth","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Collaboration","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tolmar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tolmar \/ UpScriptHealth","highestDevelopmentStatusID":"15","companyTruncated":"Tolmar \/ UpScriptHealth"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Numan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Numan","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Numan"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Duke University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Duke University School of Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Duke University School of Medicine"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"USSM","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ USSM","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ USSM"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Tolmar","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Tolmar","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Tolmar"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Antares Pharma","amount2":0.95999999999999996,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.95999999999999996,"dosageForm":"Capsule","sponsorNew":"Antares Pharma \/ Halozyme Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Antares Pharma \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Antares Pharma","amount2":0.95999999999999996,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.95999999999999996,"dosageForm":"Capsule","sponsorNew":"Antares Pharma \/ Halozyme Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Antares Pharma \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Lipocine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antares Pharma \/ Lipocine","highestDevelopmentStatusID":"15","companyTruncated":"Antares Pharma \/ Lipocine"},{"orgOrder":0,"company":"Lipocine","sponsor":"Antares Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Licensing Agreement","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Antares Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Antares Pharma"},{"orgOrder":0,"company":"Lipocine","sponsor":"Antares Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Antares Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Antares Pharma"},{"orgOrder":0,"company":"Lipocine","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.27000000000000002,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Verity Pharmaceuticals Inc"},{"orgOrder":0,"company":"Lipocine","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.27000000000000002,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Verity Pharmaceuticals Inc"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Lipocine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Undisclosed"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"||Androgen Receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clarus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Hims & Hers Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Collaboration","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Hims & Hers Health","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Hims & Hers Health"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"TRACON Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"TRC253","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ TRACON Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ TRACON Pharmaceuticals"},{"orgOrder":0,"company":"YourChoice Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"YCT529","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"YourChoice Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YourChoice Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"YourChoice Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"YourChoice Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"YCT529","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"YourChoice Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YourChoice Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"YourChoice Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"AC0176","moa":"Androgen receptor (AR)","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AccutarBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Undisclosed"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"AC0176","moa":"Androgen receptor (AR)","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AccutarBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Undisclosed"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"AC0176","moa":"Androgen receptor (AR)","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AccutarBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Undisclosed"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"ARV-471","moa":"Androgen receptor (AR)","graph1":"Oncology","graph2":"Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"ARV-471","moa":"Androgen receptor (AR)","graph1":"Oncology","graph2":"Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Arvinas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"ARV-471","moa":"Androgen receptor (AR)","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Arvinas","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Arvinas"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Arvinas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"ARV-471","moa":"Androgen receptor (AR)","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Arvinas","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Arvinas"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Arvinas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"ARV-471","moa":"Androgen receptor (AR)","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Arvinas","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Arvinas"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Arvinas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"ARV-471","moa":"Androgen receptor (AR)","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Arvinas","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Arvinas"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Arvinas","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"ARV-471","moa":"Androgen receptor (AR)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Arvinas","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Arvinas"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Arvinas","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"ARV-471","moa":"Androgen receptor (AR)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Arvinas","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Arvinas"},{"orgOrder":0,"company":"Canadian Cancer Trials Group","sponsor":"ECOG-ACRIN Cancer Research Group | NRG Oncology | Alliance for Clinical Trials in Oncology | SWOG Cancer Research Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Androgen Receptor | Steroid 5-alpha-reductase | Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase III","graph3":"Canadian Cancer Trials Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian Cancer Trials Group \/ ECOG-ACRIN Cancer Research Group | NRG Oncology | Alliance for Clinical Trials in Oncology | SWOG Cancer Research Network","highestDevelopmentStatusID":"10","companyTruncated":"Canadian Cancer Trials Group \/ ECOG-ACRIN Cancer Research Group | NRG Oncology | Alliance for Clinical Trials in Oncology | SWOG Cancer Research Network"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Dendreon","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Androgen Receptor | Steroid 5-alpha-reductase | Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Dendreon","highestDevelopmentStatusID":"8","companyTruncated":"Moffitt Cancer Center \/ Dendreon"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"National Cancer Institute | Xencor","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Androgen Receptor | Steroid 5-alpha-reductase | Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase I","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ National Cancer Institute | Xencor","highestDevelopmentStatusID":"6","companyTruncated":"Gabrail Cancer Center Research \/ National Cancer Institute | Xencor"},{"orgOrder":0,"company":"Arvinas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ARV-393","moa":"Androgen receptor\/Proteasome (Cereblon)","graph1":"Oncology","graph2":"Phase I","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arvinas \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arvinas \/ Undisclosed"},{"orgOrder":0,"company":"AnHorn Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AH 001","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"AnHorn Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnHorn Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnHorn Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Phoenix Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Oleandrin","moa":"androgens","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Phoenix Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phoenix Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Phoenix Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Oleandrin","moa":"androgens","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Phoenix Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phoenix Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Abpro","sponsor":"Atlantic Coastal Acquisition Corp II","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Merger","leadProduct":"ABP-201","moa":"ANG-2\/VEGF","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ Atlantic Coastal Acquisition Corp II","highestDevelopmentStatusID":"5","companyTruncated":"Abpro \/ Atlantic Coastal Acquisition Corp II"},{"orgOrder":0,"company":"Abpro","sponsor":"YA II PN","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"ABP-201","moa":"ANG-2\/VEGF","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ YA II PN","highestDevelopmentStatusID":"5","companyTruncated":"Abpro \/ YA II PN"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegylated Recombinant Human Endostatin","moa":"Angiogenesis","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ixaka","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Financing","leadProduct":"Rexmyelocel-T","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ixaka","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.059999999999999998,"dosageForm":"Catheter","sponsorNew":"Ixaka \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ixaka \/ Undisclosed"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Bausch Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Bausch Health"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Bausch Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Bausch Health"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||VEGF\/PDGF receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||VEGF\/PDGF receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||VEGF\/PDGF receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||VEGF\/PDGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||VEGF\/PDGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||VEGF\/PDGF receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AnewPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||VEGF receptor\/PDGFR","graph1":"Oncology","graph2":"Phase I","graph3":"AnewPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AnewPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnewPharma \/ Undisclosed"},{"orgOrder":0,"company":"AnewPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||VEGF receptor\/PDGFR","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AnewPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnewPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnewPharma \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Betta Pharmaceuticals \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ EyePoint Pharmaceuticals"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase III","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase III","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase III","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.16,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase III","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Guggenheim Securities","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Guggenheim Securities"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Xcovery","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Xcovery","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Xcovery"},{"orgOrder":0,"company":"Equinox Science","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Equinox Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equinox Science \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Equinox Science \/ EyePoint Pharmaceuticals"},{"orgOrder":0,"company":"TaiRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Foslinanib","moa":"angiogenesis inhibitors; phosphoro-derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"TaiRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiRx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TaiRx \/ Undisclosed"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"TaiRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Foslinanib","moa":"||angiogenesis inhibitors; phosphoro-derivatives","graph1":"Oncology","graph2":"Phase II","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bora Pharmaceuticals \/ TaiRx","highestDevelopmentStatusID":"8","companyTruncated":"Bora Pharmaceuticals \/ TaiRx"},{"orgOrder":0,"company":"Heartseed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Heartseed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ Undisclosed"},{"orgOrder":0,"company":"Heartseed","sponsor":"Itochu Chemical Frontier","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Heartseed \/ Itochu Chemical Frontier","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ Itochu Chemical Frontier"},{"orgOrder":0,"company":"Heartseed","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2021","type":"Collaboration","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0.59999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.59999999999999998,"dosageForm":"Injection","sponsorNew":"Heartseed \/ Novo Nordisk","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ Novo Nordisk"},{"orgOrder":0,"company":"Heartseed","sponsor":"UTokyo Innovation Platform","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2021","type":"Series C Financing","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Heartseed \/ UTokyo Innovation Platform","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ UTokyo Innovation Platform"},{"orgOrder":0,"company":"Heartseed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Heartseed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ Undisclosed"},{"orgOrder":0,"company":"Heartseed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Heartseed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ Undisclosed"},{"orgOrder":0,"company":"AL-S Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SAUDI ARABIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AP-101","moa":"Angiopoietin 1 receptor (TEK)","graph1":"Neurology","graph2":"Phase II","graph3":"AL-S Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AL-S Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AL-S Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"TIMI Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ TIMI Study Group","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ TIMI Study Group"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akcea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akcea Therapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AV-001","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vasomune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AV-001","moa":"Angiopoietin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vasomune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vasomune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ReGenTree","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Actin (ACT)||Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"ReGenTree \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree \/ Undisclosed"},{"orgOrder":0,"company":"GtreeBNT","sponsor":"HLB Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GtreeBNT","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GtreeBNT \/ HLB Group","highestDevelopmentStatusID":"10","companyTruncated":"GtreeBNT \/ HLB Group"},{"orgOrder":0,"company":"GtreeBNT","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GtreeBNT","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GtreeBNT \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GtreeBNT \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Neurology","graph2":"Phase I","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"HLB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oil\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ HLB Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ HLB Therapeutics"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"HLB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oil\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ HLB Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ HLB Therapeutics"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oil\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"ReGenTree","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ ReGenTree","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ ReGenTree"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Private Placement","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Roth Capital Partners"},{"orgOrder":0,"company":"ReGenTree","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"ReGenTree \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"||Angiopoietin-1","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"ReGenTree","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ ReGenTree","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ ReGenTree"},{"orgOrder":0,"company":"ReGenTree","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"ReGenTree \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree \/ Undisclosed"},{"orgOrder":0,"company":"ReGenTree","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"ReGenTree \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree \/ Undisclosed"},{"orgOrder":0,"company":"ReGenTree","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"ReGenTree \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree \/ Undisclosed"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"AnGes","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vasomune Therapeutics \/ AnGes","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ AnGes"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vasomune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vasomune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vasomune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vasomune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Vasomune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2020","type":"Funding","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vasomune Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Vasomune Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LY3127804","moa":"Angiopoietin-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Zifibancimig","moa":"Angiopoietin-2 (ANGPT2)","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Jaeb Center for Health Research","sponsor":"National Eye Institute | National Institutes of Health | Alimera Sciences | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Jaeb Center for Health Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jaeb Center for Health Research \/ National Eye Institute | National Institutes of Health | Alimera Sciences | Genentech","highestDevelopmentStatusID":"10","companyTruncated":"Jaeb Center for Health Research \/ National Eye Institute | National Institutes of Health | Alimera Sciences | Genentech"},{"orgOrder":0,"company":"Jaeb Center for Health Research","sponsor":"National Eye Institute | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Jaeb Center for Health Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jaeb Center for Health Research \/ National Eye Institute | Genentech","highestDevelopmentStatusID":"10","companyTruncated":"Jaeb Center for Health Research \/ National Eye Institute | Genentech"},{"orgOrder":0,"company":"McMaster University","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"McMaster University \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"11","companyTruncated":"McMaster University \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Greater Houston Retina Research","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Greater Houston Retina Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Greater Houston Retina Research \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Greater Houston Retina Research \/ Genentech"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"XOMA","sponsor":"Blue Owl Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Financing","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"XOMA","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"XOMA \/ Blue Owl Capital","highestDevelopmentStatusID":"15","companyTruncated":"XOMA \/ Blue Owl Capital"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"LNA043","moa":"Angiopoietin-related protein 3 (ANGPTL3)","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"LNA043","moa":"Angiopoietin-related protein 3 (ANGPTL3)","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"LNA043","moa":"Angiopoietin-related protein 3 (ANGPTL3)","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Canakinumab","moa":"||Angiopoietin-related protein 3 (ANGPTL3)","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Allisartan Isoproxil","moa":"Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Allisartan Isoproxil","moa":"Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CAS 138564-60-0","moa":"Angiotensin II receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CAS 138564-60-0","moa":"Angiotensin II receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Emeriti Bio","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CAS 138564-60-0","moa":"Angiotensin II receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Vicore Pharma \/ Emeriti Bio","highestDevelopmentStatusID":"4","companyTruncated":"Vicore Pharma \/ Emeriti Bio"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LCZ 696","moa":"angiotensin II receptor antagonists; endopeptidase inhibitors","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"CFTX-1554","moa":"Angiotensin II type-2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0.63,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.63,"dosageForm":"Liquid","sponsorNew":"Confo Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Confo Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFTX-1554","moa":"Angiotensin II type-2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Confo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Confo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"CFTX-1554","moa":"Angiotensin II type-2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Confo Therapeutics \/ Flanders Innovation & Entrepreneurship","highestDevelopmentStatusID":"6","companyTruncated":"Confo Therapeutics \/ Flanders Innovation & Entrepreneurship"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFTX-1554","moa":"Angiotensin II type-2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Confo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Confo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CFTX-1554","moa":"Angiotensin II type-2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Confo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Confo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CFTX-1554","moa":"Angiotensin II type-2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Confo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Confo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"CFTX-1554","moa":"Angiotensin II type-2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Confo Therapeutics \/ Flanders Innovation & Entrepreneurship","highestDevelopmentStatusID":"6","companyTruncated":"Confo Therapeutics \/ Flanders Innovation & Entrepreneurship"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CFTX-1554","moa":"Angiotensin II type-2 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Confo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Confo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Tide Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TRD205","moa":"Angiotensin II type-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Beijing Tide Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beijing Tide Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tide Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Tide Pharmaceutical","sponsor":"Beijing Jishuitan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TRD205","moa":"Angiotensin II type-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Beijing Tide Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beijing Tide Pharmaceutical \/ Beijing Jishuitan Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tide Pharmaceutical \/ Beijing Jishuitan Hospital"},{"orgOrder":0,"company":"Beijing Tide Pharmaceutical","sponsor":"The Third Affiliated Hospital of Southern Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TRD205","moa":"Angiotensin II type-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Beijing Tide Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beijing Tide Pharmaceutical \/ The Third Affiliated Hospital of Southern Medical University","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tide Pharmaceutical \/ The Third Affiliated Hospital of Southern Medical University"},{"orgOrder":0,"company":"Beijing Tide Pharmaceutical","sponsor":"China-Japan Friendship Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TRD205","moa":"Angiotensin II type-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Beijing Tide Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beijing Tide Pharmaceutical \/ China-Japan Friendship Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tide Pharmaceutical \/ China-Japan Friendship Hospital"},{"orgOrder":0,"company":"Beijing Tide Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TRD205","moa":"Angiotensin II type-2 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Beijing Tide Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beijing Tide Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Tide Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"VP01","moa":"Angiotensin II type-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"VP01","moa":"Angiotensin II type-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"VP01","moa":"Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"SynerK PharmaTech","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Collaboration","leadProduct":"SNK-2726","moa":"Angiotensin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Huadong Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huadong Medicine \/ SynerK PharmaTech","highestDevelopmentStatusID":"4","companyTruncated":"Huadong Medicine \/ SynerK PharmaTech"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Captopril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Captopril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Second Affiliated Hospital, Zhejiang University","sponsor":"National Clinical Research Center, Southern Medical University | Ningbo Yinzhou Community Health Service Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Second Affiliated Hospital, Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Second Affiliated Hospital, Zhejiang University \/ National Clinical Research Center, Southern Medical University | Ningbo Yinzhou Community Health Service Center","highestDevelopmentStatusID":"10","companyTruncated":"Second Affiliated Hospital, Zhejiang University \/ National Clinical Research Center, Southern Medical University | Ningbo Yinzhou Community Health Service Center"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Azurity Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Enalapril Maleate","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Arbor Pharmaceuticals \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Arbor Pharmaceuticals \/ Azurity Pharma"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Enalaprilat","moa":"Angiotensin-converting enzyme","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nova Scotia Health Authority \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nova Scotia Health Authority \/ Undisclosed"},{"orgOrder":0,"company":"Yiling Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Yiling Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yiling Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Yiling Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Pharmtechnology","sponsor":"ClinPharmInvest","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELARUS","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmtechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmtechnology \/ ClinPharmInvest","highestDevelopmentStatusID":"6","companyTruncated":"Pharmtechnology \/ ClinPharmInvest"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Lupus Research Alliance","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Immunology","graph2":"Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Northwell Health \/ Lupus Research Alliance","highestDevelopmentStatusID":"8","companyTruncated":"Northwell Health \/ Lupus Research Alliance"},{"orgOrder":0,"company":"ALMATICA PHARMA INC","sponsor":"TWi Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ALMATICA PHARMA INC","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"ALMATICA PHARMA INC \/ TWi Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"ALMATICA PHARMA INC \/ TWi Pharmaceuticals"},{"orgOrder":0,"company":"Alvogen","sponsor":"AZTIQ PHARMA","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Lisinopril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alvogen","amount2":0.34999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Alvogen \/ AZTIQ PHARMA","highestDevelopmentStatusID":"15","companyTruncated":"Alvogen \/ AZTIQ PHARMA"},{"orgOrder":0,"company":"Yerevan State Medical University","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ARMENIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Perindopril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Yerevan State Medical University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yerevan State Medical University \/ Servier","highestDevelopmentStatusID":"11","companyTruncated":"Yerevan State Medical University \/ Servier"},{"orgOrder":0,"company":"Academisch Ziekenhuis Maastricht","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Perindopril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Academisch Ziekenhuis Maastricht","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Ziekenhuis Maastricht \/ ZonMw","highestDevelopmentStatusID":"11","companyTruncated":"Academisch Ziekenhuis Maastricht \/ ZonMw"},{"orgOrder":0,"company":"Pharmtechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELARUS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Perindopril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmtechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmtechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharmtechnology \/ Undisclosed"},{"orgOrder":0,"company":"Pharmtechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELARUS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Perindopril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmtechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmtechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharmtechnology \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Perindopril Erbumine","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Perindopril Erbumine","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Darnitsa","sponsor":"International Pharmaceutical Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UKRAINE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Perindopril Erbumine","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Darnitsa","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Darnitsa \/ International Pharmaceutical Research Center","highestDevelopmentStatusID":"6","companyTruncated":"Darnitsa \/ International Pharmaceutical Research Center"},{"orgOrder":0,"company":"Darnitsa","sponsor":"International Pharmaceutical Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UKRAINE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Perindopril Erbumine","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Darnitsa","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Darnitsa \/ International Pharmaceutical Research Center","highestDevelopmentStatusID":"6","companyTruncated":"Darnitsa \/ International Pharmaceutical Research Center"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Quinapril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Quinapril","moa":"Angiotensin-converting enzyme","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pharmtechnology","sponsor":"Ligand Research, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELARUS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ramipril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmtechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmtechnology \/ Ligand Research, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Pharmtechnology \/ Ligand Research, LLC"},{"orgOrder":0,"company":"Pharmtechnology","sponsor":"Ligand Research, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELARUS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ramipril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmtechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmtechnology \/ Ligand Research, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Pharmtechnology \/ Ligand Research, LLC"},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ramipril","moa":"Angiotensin-converting enzyme","graph1":"Undisclosed","graph2":"Phase I","graph3":"Midas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Midas Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Midas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ramipril","moa":"Angiotensin-converting enzyme","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California, San Diego \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"University of California, San Diego \/ Pfizer Inc"},{"orgOrder":0,"company":"University of California","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ramipril","moa":"Angiotensin-converting enzyme","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"University of California \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ALN-AGT01","moa":"Angiotensinogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"RN1871","moa":"Angiotensinogen","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Rona Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rona Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Rona Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ION904","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ION904","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"||Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"||Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Partnership","leadProduct":"Zilebesiran","moa":"||Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Argo Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BW-00112","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Argo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argo Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Argo Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Argo Biopharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"BW-00112","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Argo Biopharma","amount2":5.3600000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":5.3600000000000003,"dosageForm":"Injection","sponsorNew":"Argo Biopharma \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Argo Biopharma \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Daplusiran","moa":"ANGPTL3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"SHR-1918","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SHR-1918","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SHR-1918","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"SHR-1918","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SHR-1918","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"SHR-1918","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"VERVE-201","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Verve Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Verve Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"VERVE-201","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verve Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Verve Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Zodasiran","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EPI-8207","moa":"ANITAC","graph1":"Oncology","graph2":"Preclinical","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essa Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Essa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ETD002","moa":"Anoctamin-1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Enterprise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enterprise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ETD002","moa":"Anoctamin-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enterprise Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enterprise Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"ETD002","moa":"Anoctamin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enterprise Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Enterprise Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isoamyl Nitrite","moa":"ANP-1 receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isoamyl Nitrite","moa":"ANP-1 receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Triclabendazole","moa":"anthelmintics (tibendazole type)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"RUSSIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Magaldrate","moa":"antiacid aluminum salts","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LY03005","moa":"antianxiety","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ANeuroTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pipamperone","moa":"antianxiety agents\/neuroleptics (4-fluoro-4-piperidinobutyrophenone derivatives)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ANeuroTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ANeuroTech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ANeuroTech \/ Undisclosed"},{"orgOrder":0,"company":"ANeuroTech","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pipamperone","moa":"||antianxiety agents\/neuroleptics (4-fluoro-4-piperidinobutyrophenone derivatives)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ANeuroTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ANeuroTech \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"ANeuroTech \/ Johnson & Johnson"},{"orgOrder":0,"company":"Zhittya Genesis Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FGF-1","moa":"antiasthmatics\/antiallergics (not acting primarily as antihistamines)","graph1":"Neurology","graph2":"Phase I","graph3":"Zhittya Genesis Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Zhittya Genesis Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhittya Genesis Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Zhittya Genesis Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"FGF-1","moa":"antiasthmatics\/antiallergics (not acting primarily as antihistamines)","graph1":"Neurology","graph2":"Phase I","graph3":"Zhittya Genesis Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Zhittya Genesis Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhittya Genesis Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Repirinast","moa":"antiasthmatics\/antiallergics (not acting primarily as antihistamines)","graph1":"Nephrology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Repirinast","moa":"antiasthmatics\/antiallergics (not acting primarily as antihistamines)","graph1":"Nephrology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Zhejiang Ausun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Repirinast","moa":"antiasthmatics\/antiallergics (not acting primarily as antihistamines)","graph1":"Nephrology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Zhejiang Ausun Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Algernon Pharmaceuticals \/ Zhejiang Ausun Pharmaceutical"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"National Institute of General Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ National Institute of General Medical Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova \/ National Institute of General Medical Sciences"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Immunology","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Juntendo University","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Juntendo University","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Juntendo University"},{"orgOrder":0,"company":"Medicinova","sponsor":"Korean Intellectual Property Office","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Korean Intellectual Property Office","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Korean Intellectual Property Office"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Endocrinology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Fleroxacin","moa":"antibacterials (quinolone derivatives)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Beijing YouAn Hospital","sponsor":"Shenyang Tonglian Medicines Co.,Ltd | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Huangshi Central Hospital, China | Shenyang Pharmaceutical University | First Affiliated Hospital of Chongqing Medical University | The Second Affil","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Carrimycin","moa":"antibiotics (Streptomyces strains)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Beijing YouAn Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing YouAn Hospital \/ Shenyang Tonglian Medicines Co.,Ltd | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Huangshi Central Hospital, China | Shenyang Pharmaceutical University | First Affiliated Hospital of Chongqing Medical University | The Second Affil","highestDevelopmentStatusID":"11","companyTruncated":"Beijing YouAn Hospital \/ Shenyang Tonglian Medicines Co.,Ltd | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Huangshi Central Hospital, China | Shenyang Pharmaceutical University | First Affiliated Hospital of Chongqing Medical University | The Second Affil"},{"orgOrder":0,"company":"Shenyang Tonglian Medicines Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Carrimycin","moa":"antibiotics (Streptomyces strains)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shenyang Tonglian Medicines Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Shenyang Tonglian Medicines Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shenyang Tonglian Medicines Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shenyang Tonglian Medicines Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Carrimycin","moa":"antibiotics (Streptomyces strains)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shenyang Tonglian Medicines Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Shenyang Tonglian Medicines Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shenyang Tonglian Medicines Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Public Offering","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Thinkequity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Thinkequity"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Thinkequity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Thinkequity"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Sapien Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Salinomycin","moa":"||antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Sapien Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Sapien Biosciences"},{"orgOrder":0,"company":"OncoBay Clinical","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Agreement","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"OncoBay Clinical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoBay Clinical \/ Hillstream BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"OncoBay Clinical \/ Hillstream BioPharma"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Thinkequity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Thinkequity"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Agreement","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fosfomycin Sodium","moa":"antibiotics (Streptomyces strains); phosphoro-derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Fosfomycin Sodium","moa":"antibiotics (Streptomyces strains); phosphoro-derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Nabriva Therapeutics \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"Beijing Tiantan Hospital","sponsor":"Neurodawn Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Tiantan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beijing Tiantan Hospital \/ Neurodawn Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tiantan Hospital \/ Neurodawn Pharmaceutical"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Almirall"},{"orgOrder":0,"company":"Derm Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derm Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Derm Research \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Derm Research \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Undisclosed","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"||Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Medison Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Medison Pharma"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Undisclosed","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Undisclosed","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Undisclosed","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Genethon","sponsor":"Hansa Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Genethon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Genethon \/ Hansa Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Genethon \/ Hansa Biopharma"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Undisclosed","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Undisclosed","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0.40999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.40999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Hansa Biopharma \/ Sarepta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biopharma \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"||Antibodies","graph1":"Immunology","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansa Biopharma \/ Argenx","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biopharma \/ Argenx"},{"orgOrder":0,"company":"Kineta","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Alpha CD27 mab","moa":"Anti-CD27","graph1":"Oncology","graph2":"Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kineta \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kineta \/ Undisclosed"},{"orgOrder":0,"company":"InflammX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tonabersat","moa":"anticonvulsants","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"InflammX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InflammX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InflammX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"InflammX Therapeutics","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Tonabersat","moa":"anticonvulsants","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"InflammX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflammX Therapeutics \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"9","companyTruncated":"InflammX Therapeutics \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MDG1021","moa":"Antigen HA-1","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MDG1021","moa":"Antigen HA-1","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sobetirome","moa":"antihyperlipidemic","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Yale University \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zofenopril","moa":"antihypertensives (ACE inhibitors)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zofenopril","moa":"antihypertensives (ACE inhibitors)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"S.LAB (SOLOWAYS)","sponsor":"Center of New Medical Technologies | Triangel Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"RUSSIA","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Glucomannan","moa":"anti-inflammatory agents (acetic acid derivatives)","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"S.LAB (SOLOWAYS)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"S.LAB (SOLOWAYS) \/ Center of New Medical Technologies | Triangel Scientific","highestDevelopmentStatusID":"1","companyTruncated":"S.LAB (SOLOWAYS) \/ Center of New Medical Technologies | Triangel Scientific"},{"orgOrder":0,"company":"NeuroTau, Inc.","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tolfenamic Acid","moa":"anti-inflammatory agents (anthranilic acid derivatives) and their salts or esters","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NeuroTau, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroTau, Inc. \/ Cleveland Clinic","highestDevelopmentStatusID":"7","companyTruncated":"NeuroTau, Inc. \/ Cleveland Clinic"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bile Salts","moa":"anti-inflammatory agents (salicylic acid derivatives)","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyme Technologies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Tyme Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Beech Tree Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Thimerosal","moa":"anti-inflammatory agents (salicylic acid derivatives)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Beech Tree Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Beech Tree Labs \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Beech Tree Labs \/ Undisclosed"},{"orgOrder":0,"company":"Asili Research Alliance","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Artemisinin","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Asili Research Alliance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asili Research Alliance \/ Mateon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Asili Research Alliance \/ Mateon Therapeutics"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Artemisinin","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fosun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Swiss PharmaCan","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Artemisinin","moa":"||antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Swiss PharmaCan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Swiss PharmaCan \/ MGC Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Swiss PharmaCan \/ MGC Pharmaceuticals"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Artemisinin","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oncotelic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Oncotelic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Windlas Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Artemisinin","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Windlas Biotech","highestDevelopmentStatusID":"11","companyTruncated":"Mateon Therapeutics \/ Windlas Biotech"},{"orgOrder":0,"company":"Manus Bio","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Artemisinin","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Manus Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Manus Bio \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Manus Bio \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Artemisinin","moa":"||antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"MGC Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MGC Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Artemisinin","moa":"||antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"MGC Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MGC Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Malta Enerprises","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Artemisinin","moa":"||antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"MGC Pharmaceuticals \/ Malta Enerprises","highestDevelopmentStatusID":"8","companyTruncated":"MGC Pharmaceuticals \/ Malta Enerprises"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Artemisinin","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Undisclosed \/ Mateon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Undisclosed \/ Mateon Therapeutics"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase I","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odonate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Odonate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"||antineoplastics","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odonate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"||antineoplastics","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odonate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"antineoplastics","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odonate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"||antineoplastics","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odonate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Public Offering","leadProduct":"Tesetaxel","moa":"||antineoplastics","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Odonate Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deruxtecan","moa":"antineoplastics (camptothecine derivatives)","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deruxtecan","moa":"antineoplastics (camptothecine derivatives)","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deruxtecan","moa":"antineoplastics (camptothecine derivatives)","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deruxtecan","moa":"antineoplastics (camptothecine derivatives)","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deruxtecan","moa":"antineoplastics (camptothecine derivatives)","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Royal Marsden NHS Foundation Trust","sponsor":"Merck & Co | Mundipharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tinostamustine","moa":"antineoplastics (chloroethylamine derivatives)","graph1":"Oncology","graph2":"Phase I","graph3":"Royal Marsden NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal Marsden NHS Foundation Trust \/ Merck & Co | Mundipharma","highestDevelopmentStatusID":"6","companyTruncated":"Royal Marsden NHS Foundation Trust \/ Merck & Co | Mundipharma"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tinostamustine","moa":"antineoplastics (chloroethylamine derivatives)","graph1":"Oncology","graph2":"Phase I","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tinostamustine","moa":"antineoplastics (chloroethylamine derivatives)","graph1":"Oncology","graph2":"Phase I","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Glioblastoma Foundation Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Lisavanbulin","moa":"antineoplastics (mitotic inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Glioblastoma Foundation Inc","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Glioblastoma Foundation Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lisavanbulin","moa":"antineoplastics (mitotic inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Rabies Immunoglobulin","moa":"antineoplastics (mitotic inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Unesbulin","moa":"antineoplastics (mitotic inhibitors","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Unesbulin","moa":"antineoplastics (mitotic inhibitors","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Unesbulin","moa":"antineoplastics (mitotic inhibitors","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LianBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LianBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ Undisclosed"},{"orgOrder":0,"company":"LianBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LianBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ Undisclosed"},{"orgOrder":0,"company":"LianBio","sponsor":"Tarsus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LianBio \/ Tarsus Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ Tarsus Pharmaceuticals"},{"orgOrder":0,"company":"LianBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LianBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Dermatology","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series B Financing","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.059999999999999998,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Vivo Capital","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Vivo Capital"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorio Elea Phoenix","sponsor":"Drugs for Neglected Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ARGENTINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Benznidazole","moa":"antiprotozoal substances (metronidazole type)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laboratorio Elea Phoenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laboratorio Elea Phoenix \/ Drugs for Neglected Diseases","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorio Elea Phoenix \/ Drugs for Neglected Diseases"},{"orgOrder":0,"company":"Fiocruz","sponsor":"Nortec Quimica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2023","type":"Partnership","leadProduct":"Benznidazole","moa":"antiprotozoal substances (metronidazole type)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Fiocruz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fiocruz \/ Nortec Quimica","highestDevelopmentStatusID":"8","companyTruncated":"Fiocruz \/ Nortec Quimica"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fexinidazole","moa":"antiprotozoal substances (metronidazole type)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fexinidazole","moa":"antiprotozoal substances (metronidazole type)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fexinidazole","moa":"antiprotozoal substances (metronidazole type)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"World Health Organization","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Fexinidazole","moa":"antiprotozoal substances (metronidazole type)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"World Health Organization","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"World Health Organization \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"World Health Organization \/ Sanofi"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Bain Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":3.2999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":3.2999999999999998,"dosageForm":"Tablet, Modified Release","sponsorNew":"Mitsubishi Tanabe Pharma \/ Bain Capital","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Bain Capital"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roluperidone","moa":"antipsychotics (risperidone type)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Xyra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Budiodarone","moa":"antirrhythmics: indicates high iodine content","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Xyra","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xyra \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xyra \/ Undisclosed"},{"orgOrder":0,"company":"Xyra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Budiodarone","moa":"antirrhythmics: indicates high iodine content","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Xyra","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xyra \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xyra \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Fesomersen Sodium","moa":"Antisense oligonucleotide (FXI mRNA)","graph1":"Nephrology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"BIIB078","moa":"antisense oligonucleotides","graph1":"Neurology","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"BIIB078","moa":"antisense oligonucleotides","graph1":"Neurology","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"BIIB078","moa":"antisense oligonucleotides","graph1":"Neurology","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Donidalorsen","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Donidalorsen","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Donidalorsen","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Donidalorsen","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Licensing Agreement","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"antisense oligonucleotides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"antisense oligonucleotides","graph1":"Neurology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"antisense oligonucleotides","graph1":"Neurology","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ION251","moa":"antisense oligonucleotides","graph1":"Oncology","graph2":"Phase I","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Olezarsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Licensing Agreement","leadProduct":"Olezarsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Olezarsen Sodium","moa":"antisense oligonucleotides","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"WVE-120101","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wave Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"WVE-120102","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wave Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"WVE-120102","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wave Life Sciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Atenativ","moa":"Antithrombin III","graph1":"Hematology","graph2":"Phase IV","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Fitusiran","moa":"Antithrombin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Fitusiran","moa":"Antithrombin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Fitusiran","moa":"Antithrombin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Fitusiran","moa":"Antithrombin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Fitusiran","moa":"Antithrombin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galician Research Group on Digestive Tumors","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Oncology","graph2":"Phase III","graph3":"Galician Research Group on Digestive Tumors","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galician Research Group on Digestive Tumors \/ Leo Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Galician Research Group on Digestive Tumors \/ Leo Pharma"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Leo Pharma | Sunnybrook Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase IV","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Leo Pharma | Sunnybrook Research Institute","highestDevelopmentStatusID":"11","companyTruncated":"Sunnybrook Health Sciences Centre \/ Leo Pharma | Sunnybrook Research Institute"},{"orgOrder":0,"company":"Thrombosis Research Institute","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Thrombosis Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Thrombosis Research Institute \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Thrombosis Research Institute \/ Sanofi"},{"orgOrder":0,"company":"Valleywise Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Valleywise Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valleywise Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Valleywise Health \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"Children's Hospital Colorado | Children's Hospital of Philadelphia | BJC HealthCare | Medical College of Wisconsin | Children's of Alabama | Golisano Children's Hospital | Maria Fareri Children's Hospital | Nationwide Children\u2019s Hospital | New York Presby","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Yale University \/ Children's Hospital Colorado | Children's Hospital of Philadelphia | BJC HealthCare | Medical College of Wisconsin | Children's of Alabama | Golisano Children's Hospital | Maria Fareri Children's Hospital | Nationwide Children\u2019s Hospital | New York Presby","highestDevelopmentStatusID":"9","companyTruncated":"Yale University \/ Children's Hospital Colorado | Children's Hospital of Philadelphia | BJC HealthCare | Medical College of Wisconsin | Children's of Alabama | Golisano Children's Hospital | Maria Fareri Children's Hospital | Nationwide Children\u2019s Hospital | New York Presby"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"St. David's HealthCare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"St. David's HealthCare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. David's HealthCare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"St. David's HealthCare \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Farma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bio Farma \/ Undisclosed"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Venus Remedies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Venus Remedies \/ Undisclosed"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Saint Etienne","sponsor":"CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Centre Hospitalier Universitaire de Saint Etienne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centre Hospitalier Universitaire de Saint Etienne \/ CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang","highestDevelopmentStatusID":"11","companyTruncated":"Centre Hospitalier Universitaire de Saint Etienne \/ CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Minapharm Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"EGYPT","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Minapharm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minapharm Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Minapharm Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Western University, Canada","sponsor":"Valeo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Western University, Canada","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Western University, Canada \/ Valeo Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Western University, Canada \/ Valeo Pharma"},{"orgOrder":0,"company":"Techdow USA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Techdow USA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Techdow USA \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Techdow USA \/ Undisclosed"},{"orgOrder":0,"company":"Techdow USA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Techdow USA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Techdow USA \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Techdow USA \/ Undisclosed"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meitheal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Meitheal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Desjardins Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Private Placement","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Valeo Pharma","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Valeo Pharma \/ Desjardins Capital Markets","highestDevelopmentStatusID":"15","companyTruncated":"Valeo Pharma \/ Desjardins Capital Markets"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Group Purchasing Organizations","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valeo Pharma \/ Group Purchasing Organizations","highestDevelopmentStatusID":"15","companyTruncated":"Valeo Pharma \/ Group Purchasing Organizations"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valeo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Valeo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Premier","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Undisclosed","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meitheal Pharmaceuticals \/ Premier","highestDevelopmentStatusID":"1","companyTruncated":"Meitheal Pharmaceuticals \/ Premier"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase II","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Health \/ Undisclosed"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SOUTH AFRICA","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Fondaparinux Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0.76000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0.76000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Aspen Pharmacare Holdings \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Viatris"},{"orgOrder":0,"company":"Tabba Heart Institute","sponsor":"InnoTherapy Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"PAKISTAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tabba Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Tabba Heart Institute \/ InnoTherapy Inc","highestDevelopmentStatusID":"10","companyTruncated":"Tabba Heart Institute \/ InnoTherapy Inc"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"ZonMw | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Leiden University Medical Center | St. Antonius Hospital | Academisch Medisch Centrum - Universiteit van Amsterdam | Isala | OLVG | Radboud U","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ ZonMw | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Leiden University Medical Center | St. Antonius Hospital | Academisch Medisch Centrum - Universiteit van Amsterdam | Isala | OLVG | Radboud U","highestDevelopmentStatusID":"10","companyTruncated":"University Medical Center Groningen \/ ZonMw | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Leiden University Medical Center | St. Antonius Hospital | Academisch Medisch Centrum - Universiteit van Amsterdam | Isala | OLVG | Radboud U"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Blau Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I","graph3":"Blau Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blau Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Blau Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Blau Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I","graph3":"Blau Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blau Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Blau Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"University of Manitoba","sponsor":"Canadian Institutes of Health Research | Research Manitoba | Ozmosis Research | CanVECTOR Network | Canadian Critical Care Trials Group | AVANTI","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Manitoba \/ Canadian Institutes of Health Research | Research Manitoba | Ozmosis Research | CanVECTOR Network | Canadian Critical Care Trials Group | AVANTI","highestDevelopmentStatusID":"10","companyTruncated":"University of Manitoba \/ Canadian Institutes of Health Research | Research Manitoba | Ozmosis Research | CanVECTOR Network | Canadian Critical Care Trials Group | AVANTI"},{"orgOrder":0,"company":"Frederick Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Frederick Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Frederick Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Frederick Health \/ Undisclosed"},{"orgOrder":0,"company":"Frederick Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Frederick Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Frederick Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Frederick Health \/ Undisclosed"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"National PERT Consortium, Inc. | University Medical Center Mainz","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Scientific \/ National PERT Consortium, Inc. | University Medical Center Mainz","highestDevelopmentStatusID":"11","companyTruncated":"Boston Scientific \/ National PERT Consortium, Inc. | University Medical Center Mainz"},{"orgOrder":0,"company":"Australian National University","sponsor":"Helwan University | Clinica San Camilo, Argentina | Frederick Health | Coney Island Hospital, Brooklyn, NY | Galeno Desenvolvimento de Pesquisas Cl\u00ednicas | Dr Cipto Mangunkusumo General Hospital | Dr. Moewardi General Hospital, Surakarta, Indonesia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Australian National University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Australian National University \/ Helwan University | Clinica San Camilo, Argentina | Frederick Health | Coney Island Hospital, Brooklyn, NY | Galeno Desenvolvimento de Pesquisas Cl\u00ednicas | Dr Cipto Mangunkusumo General Hospital | Dr. Moewardi General Hospital, Surakarta, Indonesia","highestDevelopmentStatusID":"9","companyTruncated":"Australian National University \/ Helwan University | Clinica San Camilo, Argentina | Frederick Health | Coney Island Hospital, Brooklyn, NY | Galeno Desenvolvimento de Pesquisas Cl\u00ednicas | Dr Cipto Mangunkusumo General Hospital | Dr. Moewardi General Hospital, Surakarta, Indonesia"},{"orgOrder":0,"company":"Fundaci\u00f3n HM","sponsor":"Syntax for Science, S.L","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III||Coagulation factor X","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Fundaci\u00f3n HM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundaci\u00f3n HM \/ Syntax for Science, S.L","highestDevelopmentStatusID":"8","companyTruncated":"Fundaci\u00f3n HM \/ Syntax for Science, S.L"},{"orgOrder":0,"company":"Laboratori Derivati Organici","sponsor":"Cerus Dmcc","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Undisclosed","graph3":"Laboratori Derivati Organici","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratori Derivati Organici \/ Cerus Dmcc","highestDevelopmentStatusID":"1","companyTruncated":"Laboratori Derivati Organici \/ Cerus Dmcc"},{"orgOrder":0,"company":"Rensselaer Polytechnic Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rensselaer Polytechnic Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rensselaer Polytechnic Institute \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rensselaer Polytechnic Institute \/ Undisclosed"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boston Scientific \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Boston Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Premier","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Premier","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Premier \/ Fresenius Kabi AG","highestDevelopmentStatusID":"15","companyTruncated":"Premier \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"Versiti","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase III","graph3":"Versiti","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Versiti \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Versiti \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"Glasgow Caledonian University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Glasgow Caledonian University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Glasgow Caledonian University \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Glasgow Caledonian University \/ Undisclosed"},{"orgOrder":0,"company":"TIMI Study Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III (ATIII)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"TIMI Study Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TIMI Study Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"TIMI Study Group \/ Undisclosed"},{"orgOrder":0,"company":"Value Outcomes Ltd.","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sulodexide","moa":"Antithrombin-III (ATIII)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Value Outcomes Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Value Outcomes Ltd. \/ Alfasigma","highestDevelopmentStatusID":"10","companyTruncated":"Value Outcomes Ltd. \/ Alfasigma"},{"orgOrder":0,"company":"Centro Medico del Noroeste","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MEXICO","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sulodexide","moa":"Antithrombin-III (ATIII)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Centro Medico del Noroeste","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centro Medico del Noroeste \/ Alfasigma","highestDevelopmentStatusID":"10","companyTruncated":"Centro Medico del Noroeste \/ Alfasigma"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lixiana","moa":"antithrombotic: blood coagulation factor XA inhibitors","graph1":"Undisclosed","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lixiana","moa":"antithrombotic: blood coagulation factor XA inhibitors","graph1":"Undisclosed","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"NuCana","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NuCana \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NuCana \/ Undisclosed"},{"orgOrder":0,"company":"NuCana","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"antivirals","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NuCana \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NuCana \/ Undisclosed"},{"orgOrder":0,"company":"NuCana","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"||antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NuCana \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NuCana \/ Undisclosed"},{"orgOrder":0,"company":"NuCana","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"||antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NuCana \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NuCana \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ingavirin","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ingavirin","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ingavirin","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ingavirin","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Inarigivir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Spring Bank Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spring Bank Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spring Bank Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ridgeback Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ridgeback Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mankind Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mankind Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Entod Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Entod Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Entod Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Entod Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"Fermenta Biotech Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aurigene Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurigene Pharmaceutical Services \/ Fermenta Biotech Limited","highestDevelopmentStatusID":"15","companyTruncated":"Aurigene Pharmaceutical Services \/ Fermenta Biotech Limited"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Strides Pharma Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Undisclosed"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Strides Pharma Science \/ The Medicines Patent Pool","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ The Medicines Patent Pool"},{"orgOrder":0,"company":"Cipla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cipla \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Undisclosed"},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ The Medicines Patent Pool","highestDevelopmentStatusID":"15","companyTruncated":"Biophore India Pharmaceuticals Pvt Ltd \/ The Medicines Patent Pool"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Natco Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Natco Pharma \/ The Medicines Patent Pool","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ The Medicines Patent Pool"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Cipla"},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MSN Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MSN Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Hetero Drugs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Natco Pharma \/ Hetero","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Hetero"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Natco Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Optimus Pharma","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Optimus Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Optimus Pharma \/ JSS Medical Research","highestDevelopmentStatusID":"10","companyTruncated":"Optimus Pharma \/ JSS Medical Research"},{"orgOrder":0,"company":"Beximco Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BANGLADESH","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Beximco Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beximco Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Beximco Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"University of Liverpool","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"University of Liverpool","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Liverpool \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"University of Liverpool \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Medicines Patent Pool \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"The Medicines Patent Pool \/ Merck & Co"},{"orgOrder":0,"company":"Georgia State University Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Georgia State University Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Georgia State University Institute \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Georgia State University Institute \/ Merck & Co"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Nephrology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Thermo Fisher Scientific \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Thermo Fisher Scientific \/ Merck & Co"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of North Carolina \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"University of North Carolina \/ Undisclosed"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Carbon Health","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Carbon Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Carbon Health \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Carbon Health \/ Merck & Co"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Drug Innovation Ventures at Emory","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Drug Innovation Ventures at Emory","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Drug Innovation Ventures at Emory \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Drug Innovation Ventures at Emory \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"US Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":1.2,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":1.2,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ US Government","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ US Government"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"United Nations Children\u2019s Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ United Nations Children\u2019s Fund","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ United Nations Children\u2019s Fund"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0.12,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hetero Drugs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Hetero","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Hetero"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Drug Innovation Ventures at Emory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Drug Innovation Ventures at Emory","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Drug Innovation Ventures at Emory \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Drug Innovation Ventures at Emory \/ Undisclosed"},{"orgOrder":0,"company":"Promomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Promomed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Promomed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Promomed \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Theradex Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"||antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Theradex Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Theradex Oncology"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"University of Iowa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ University of Iowa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ University of Iowa Pharmaceuticals"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase I","graph3":"Shuttle Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Boustead Securities","highestDevelopmentStatusID":"6","companyTruncated":"Shuttle Pharmaceuticals \/ Boustead Securities"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"WestPark Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ WestPark Capital","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ WestPark Capital"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"WestPark Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ WestPark Capital","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ WestPark Capital"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase I","graph3":"Shuttle Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Boustead Securities","highestDevelopmentStatusID":"6","companyTruncated":"Shuttle Pharmaceuticals \/ Boustead Securities"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"TCG GreenChem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase I","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ TCG GreenChem","highestDevelopmentStatusID":"6","companyTruncated":"Shuttle Pharmaceuticals \/ TCG GreenChem"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Elsulfavirine","moa":"antivirals: non-nucleoside reverse transcriptase inhibitors||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Elsulfavirine","moa":"antivirals: non-nucleoside reverse transcriptase inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Elsulfavirine","moa":"antivirals: non-nucleoside reverse transcriptase inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Elsulfavirine","moa":"||antivirals: non-nucleoside reverse transcriptase inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AMT\u2011240","moa":"AOPE","graph1":"Neurology","graph2":"Preclinical","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"BlackfinBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BFB-101","moa":"AP4B1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BlackfinBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BlackfinBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BlackfinBio \/ Undisclosed"},{"orgOrder":0,"company":"BlackfinBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BFB-101","moa":"AP4B1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BlackfinBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BlackfinBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BlackfinBio \/ Undisclosed"},{"orgOrder":0,"company":"BlackfinBio","sponsor":"Boston Children's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BFB-101","moa":"AP4B1","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"BlackfinBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"BlackfinBio \/ Boston Children's Hospital","highestDevelopmentStatusID":"7","companyTruncated":"BlackfinBio \/ Boston Children's Hospital"},{"orgOrder":0,"company":"Viralgen","sponsor":"Elpida","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2023","type":"Partnership","leadProduct":"Melpida","moa":"AP4M1","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Viralgen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viralgen \/ Elpida","highestDevelopmentStatusID":"7","companyTruncated":"Viralgen \/ Elpida"},{"orgOrder":0,"company":"Eoc Pharma","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Eoc Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eoc Pharma \/ Immutep","highestDevelopmentStatusID":"6","companyTruncated":"Eoc Pharma \/ Immutep"},{"orgOrder":0,"company":"Merck Group","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck Group \/ Immutep","highestDevelopmentStatusID":"5","companyTruncated":"Merck Group \/ Immutep"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Immutep","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Immutep"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Immutep","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Australian Ethical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Australian Ethical","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Australian Ethical"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Maria Sk\u0142odowska-Curie National Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Maria Sk\u0142odowska-Curie National Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Maria Sk\u0142odowska-Curie National Research Institute"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Merck Group"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Merck Group"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Eoc Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Eoc Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Eoc Pharma"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"University Hospital Pilsen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Eftilagimod Alpha","moa":"APC receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immutep \/ University Hospital Pilsen","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ University Hospital Pilsen"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"F. Hoffmann-La Roche | Nykode Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VB10.16","moa":"APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nykode Therapeutics \/ F. Hoffmann-La Roche | Nykode Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ F. Hoffmann-La Roche | Nykode Therapeutics"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"F. Hoffmann-La Roche | GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VB10.16","moa":"APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nykode Therapeutics \/ F. Hoffmann-La Roche | GOG Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ F. Hoffmann-La Roche | GOG Foundation"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VB10.16","moa":"APC receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nykode Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Nykode Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"GOG Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nykode Therapeutics \/ GOG Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ GOG Foundation"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nykode Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Expanded Collaboration","leadProduct":"Atezolizumab","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nykode Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||APC receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nykode Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nykode Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VB10.16","moa":"APC receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nykode Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nykode Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||APC receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nykode Therapeutics \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Nykode Therapeutics \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nykode Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nykode Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azelaprag","moa":"Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Eli Lilly"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azelaprag","moa":"||Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Undisclosed"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azelaprag","moa":"||Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Undisclosed"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Azelaprag","moa":"||Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Eli Lilly"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series D Financing","leadProduct":"Azelaprag","moa":"||Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.17000000000000001,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Sofinnova Investments","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Sofinnova Investments"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Azelaprag","moa":"Apelin receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioAge Labs \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioAge Labs \/ Undisclosed"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Azelaprag","moa":"Apelin receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioAge Labs \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioAge Labs \/ Undisclosed"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Azelaprag","moa":"Apelin receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioAge Labs \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioAge Labs \/ Undisclosed"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azelaprag","moa":"Apelin receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAge Labs \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioAge Labs \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CB5064 Analog","moa":"Apelin receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CohBar","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"CB5064 Analog","moa":"Apelin receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CohBar \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ National Institutes of Health"},{"orgOrder":0,"company":"Corvidia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"D6PV","moa":"APOC-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Corvidia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corvidia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Corvidia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mammoth Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"MB-111","moa":"APOC-3","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Mammoth Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mammoth Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Mammoth Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Visirna","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Licensing Agreement","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Visirna","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.40000000000000002,"dosageForm":"Injection","sponsorNew":"Visirna \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Visirna \/ Sanofi"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Sixth Street","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Financing","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Sixth Street","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Sixth Street"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Staten Biotechnology","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SST-5058","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Staten Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Staten Biotechnology \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Staten Biotechnology \/ Novo Nordisk"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ALN-APOC3","moa":"APOC-3 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"RN0361","moa":"APOC-3 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rona Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rona Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ikaria Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RN0361","moa":"APOC-3 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Ikaria Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ikaria Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ikaria Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-APOC3","moa":"ApoC-III messenger RNA (APOC3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-APOC3","moa":"ApoC-III messenger RNA (APOC3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-APOC3","moa":"ApoC-III messenger RNA (APOC3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Inaxaplin","moa":"APOL1","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Inaxaplin","moa":"APOL1","graph1":"Nephrology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Inaxaplin","moa":"APOL1","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Inaxaplin","moa":"APOL1","graph1":"Nephrology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Inaxaplin","moa":"APOL1","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Inaxaplin","moa":"APOL1","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Inaxaplin","moa":"APOL1","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Inaxaplin","moa":"APOL1","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MZ-301","moa":"APOL-1","graph1":"Nephrology","graph2":"Preclinical","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maze Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Maze Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MZE829","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Maze Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maze Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"MZE829","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Maze Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Maze Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Maze Therapeutics \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MZE829","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maze Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maze Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"MZE829","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Maze Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Maze Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Maze Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"MZE829","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Maze Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Maze Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MZE829","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maze Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maze Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"MZE829","moa":"APOL-1","graph1":"Nephrology","graph2":"Phase II","graph3":"Maze Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.14999999999999999,"dosageForm":"Capsule","sponsorNew":"Maze Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Maze Therapeutics \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VX-147","moa":"APOL-1","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"VX-147","moa":"APOL-1","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VX-147","moa":"APOL-1","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"TQJ230","moa":"Apolipoprotein A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"LY3819469","moa":"Apolipoprotein A messenger RNA (LPA mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"LY3819469","moa":"Apolipoprotein A messenger RNA (LPA mRNA)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"LY3819469","moa":"Apolipoprotein A messenger RNA (LPA mRNA)","graph1":"Nephrology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"LY3819469","moa":"Apolipoprotein A messenger RNA (LPA mRNA)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"SLN360","moa":"Apolipoprotein A messenger RNA (LPA mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silence Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Silence Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"SLN360","moa":"Apolipoprotein A messenger RNA (LPA mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CER-001","moa":"||Apolipoprotein A-I (APOA1)","graph1":"Nephrology","graph2":"Phase II","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Abionyx Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Abionyx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Protein","year":"2025","type":"Funding","leadProduct":"CER-001","moa":"Apolipoprotein A-I (APOA1)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abionyx Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Abionyx Pharma \/ Bpifrance","highestDevelopmentStatusID":"9","companyTruncated":"Abionyx Pharma \/ Bpifrance"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CER-001","moa":"||Apolipoprotein A-I (APOA1)","graph1":"Nephrology","graph2":"Phase II","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Abionyx Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Abionyx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CER-001","moa":"Apolipoprotein A-I (APOA1)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Abionyx Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abionyx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"CER-001","moa":"Apolipoprotein A-I (APOA1)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Abionyx Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abionyx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CER-001","moa":"||Apolipoprotein A-I (APOA1)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abionyx Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abionyx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"AKCEA-APOCIII-LRx","moa":"Apolipoprotein C-III mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akcea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"AKCEA-APOCIII-LRx","moa":"Apolipoprotein C-III mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akcea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Theratechnologies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Theratechnologies","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Theratechnologies"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Apolipoprotein C-III mRNA 3'UTR","graph1":"Nephrology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Volanesorsen","moa":"Apolipoprotein C-III mRNA 3'UTR","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Tiantan Hospital","sponsor":"SDM Bio Service","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CN-105","moa":"Apolipoprotein E (APOE)","graph1":"Neurology","graph2":"Phase II","graph3":"Beijing Tiantan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Tiantan Hospital \/ SDM Bio Service","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tiantan Hospital \/ SDM Bio Service"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"LX1001","moa":"Apolipoprotein E (APOE)","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"LX1001","moa":"Apolipoprotein E (APOE)","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"LX1001","moa":"Apolipoprotein E (APOE)","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"LX1001","moa":"Apolipoprotein E (APOE)","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cerveau Technologies","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Licensing Agreement","leadProduct":"LX1001","moa":"Apolipoprotein E (APOE)","graph1":"Neurology","graph2":"Phase I","graph3":"Cerveau Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cerveau Technologies \/ Lexeo Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Cerveau Technologies \/ Lexeo Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"18-F FluorApoTrace","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ AbbVie Inc"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"9MW2921","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"9MW2921","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BI894416","moa":"Apoptosis","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"LianBio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LianBio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":3.6099999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":3.6099999999999999,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ GSK"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Jefferies"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Jefferies"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Hsbc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Nanobiotix","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Hsbc","highestDevelopmentStatusID":"9","companyTruncated":"Nanobiotix \/ Hsbc"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"LianBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.23999999999999999,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ LianBio","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ LianBio"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":2.5899999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.5899999999999999,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Johnson & Johnson","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Johnson & Johnson"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":2.73,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.73,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Johnson & Johnson","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Johnson & Johnson"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Johnson & Johnson","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Johnson & Johnson"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Undisclosed"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NBTXR3","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SCB-313","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novatek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Thymoquinone","moa":"Apoptosis regulator BAX (BAX)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Novatek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Enteric Coated","sponsorNew":"Novatek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novatek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"St. Jude Children \/ AbbVie Inc"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"Karyopharm Therapeutics | AbbVie Inc | Gateway for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ Karyopharm Therapeutics | AbbVie Inc | Gateway for Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"St. Jude Children \/ Karyopharm Therapeutics | AbbVie Inc | Gateway for Cancer Research"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude Children \/ AbbVie Inc"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Suzhou Yasheng Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Suzhou Yasheng Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Lisaftoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Lisaftoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ J.P. Morgan"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Lisaftoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ J.P. Morgan"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Lisaftoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ J.P. Morgan"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Lisaftoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Ascentage Pharma"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Lisaftoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acerta Pharma \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Acerta Pharma \/ Ascentage Pharma"},{"orgOrder":0,"company":"The First Affiliated Hospital with Nanjing Medical University","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"The First Affiliated Hospital with Nanjing Medical University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The First Affiliated Hospital with Nanjing Medical University \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"The First Affiliated Hospital with Nanjing Medical University \/ AbbVie Inc"},{"orgOrder":0,"company":"The First Affiliated Hospital of Xiamen University","sponsor":"Huizhou Municipal Central Hospital | Shenzhen Chipscreen Biosciences | CSPC Pharmaceutical Group | Fujian Provincial Hospital | Fujian Cancer Hospital | Zhangzhou Municipal Hospital, Fujian Province | Jieyang People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"The First Affiliated Hospital of Xiamen University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The First Affiliated Hospital of Xiamen University \/ Huizhou Municipal Central Hospital | Shenzhen Chipscreen Biosciences | CSPC Pharmaceutical Group | Fujian Provincial Hospital | Fujian Cancer Hospital | Zhangzhou Municipal Hospital, Fujian Province | Jieyang People's Hospital","highestDevelopmentStatusID":"8","companyTruncated":"The First Affiliated Hospital of Xiamen University \/ Huizhou Municipal Central Hospital | Shenzhen Chipscreen Biosciences | CSPC Pharmaceutical Group | Fujian Provincial Hospital | Fujian Cancer Hospital | Zhangzhou Municipal Hospital, Fujian Province | Jieyang People's Hospital"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Francophone des Myelodysplasies \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Groupe Francophone des Myelodysplasies \/ AbbVie Inc"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Francophone des Myelodysplasies \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Groupe Francophone des Myelodysplasies \/ AbbVie Inc"},{"orgOrder":0,"company":"French Innovative Leukemia Organisation","sponsor":"Stemline Therapeutics | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"French Innovative Leukemia Organisation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"French Innovative Leukemia Organisation \/ Stemline Therapeutics | AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"French Innovative Leukemia Organisation \/ Stemline Therapeutics | AbbVie Inc"},{"orgOrder":0,"company":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori","sponsor":"Hospital Vall d'Hebron | Cyprus Institute of Neurology and Genetics | European Leukemia Net | Fundacion Para La Investigacion Hospital La Fe | Ostdeutsche Studiengruppe Haematologie und Onkologie | Ospedale Pediatrico Bambino Gesu | Czech Lymphoma Study G","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori \/ Hospital Vall d'Hebron | Cyprus Institute of Neurology and Genetics | European Leukemia Net | Fundacion Para La Investigacion Hospital La Fe | Ostdeutsche Studiengruppe Haematologie und Onkologie | Ospedale Pediatrico Bambino Gesu | Czech Lymphoma Study G","highestDevelopmentStatusID":"10","companyTruncated":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori \/ Hospital Vall d'Hebron | Cyprus Institute of Neurology and Genetics | European Leukemia Net | Fundacion Para La Investigacion Hospital La Fe | Ostdeutsche Studiengruppe Haematologie und Onkologie | Ospedale Pediatrico Bambino Gesu | Czech Lymphoma Study G"},{"orgOrder":0,"company":"Stichting Hemato-Oncologie voor Volwassenen Nederland","sponsor":"German-Austrian Acute Myeloid Leukemia Study Group | United Kingdom AML Research Network | Gruppo Italiano Malattie EMatologiche dell'Adulto | Swiss Group for Clinical Cancer Research | Danish Acute Leukemia Group | Grupo Cooperativo de Estudio y Tratamie","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Stichting Hemato-Oncologie voor Volwassenen Nederland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stichting Hemato-Oncologie voor Volwassenen Nederland \/ German-Austrian Acute Myeloid Leukemia Study Group | United Kingdom AML Research Network | Gruppo Italiano Malattie EMatologiche dell'Adulto | Swiss Group for Clinical Cancer Research | Danish Acute Leukemia Group | Grupo Cooperativo de Estudio y Tratamie","highestDevelopmentStatusID":"10","companyTruncated":"Stichting Hemato-Oncologie voor Volwassenen Nederland \/ German-Austrian Acute Myeloid Leukemia Study Group | United Kingdom AML Research Network | Gruppo Italiano Malattie EMatologiche dell'Adulto | Swiss Group for Clinical Cancer Research | Danish Acute Leukemia Group | Grupo Cooperativo de Estudio y Tratamie"},{"orgOrder":0,"company":"Technische Universit\u00e4t Dresden","sponsor":"University Hospital Heidelberg | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Technische Universit\u00e4t Dresden","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Technische Universit\u00e4t Dresden \/ University Hospital Heidelberg | AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Technische Universit\u00e4t Dresden \/ University Hospital Heidelberg | AbbVie Inc"},{"orgOrder":0,"company":"Technische Universit\u00e4t Dresden","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Technische Universit\u00e4t Dresden","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Technische Universit\u00e4t Dresden \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Technische Universit\u00e4t Dresden \/ AbbVie Inc"},{"orgOrder":0,"company":"University of Leipzig","sponsor":"AbbVie Inc | University Hospital Leipzig (Hematology Diagnostics Lab) | University of Leipzig Clinical Trial Centre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"University of Leipzig","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Leipzig \/ AbbVie Inc | University Hospital Leipzig (Hematology Diagnostics Lab) | University of Leipzig Clinical Trial Centre","highestDevelopmentStatusID":"8","companyTruncated":"University of Leipzig \/ AbbVie Inc | University Hospital Leipzig (Hematology Diagnostics Lab) | University of Leipzig Clinical Trial Centre"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ AbbVie Inc"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"University of Colorado, Denver \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ AbbVie Inc"},{"orgOrder":0,"company":"University of Michigan Rogel Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"University of Michigan Rogel Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan Rogel Cancer Center \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"University of Michigan Rogel Cancer Center \/ Genentech"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Genentech | Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ Genentech | Epizyme","highestDevelopmentStatusID":"6","companyTruncated":"Weill Medical College of Cornell University \/ Genentech | Epizyme"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Syndax Pharmaceuticals | Break Through Cancer | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Syndax Pharmaceuticals | Break Through Cancer | AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Syndax Pharmaceuticals | Break Through Cancer | AbbVie Inc"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Kura Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Kura Oncology","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Kura Oncology"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Commonwealth University \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Virginia Commonwealth University \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Massachusetts General Hospital \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"General Hospital of Chinese Armed Police Forces","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ General Hospital of Chinese Armed Police Forces","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ General Hospital of Chinese Armed Police Forces"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Nephrology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"St. Jude Children \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"St. Jude Children \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ BeOne Medicines","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ BeOne Medicines"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Adaptive Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Adaptive Biotechnologies","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Adaptive Biotechnologies"},{"orgOrder":0,"company":"ONCOtherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"ONCOtherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONCOtherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONCOtherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Melbourne Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Melbourne Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melbourne Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Melbourne Health \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AZD0466","moa":"Apoptosis regulator Bcl-2 (BCL-2)","graph1":"Hematology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AZD0466","moa":"Apoptosis regulator Bcl-2 (BCL-2)","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BGB-11417","moa":"Apoptosis regulator Bcl-2 (BCL-2)","graph1":"Oncology","graph2":"Phase I","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BGB-11417","moa":"Apoptosis regulator Bcl-2 (BCL-2)","graph1":"Oncology","graph2":"Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BGB-11417","moa":"Apoptosis regulator Bcl-2 (BCL-2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BGB-11417","moa":"Apoptosis regulator Bcl-2 (BCL-2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BGB-11417","moa":"Apoptosis regulator Bcl-2 (BCL-2)","graph1":"Oncology","graph2":"Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LOXO-338","moa":"Apoptosis regulator Bcl-2 (BCL-2)","graph1":"Oncology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"The First Affiliated Hospital with Nanjing Medical University","sponsor":"Lupeng Pharmaceutical | Newave Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"LP-108","moa":"Apoptosis regulator Bcl-2 (BCL-2)","graph1":"Oncology","graph2":"Phase I","graph3":"The First Affiliated Hospital with Nanjing Medical University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The First Affiliated Hospital with Nanjing Medical University \/ Lupeng Pharmaceutical | Newave Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"The First Affiliated Hospital with Nanjing Medical University \/ Lupeng Pharmaceutical | Newave Pharmaceutical"},{"orgOrder":0,"company":"Lupeng Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LP-108","moa":"Apoptosis regulator Bcl-2 (BCL-2)","graph1":"Oncology","graph2":"Phase I","graph3":"Lupeng Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupeng Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lupeng Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"VOB560","moa":"Apoptosis regulator Bcl-2 (BCL-2)","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Israeli Medical Association","sponsor":"Rabin Medical Center | Sheba Medical Center | Rambam Health Care Campus | Tel Aviv Medical Center | Soroka University Medical Center | Shaare Zedek Medical Center | Hadassah Medical Organization","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Navitoclax","moa":"Apoptosis regulator Bcl-2 | Apoptosis regulator Bcl-X | Apoptosis regulator Bcl-W","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Israeli Medical Association","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Israeli Medical Association \/ Rabin Medical Center | Sheba Medical Center | Rambam Health Care Campus | Tel Aviv Medical Center | Soroka University Medical Center | Shaare Zedek Medical Center | Hadassah Medical Organization","highestDevelopmentStatusID":"7","companyTruncated":"Israeli Medical Association \/ Rabin Medical Center | Sheba Medical Center | Rambam Health Care Campus | Tel Aviv Medical Center | Soroka University Medical Center | Shaare Zedek Medical Center | Hadassah Medical Organization"},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Navitoclax","moa":"Apoptosis regulator Bcl-2 | Apoptosis regulator Bcl-X | Apoptosis regulator Bcl-W","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thomas Jefferson University \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Thomas Jefferson University \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Navitoclax","moa":"Apoptosis regulator Bcl-2 | Apoptosis regulator Bcl-X | Apoptosis regulator Bcl-W","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Navitoclax","moa":"Apoptosis regulator Bcl-2 | Apoptosis regulator Bcl-X | Apoptosis regulator Bcl-W","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Navitoclax","moa":"||Apoptosis regulator Bcl-2 | Apoptosis regulator Bcl-X | Apoptosis regulator Bcl-W","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Navitoclax","moa":"||Apoptosis regulator Bcl-2 | Apoptosis regulator Bcl-X | Apoptosis regulator Bcl-W","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GAL-101","moa":"APP","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galimedix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Galimedix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Lexitas","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GAL-101","moa":"APP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Galimedix Therapeutics \/ Lexitas","highestDevelopmentStatusID":"8","companyTruncated":"Galimedix Therapeutics \/ Lexitas"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GAL-101","moa":"APP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Galimedix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galimedix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"GAL-101","moa":"APP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Galimedix Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"8","companyTruncated":"Galimedix Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase I","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Halozyme Therapeutics \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Halozyme Therapeutics \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Alzheimer's Memory Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase I","graph3":"Alzheimer\\'s Memory Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alzheimer\\'s Memory Center \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alzheimer\\'s Memory Center \/ Undisclosed"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Expanded Collaboration","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Biologics Inc \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Biologics Inc \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Biologics Inc \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Biologics Inc \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Expanded Collaboration","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Lonza Group","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Lonza Group"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ BofA Securities"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ BofA Securities"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Public Offering","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0.16,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ BofA Securities"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Hoag","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Hoag","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Hoag"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Financing","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ K2 HealthVentures","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ K2 HealthVentures"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Hyaluronidase Enzyme","moa":"||APP","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acumen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acumen Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ALN-APP","moa":"APP messenger RNA (APP mRNA)","graph1":"Neurology","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ALN-APP","moa":"APP messenger RNA (APP mRNA)","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ALN-APP","moa":"APP messenger RNA (APP mRNA)","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Cerveau Technologies","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"ALN-APP","moa":"APP messenger RNA (APP mRNA)","graph1":"Neurology","graph2":"Phase I","graph3":"Cerveau Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cerveau Technologies \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Cerveau Technologies \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ALN-APP","moa":"APP messenger RNA (APP mRNA)","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ALN-APP","moa":"APP messenger RNA (APP mRNA)","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ALN-APP","moa":"APP messenger RNA (APP mRNA)","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ALN-APP","moa":"APP messenger RNA (APP mRNA)","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Amyloid Solution","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AS-S603","moa":"APP\/TAU","graph1":"Undisclosed","graph2":"Phase I","graph3":"Amyloid Solution","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amyloid Solution \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amyloid Solution \/ Undisclosed"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Aplitabart","moa":"APRIL","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGM Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Yake Biotechnology Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"April Car-T Cell","moa":"APRIL","graph1":"Oncology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zhejiang University \/ Yake Biotechnology Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Yake Biotechnology Ltd."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BION-1301","moa":"APRIL","graph1":"Undisclosed","graph2":"Phase I","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chinook Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chinook Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"BION-1301","moa":"APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinook Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Climb Bio","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"CLYM116","moa":"APRIL","graph1":"Nephrology","graph2":"Preclinical","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Mabworks Biotech \/ Climb Bio","highestDevelopmentStatusID":"4","companyTruncated":"Beijing Mabworks Biotech \/ Climb Bio"},{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"JADE101","moa":"APRIL","graph1":"Undisclosed","graph2":"Phase I","graph3":"Jade Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jade Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jade Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Avrio Health","sponsor":"Arcadia Consumer Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Sennosides","moa":"AQP-3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Avrio Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Avrio Health \/ Arcadia Consumer Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Avrio Health \/ Arcadia Consumer Healthcare"},{"orgOrder":0,"company":"Avrio Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sennosides","moa":"AQP-3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Avrio Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Avrio Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avrio Health \/ Undisclosed"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"AAV-AQP1","moa":"Aquaporin-1 (AQP1)","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"MeiraGTx","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"MeiraGTx \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"MeiraGTx \/ Sanofi"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2020","type":"Inapplicable","leadProduct":"CC-94676","moa":"AR","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2021","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2021","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2021","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase I","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Suzhou Koshine Biomedica, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Suzhou Koshine Biomedica, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Suzhou Koshine Biomedica, Inc."},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VLX-1005","moa":"Arachidonate 12-lipoxygenase, 12R-type (ALOX12B)","graph1":"Immunology","graph2":"Phase II","graph3":"Veralox Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Veralox Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veralox Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"VLX-1005","moa":"Arachidonate 12-lipoxygenase, 12R-type (ALOX12B)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Veralox Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Veralox Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Veralox Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VLX-1005","moa":"Arachidonate 12-lipoxygenase, 12R-type (ALOX12B)","graph1":"Hematology","graph2":"Phase II","graph3":"Veralox Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Veralox Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veralox Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Hatteras Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"VLX-1005","moa":"Arachidonate 12-lipoxygenase, 12R-type (ALOX12B)","graph1":"Hematology","graph2":"Phase II","graph3":"Veralox Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Veralox Therapeutics \/ Hatteras Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"Veralox Therapeutics \/ Hatteras Venture Partners"},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VLX-1005","moa":"Arachidonate 12-lipoxygenase, 12R-type (ALOX12B)","graph1":"Hematology","graph2":"Phase II","graph3":"Veralox Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veralox Therapeutics \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Veralox Therapeutics \/ Celerion"},{"orgOrder":0,"company":"Novateur Ventures","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zileuton","moa":"||Arachidonate 5-lipoxygenase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novateur Ventures","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novateur Ventures \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Novateur Ventures \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sulfasalazine","moa":"Arachidonate 5-lipoxygenase | Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calithera Biosciences \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calithera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Molecure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"OATD-02","moa":"Arginase","graph1":"Oncology","graph2":"Phase I","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecure \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Molecure \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"C0021158","moa":"Arginase-2","graph1":"Oncology","graph2":"Discovery","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"HanX Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HX301","moa":"ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HanX Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HanX Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HanX Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HanX Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HX301","moa":"ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"HanX Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HanX Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HanX Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3||CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"||ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconova Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Onconova Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"HanX Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconova Therapeutics \/ HanX Biopharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ HanX Biopharmaceuticals"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconova Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconova Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconova Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconova Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconova Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Traws Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Traws Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ReproNovo","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"Leflutrozole","moa":"Aromatase","graph1":"Endocrinology","graph2":"Phase II","graph3":"ReproNovo","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"ReproNovo \/ Jeito Capital","highestDevelopmentStatusID":"8","companyTruncated":"ReproNovo \/ Jeito Capital"},{"orgOrder":0,"company":"ReproNovo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Leflutrozole","moa":"Aromatase","graph1":"Endocrinology","graph2":"Phase II","graph3":"ReproNovo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReproNovo \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ReproNovo \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Voyager Therapeutics, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurocrine Biosciences \/ Voyager Therapeutics, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Voyager Therapeutics, Inc"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"VY-AADC","moa":"Aromatic-L-amino-acid decarboxylase (DDC)","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"VY-AADC","moa":"Aromatic-L-amino-acid decarboxylase (DDC)","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Avivagen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Beta Carotene","moa":"arotinoid derivatives","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avivagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avivagen \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Avivagen \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Italian Medicines Agency","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Agreement","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Italian Medicines Agency","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Italian Medicines Agency"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Acquisition","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0.39000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0.47999999999999998,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Kyowa Kirin"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"NHS England","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Agreement","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ NHS England","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ NHS England"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Public Offering","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Erkim","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Partnership","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Erkim","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Erkim"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Beneluxa Initiative","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Agreement","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Beneluxa Initiative","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Beneluxa Initiative"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Genpharm","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Collaboration","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Genpharm"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Acquisition","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0.47999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0.47999999999999998,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Kyowa Kirin"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"New Therapies Council","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ New Therapies Council","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ New Therapies Council"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Private Placement","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"MolMed","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"Libmeldy","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"MolMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MolMed \/ Orchard Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"MolMed \/ Orchard Therapeutics"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Libmeldy","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Private Placement","leadProduct":"Libmeldy","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Libmeldy","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Libmeldy","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Libmeldy","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Ospedale San Raffaele","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-200","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Ospedale San Raffaele","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Ospedale San Raffaele"},{"orgOrder":0,"company":"Passage Bio","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"PBML04","moa":"ARSA","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Passage Bio \/ University of Pennsylvania","highestDevelopmentStatusID":"5","companyTruncated":"Passage Bio \/ University of Pennsylvania"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BAY2416964","moa":"Aryl hydrocarbon receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BAY2416964","moa":"Aryl hydrocarbon receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Giellepi S.p.A","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Diosmin","moa":"Aryl hydrocarbon receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Giellepi S.p.A","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Giellepi S.p.A \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Giellepi S.p.A \/ Tigermed"},{"orgOrder":0,"company":"Primus Pharmaceutical","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Diosmin","moa":"Aryl hydrocarbon receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Primus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primus Pharmaceutical \/ KGK Science","highestDevelopmentStatusID":"1","companyTruncated":"Primus Pharmaceutical \/ KGK Science"},{"orgOrder":0,"company":"Andromaco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHILE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Diosmin","moa":"Aryl hydrocarbon receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Andromaco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Andromaco \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Andromaco \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"ADAR1 Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"EQ504","moa":"Aryl hydrocarbon receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Equillium","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Equillium \/ ADAR1 Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"Equillium \/ ADAR1 Capital Management"},{"orgOrder":0,"company":"Hercules Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"HP163","moa":"Aryl hydrocarbon receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hercules Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hercules Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hercules Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Zhonghao Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Peking University People's Hospital \/ Zhonghao Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Peking University People's Hospital \/ Zhonghao Pharmaceutical"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Zhonghao Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Peking University People's Hospital \/ Zhonghao Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Peking University People's Hospital \/ Zhonghao Pharmaceutical"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Zhonghao Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Peking University People's Hospital \/ Zhonghao Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Peking University People's Hospital \/ Zhonghao Pharmaceutical"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Torii Pharmaceutical","amount2":1.05,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":1.05,"dosageForm":"Cream","sponsorNew":"Torii Pharmaceutical \/ Shionogi","highestDevelopmentStatusID":"15","companyTruncated":"Torii Pharmaceutical \/ Shionogi"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Indiana University","sponsor":"Dermavant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Indiana University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indiana University \/ Dermavant Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Indiana University \/ Dermavant Sciences"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ IQVIA"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Marathon Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Marathon Asset Management"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Montes Archimedes Acquisition Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Merger","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Roivant Sciences","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Cream","sponsorNew":"Roivant Sciences \/ Montes Archimedes Acquisition Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Roivant Sciences \/ Montes Archimedes Acquisition Corporation"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Derm-Biome Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Innovaderm","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Innovaderm"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":1.2,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":1.2,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Organon"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ IQVIA"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ IQVIA"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.11,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.11,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":1.2,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":1.2,"dosageForm":"Undisclosed","sponsorNew":"Dermavant Sciences \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Organon"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IK-175","moa":"Aryl hydrocarbon receptor (AHR)","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ikena Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IK-175","moa":"||Aryl hydrocarbon receptor (AHR)","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ikena Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IK-175","moa":"||Aryl hydrocarbon receptor (AHR)","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ikena Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IK-175","moa":"Aryl hydrocarbon receptor (AHR)","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ikena Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IK-175","moa":"Aryl hydrocarbon receptor (AHR)","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ikena Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IK-175","moa":"Aryl hydrocarbon receptor (AHR)","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ikena Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Europharma","sponsor":"Phytomed AB | Center of Drug and Medical Technologies Expertise, Armenia | CARDIOMED Family Health Center, LLC of the Ministry of Health of Armenia | Institute of Fine Organic Chemistry of the National Academy of Science Yerevan, Armenia","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Red Ginseng","moa":"Aryl hydrocarbon receptor; Interleukin-6; Prostaglandin G\/H synthase 2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Europharma \/ Phytomed AB | Center of Drug and Medical Technologies Expertise, Armenia | CARDIOMED Family Health Center, LLC of the Ministry of Health of Armenia | Institute of Fine Organic Chemistry of the National Academy of Science Yerevan, Armenia","highestDevelopmentStatusID":"6","companyTruncated":"Europharma \/ Phytomed AB | Center of Drug and Medical Technologies Expertise, Armenia | CARDIOMED Family Health Center, LLC of the Ministry of Health of Armenia | Institute of Fine Organic Chemistry of the National Academy of Science Yerevan, Armenia"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Asc","moa":"ASC","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition Corp","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"University of Miami","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Funding","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ University of Miami","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ University of Miami"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition Corp.","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp."},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IC 100","moa":"ASC","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Seal Rock Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SRT-015","moa":"ASK1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Seal Rock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Seal Rock Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seal Rock Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seal Rock Therapeutics","sponsor":"Genfit","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"SRT-015","moa":"ASK1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Seal Rock Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0.11,"dosageForm":"Suspension","sponsorNew":"Seal Rock Therapeutics \/ Genfit","highestDevelopmentStatusID":"6","companyTruncated":"Seal Rock Therapeutics \/ Genfit"},{"orgOrder":0,"company":"Seal Rock Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SRT-015","moa":"ASK1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Seal Rock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Seal Rock Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seal Rock Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seal Rock Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SRT-015","moa":"ASK1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Seal Rock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Seal Rock Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seal Rock Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SRT-015","moa":"ASK1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Undisclosed"},{"orgOrder":0,"company":"Porton Biopharma","sponsor":"Clinigen Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"Asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Porton Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Porton Biopharma \/ Clinigen Group","highestDevelopmentStatusID":"15","companyTruncated":"Porton Biopharma \/ Clinigen Group"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of Washington","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University of Washington \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Partnership","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ligand Pharmaceuticals","amount2":0.16,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"Ligand Pharmaceuticals \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ligand Pharmaceuticals \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Peg L asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"9","companyTruncated":"Servier \/ Servier"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Peg L asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase III","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Children's Oncology Group \/ Undisclosed"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Peg L asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase III","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Children's Oncology Group \/ Undisclosed"},{"orgOrder":0,"company":"OHSU Knight Cancer Institute","sponsor":"Oregon Health and Science University | Genentech | Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Peg L asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase I","graph3":"OHSU Knight Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OHSU Knight Cancer Institute \/ Oregon Health and Science University | Genentech | Servier","highestDevelopmentStatusID":"6","companyTruncated":"OHSU Knight Cancer Institute \/ Oregon Health and Science University | Genentech | Servier"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Acquisition","leadProduct":"Eryaspase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Erytech Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"9","companyTruncated":"Erytech Pharma \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Eryaspase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Erytech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Erytech Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Eryaspase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase I","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgetown University \/ Erytech Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Georgetown University \/ Erytech Pharma"},{"orgOrder":0,"company":"Grcbds","sponsor":"Erytech Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Enzyme","year":"2020","type":"Partnership","leadProduct":"L-Asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase III","graph3":"Grcbds","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Grcbds \/ Erytech Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Grcbds \/ Erytech Pharma"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Asparagine","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Erytech Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"L-Asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Erytech Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Erytech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"L-Asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Erytech Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Erytech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"L-Asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Erytech Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Erytech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"L-Asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Erytech Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Erytech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Asparagine","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Asparagine","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Asparagine","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BBP-812","moa":"Aspartoacylase (ASPA)","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BridgeBio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Resilience","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Collaboration","leadProduct":"BBP-812","moa":"Aspartoacylase (ASPA)","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Resilience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Resilience \/ BridgeBio Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Resilience \/ BridgeBio Pharma"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BBP-812","moa":"Aspartoacylase (ASPA)","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BridgeBio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"rAAV-Olig001-ASPA","moa":"Aspartoacylase gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Myrtelle \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Undisclosed"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"rAAV-Olig001-ASPA","moa":"Aspartoacylase gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Myrtelle \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Undisclosed"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"rAAV-Olig001-ASPA","moa":"Aspartoacylase gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Myrtelle \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Undisclosed"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Licensing Agreement","leadProduct":"rAAV-Olig001-ASPA","moa":"Aspartoacylase gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Myrtelle \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Pfizer Inc"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SNS-301","moa":"Aspartyl-beta-hydroxylase","graph1":"Oncology","graph2":"Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sensei Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Series B Financing","leadProduct":"Pembrolizumab","moa":"||Aspartyl-beta-hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Apeiron Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Apeiron Biologics"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||Aspartyl-beta-hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Citigroup","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Citigroup"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Aspartyl-beta-hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Cambrian Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"SNS-301","moa":"Aspartyl-beta-hydroxylase","graph1":"Oncology","graph2":"Phase II","graph3":"Sensei Biotherapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Cambrian Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Sensei Biotherapeutics \/ Cambrian Biopharma"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||Aspartyl-beta-hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Piper Sandler","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Aspartyl-beta-hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mannitol","moa":"Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH)","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ Chiesi Group","highestDevelopmentStatusID":"11","companyTruncated":"University of North Carolina \/ Chiesi Group"},{"orgOrder":0,"company":"Sinew Pharma Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mannitol","moa":"Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Sinew Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sinew Pharma Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sinew Pharma Inc. \/ Undisclosed"},{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mannitol","moa":"Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CHIESI USA INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"CHIESI USA INC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CHIESI USA INC \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mannitol","moa":"Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ McMaster University","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ McMaster University"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Aptar Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Mannitol","moa":"Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH)","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pharmaxis \/ Aptar Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Pharmaxis \/ Aptar Pharma"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ARO-ATXN2","moa":"Ataxin-2","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ION541","moa":"Ataxin-2","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Biogen","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Biogen"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ION541","moa":"Ataxin-2","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"BIIB105","moa":"Ataxin-2 messenger RNA (ATXN2 mRNA)","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"BIIB132","moa":"Ataxin-3 messenger RNA (ATXN3 mRNA)","graph1":"Neurology","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Citrulline","moa":"Atherogenic","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Baylor College of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Global Coalition for Adaptive Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AZD1390","moa":"ATM serine\/threonine kinase (ATM)","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Global Coalition for Adaptive Research","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Global Coalition for Adaptive Research"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"GCAR","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"AZD1390","moa":"ATM serine\/threonine kinase (ATM)","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ GCAR","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ GCAR"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AZD1390","moa":"ATM serine\/threonine kinase (ATM)","graph1":"Oncology","graph2":"Phase I","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Children's Oncology Group \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AZD1390","moa":"ATM serine\/threonine kinase (ATM)","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ AstraZeneca"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"Hawaii Pacific Neuroscience","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"nL-ATN1-002","moa":"ATN1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ Hawaii Pacific Neuroscience","highestDevelopmentStatusID":"7","companyTruncated":"n-Lorem Foundation \/ Hawaii Pacific Neuroscience"},{"orgOrder":0,"company":"University College, London","sponsor":"Radboud University Medical Center | London School of Hygiene & Tropical Medicine | University of Oxford | Research Center Borstel | Lygature | TASK Applied Science | Vita-Salute San Raffaele University | Helmholtz Zentrum M\u00fcnchen | KNCV Tuberculosis Found","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University College, London","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University College, London \/ Radboud University Medical Center | London School of Hygiene & Tropical Medicine | University of Oxford | Research Center Borstel | Lygature | TASK Applied Science | Vita-Salute San Raffaele University | Helmholtz Zentrum M\u00fcnchen | KNCV Tuberculosis Found","highestDevelopmentStatusID":"8","companyTruncated":"University College, London \/ Radboud University Medical Center | London School of Hygiene & Tropical Medicine | University of Oxford | Research Center Borstel | Lygature | TASK Applied Science | Vita-Salute San Raffaele University | Helmholtz Zentrum M\u00fcnchen | KNCV Tuberculosis Found"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"University of Cape Town | Haitian Group for Study of Kaposi's Sarcoma | University of Stellenbosch | University of California, Los Angeles | Harvard School of Public Health (HSPH)","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ University of Cape Town | Haitian Group for Study of Kaposi's Sarcoma | University of Stellenbosch | University of California, Los Angeles | Harvard School of Public Health (HSPH)","highestDevelopmentStatusID":"8","companyTruncated":"Brigham and Women's Hospital \/ University of Cape Town | Haitian Group for Study of Kaposi's Sarcoma | University of Stellenbosch | University of California, Los Angeles | Harvard School of Public Health (HSPH)"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Nepal Health Research Council","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NEPAL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Nepal Health Research Council","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nepal Health Research Council \/ World Health Organization","highestDevelopmentStatusID":"11","companyTruncated":"Nepal Health Research Council \/ World Health Organization"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shin Poong Pharm Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shin Poong Pharm Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shin Poong Pharm Co Ltd \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"10","companyTruncated":"Shin Poong Pharm Co Ltd \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shin Poong Pharm Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shin Poong Pharm Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"AbbVie Inc | Apotex Inc | World Health Organization | University of British Columbia | Arch Biopartners","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ AbbVie Inc | Apotex Inc | World Health Organization | University of British Columbia | Arch Biopartners","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ AbbVie Inc | Apotex Inc | World Health Organization | University of British Columbia | Arch Biopartners"},{"orgOrder":0,"company":"UNC Lineberger Comprehensive Cancer Center","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Oncology","graph2":"Phase I","graph3":"UNC Lineberger Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pessary","sponsorNew":"UNC Lineberger Comprehensive Cancer Center \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"UNC Lineberger Comprehensive Cancer Center \/ Gilead Sciences"},{"orgOrder":0,"company":"Amivas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Amivas","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amivas \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amivas \/ Undisclosed"},{"orgOrder":0,"company":"Amivas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Amivas","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amivas \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amivas \/ Undisclosed"},{"orgOrder":0,"company":"Frantz Viral Therapeutics","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Frantz Viral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Frantz Viral Therapeutics \/ Cleveland Clinic","highestDevelopmentStatusID":"8","companyTruncated":"Frantz Viral Therapeutics \/ Cleveland Clinic"},{"orgOrder":0,"company":"Frantz Viral Therapeutics","sponsor":"Laser Surgery Care | Anal Dysplasia Clinic MidWest","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Frantz Viral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Frantz Viral Therapeutics \/ Laser Surgery Care | Anal Dysplasia Clinic MidWest","highestDevelopmentStatusID":"8","companyTruncated":"Frantz Viral Therapeutics \/ Laser Surgery Care | Anal Dysplasia Clinic MidWest"},{"orgOrder":0,"company":"Frantz Viral Therapeutics","sponsor":"Amarex Clinical Research | University of California, San Francisco | Anal Dysplasia Clinic MidWest | Laser Surgery Care","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Frantz Viral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Frantz Viral Therapeutics \/ Amarex Clinical Research | University of California, San Francisco | Anal Dysplasia Clinic MidWest | Laser Surgery Care","highestDevelopmentStatusID":"8","companyTruncated":"Frantz Viral Therapeutics \/ Amarex Clinical Research | University of California, San Francisco | Anal Dysplasia Clinic MidWest | Laser Surgery Care"},{"orgOrder":0,"company":"Amivas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Amivas","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amivas \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amivas \/ Undisclosed"},{"orgOrder":0,"company":"Metanoic Health Ltd.","sponsor":"Clinical Research Malaysia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Artesunate","moa":"ATP2A1 | SERCA2","graph1":"Oncology","graph2":"Phase II","graph3":"Metanoic Health Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metanoic Health Ltd. \/ Clinical Research Malaysia","highestDevelopmentStatusID":"8","companyTruncated":"Metanoic Health Ltd. \/ Clinical Research Malaysia"},{"orgOrder":0,"company":"Metanoic Health Ltd.","sponsor":"Clinical Research Malaysia","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Artesunate","moa":"ATP2A1 | SERCA2","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Metanoic Health Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metanoic Health Ltd. \/ Clinical Research Malaysia","highestDevelopmentStatusID":"8","companyTruncated":"Metanoic Health Ltd. \/ Clinical Research Malaysia"},{"orgOrder":0,"company":"First Affiliated Hospital of Wannan Medical College","sponsor":"Beijing Tiantan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Probucol","moa":"ATP-binding cassette sub-family A member 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"First Affiliated Hospital of Wannan Medical College","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"First Affiliated Hospital of Wannan Medical College \/ Beijing Tiantan Hospital","highestDevelopmentStatusID":"10","companyTruncated":"First Affiliated Hospital of Wannan Medical College \/ Beijing Tiantan Hospital"},{"orgOrder":0,"company":"RiboNova Inc.","sponsor":"Children's Hospital of Philadelphia","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Probucol","moa":"ATP-binding cassette sub-family A member 1","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"RiboNova Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RiboNova Inc. \/ Children's Hospital of Philadelphia","highestDevelopmentStatusID":"1","companyTruncated":"RiboNova Inc. \/ Children's Hospital of Philadelphia"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gan & Lee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Humanis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TURKEY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Humanis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Humanis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Humanis \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":1.26,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.26,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":1.1299999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.1299999999999999,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0.51000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.51000000000000001,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Neopharm","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Esperion Therapeutics \/ Neopharm","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Neopharm"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Tablet, Film Coated","sponsorNew":"Esperion Therapeutics \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ CSL"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"HLS Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Tablet, Film Coated","sponsorNew":"Esperion Therapeutics \/ HLS Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ HLS Therapeutics"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Esperion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Esperion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"14-C AZD6738","moa":"ATR","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"14-C Berzosertib","moa":"ATR","graph1":"Oncology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"14-C Tuvusertib","moa":"ATR","graph1":"Oncology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ART0380","moa":"ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artios Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Artios Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ART0380","moa":"ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artios Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Artios Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ART0380","moa":"||ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artios Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Artios Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ART0380","moa":"||ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artios Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artios Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATG-018","moa":"ATR","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATG-018","moa":"ATR","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aprea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aprea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aprea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aprea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Aprea Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Aprea Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aprea Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"University of Utah","sponsor":"Repare Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Camonsertib","moa":"ATR||Serine\/threonine-protein kinase ATR (FRP1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Utah","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Utah \/ Repare Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"University of Utah \/ Repare Therapeutics"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Repare Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Camonsertib","moa":"ATR||Serine\/threonine-protein kinase ATR (FRP1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Repare Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Repare Therapeutics"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Camonsertib","moa":"ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Camonsertib","moa":"ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Termination","leadProduct":"Camonsertib","moa":"ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":1.3300000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":1.3300000000000001,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Camonsertib","moa":"ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Camonsertib","moa":"||ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Camonsertib","moa":"||ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Camonsertib","moa":"||ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Camonsertib","moa":"||ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Camonsertib","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Repare Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Camonsertib","moa":"ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":1.3400000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":1.3400000000000001,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Camonsertib","moa":"||ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Camonsertib","moa":"||ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Camonsertib","moa":"ATR","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Edecesertib","moa":"ATR","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Edecesertib","moa":"ATR","graph1":"Immunology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMP9064","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMPACT Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IMPACT Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Burning Rock Dx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"IMP9064","moa":"||ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMPACT Therapeutics, Inc \/ Burning Rock Dx","highestDevelopmentStatusID":"7","companyTruncated":"IMPACT Therapeutics, Inc \/ Burning Rock Dx"},{"orgOrder":0,"company":"Institut Paoli-Calmettes","sponsor":"National Cancer Institute, France | Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"M1774","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institut Paoli-Calmettes","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Paoli-Calmettes \/ National Cancer Institute, France | Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Institut Paoli-Calmettes \/ National Cancer Institute, France | Merck Group"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"M1774","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tuvusertib","moa":"ATR","graph1":"Oncology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tuvusertib","moa":"ATR","graph1":"Oncology","graph2":"Phase I","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VX-973","moa":"ATR","graph1":"Neurology","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"VX-973","moa":"ATR","graph1":"Neurology","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"PL-3994","moa":"Atrial natriuretic peptide receptor A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Divestment","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Endocrinology","graph2":"Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioMarin Pharmaceutical \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"BioMarin Pharmaceutical \/ Icon Plc"},{"orgOrder":0,"company":"GE Healthcare","sponsor":"Fortrea","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"N-Iodoallyl-2-Carbomethoxy-3-4-Fluorophenyl-Tropane","moa":"atropine derivatives","graph1":"Neurology","graph2":"Phase II","graph3":"GE Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GE Healthcare \/ Fortrea","highestDevelopmentStatusID":"8","companyTruncated":"GE Healthcare \/ Fortrea"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"NT-501","moa":"atropine derivatives","graph1":"Rare Diseases and Disorders","graph2":"Phase IV","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Neurotech Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NT-501","moa":"atropine derivatives","graph1":"Rare Diseases and Disorders","graph2":"Phase IV","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Neurotech Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"The Lowy Medical Research Institute Limited","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"NT-501","moa":"atropine derivatives","graph1":"Rare Diseases and Disorders","graph2":"Phase IV","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ The Lowy Medical Research Institute Limited","highestDevelopmentStatusID":"11","companyTruncated":"Neurotech Pharmaceuticals \/ The Lowy Medical Research Institute Limited"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OTO-413","moa":"atropine derivatives","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"OTO-413","moa":"atropine derivatives","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"OTO-413","moa":"atropine derivatives","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Otonomy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OTO-413","moa":"atropine derivatives","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otonomy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Undisclosed"},{"orgOrder":0,"company":"Prothena","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"PRX004","moa":"ATTR protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Prothena","amount2":1.2,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":1.2,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Novo Nordisk"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PRX004","moa":"ATTR protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"PRX004","moa":"ATTR protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TT-00420","moa":"AURKA","graph1":"Oncology","graph2":"Phase III","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TransThera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TransThera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TT-00420","moa":"AURKA","graph1":"Oncology","graph2":"Phase III","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TransThera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TransThera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TT-00420","moa":"AURKA","graph1":"Oncology","graph2":"Undisclosed","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransThera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TransThera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"TransThera Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TT-00420","moa":"AURKA","graph1":"Oncology","graph2":"Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ TransThera Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ TransThera Biosciences"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"TransThera Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TT-00420","moa":"AURKA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ TransThera Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ TransThera Biosciences"},{"orgOrder":0,"company":"Advenchen Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"14-C AL8326","moa":"Aurora B | FGFR | VEGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Advenchen Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advenchen Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Advenchen Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JAB-2485","moa":"Aurora kinase A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"JAB-2485","moa":"Aurora kinase A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TAK-667","moa":"Aurora kinase A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiesi Yingda Pharmaceutical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VIC-1911","moa":"Aurora kinase A (AURKA)","graph1":"Oncology","graph2":"Phase I","graph3":"Jiesi Yingda Pharmaceutical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiesi Yingda Pharmaceutical Technology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiesi Yingda Pharmaceutical Technology \/ Undisclosed"},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"Westat","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VIC-1911","moa":"Aurora kinase A (AURKA)","graph1":"Oncology","graph2":"Phase I","graph3":"VITRAC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"VITRAC Therapeutics \/ Westat","highestDevelopmentStatusID":"6","companyTruncated":"VITRAC Therapeutics \/ Westat"},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VIC-1911","moa":"||Aurora kinase A (AURKA)","graph1":"Oncology","graph2":"Phase I","graph3":"VITRAC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"VITRAC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VITRAC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VIC-1911","moa":"||Aurora kinase A (AURKA)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"VITRAC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VITRAC Therapeutics \/ University of Minnesota","highestDevelopmentStatusID":"7","companyTruncated":"VITRAC Therapeutics \/ University of Minnesota"},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"VIC-1911","moa":"Aurora kinase A (AURKA)","graph1":"Oncology","graph2":"Phase I","graph3":"VITRAC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VITRAC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VITRAC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PhotonPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Innocell Autologous Cellular Immunotherapy","moa":"Autologous immune cells","graph1":"Oncology","graph2":"Phase I","graph3":"PhotonPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PhotonPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PhotonPharma \/ Undisclosed"},{"orgOrder":0,"company":"Corestemchemon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Lenzumestrocel","moa":"Autologous mesenchymal stem cells","graph1":"Neurology","graph2":"Phase III","graph3":"Corestemchemon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Corestemchemon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corestemchemon \/ Undisclosed"},{"orgOrder":0,"company":"Corestemchemon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Lenzumestrocel","moa":"Autologous mesenchymal stem cells","graph1":"Neurology","graph2":"Phase III","graph3":"Corestemchemon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Corestemchemon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corestemchemon \/ Undisclosed"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"CAT-5571","moa":"Autophagy","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catabasis Pharmaceuticals \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Catabasis Pharmaceuticals \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BBT-877","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BBT-877","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Termination","leadProduct":"BBT-877","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BBT-877","moa":"||Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BBT-877","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Emory University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"BBT-877","moa":"||Autotaxin","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Emory University","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Biotherapeutics \/ Emory University"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"University of Colorado","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"BBT-877","moa":"Autotaxin","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ University of Colorado","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Biotherapeutics \/ University of Colorado"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"||Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"||Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Cambritaxestat","moa":"||Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ European Investment Bank","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ European Investment Bank"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"autotaxin","graph1":"Undisclosed","graph2":"Phase I","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Biotech Acquisition Company","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Biotech Acquisition Company","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Biotech Acquisition Company"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Biotech Acquisition Company","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Biotech Acquisition Company","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Biotech Acquisition Company"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IOA-289","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Ionctura","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"IOA-289","moa":"Autotaxin","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","graph1":"Dermatology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BAY2327949","moa":"AVPR1","graph1":"Nephrology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BAY2327949","moa":"AVPR1","graph1":"Nephrology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Viage Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"DGX-001","moa":"AVPR1A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Viage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viage Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Viage Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Digestome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"DGX-001","moa":"AVPR1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Digestome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Digestome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Digestome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioAtla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Mecbotamab Vedotin","moa":"AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAtla \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ Undisclosed"},{"orgOrder":0,"company":"BioAtla","sponsor":"Acuta Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Public Offering","leadProduct":"Mecbotamab Vedotin","moa":"AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"BioAtla \/ Acuta Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ Acuta Capital Partners"},{"orgOrder":0,"company":"BioAtla","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"Mecbotamab Vedotin","moa":"||AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"BioAtla \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ J.P. Morgan"},{"orgOrder":0,"company":"BioAtla","sponsor":"Tungsten Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Private Placement","leadProduct":"Mecbotamab Vedotin","moa":"AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"BioAtla \/ Tungsten Advisors","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ Tungsten Advisors"},{"orgOrder":0,"company":"BioAtla","sponsor":"Soleus Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Series D Financing","leadProduct":"Mecbotamab Vedotin","moa":"AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"BioAtla \/ Soleus Capital","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ Soleus Capital"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"BerGenBio ASA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||AXL","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ BerGenBio ASA","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ BerGenBio ASA"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AB-329","moa":"AXL receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnHeart Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnHeart Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ADCT-601","moa":"AXL receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oscotec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SKI-G-801","moa":"AXL\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oscotec \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oscotec \/ Undisclosed"},{"orgOrder":0,"company":"Qurient","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Q702","moa":"AXL\/Mer\/CSF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qurient \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Qurient \/ Merck & Co"},{"orgOrder":0,"company":"Qurient","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Q702","moa":"AXL\/Mer\/CSF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qurient \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qurient \/ Undisclosed"},{"orgOrder":0,"company":"Qurient","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Adrixetinib","moa":"||AXL\/Mer\/CSF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qurient \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Qurient \/ Undisclosed"},{"orgOrder":0,"company":"Qurient","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Adrixetinib","moa":"||AXL\/Mer\/CSF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qurient \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qurient \/ Undisclosed"},{"orgOrder":0,"company":"Qurient","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Adrixetinib","moa":"AXL|Mer|CSF-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qurient \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qurient \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"JS004","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JS004","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"JS004","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JS004","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"JS004","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"JS004","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JS004","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"JS004","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Sponsor GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Sponsor GmbH"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LY3361237","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Immunology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LY3361237","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Dermatology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"KOMO Biosciences","sponsor":"Caravan Biologix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Licensing Agreement","leadProduct":"CAR001","moa":"B cell","graph1":"Oncology","graph2":"Preclinical","graph3":"KOMO Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KOMO Biosciences \/ Caravan Biologix","highestDevelopmentStatusID":"4","companyTruncated":"KOMO Biosciences \/ Caravan Biologix"},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PRT120","moa":"B Cell Ige production","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prota Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prota Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PRT120","moa":"B Cell Ige production","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prota Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prota Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"PRT120","moa":"B Cell Ige production","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Prota Therapeutics \/ SPRIM Global Investments","highestDevelopmentStatusID":"8","companyTruncated":"Prota Therapeutics \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Indonesia University","sponsor":"Blackmores Institute","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDONESIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Zinc","moa":"B1 bradykinin receptor; Methylated-DNA--protein-cysteine methyltransferase; Fructose-bisphosphate aldolase A; Elongation factor 1-alpha 1; Alpha-enolase; Glyceraldehyde-3-phosphate dehydrogenase, testis-specific; Nucleoside diphosphate kinase A; Protein disulfide-isomerase; Protein disulfide-isomerase A3; Peroxiredoxin-1; Phosphoserine phosphatase; Triosephosphate isomerase; Elongation factor Tu, mitochondrial; Estrogen receptor; Interleukin-3; Metallothionein-2; Copper chaperone for superoxide dismutase; Histone deacetylase 1; Histone deacetylase 4; DNA-3-methyladenine glycosylase; Semenogelin-1; Superoxide dismutase [Cu-Zn]; Histone deacetylase 8; Apoptosis regulatory protein Siva; Glycine receptor subunit alpha-1; E3 ubiquitin-protein ligase Mdm2; Insulin; Utrophin; Aspartoacylase; Protein S100-A8; Protein S100-A9; Matrix metalloproteinase-9; Tumor protein p73; Protein S100-A2; Cellular tumor antigen p53; Metallothionein-3; Programmed cell death protein 6; DAN domain family member 5","graph1":"Endocrinology","graph2":"Phase II","graph3":"Indonesia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indonesia University \/ Blackmores Institute","highestDevelopmentStatusID":"8","companyTruncated":"Indonesia University \/ Blackmores Institute"},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Zinc","moa":"B1 bradykinin receptor; Methylated-DNA--protein-cysteine methyltransferase; Fructose-bisphosphate aldolase A; Elongation factor 1-alpha 1; Alpha-enolase; Glyceraldehyde-3-phosphate dehydrogenase, testis-specific; Nucleoside diphosphate kinase A; Protein disulfide-isomerase; Protein disulfide-isomerase A3; Peroxiredoxin-1; Phosphoserine phosphatase; Triosephosphate isomerase; Elongation factor Tu, mitochondrial; Estrogen receptor; Interleukin-3; Metallothionein-2; Copper chaperone for superoxide dismutase; Histone deacetylase 1; Histone deacetylase 4; DNA-3-methyladenine glycosylase; Semenogelin-1; Superoxide dismutase [Cu-Zn]; Histone deacetylase 8; Apoptosis regulatory protein Siva; Glycine receptor subunit alpha-1; E3 ubiquitin-protein ligase Mdm2; Insulin; Utrophin; Aspartoacylase; Protein S100-A8; Protein S100-A9; Matrix metalloproteinase-9; Tumor protein p73; Protein S100-A2; Cellular tumor antigen p53; Metallothionein-3; Programmed cell death protein 6; DAN domain family member 5","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Colgate Palmolive \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Colgate Palmolive \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Zinc","moa":"||B1 bradykinin receptor; Methylated-DNA--protein-cysteine methyltransferase; Fructose-bisphosphate aldolase A; Elongation factor 1-alpha 1; Alpha-enolase; Glyceraldehyde-3-phosphate dehydrogenase, testis-specific; Nucleoside diphosphate kinase A; Protein disulfide-isomerase; Protein disulfide-isomerase A3; Peroxiredoxin-1; Phosphoserine phosphatase; Triosephosphate isomerase; Elongation factor Tu, mitochondrial; Estrogen receptor; Interleukin-3; Metallothionein-2; Copper chaperone for superoxide dismutase; Histone deacetylase 1; Histone deacetylase 4; DNA-3-methyladenine glycosylase; Semenogelin-1; Superoxide dismutase [Cu-Zn]; Histone deacetylase 8; Apoptosis regulatory protein Siva; Glycine receptor subunit alpha-1; E3 ubiquitin-protein ligase Mdm2; Insulin; Utrophin; Aspartoacylase; Protein S100-A8; Protein S100-A9; Matrix metalloproteinase-9; Tumor protein p73; Protein S100-A2; Cellular tumor antigen p53; Metallothionein-3; Programmed cell death protein 6; DAN domain family member 5","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Israelita Albert Einstein","sponsor":"Colgate Palmolive | Associa\u00e7\u00e3o Latinoamericana para Promo\u00e7\u00e3o de Sa\u00fade Bucal e Pesquisa Odontol\u00f3gica","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"BRAZIL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Zinc","moa":"B1 bradykinin receptor; Methylated-DNA--protein-cysteine methyltransferase; Fructose-bisphosphate aldolase A; Elongation factor 1-alpha 1; Alpha-enolase; Glyceraldehyde-3-phosphate dehydrogenase, testis-specific; Nucleoside diphosphate kinase A; Protein disulfide-isomerase; Protein disulfide-isomerase A3; Peroxiredoxin-1; Phosphoserine phosphatase; Triosephosphate isomerase; Elongation factor Tu, mitochondrial; Estrogen receptor; Interleukin-3; Metallothionein-2; Copper chaperone for superoxide dismutase; Histone deacetylase 1; Histone deacetylase 4; DNA-3-methyladenine glycosylase; Semenogelin-1; Superoxide dismutase [Cu-Zn]; Histone deacetylase 8; Apoptosis regulatory protein Siva; Glycine receptor subunit alpha-1; E3 ubiquitin-protein ligase Mdm2; Insulin; Utrophin; Aspartoacylase; Protein S100-A8; Protein S100-A9; Matrix metalloproteinase-9; Tumor protein p73; Protein S100-A2; Cellular tumor antigen p53; Metallothionein-3; Programmed cell death protein 6; DAN domain family member 5","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Hospital Israelita Albert Einstein","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"Hospital Israelita Albert Einstein \/ Colgate Palmolive | Associa\u00e7\u00e3o Latinoamericana para Promo\u00e7\u00e3o de Sa\u00fade Bucal e Pesquisa Odontol\u00f3gica","highestDevelopmentStatusID":"10","companyTruncated":"Hospital Israelita Albert Einstein \/ Colgate Palmolive | Associa\u00e7\u00e3o Latinoamericana para Promo\u00e7\u00e3o de Sa\u00fade Bucal e Pesquisa Odontol\u00f3gica"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Zinc","moa":"B1 bradykinin receptor; Methylated-DNA--protein-cysteine methyltransferase; Fructose-bisphosphate aldolase A; Elongation factor 1-alpha 1; Alpha-enolase; Glyceraldehyde-3-phosphate dehydrogenase, testis-specific; Nucleoside diphosphate kinase A; Protein disulfide-isomerase; Protein disulfide-isomerase A3; Peroxiredoxin-1; Phosphoserine phosphatase; Triosephosphate isomerase; Elongation factor Tu, mitochondrial; Estrogen receptor; Interleukin-3; Metallothionein-2; Copper chaperone for superoxide dismutase; Histone deacetylase 1; Histone deacetylase 4; DNA-3-methyladenine glycosylase; Semenogelin-1; Superoxide dismutase [Cu-Zn]; Histone deacetylase 8; Apoptosis regulatory protein Siva; Glycine receptor subunit alpha-1; E3 ubiquitin-protein ligase Mdm2; Insulin; Utrophin; Aspartoacylase; Protein S100-A8; Protein S100-A9; Matrix metalloproteinase-9; Tumor protein p73; Protein S100-A2; Cellular tumor antigen p53; Metallothionein-3; Programmed cell death protein 6; DAN domain family member 5","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Egymedicalpedia \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BAY2395840","moa":"B1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BAY2395840","moa":"B1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BAY2395840","moa":"B1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BAY2395840","moa":"B1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Hong Kong Polytechnic University","sponsor":"Alcon Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Propylene Glycol","moa":"B12-independent glycerol dehydratase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Hong Kong Polytechnic University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hong Kong Polytechnic University \/ Alcon Inc","highestDevelopmentStatusID":"8","companyTruncated":"Hong Kong Polytechnic University \/ Alcon Inc"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Alcon Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Propylene Glycol","moa":"B12-independent glycerol dehydratase","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Alcon Inc","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Alcon Inc"},{"orgOrder":0,"company":"University of California, Berkeley","sponsor":"Alcon Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Propylene Glycol","moa":"B12-independent glycerol dehydratase","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"University of California, Berkeley","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Berkeley \/ Alcon Inc","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Berkeley \/ Alcon Inc"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"DM199","moa":"B2 bradykinin receptor (BDKRB2)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DiaMedica Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"DiaMedica Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Georgetown University","sponsor":"MacroGenics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"MGC018","moa":"B7 homolog 3 (CD276)","graph1":"Oncology","graph2":"Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Georgetown University \/ MacroGenics","highestDevelopmentStatusID":"8","companyTruncated":"Georgetown University \/ MacroGenics"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TAK-280","moa":"B7 homolog 3 (CD276)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"177-Lu DTPA-Omburtamab","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Y-mAbs Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Y-mAbs Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"7MW3711","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"7MW3711","moa":"||B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"7MW3711","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"7MW3711","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"7MW3711","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"Mabwell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"7MW3711","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Undisclosed"},{"orgOrder":0,"company":"The Affiliated Hospital of Xuzhou Medical University","sponsor":"Xuzhou Medical University | Meditech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"B7H3 CAR-T Cell","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Affiliated Hospital of Xuzhou Medical University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The Affiliated Hospital of Xuzhou Medical University \/ Xuzhou Medical University | Meditech","highestDevelopmentStatusID":"7","companyTruncated":"The Affiliated Hospital of Xuzhou Medical University \/ Xuzhou Medical University | Meditech"},{"orgOrder":0,"company":"The Affiliated Hospital of Xuzhou Medical University","sponsor":"Xuzhou Medical University | Meditech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"B7H3 CAR-T Cell","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Affiliated Hospital of Xuzhou Medical University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The Affiliated Hospital of Xuzhou Medical University \/ Xuzhou Medical University | Meditech","highestDevelopmentStatusID":"7","companyTruncated":"The Affiliated Hospital of Xuzhou Medical University \/ Xuzhou Medical University | Meditech"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"Tianjin Medical University Cancer Institute and Hospital | Shandong Cancer Hospital and Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"B7-H3 CAR-T Cell","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PersonGen BioTherapeutics \/ Tianjin Medical University Cancer Institute and Hospital | Shandong Cancer Hospital and Institute","highestDevelopmentStatusID":"6","companyTruncated":"PersonGen BioTherapeutics \/ Tianjin Medical University Cancer Institute and Hospital | Shandong Cancer Hospital and Institute"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"B7-H3 CAR-T Cell","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PersonGen BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PersonGen BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"B7H3-IRDye800CW","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University People's Hospital \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Peking University People's Hospital \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"BrainChild Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BCB-276","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"BrainChild Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BrainChild Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BrainChild Bio \/ Undisclosed"},{"orgOrder":0,"company":"BrainChild Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BCB-276","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"BrainChild Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BrainChild Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BrainChild Bio \/ Undisclosed"},{"orgOrder":0,"company":"BrainChild Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BCB-276","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"BrainChild Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BrainChild Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BrainChild Bio \/ Undisclosed"},{"orgOrder":0,"company":"UNC Lineberger Comprehensive Cancer Center","sponsor":"National Cancer Institute | MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"iC9-CAR.B7-H3 T Cell","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"UNC Lineberger Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNC Lineberger Comprehensive Cancer Center \/ National Cancer Institute | MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"UNC Lineberger Comprehensive Cancer Center \/ National Cancer Institute | MD Anderson Cancer Center"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TORL-2-307-ADC","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Translational Research in Oncology"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TORL-2-307-MAB","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Translational Research in Oncology"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IBI334","moa":"B7-H3 \/ EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IDE034","moa":"B7-H3\/PTK7","graph1":"Oncology","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Puxitatug Samrotecan","moa":"B7H4","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mersana Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mersana Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mersana Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mersana Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mersana Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"LNCB74","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"LNCB74","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Ligachem Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"LNCB74","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NextCure \/ Ligachem Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"NextCure \/ Ligachem Biosciences"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"NC762","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NC762","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"NC762","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"NextCure","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"NC762","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ LegoChem Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ LegoChem Biosciences"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"XMT-1660","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mersana Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ABL103","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ABL Bio \/ Undisclosed"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"ABL103","moa":"||B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"ABL Bio \/ Merck & Co"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"HBM7008","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0.58999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.58999999999999997,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Cullinan Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Cullinan Therapeutics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"HBM7008","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"HBM7008","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"HBM1020","moa":"B7-H7","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"HBM1020","moa":"B7-H7","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"HBM1020","moa":"B7-H7","graph1":"Oncology","graph2":"Phase I","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbour BioMed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Harbour BioMed \/ Undisclosed"},{"orgOrder":0,"company":"IMMvention Therapeutix","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"IMM\u2013004","moa":"BACH1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"IMMvention Therapeutix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMMvention Therapeutix \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"IMMvention Therapeutix \/ Novo Nordisk"},{"orgOrder":0,"company":"Nterica Bio inc","sponsor":"Southern California Liver Centers","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Bacteriophage","moa":"Bacteria","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Nterica Bio inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nterica Bio inc \/ Southern California Liver Centers","highestDevelopmentStatusID":"6","companyTruncated":"Nterica Bio inc \/ Southern California Liver Centers"},{"orgOrder":0,"company":"Ottawa Hospital Research Institute","sponsor":"Cytophage Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Bacteriophage","moa":"Bacteria","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ottawa Hospital Research Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ottawa Hospital Research Institute \/ Cytophage Technologies","highestDevelopmentStatusID":"6","companyTruncated":"Ottawa Hospital Research Institute \/ Cytophage Technologies"},{"orgOrder":0,"company":"Intralytix","sponsor":"University of Maryland, Baltimore","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Bacteriophage","moa":"Bacteria","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Intralytix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Intralytix \/ University of Maryland, Baltimore","highestDevelopmentStatusID":"7","companyTruncated":"Intralytix \/ University of Maryland, Baltimore"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Bacteriophage","moa":"Bacteria","graph1":"Rheumatology","graph2":"Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adaptive Phage Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Precisio Biotix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Bacteriophage Cocktail","moa":"Bacteria","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Precisio Biotix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Precisio Biotix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Precisio Biotix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Precisio Biotix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Bacteriophage Microcapsule","moa":"Bacteria","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Precisio Biotix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Precisio Biotix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precisio Biotix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Bacteriophage Therapy","moa":"Bacteria","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Helmholtz Zentrum M\u00fcnchen","sponsor":"Technical University of Munich | Kinderkrankenhaus auf der Bult | University Hospital Carl Gustav Carus | Skane University Hospital | Universitaire Ziekenhuizen KU Leuven | Medical University of Warsaw | Cambridge Biomedical Campus, Cambridge, UK | Royal ","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bifidobacterium Infantis","moa":"Bacteria microbiome","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Helmholtz Zentrum M\u00fcnchen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helmholtz Zentrum M\u00fcnchen \/ Technical University of Munich | Kinderkrankenhaus auf der Bult | University Hospital Carl Gustav Carus | Skane University Hospital | Universitaire Ziekenhuizen KU Leuven | Medical University of Warsaw | Cambridge Biomedical Campus, Cambridge, UK | Royal ","highestDevelopmentStatusID":"1","companyTruncated":"Helmholtz Zentrum M\u00fcnchen \/ Technical University of Munich | Kinderkrankenhaus auf der Bult | University Hospital Carl Gustav Carus | Skane University Hospital | Universitaire Ziekenhuizen KU Leuven | Medical University of Warsaw | Cambridge Biomedical Campus, Cambridge, UK | Royal "},{"orgOrder":0,"company":"Prolacta Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Bifidobacterium Infantis","moa":"Bacteria microbiome","graph1":"Oncology","graph2":"Phase II","graph3":"Prolacta Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prolacta Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prolacta Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"Hanoi University of Science","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Bacillus Spore","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ Hanoi University of Science","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ Hanoi University of Science"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"Hanoi Obstetrics and Gynecology Hospital | Centers for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"VIETNAM","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Bacillus Spore","moa":"Bacteria microbiome","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ Hanoi Obstetrics and Gynecology Hospital | Centers for Disease Control and Prevention","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ Hanoi Obstetrics and Gynecology Hospital | Centers for Disease Control and Prevention"},{"orgOrder":0,"company":"DreamTec Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DreamTec Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DreamTec Research \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"DreamTec Research \/ Undisclosed"},{"orgOrder":0,"company":"DreamTec Research","sponsor":"Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DreamTec Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DreamTec Research \/ Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"DreamTec Research \/ Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"Thai Binh University of Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ Thai Binh University of Medicine and Pharmacy","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ Thai Binh University of Medicine and Pharmacy"},{"orgOrder":0,"company":"National Children's Hospital, Vietnam","sponsor":"Anabio R&D","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Children's Hospital, Vietnam","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Children's Hospital, Vietnam \/ Anabio R&D","highestDevelopmentStatusID":"1","companyTruncated":"National Children's Hospital, Vietnam \/ Anabio R&D"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"VIETNAM","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy"},{"orgOrder":0,"company":"University of Edinburgh","sponsor":"Helse Stavanger | ADM Protexin","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of Edinburgh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Edinburgh \/ Helse Stavanger | ADM Protexin","highestDevelopmentStatusID":"1","companyTruncated":"University of Edinburgh \/ Helse Stavanger | ADM Protexin"},{"orgOrder":0,"company":"BILIX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BX-001N","moa":"Bacteria microbiome","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"BILIX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BILIX \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BILIX \/ Undisclosed"},{"orgOrder":0,"company":"BiomX","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BX005-A","moa":"Bacteria microbiome","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BiomX \/ Maruho","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Maruho"},{"orgOrder":0,"company":"Osel","sponsor":"City of Hope | Miyarisan Pharmaceuticals | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CBM588","moa":"Bacteria microbiome","graph1":"Oncology","graph2":"Phase I","graph3":"Osel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Osel \/ City of Hope | Miyarisan Pharmaceuticals | National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Osel \/ City of Hope | Miyarisan Pharmaceuticals | National Cancer Institute"},{"orgOrder":0,"company":"Universiti Kebangsaan Malaysia Medical Centre","sponsor":"Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MALAYSIA","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Universiti Kebangsaan Malaysia Medical Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universiti Kebangsaan Malaysia Medical Centre \/ Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia","highestDevelopmentStatusID":"1","companyTruncated":"Universiti Kebangsaan Malaysia Medical Centre \/ Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia"},{"orgOrder":0,"company":"NovoNatum Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"NovoNatum Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovoNatum Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NovoNatum Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Atlantia Food Clinical Trials | CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Atlantia Food Clinical Trials | CTC Clinical Trial Consultants","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Atlantia Food Clinical Trials | CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"||Bacteria microbiome","graph1":"Neurology","graph2":"Phase I","graph3":"Scioto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scioto Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Scioto Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Genome & Company","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series B Financing","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Scioto Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Scioto Biosciences \/ Genome & Company","highestDevelopmentStatusID":"7","companyTruncated":"Scioto Biosciences \/ Genome & Company"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"||Bacteria microbiome","graph1":"Neurology","graph2":"Phase I","graph3":"Scioto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scioto Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Scioto Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"SB-121","moa":"Bacteria microbiome","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Scioto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scioto Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Scioto Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Insmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amikacin","moa":"Bacterial 70S ribosome||Bacterial ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Insmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Insmed \/ Undisclosed"},{"orgOrder":0,"company":"Insmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Amikacin","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Insmed \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Insmed \/ Undisclosed"},{"orgOrder":0,"company":"Insmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Amikacin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Insmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Insmed \/ Undisclosed"},{"orgOrder":0,"company":"Insmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Amikacin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Insmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Insmed \/ Undisclosed"},{"orgOrder":0,"company":"Insmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amikacin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Insmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Insmed \/ Undisclosed"},{"orgOrder":0,"company":"Insmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amikacin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Insmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Insmed \/ Undisclosed"},{"orgOrder":0,"company":"Insmed","sponsor":"Taiba Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Agreement","leadProduct":"Amikacin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Insmed \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Insmed \/ Taiba Healthcare"},{"orgOrder":0,"company":"Rwanda Biomedical Centre","sponsor":"Institute of Tropical Medicine | World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RWANDA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Amikacin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rwanda Biomedical Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Rwanda Biomedical Centre \/ Institute of Tropical Medicine | World Health Organization","highestDevelopmentStatusID":"8","companyTruncated":"Rwanda Biomedical Centre \/ Institute of Tropical Medicine | World Health Organization"},{"orgOrder":0,"company":"Insmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Amikacin","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Insmed \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Insmed \/ Undisclosed"},{"orgOrder":0,"company":"Insmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Amikacin","moa":"Bacterial 70S ribosome","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Insmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Undisclosed"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amikacin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Valeo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Valeo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Veritaz Healthcare","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Veritaz Healthcare","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Veritaz Healthcare \/ Aurobindo Pharma Limited","highestDevelopmentStatusID":"15","companyTruncated":"Veritaz Healthcare \/ Aurobindo Pharma Limited"},{"orgOrder":0,"company":"Tampere University","sponsor":"Center for Vaccine Development - Mali | University College London Hospitals | Tro Da Ltd, UK | Duke-NUS Graduate Medical School | Bill & Melinda Gates Foundation | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FINLAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase III","graph3":"Tampere University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tampere University \/ Center for Vaccine Development - Mali | University College London Hospitals | Tro Da Ltd, UK | Duke-NUS Graduate Medical School | Bill & Melinda Gates Foundation | Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Tampere University \/ Center for Vaccine Development - Mali | University College London Hospitals | Tro Da Ltd, UK | Duke-NUS Graduate Medical School | Bill & Melinda Gates Foundation | Pfizer Inc"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Oxford \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Pfizer Inc"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Oxford \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Oxford \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Waterbury Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iterum Therapeutics \/ Waterbury Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Waterbury Hospital"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase II","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Lundquist Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lundquist Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lundquist Institute \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lundquist Institute \/ Undisclosed"},{"orgOrder":0,"company":"UC San Francisco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"UC San Francisco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UC San Francisco \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UC San Francisco \/ Undisclosed"},{"orgOrder":0,"company":"Rutgers Cancer Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rutgers Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rutgers Cancer Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rutgers Cancer Institute \/ Undisclosed"},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"Christiana Care Health Services","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thomas Jefferson University \/ Christiana Care Health Services","highestDevelopmentStatusID":"11","companyTruncated":"Thomas Jefferson University \/ Christiana Care Health Services"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Dr Ian B Wilkinson","sponsor":"University of Aberdeen | NHS Greater Glasgow and Clyde | University of East Anglia | Nottingham City Hospital | Swansea University | Newcastle University | University of Cambridge | NHS Sunderland Clinical Commissioning Group | Liverpool School of Tropica","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Dr Ian B Wilkinson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Dr Ian B Wilkinson \/ University of Aberdeen | NHS Greater Glasgow and Clyde | University of East Anglia | Nottingham City Hospital | Swansea University | Newcastle University | University of Cambridge | NHS Sunderland Clinical Commissioning Group | Liverpool School of Tropica","highestDevelopmentStatusID":"11","companyTruncated":"Dr Ian B Wilkinson \/ University of Aberdeen | NHS Greater Glasgow and Clyde | University of East Anglia | Nottingham City Hospital | Swansea University | Newcastle University | University of Cambridge | NHS Sunderland Clinical Commissioning Group | Liverpool School of Tropica"},{"orgOrder":0,"company":"Manimarane Arjunan, MD,DM (Cardiology)","sponsor":"UR Anoop Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Manimarane Arjunan, MD,DM (Cardiology)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Manimarane Arjunan, MD,DM (Cardiology) \/ UR Anoop Research Group","highestDevelopmentStatusID":"1","companyTruncated":"Manimarane Arjunan, MD,DM (Cardiology) \/ UR Anoop Research Group"},{"orgOrder":0,"company":"The First Affiliated Hospital of Soochow University","sponsor":"Changshu First People's Hospital | The Second People's Hospital of Huai'an | Affiliated Hospital of Jiangnan University | Jiangsu Province Hospital of Traditional Chinese Medicine | Jiangyin People's Hospital | Jingjiang People's Hospital | The Third Peop","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"Bacterial 70S ribosome","graph1":"Oncology","graph2":"Phase III","graph3":"The First Affiliated Hospital of Soochow University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The First Affiliated Hospital of Soochow University \/ Changshu First People's Hospital | The Second People's Hospital of Huai'an | Affiliated Hospital of Jiangnan University | Jiangsu Province Hospital of Traditional Chinese Medicine | Jiangyin People's Hospital | Jingjiang People's Hospital | The Third Peop","highestDevelopmentStatusID":"10","companyTruncated":"The First Affiliated Hospital of Soochow University \/ Changshu First People's Hospital | The Second People's Hospital of Huai'an | Affiliated Hospital of Jiangnan University | Jiangsu Province Hospital of Traditional Chinese Medicine | Jiangyin People's Hospital | Jingjiang People's Hospital | The Third Peop"},{"orgOrder":0,"company":"University of Karachi","sponsor":"Merck & Co | Center for Bioequivalence Studies and Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"PAKISTAN","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"University of Karachi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Karachi \/ Merck & Co | Center for Bioequivalence Studies and Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"University of Karachi \/ Merck & Co | Center for Bioequivalence Studies and Clinical Research"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Financing","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Private Placement","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Financing","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ ","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ "},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Organon \/ Dar\u00e9 Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Dar\u00e9 Bioscience"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ortho Dermatologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ortho Dermatologics \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.19,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Organon"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.19,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Organon"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.19,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Organon"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Divestment","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amneal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Solaris Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Solaris Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Solaris Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Solaris Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ortho Dermatologics \/ Bausch Health","highestDevelopmentStatusID":"10","companyTruncated":"Ortho Dermatologics \/ Bausch Health"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Contezolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"MicuRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MicuRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Contezolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MicuRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Beijing Chest Hospital, Capital Medical University | Jiangxi Provincial Chest Hospital | Bin Cao","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Contezolid","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ Beijing Chest Hospital, Capital Medical University | Jiangxi Provincial Chest Hospital | Bin Cao","highestDevelopmentStatusID":"11","companyTruncated":"MicuRx Pharmaceuticals \/ Beijing Chest Hospital, Capital Medical University | Jiangxi Provincial Chest Hospital | Bin Cao"},{"orgOrder":0,"company":"MicuRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Contezolid Acefosamil","moa":"Bacterial 70S ribosome","graph1":"Podiatry","graph2":"Phase III","graph3":"MicuRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MicuRx \/ Undisclosed"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Contezolid Acefosamil","moa":"Bacterial 70S ribosome","graph1":"Podiatry","graph2":"Phase I","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"MicuRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MicuRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Delpazolid","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ligachem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ligachem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ligachem Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Delpazolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ligachem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ligachem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ligachem Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"Ludwig Maximilian University of Munich | Radboud University Medical Center | University of California, San Francisco","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Delpazolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ligachem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ligachem Biosciences \/ Ludwig Maximilian University of Munich | Radboud University Medical Center | University of California, San Francisco","highestDevelopmentStatusID":"8","companyTruncated":"Ligachem Biosciences \/ Ludwig Maximilian University of Munich | Radboud University Medical Center | University of California, San Francisco"},{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Delpazolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ligachem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ligachem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ligachem Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ewha Womans University","sponsor":"SOM Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ewha Womans University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ewha Womans University \/ SOM Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Ewha Womans University \/ SOM Biotech"},{"orgOrder":0,"company":"Shanghai Pharma Group","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Partnership","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shanghai Pharma Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Pharma Group \/ Everest Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Pharma Group \/ Everest Medicines"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SOM Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SOM Biotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"SOM Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Innoviva Specialty Therapeutics","sponsor":"Tetraphase Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innoviva Specialty Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innoviva Specialty Therapeutics \/ Tetraphase Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Innoviva Specialty Therapeutics \/ Tetraphase Pharmaceuticals"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tetraphase Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Tetraphase Pharmaceuticals \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"TTY BIOPHARM CO LTD","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ TTY BIOPHARM CO LTD","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ TTY BIOPHARM CO LTD"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tetraphase Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ AcelRx Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Tetraphase Pharmaceuticals \/ AcelRx Pharmaceuticals"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Armistice Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tetraphase Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ Armistice Capital","highestDevelopmentStatusID":"15","companyTruncated":"Tetraphase Pharmaceuticals \/ Armistice Capital"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tetraphase Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Tetraphase Pharmaceuticals \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"La Jolla Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"La Jolla Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Everest Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Everest Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Erythromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Inova Health Care Services","sponsor":"Eastern Virginia Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Erythromycin","moa":"Bacterial 70S ribosome","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Inova Health Care Services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inova Health Care Services \/ Eastern Virginia Medical School","highestDevelopmentStatusID":"10","companyTruncated":"Inova Health Care Services \/ Eastern Virginia Medical School"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Erythromycin Lactobionate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nexus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Erythromycin Lactobionate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nexus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Institut Pasteur \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Institut Pasteur \/ Undisclosed"},{"orgOrder":0,"company":"Spaarne Gasthuis","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Spaarne Gasthuis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spaarne Gasthuis \/ ZonMw","highestDevelopmentStatusID":"10","companyTruncated":"Spaarne Gasthuis \/ ZonMw"},{"orgOrder":0,"company":"Mercy Health","sponsor":"Northeast Ohio Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mercy Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mercy Health \/ Northeast Ohio Medical University","highestDevelopmentStatusID":"8","companyTruncated":"Mercy Health \/ Northeast Ohio Medical University"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Washington","sponsor":"Nabriva Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Washington \/ Nabriva Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"University of Washington \/ Nabriva Therapeutics"},{"orgOrder":0,"company":"Nanjing King-friend Biochemical Pharmaceutical","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nanjing King-friend Biochemical Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanjing King-friend Biochemical Pharmaceutical \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Nanjing King-friend Biochemical Pharmaceutical \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"Sinovant Sciences","sponsor":"Nabriva Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinovant Sciences \/ Nabriva Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Sinovant Sciences \/ Nabriva Therapeutics"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"WEP Clinical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ WEP Clinical","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ WEP Clinical"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Erkim","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Erkim","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Erkim"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Sinovant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Nabriva Therapeutics \/ Sinovant Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Sinovant Sciences"},{"orgOrder":0,"company":"London School of Hygiene & Tropical Medicine","sponsor":"University College Dublin | University of Stellenbosch | Malawi Liverpool Wellcome Programme | University of Sydney | Murdoch Childrens Research Institute | MRC CTU at UCL | PHPT\/AMS Laboratory","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"London School of Hygiene & Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London School of Hygiene & Tropical Medicine \/ University College Dublin | University of Stellenbosch | Malawi Liverpool Wellcome Programme | University of Sydney | Murdoch Childrens Research Institute | MRC CTU at UCL | PHPT\/AMS Laboratory","highestDevelopmentStatusID":"8","companyTruncated":"London School of Hygiene & Tropical Medicine \/ University College Dublin | University of Stellenbosch | Malawi Liverpool Wellcome Programme | University of Sydney | Murdoch Childrens Research Institute | MRC CTU at UCL | PHPT\/AMS Laboratory"},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Persica Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Persica Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Persica Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Persica Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Micron Research Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Persica Pharmaceuticals \/ Micron Research Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Persica Pharmaceuticals \/ Micron Research Ltd"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Premier Research Group","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Premier Research Group"},{"orgOrder":0,"company":"Beijing Tiantan Hospital","sponsor":"Neurodawn Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Beijing Tiantan Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Beijing Tiantan Hospital \/ Neurodawn Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Tiantan Hospital \/ Neurodawn Pharmaceutical"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Hovione","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"PORTUGAL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Hovione","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Hovione \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hovione \/ Undisclosed"},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Foamix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Foamix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Foamix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Cutia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Foamix Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Foam","sponsorNew":"Foamix Pharmaceuticals \/ Cutia Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Foamix Pharmaceuticals \/ Cutia Therapeutics"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Citius Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Film, Soluble","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ SWK Holdings Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dental and Oral Health","graph2":"Approved FDF","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Powder","sponsorNew":"ORAPHARMA \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"ORAPHARMA \/ Bausch Health"},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dental and Oral Health","graph2":"Approved FDF","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Powder","sponsorNew":"ORAPHARMA \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ORAPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Menlo Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Menlo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Menlo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Menlo Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Menlo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Menlo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Divestment","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"VYNE Therapeutics","amount2":0.47999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Journey Medical Corporation","highestDevelopmentStatusID":"15","companyTruncated":"VYNE Therapeutics \/ Journey Medical Corporation"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase II","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biorasi","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Biorasi \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Biorasi \/ Citius Pharmaceuticals"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Nafithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Wockhardt \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Wockhardt \/ Undisclosed"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Nafithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Wockhardt \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Wockhardt \/ Undisclosed"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Jiangxi Jemincare Group Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Partnership","leadProduct":"Nafithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wockhardt \/ Jiangxi Jemincare Group Company","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ Jiangxi Jemincare Group Company"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Axplora","sponsor":"Paratek Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Axplora","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axplora \/ Paratek Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Axplora \/ Paratek Pharmaceuticals"},{"orgOrder":0,"company":"Lundquist Institute for Biomedical Innovation","sponsor":"Chapman University | Paratek Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lundquist Institute for Biomedical Innovation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Lundquist Institute for Biomedical Innovation \/ Chapman University | Paratek Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lundquist Institute for Biomedical Innovation \/ Chapman University | Paratek Pharmaceuticals"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"University of Houston | High Point University | Paratek Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wake Forest University Health Sciences \/ University of Houston | High Point University | Paratek Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Wake Forest University Health Sciences \/ University of Houston | High Point University | Paratek Pharmaceuticals"},{"orgOrder":0,"company":"University of Houston","sponsor":"Paratek Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"University of Houston","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Houston \/ Paratek Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"University of Houston \/ Paratek Pharmaceuticals"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0.28999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Agreement","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.29999999999999999,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Funding","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.29999999999999999,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Partnership","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0.28000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.28000000000000003,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Acquisition","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0.28999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Zai Lab"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Acquisition","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0.46000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.46000000000000002,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Gurnet Point Capital","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Pharmaceuticals \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Paratek Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Paratek Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Paromomycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Appili Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Public Offering","leadProduct":"Paromomycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Public Offering","leadProduct":"Paromomycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Paromomycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Appili Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Paromomycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Appili Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cipla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Plazomicin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cipla \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Undisclosed"},{"orgOrder":0,"company":"Cipla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plazomicin","moa":"Bacterial 70S ribosome","graph1":"Nephrology","graph2":"Phase I","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cipla \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cipla \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Ouyi Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CSPC Ouyi Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Hetero Drugs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hetero Drugs","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hetero Drugs \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hetero Drugs \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Merck & Co"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nabriva Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nabriva Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"NanoSHIFT","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase 13 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Massachusetts General Hospital \/ NanoSHIFT","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ NanoSHIFT"},{"orgOrder":0,"company":"Appalachian State University","sponsor":"Ocean Spray, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Cranberry","moa":"Bacterial adhesion","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Appalachian State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gummies","sponsorNew":"Appalachian State University \/ Ocean Spray, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Appalachian State University \/ Ocean Spray, Inc."},{"orgOrder":0,"company":"Inmunotek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MV130","moa":"Bacterial antigens","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Inmunotek \/ Undisclosed"},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Shionogi | Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Xeruborbactam Prodrug","moa":"Bacterial beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qpex Biopharma \/ Shionogi | Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Biopharma \/ Shionogi | Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Shionogi | Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Xeruborbactam Prodrug","moa":"Bacterial beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qpex Biopharma \/ Shionogi | Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Biopharma \/ Shionogi | Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avibactam Sodium","moa":"Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avibactam Sodium","moa":"Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Pfizer Inc"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Private Placement","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Innoviva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innoviva \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innoviva \/ Undisclosed"},{"orgOrder":0,"company":"Innoviva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innoviva \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innoviva \/ Undisclosed"},{"orgOrder":0,"company":"Innoviva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innoviva \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/ Undisclosed"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Innoviva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innoviva \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/ Undisclosed"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Private Placement","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Innoviva Specialty Therapeutics","sponsor":"Entasis Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sulbactam","moa":"Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innoviva Specialty Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innoviva Specialty Therapeutics \/ Entasis Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Innoviva Specialty Therapeutics \/ Entasis Therapeutics"},{"orgOrder":0,"company":"Trellis Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TRL1068","moa":"Bacterial biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Trellis Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trellis Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trellis Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CMTX-101","moa":"Bacterial biofilm","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarametyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarametyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Ohio Innovation Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Series A Financing","leadProduct":"CMTX-101","moa":"Bacterial biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Clarametyx Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Clarametyx Biosciences \/ Ohio Innovation Fund","highestDevelopmentStatusID":"7","companyTruncated":"Clarametyx Biosciences \/ Ohio Innovation Fund"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CMTX-101","moa":"Bacterial biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarametyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clarametyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CMTX-101","moa":"Bacterial biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarametyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clarametyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"KAMRA Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Funding","leadProduct":"CMTX-101","moa":"Bacterial biofilm","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarametyx Biosciences \/ KAMRA Fund","highestDevelopmentStatusID":"7","companyTruncated":"Clarametyx Biosciences \/ KAMRA Fund"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CMTX-101","moa":"Bacterial biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarametyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clarametyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Funding","leadProduct":"CMTX-101","moa":"Bacterial biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarametyx Biosciences \/ CARB-X","highestDevelopmentStatusID":"6","companyTruncated":"Clarametyx Biosciences \/ CARB-X"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CMTX-101","moa":"Bacterial biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarametyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Clarametyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CMTX-101","moa":"Bacterial biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarametyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarametyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Haleon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Dentifrice","moa":"Bacterial biofilm","graph1":"Dental and Oral Health","graph2":"Undisclosed","graph3":"Haleon","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haleon \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Haleon \/ Undisclosed"},{"orgOrder":0,"company":"Haleon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Dentifrice","moa":"Bacterial biofilm","graph1":"Dental and Oral Health","graph2":"Phase IV","graph3":"Haleon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haleon \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Haleon \/ Undisclosed"},{"orgOrder":0,"company":"Haleon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Dentifrice","moa":"Bacterial biofilm","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Haleon","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haleon \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Haleon \/ Undisclosed"},{"orgOrder":0,"company":"Church & Dwight Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Dentifrice","moa":"Bacterial biofilm","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Church & Dwight Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Church & Dwight Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Church & Dwight Co \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Grammidin","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Loma Linda University","sponsor":"Irrimax Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Irrisept","moa":"Bacterial cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Loma Linda University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Loma Linda University \/ Irrimax Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Loma Linda University \/ Irrimax Corporation"},{"orgOrder":0,"company":"Megainpharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Miramistin","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Megainpharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Megainpharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Megainpharm \/ Undisclosed"},{"orgOrder":0,"company":"MicuRx","sponsor":"Biomedical Advanced Research and Development Authority | Wellcome Trust","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"MRX-8","moa":"Bacterial cell membrane","graph1":"Undisclosed","graph2":"Phase I","graph3":"MicuRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx \/ Biomedical Advanced Research and Development Authority | Wellcome Trust","highestDevelopmentStatusID":"6","companyTruncated":"MicuRx \/ Biomedical Advanced Research and Development Authority | Wellcome Trust"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Presight Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Series B Financing","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Peptilogics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Peptilogics \/ Presight Capital","highestDevelopmentStatusID":"8","companyTruncated":"Peptilogics \/ Presight Capital"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Peptilogics","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Peptilogics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Peptilogics \/ CARB-X","highestDevelopmentStatusID":"8","companyTruncated":"Peptilogics \/ CARB-X"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Department of Health and Human Services | Wellcome Trust","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Rheumatology","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peptilogics \/ Department of Health and Human Services | Wellcome Trust","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogics \/ Department of Health and Human Services | Wellcome Trust"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Polymyxin","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Everest Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Everest Medicines \/ Undisclosed"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Polymyxin","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MicuRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Financing","leadProduct":"Polymyxin","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"MicuRx Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ CARB-X","highestDevelopmentStatusID":"5","companyTruncated":"MicuRx Pharmaceuticals \/ CARB-X"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pudexacianinium Chloride","moa":"Bacterial cell membrane","graph1":"Oncology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pudexacianinium Chloride","moa":"Bacterial cell membrane","graph1":"Undisclosed","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pudexacianinium Chloride","moa":"Bacterial cell membrane","graph1":"Undisclosed","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pudexacianinium Chloride","moa":"Bacterial cell membrane","graph1":"Undisclosed","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pudexacianinium Chloride","moa":"Bacterial cell membrane","graph1":"Undisclosed","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pudexacianinium Chloride","moa":"Bacterial cell membrane","graph1":"Nephrology","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vaxiion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VAX014","moa":"Bacterial cell membrane","graph1":"Oncology","graph2":"Phase I","graph3":"Vaxiion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxiion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vaxiion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Xinnate","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TCP-25","moa":"Bacterial cell wall","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Xinnate","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Xinnate \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xinnate \/ Undisclosed"},{"orgOrder":0,"company":"Xinnate","sponsor":"Region Skane","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TCP-25","moa":"Bacterial cell wall","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Xinnate","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"Xinnate \/ Region Skane","highestDevelopmentStatusID":"6","companyTruncated":"Xinnate \/ Region Skane"},{"orgOrder":0,"company":"Cutia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"FMX101","moa":"Bacterial cell wall","graph1":"Dermatology","graph2":"Phase III","graph3":"Cutia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cutia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cutia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SoftOx Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"SoftOx Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"SoftOx Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SoftOx Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Benapenem","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sihuan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sihuan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Benapenem","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sihuan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sihuan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Juvise Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Bismuth Potassium Citrate","moa":"||Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Juvise Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Juvise Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Juvise Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"CDL200","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"iNtRON Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"iNtRON Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Nanyang Technological University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CSM5-K5","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Nanyang Technological University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanyang Technological University \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Nanyang Technological University \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ SWK Holdings Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Relief Therapeutics \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ SWK Holdings Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Relief Therapeutics \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Sonoma Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Sonoma Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Sonoma Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sonoma Pharmaceuticals \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Brill International S.L","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Pharmaceuticals \/ Brill International S.L","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Brill International S.L"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lumen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Funding","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Lumen Bioscience \/ US Department of Defense","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ US Department of Defense"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lumen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Congressionally Directed Medical Research Programs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lumen Bioscience \/ Congressionally Directed Medical Research Programs","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ Congressionally Directed Medical Research Programs"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lumen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Path BioAnalytics","sponsor":"Recce Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Path BioAnalytics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Path BioAnalytics \/ Recce Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Path BioAnalytics \/ Recce Pharmaceuticals"},{"orgOrder":0,"company":"Fiona Stanley Hospital","sponsor":"Recce Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2021","type":"Agreement","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Fiona Stanley Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Fiona Stanley Hospital \/ Recce Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Fiona Stanley Hospital \/ Recce Pharmaceuticals"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2025","type":"Private Placement","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Murdoch Children\u2019s Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Murdoch Children\u2019s Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Murdoch Children\u2019s Research Institute"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ US Department of Defense"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"PT Etana Biotechnologies Indonesia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Partnership","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ PT Etana Biotechnologies Indonesia","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ PT Etana Biotechnologies Indonesia"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Private Placement","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Canaccord Genuity","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Canaccord Genuity"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Murdoch Children\u2019s Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Partnership","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Murdoch Children\u2019s Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Murdoch Children\u2019s Research Institute"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Australian Government Department Of Industry, Science, Energy And Resources","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Recce Pharmaceuticals \/ Australian Government Department Of Industry, Science, Energy And Resources","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Australian Government Department Of Industry, Science, Energy And Resources"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"CSIRO","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Recce Pharmaceuticals \/ CSIRO","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ CSIRO"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TAXIS Pharmaceuticals","sponsor":"Boston University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Funding","leadProduct":"TXA709","moa":"Bacterial Celldivision protein FtsZ (Bact ftsZ)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TAXIS Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"TAXIS Pharmaceuticals \/ Boston University","highestDevelopmentStatusID":"6","companyTruncated":"TAXIS Pharmaceuticals \/ Boston University"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Trimethoprim","moa":"Bacterial dihydrofolate reductase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Trimethoprim","moa":"Bacterial dihydrofolate reductase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"David J. Gagnon","sponsor":"MaineHealth | National Institute of General Medical Sciences | University of New England","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Trimethoprim","moa":"Bacterial dihydrofolate reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"David J. Gagnon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"David J. Gagnon \/ MaineHealth | National Institute of General Medical Sciences | University of New England","highestDevelopmentStatusID":"8","companyTruncated":"David J. Gagnon \/ MaineHealth | National Institute of General Medical Sciences | University of New England"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"ZonMw | Universitaire Ziekenhuizen KU Leuven","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sulfadiazine","moa":"Bacterial dihydropteroate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ ZonMw | Universitaire Ziekenhuizen KU Leuven","highestDevelopmentStatusID":"10","companyTruncated":"Radboud University Medical Center \/ ZonMw | Universitaire Ziekenhuizen KU Leuven"},{"orgOrder":0,"company":"Somerset Pharmaceuticals Inc","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Sulfamethoxazole","moa":"||Bacterial dihydropteroate synthase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Somerset Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Somerset Pharmaceuticals Inc \/ Premier","highestDevelopmentStatusID":"1","companyTruncated":"Somerset Pharmaceuticals Inc \/ Premier"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"The First Affiliated Hospital of Soochow University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"14-C TGRX-326","moa":"Bacterial DNA gyrase","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ The First Affiliated Hospital of Soochow University","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen TargetRx \/ The First Affiliated Hospital of Soochow University"},{"orgOrder":0,"company":"Minapharm Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"EGYPT","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprodiazole","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Minapharm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minapharm Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Minapharm Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Melinta Therapeutics \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Melinta Therapeutics \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Partnership","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"Melinta Therapeutics \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Xediton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melinta Therapeutics \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Xediton Pharmaceuticals"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibafloxacin","moa":"Bacterial DNA gyrase","graph1":"Immunology","graph2":"Phase I","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibafloxacin","moa":"Bacterial DNA gyrase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Indonesia University","sponsor":"Dexa Medica","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDONESIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Moxifloxacin","moa":"Bacterial DNA gyrase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Indonesia University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Indonesia University \/ Dexa Medica","highestDevelopmentStatusID":"6","companyTruncated":"Indonesia University \/ Dexa Medica"},{"orgOrder":0,"company":"University of Karachi","sponsor":"SAMI Pharmaceutical | Center for Bioequivalence Studies and Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"PAKISTAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Moxifloxacin","moa":"Bacterial DNA gyrase","graph1":"Undisclosed","graph2":"Phase I","graph3":"University of Karachi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Karachi \/ SAMI Pharmaceutical | Center for Bioequivalence Studies and Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"University of Karachi \/ SAMI Pharmaceutical | Center for Bioequivalence Studies and Clinical Research"},{"orgOrder":0,"company":"Merck Group","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Moxifloxacin","moa":"Bacterial DNA gyrase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Merck Group"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Moxifloxacin","moa":"Bacterial DNA gyrase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Peschke","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Moxifloxacin","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peschke","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Peschke \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peschke \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Savara","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Grifols International \/ Savara","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Savara"},{"orgOrder":0,"company":"Binnopharm Group","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Binnopharm Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Binnopharm Group \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Binnopharm Group \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"ALK","sponsor":"Otonomy","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Otonomy","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Otonomy"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Lonza Group","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Lonza Group"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"NeuraLight","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ NeuraLight","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ NeuraLight"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Biogen"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"PhaseV","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Partnership","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ PhaseV","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ PhaseV"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aradigm","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aradigm","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Aradigm \/ Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"Aradigm \/ Grifols International"},{"orgOrder":0,"company":"Otonomy","sponsor":"ALK","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Otonomy \/ ALK","highestDevelopmentStatusID":"15","companyTruncated":"Otonomy \/ ALK"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amneal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Genetika","sponsor":"NeuroSense Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"Genetika","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Genetika \/ NeuroSense Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Genetika \/ NeuroSense Therapeutics"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Nemonoxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiGen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"TaiGen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Luminarie","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Nemonoxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiGen Biotechnology \/ Luminarie","highestDevelopmentStatusID":"15","companyTruncated":"TaiGen Biotechnology \/ Luminarie"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sitafloxacin Hydrate","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"TNP-2092","moa":"Bacterial DNA gyrase | Topoisomerase IV | Bacterial DNA-directed RNA polymerase","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TenNor Therapeutics \/ The First Hospital of Jilin University","highestDevelopmentStatusID":"7","companyTruncated":"TenNor Therapeutics \/ The First Hospital of Jilin University"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"TNP-2092","moa":"Bacterial DNA gyrase | Topoisomerase IV | Bacterial DNA-directed RNA polymerase","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TenNor Therapeutics \/ The First Hospital of Jilin University","highestDevelopmentStatusID":"7","companyTruncated":"TenNor Therapeutics \/ The First Hospital of Jilin University"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"TNP-2092","moa":"Bacterial DNA gyrase | Topoisomerase IV | Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TenNor Therapeutics \/ The First Hospital of Jilin University","highestDevelopmentStatusID":"6","companyTruncated":"TenNor Therapeutics \/ The First Hospital of Jilin University"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"TNP-2092","moa":"Bacterial DNA gyrase | Topoisomerase IV | Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TenNor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TenNor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"TNP-2092","moa":"Bacterial DNA gyrase | Topoisomerase IV | Bacterial DNA-directed RNA polymerase","graph1":"Neurology","graph2":"Phase II","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TenNor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TenNor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"First Affiliated Hospital of Xinjiang Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"TNP-2092","moa":"Bacterial DNA gyrase | Topoisomerase IV | Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"TenNor Therapeutics \/ First Affiliated Hospital of Xinjiang Medical University","highestDevelopmentStatusID":"7","companyTruncated":"TenNor Therapeutics \/ First Affiliated Hospital of Xinjiang Medical University"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"TNP-2092","moa":"Bacterial DNA gyrase | Topoisomerase IV | Bacterial DNA-directed RNA polymerase","graph1":"Rheumatology","graph2":"Phase I","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TenNor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TenNor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"TNP-2092","moa":"Bacterial DNA gyrase | Topoisomerase IV | Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"TenNor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TenNor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"TNP-2092","moa":"Bacterial DNA gyrase | Topoisomerase IV | Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"TenNor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TenNor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SPR720","moa":"Bacterial DNA gyrase B (Bact gyrB)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SPR720","moa":"Bacterial DNA gyrase B (Bact gyrB)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SPR720","moa":"Bacterial DNA gyrase B (Bact gyrB)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SPR720","moa":"Bacterial DNA gyrase B (Bact gyrB)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SPR720","moa":"Bacterial DNA gyrase B (Bact gyrB)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SPR720","moa":"Bacterial DNA gyrase B (Bact gyrB)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SPR720","moa":"Bacterial DNA gyrase B (Bact gyrB)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"OPS-2071","moa":"Bacterial DNA replication","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Yabao Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Endocrinology","graph2":"Phase I","graph3":"Suzhou Yabao Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Yabao Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Suzhou Yabao Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of North Carolina \/ Bausch Health","highestDevelopmentStatusID":"11","companyTruncated":"University of North Carolina \/ Bausch Health"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GIBF2","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2024","type":"Financing","leadProduct":"Rifabutin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"BioVersys AG \/ GIBF2","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ GIBF2"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifabutin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioVersys AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioVersys AG \/ Undisclosed"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2024","type":"Series C Financing","leadProduct":"Rifabutin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"BioVersys AG \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ GSK"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifabutin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioVersys AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ Undisclosed"},{"orgOrder":0,"company":"Curetis","sponsor":"BioVersys AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Rifabutin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Curetis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Curetis \/ BioVersys AG","highestDevelopmentStatusID":"6","companyTruncated":"Curetis \/ BioVersys AG"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2021","type":"Financing","leadProduct":"Rifabutin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioVersys AG \/ European Investment Bank","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ European Investment Bank"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Colorado, Denver \/ Merck & Co"},{"orgOrder":0,"company":"Ahon Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ahon Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ahon Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ahon Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Vincentage Pharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vincentage Pharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vincentage Pharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vincentage Pharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Oncology","graph2":"Phase I","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aosaikang Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aosaikang Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fundacion Agencia Aragonesa para la Investigacion y Desarrollo","sponsor":"Universidad de Zaragoza | Fondation Raoul Follereau | Universit\u00e9 d'Abomey-Calavi | Instituto de Salud Carlos III | Fundaci\u00f3n Anesvad | Tres Cantos Open Lab Foundation | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Fundacion Agencia Aragonesa para la Investigacion y Desarrollo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundacion Agencia Aragonesa para la Investigacion y Desarrollo \/ Universidad de Zaragoza | Fondation Raoul Follereau | Universit\u00e9 d'Abomey-Calavi | Instituto de Salud Carlos III | Fundaci\u00f3n Anesvad | Tres Cantos Open Lab Foundation | GSK","highestDevelopmentStatusID":"8","companyTruncated":"Fundacion Agencia Aragonesa para la Investigacion y Desarrollo \/ Universidad de Zaragoza | Fondation Raoul Follereau | Universit\u00e9 d'Abomey-Calavi | Instituto de Salud Carlos III | Fundaci\u00f3n Anesvad | Tres Cantos Open Lab Foundation | GSK"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"University of Oxford | KEMRI-Wellcome Trust Research Program | University of Washington | Wageningen University | Zvitambo Institute for Maternal & Child Health | Tropical Gastroenterology & Nutrition Group (TROPGAN) | University of Cambridge | Kenya Medi","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Queen Mary University of London \/ University of Oxford | KEMRI-Wellcome Trust Research Program | University of Washington | Wageningen University | Zvitambo Institute for Maternal & Child Health | Tropical Gastroenterology & Nutrition Group (TROPGAN) | University of Cambridge | Kenya Medi","highestDevelopmentStatusID":"10","companyTruncated":"Queen Mary University of London \/ University of Oxford | KEMRI-Wellcome Trust Research Program | University of Washington | Wageningen University | Zvitambo Institute for Maternal & Child Health | Tropical Gastroenterology & Nutrition Group (TROPGAN) | University of Cambridge | Kenya Medi"},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Divestment","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Elutia \/ Berkeley Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Berkeley Biologics"},{"orgOrder":0,"company":"Elutia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Undisclosed"},{"orgOrder":0,"company":"Elutia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Undisclosed"},{"orgOrder":0,"company":"Elutia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Undisclosed"},{"orgOrder":0,"company":"Elutia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Undisclosed"},{"orgOrder":0,"company":"Elutia","sponsor":"Lake Street Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Implant","sponsorNew":"Elutia \/ Lake Street Capital Markets","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Lake Street Capital Markets"},{"orgOrder":0,"company":"Elutia","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Financing","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ SWK Holdings Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"Elutia","sponsor":"Vizient","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Agreement","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Vizient","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Vizient"},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Divestment","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Elutia \/ Berkeley Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Berkeley Biologics"},{"orgOrder":0,"company":"Elutia","sponsor":"HighCape Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Private Placement","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Implant","sponsorNew":"Elutia \/ HighCape Capital","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ HighCape Capital"},{"orgOrder":0,"company":"Elutia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"St George's, University of London | McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ St George's, University of London | McMaster University","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ St George's, University of London | McMaster University"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Unitaid","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"Rifapentine","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Unitaid","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Unitaid"},{"orgOrder":0,"company":"Yale University","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifapentine","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Yale University \/ Gilead Sciences"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Dermatology","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alfasigma \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ Biorasi"},{"orgOrder":0,"company":"Soroka University Medical Center","sponsor":"Biotax Labs | Israel Cancer Association","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Soroka University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soroka University Medical Center \/ Biotax Labs | Israel Cancer Association","highestDevelopmentStatusID":"8","companyTruncated":"Soroka University Medical Center \/ Biotax Labs | Israel Cancer Association"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alvogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Alvogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alvogen \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alvogen \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Salix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Salix Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Salix Pharmaceuticals"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Alvogen","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Alvogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alvogen \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Alvogen \/ Bausch Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cedars-Sinai \/ Bausch Health","highestDevelopmentStatusID":"7","companyTruncated":"Cedars-Sinai \/ Bausch Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Salix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Department of Health and Human Services | Wellcome Trust","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GSK3882347","moa":"Bacterial Fimbrin D-mannose adhesin (Bact FimH)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Department of Health and Human Services | Wellcome Trust","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Department of Health and Human Services | Wellcome Trust"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GSK3882347","moa":"Bacterial Fimbrin D-mannose adhesin (Bact FimH)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NuLiv Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AstraGin","moa":"Bacterial gut","graph1":"Immunology","graph2":"Undisclosed","graph3":"NuLiv Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NuLiv Science \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NuLiv Science \/ Undisclosed"},{"orgOrder":0,"company":"Northern Antibiotics","sponsor":"Prokaryotics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FINLAND","productType":"Antibiotic","year":"2025","type":"Licensing Agreement","leadProduct":"Spr 741","moa":"Bacterial outer membrane protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Northern Antibiotics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Northern Antibiotics \/ Prokaryotics","highestDevelopmentStatusID":"6","companyTruncated":"Northern Antibiotics \/ Prokaryotics"},{"orgOrder":0,"company":"TASK Applied Science","sponsor":"GSK | European & Developing Countries Clinical Trials Partnership","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sanfetrinem Cilexetil","moa":"Bacterial Penicillin binding protein (Bact PBP)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TASK Applied Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"TASK Applied Science \/ GSK | European & Developing Countries Clinical Trials Partnership","highestDevelopmentStatusID":"8","companyTruncated":"TASK Applied Science \/ GSK | European & Developing Countries Clinical Trials Partnership"},{"orgOrder":0,"company":"Shandong University","sponsor":"The Affiliated Hospital of Qingdao University | The People's Hospital of Guangrao | Weihai Municipal Hospital | Shandong Province Third Hospital | Taian City Central Hospital | Jining No.2 People's Hospital | Maternity and Child Care Health Center of Dezh","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Shandong University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong University \/ The Affiliated Hospital of Qingdao University | The People's Hospital of Guangrao | Weihai Municipal Hospital | Shandong Province Third Hospital | Taian City Central Hospital | Jining No.2 People's Hospital | Maternity and Child Care Health Center of Dezh","highestDevelopmentStatusID":"11","companyTruncated":"Shandong University \/ The Affiliated Hospital of Qingdao University | The People's Hospital of Guangrao | Weihai Municipal Hospital | Shandong Province Third Hospital | Taian City Central Hospital | Jining No.2 People's Hospital | Maternity and Child Care Health Center of Dezh"},{"orgOrder":0,"company":"Shandong University","sponsor":"Maternity and Child Care Health Center of Dezhou | Heze Municipal 3rd people's hospital | Peking University Care Luzhong Hospital | The People's Hospital of Jimo.Qingdao","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Shandong University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong University \/ Maternity and Child Care Health Center of Dezhou | Heze Municipal 3rd people's hospital | Peking University Care Luzhong Hospital | The People's Hospital of Jimo.Qingdao","highestDevelopmentStatusID":"11","companyTruncated":"Shandong University \/ Maternity and Child Care Health Center of Dezhou | Heze Municipal 3rd people's hospital | Peking University Care Luzhong Hospital | The People's Hospital of Jimo.Qingdao"},{"orgOrder":0,"company":"Central Hospital, Nancy, France","sponsor":"Soci\u00e9t\u00e9 Francophone Nutrition Clinique et M\u00e9tabolisme | Fimatho | Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Central Hospital, Nancy, France","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Central Hospital, Nancy, France \/ Soci\u00e9t\u00e9 Francophone Nutrition Clinique et M\u00e9tabolisme | Fimatho | Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"6","companyTruncated":"Central Hospital, Nancy, France \/ Soci\u00e9t\u00e9 Francophone Nutrition Clinique et M\u00e9tabolisme | Fimatho | Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Laboratoires des M\u00e9dicaments St\u00e9riles","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Laboratoires des M\u00e9dicaments St\u00e9riles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratoires des M\u00e9dicaments St\u00e9riles \/ Undisclosed"},{"orgOrder":0,"company":"Helse Stavanger","sponsor":"Oslo University Hospital | Haukeland University Hospital | Alesund Hospital | Akershus University Hospital | Trondheim University Hospital | University Hospital of North Norway","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NORWAY","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Helse Stavanger","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Helse Stavanger \/ Oslo University Hospital | Haukeland University Hospital | Alesund Hospital | Akershus University Hospital | Trondheim University Hospital | University Hospital of North Norway","highestDevelopmentStatusID":"11","companyTruncated":"Helse Stavanger \/ Oslo University Hospital | Haukeland University Hospital | Alesund Hospital | Akershus University Hospital | Trondheim University Hospital | University Hospital of North Norway"},{"orgOrder":0,"company":"GSK","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"GSK \/ IQVIA","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ IQVIA"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Dermatology","graph2":"Phase IV","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Saskatchewan Health Authority \u2013 Regina Area","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Immunology","graph2":"Undisclosed","graph3":"Saskatchewan Health Authority \u2013 Regina Area","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saskatchewan Health Authority \u2013 Regina Area \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Saskatchewan Health Authority \u2013 Regina Area \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Project Peanut Butter | Kamuzu University of Health Sciences | BALCHEM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Washington University School of Medicine \/ Project Peanut Butter | Kamuzu University of Health Sciences | BALCHEM","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Project Peanut Butter | Kamuzu University of Health Sciences | BALCHEM"},{"orgOrder":0,"company":"Kaizen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Kaizen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaizen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kaizen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Kaizen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"||Bacterial penicillin-binding protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Kaizen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaizen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kaizen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Juno Pharmaceuticals Pty Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Juno Pharmaceuticals Pty Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Juno Pharmaceuticals Pty Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Sharp HealthCare","sponsor":"The University of Pittsburgh School of Medicine | Morgan Stanley Children\u2019s Hospital | University of Louisville | Sharp Mary Birch Hospital for Women & Newborns | Children's Hospital of Philadelphia | Jefferson Medical College of Thomas Jefferson Universi","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ampicillin","moa":"Bacterial penicillin-binding protein","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Sharp HealthCare","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sharp HealthCare \/ The University of Pittsburgh School of Medicine | Morgan Stanley Children\u2019s Hospital | University of Louisville | Sharp Mary Birch Hospital for Women & Newborns | Children's Hospital of Philadelphia | Jefferson Medical College of Thomas Jefferson Universi","highestDevelopmentStatusID":"10","companyTruncated":"Sharp HealthCare \/ The University of Pittsburgh School of Medicine | Morgan Stanley Children\u2019s Hospital | University of Louisville | Sharp Mary Birch Hospital for Women & Newborns | Children's Hospital of Philadelphia | Jefferson Medical College of Thomas Jefferson Universi"},{"orgOrder":0,"company":"Avenacy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Ampicillin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenacy \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Aztreonam","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Advanz Pharma"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Aztreonam","moa":"Bacterial penicillin-binding protein","graph1":"Nephrology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Aztreonam","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Aztreonam","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Aztreonam","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Aztreonam","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Aztreonam","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"ProvideGx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2021","type":"Partnership","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apotex Inc \/ ProvideGx","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Inc \/ ProvideGx"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Canadian Institutes of Health Research","highestDevelopmentStatusID":"11","companyTruncated":"Hamilton Health Sciences \/ Canadian Institutes of Health Research"},{"orgOrder":0,"company":"University of Melbourne","sponsor":"Berry Consultants | McGill University Health Centre Research Institute | Menzies School of Health Research | Aotearoa Clinical Trials | Queensland University of Technology | Sunnybrook Health Sciences Centre | Tan Tock Seng Hospital | Telethon Kids Instit","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of Melbourne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Melbourne \/ Berry Consultants | McGill University Health Centre Research Institute | Menzies School of Health Research | Aotearoa Clinical Trials | Queensland University of Technology | Sunnybrook Health Sciences Centre | Tan Tock Seng Hospital | Telethon Kids Instit","highestDevelopmentStatusID":"11","companyTruncated":"University of Melbourne \/ Berry Consultants | McGill University Health Centre Research Institute | Menzies School of Health Research | Aotearoa Clinical Trials | Queensland University of Technology | Sunnybrook Health Sciences Centre | Tan Tock Seng Hospital | Telethon Kids Instit"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Cefazolin Sodium","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cefditoren Pivoxil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meiji Seika Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Meiji Seika Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wockhardt \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ Medpace, Inc"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Meiji Seika Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Meiji Seika Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Orchid Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Orchid Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchid Pharma \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Orchid Pharma \/ Cipla"},{"orgOrder":0,"company":"Orchid Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Orchid Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchid Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Orchid Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Wockhardt","sponsor":"ICICI Prudential","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Wockhardt \/ ICICI Prudential","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ ICICI Prudential"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Allecra Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allecra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allecra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Acino Pharma","sponsor":"Allecra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Acino Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acino Pharma \/ Allecra Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acino Pharma \/ Allecra Therapeutics"},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Allecra Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allecra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allecra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"VenatoRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Melinta Therapeutics \/ VenatoRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ VenatoRx Pharmaceuticals"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Everest Medicines","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Everest Medicines"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Licensing Agreement","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Menarini"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Everest Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Everest Medicines \/ Undisclosed"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Everest Medicines","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Everest Medicines"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Gardp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Collaboration","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Gardp","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Gardp"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Melinta Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Melinta Therapeutics"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VenatoRx Pharmaceuticals \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VenatoRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VenatoRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center","highestDevelopmentStatusID":"11","companyTruncated":"Rambam Health Care Campus \/ Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center"},{"orgOrder":0,"company":"Hartford Hospital","sponsor":"Shionogi | Keystone Bioanalytical | Indiana University Health Methodist Hospital | University of Pittsburgh Medical Center | University of Texas System","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Hartford Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hartford Hospital \/ Shionogi | Keystone Bioanalytical | Indiana University Health Methodist Hospital | University of Pittsburgh Medical Center | University of Texas System","highestDevelopmentStatusID":"11","companyTruncated":"Hartford Hospital \/ Shionogi | Keystone Bioanalytical | Indiana University Health Methodist Hospital | University of Pittsburgh Medical Center | University of Texas System"},{"orgOrder":0,"company":"Hartford Hospital","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hartford Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hartford Hospital \/ Shionogi","highestDevelopmentStatusID":"6","companyTruncated":"Hartford Hospital \/ Shionogi"},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Shionogi | Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qpex Biopharma \/ Shionogi | Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Biopharma \/ Shionogi | Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Shionogi","sponsor":"Clinton Health Access Initiative","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Cefiderocol sulfate tosylate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Clinton Health Access Initiative","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Clinton Health Access Initiative"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"University of Washington","sponsor":"Aurum Institute | Nyanza Reproductive Health Society | Partners for Health and Development in Africa | National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cefixime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Aurum Institute | Nyanza Reproductive Health Society | Partners for Health and Development in Africa | National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"11","companyTruncated":"University of Washington \/ Aurum Institute | Nyanza Reproductive Health Society | Partners for Health and Development in Africa | National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Bernofarm Pharmaceutical Company","sponsor":"Pharma Metric Labs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDONESIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cefixime","moa":"Bacterial penicillin-binding protein","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Bernofarm Pharmaceutical Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Bernofarm Pharmaceutical Company \/ Pharma Metric Labs","highestDevelopmentStatusID":"1","companyTruncated":"Bernofarm Pharmaceutical Company \/ Pharma Metric Labs"},{"orgOrder":0,"company":"Yung Shin Pharm Industrial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cefoperazone Sodium","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Yung Shin Pharm Industrial","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yung Shin Pharm Industrial \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yung Shin Pharm Industrial \/ Undisclosed"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ceftazidime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alkem Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alkem Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Arrevus","sponsor":"Arnasi Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ceftazidime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arrevus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrevus \/ Arnasi Group","highestDevelopmentStatusID":"8","companyTruncated":"Arrevus \/ Arnasi Group"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ceftibuten","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Shenzhen China Resources Gosun Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Shenzhen China Resources Gosun Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Shenzhen China Resources Gosun Pharmaceuticals"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Nordic Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Acquisition","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0.84999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.84999999999999998,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Nordic Capital","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Nordic Capital"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ BARDA"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Innoviva Specialty Therapeutics","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Licensing Agreement","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Innoviva Specialty Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innoviva Specialty Therapeutics \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"15","companyTruncated":"Innoviva Specialty Therapeutics \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"QATAR","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Hematology","graph2":"Phase IV","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Hamad Medical Corporation \/ Merck & Co"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Weill Medical College of Cornell University \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Weill Medical College of Cornell University \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"University of Queensland","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Queensland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Queensland \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"University of Queensland \/ Merck & Co"},{"orgOrder":0,"company":"Sunshine Coast Hospital and Health Service","sponsor":"The Prince Charles Hospital | Mater","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Sunshine Coast Hospital and Health Service","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Coast Hospital and Health Service \/ The Prince Charles Hospital | Mater","highestDevelopmentStatusID":"11","companyTruncated":"Sunshine Coast Hospital and Health Service \/ The Prince Charles Hospital | Mater"},{"orgOrder":0,"company":"Benefic\u00eancia Portuguesa de S\u00e3o Paulo","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"BRAZIL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Hematology","graph2":"Phase IV","graph3":"Benefic\u00eancia Portuguesa de S\u00e3o Paulo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Benefic\u00eancia Portuguesa de S\u00e3o Paulo \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Benefic\u00eancia Portuguesa de S\u00e3o Paulo \/ Merck & Co"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Venus Remedies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Undisclosed"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Centre Hospitalier Universitaire de Caen | H\u00f4pital Necker-Enfants Malades | Ministry of Health, France | Assistance Publique Hopitaux De Marseille","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"Bacterial penicillin-binding protein","graph1":"Dermatology","graph2":"Phase III","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Institut Pasteur \/ Centre Hospitalier Universitaire de Caen | H\u00f4pital Necker-Enfants Malades | Ministry of Health, France | Assistance Publique Hopitaux De Marseille","highestDevelopmentStatusID":"10","companyTruncated":"Institut Pasteur \/ Centre Hospitalier Universitaire de Caen | H\u00f4pital Necker-Enfants Malades | Ministry of Health, France | Assistance Publique Hopitaux De Marseille"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"Bacterial penicillin-binding protein","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw","highestDevelopmentStatusID":"1","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw"},{"orgOrder":0,"company":"Institute of Cell Therapy","sponsor":"Kyiv City Clinical Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UKRAINE","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Institute of Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Cell Therapy \/ Kyiv City Clinical Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Institute of Cell Therapy \/ Kyiv City Clinical Hospital"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Acquisition","leadProduct":"Ceftriaxone","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"UConn Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"UConn Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UConn Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"UConn Health \/ Undisclosed"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Columbia Clinical Trials Network for Lyme and Other Tick-Borne Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hackensack Meridian Health \/ Columbia Clinical Trials Network for Lyme and Other Tick-Borne Diseases","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Columbia Clinical Trials Network for Lyme and Other Tick-Borne Diseases"},{"orgOrder":0,"company":"Korea United Pharm. Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cefuroxime Axetil","moa":"Bacterial penicillin-binding protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Korea United Pharm. Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Korea United Pharm. Inc. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Korea United Pharm. Inc. \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Divestment","leadProduct":"Cefuroxime Axetil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0.5,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.5,"dosageForm":"Tablet","sponsorNew":"GSK \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Sandoz B2B"},{"orgOrder":0,"company":"GSK","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Acquisition","leadProduct":"Cefuroxime Axetil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Sandoz B2B"},{"orgOrder":0,"company":"Ottawa Hospital Research Institute","sponsor":"The Ottawa Hospital Academic Medical Association | Canadian Association of Emergency Physicians","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cephalexin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Ottawa Hospital Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ottawa Hospital Research Institute \/ The Ottawa Hospital Academic Medical Association | Canadian Association of Emergency Physicians","highestDevelopmentStatusID":"11","companyTruncated":"Ottawa Hospital Research Institute \/ The Ottawa Hospital Academic Medical Association | Canadian Association of Emergency Physicians"},{"orgOrder":0,"company":"Western Sydney Local Health District","sponsor":"Centre Of Research Excellence in Tuberculosis Control","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cephalexin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Western Sydney Local Health District","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Western Sydney Local Health District \/ Centre Of Research Excellence in Tuberculosis Control","highestDevelopmentStatusID":"8","companyTruncated":"Western Sydney Local Health District \/ Centre Of Research Excellence in Tuberculosis Control"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ertapenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Md. Alimur Reza","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Faropenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Md. Alimur Reza","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Md. Alimur Reza \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Md. Alimur Reza \/ Undisclosed"},{"orgOrder":0,"company":"University of Southern Denmark","sponsor":"SignaTope GmbH, Germany","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Floxacillin","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"University of Southern Denmark","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Southern Denmark \/ SignaTope GmbH, Germany","highestDevelopmentStatusID":"6","companyTruncated":"University of Southern Denmark \/ SignaTope GmbH, Germany"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evopoint Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evopoint Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evopoint Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evopoint Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Hartford Hospital","sponsor":"Merck & Co | Q2 Solutions | Connecticut Children's Medical Center | St. Christopher's Hospital for Children | UT Southwestern Medical Center | University of Pittsburgh Medical Center | Indiana University Health Methodist Hospital | James Whitcomb Riley Ho","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Hartford Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hartford Hospital \/ Merck & Co | Q2 Solutions | Connecticut Children's Medical Center | St. Christopher's Hospital for Children | UT Southwestern Medical Center | University of Pittsburgh Medical Center | Indiana University Health Methodist Hospital | James Whitcomb Riley Ho","highestDevelopmentStatusID":"11","companyTruncated":"Hartford Hospital \/ Merck & Co | Q2 Solutions | Connecticut Children's Medical Center | St. Christopher's Hospital for Children | UT Southwestern Medical Center | University of Pittsburgh Medical Center | Indiana University Health Methodist Hospital | James Whitcomb Riley Ho"},{"orgOrder":0,"company":"University of Illinois, Chicago","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Illinois, Chicago","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Illinois, Chicago \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Illinois, Chicago \/ Merck & Co"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Forest University Health Sciences \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Wake Forest University Health Sciences \/ Merck & Co"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Imipenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Imipenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Meropenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Marubeni Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibiotic","year":"2025","type":"Acquisition","leadProduct":"Meropenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sumitomo Pharma","amount2":0.29999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.29999999999999999,"dosageForm":"Injection","sponsorNew":"Sumitomo Pharma \/ Marubeni Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Sumitomo Pharma \/ Marubeni Corporation"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Meropenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Meropenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Meropenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Meropenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Menarini","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Injection","sponsorNew":"Menarini \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Meropenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Licensing Agreement","leadProduct":"Meropenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Melinta Therapeutics \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Meropenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"8","companyTruncated":"Melinta Therapeutics \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Scandinavian Critical Care Trials Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Meropenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Scandinavian Critical Care Trials Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Scandinavian Critical Care Trials Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Scandinavian Critical Care Trials Group \/ Undisclosed"},{"orgOrder":0,"company":"ArTara Therapeutics","sponsor":"Proteon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Penicillin G Potassium","moa":"Bacterial penicillin-binding protein","graph1":"Oncology","graph2":"Phase III","graph3":"ArTara Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"ArTara Therapeutics \/ Proteon Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"ArTara Therapeutics \/ Proteon Therapeutics"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization","highestDevelopmentStatusID":"11","companyTruncated":"Rambam Health Care Campus \/ The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sulopenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sulopenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulopenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sulopenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Public Offering","leadProduct":"Sulopenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Iterum Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sulopenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Public Offering","leadProduct":"Sulopenem Etzadroxil","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Iterum Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Iterum Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"US Food & Drug Administration","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"Sulopenem Etzadroxil","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ US Food & Drug Administration","highestDevelopmentStatusID":"15","companyTruncated":"Iterum Therapeutics \/ US Food & Drug Administration"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Public Offering","leadProduct":"Sulopenem Etzadroxil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Iterum Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Iterum Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Iterum Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hartford Hospital","sponsor":"Spero Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hartford Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hartford Hospital \/ Spero Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Hartford Hospital \/ Spero Therapeutics"},{"orgOrder":0,"company":"International Centre for Diarrhoeal Disease Research, Bangladesh","sponsor":"University of Washington | GSK | Tres Cantos Open Lab Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BANGLADESH","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"International Centre for Diarrhoeal Disease Research, Bangladesh","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ University of Washington | GSK | Tres Cantos Open Lab Foundation","highestDevelopmentStatusID":"8","companyTruncated":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ University of Washington | GSK | Tres Cantos Open Lab Foundation"},{"orgOrder":0,"company":"Burke Neurological Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vitamin B1","moa":"Bacterial Pyruvate decarboxylase (Bact aceE)","graph1":"Neurology","graph2":"Phase II","graph3":"Burke Neurological Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Burke Neurological Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Burke Neurological Institute \/ Undisclosed"},{"orgOrder":0,"company":"Hoskinson Health and Wellness Clinic","sponsor":"Buck Institute for Research on Aging | University of Wyoming","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vitamin B1","moa":"Bacterial Pyruvate decarboxylase (Bact aceE)","graph1":"Endocrinology","graph2":"Phase I","graph3":"Hoskinson Health and Wellness Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hoskinson Health and Wellness Clinic \/ Buck Institute for Research on Aging | University of Wyoming","highestDevelopmentStatusID":"6","companyTruncated":"Hoskinson Health and Wellness Clinic \/ Buck Institute for Research on Aging | University of Wyoming"},{"orgOrder":0,"company":"PROCTER AND GAMBLE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vitamin B1","moa":"Bacterial Pyruvate decarboxylase (Bact aceE)","graph1":"Neurology","graph2":"Phase III","graph3":"PROCTER AND GAMBLE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"PROCTER AND GAMBLE \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PROCTER AND GAMBLE \/ Undisclosed"},{"orgOrder":0,"company":"Bugworks","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BWC0977","moa":"Bacterial topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bugworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bugworks \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Bugworks \/ Avance Clinical"},{"orgOrder":0,"company":"Bugworks","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BWC0977","moa":"Bacterial topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bugworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bugworks \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Bugworks \/ Avance Clinical"},{"orgOrder":0,"company":"Bugworks","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BWC0977","moa":"Bacterial topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bugworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bugworks \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bugworks \/ Undisclosed"},{"orgOrder":0,"company":"Bugworks","sponsor":"Nucleus Network","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BWC0977","moa":"Bacterial topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bugworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bugworks \/ Nucleus Network","highestDevelopmentStatusID":"6","companyTruncated":"Bugworks \/ Nucleus Network"},{"orgOrder":0,"company":"Arixa Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"ARX-1796","moa":"Bacterial-beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Arixa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arixa Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Arixa Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Atm-Avi","moa":"Bacterial-beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ALPN-30x","moa":"BAFF","graph1":"Immunology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Luminary Therapeutics","sponsor":"Case Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Baff Car-T Cell","moa":"BAFF","graph1":"Oncology","graph2":"Phase I","graph3":"Luminary Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luminary Therapeutics \/ Case Comprehensive Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Luminary Therapeutics \/ Case Comprehensive Cancer Center"},{"orgOrder":0,"company":"PeproMene Bio","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Baffr Car-T Cell","moa":"BAFF receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PeproMene Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PeproMene Bio \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"PeproMene Bio \/ City of Hope"},{"orgOrder":0,"company":"PeproMene Bio","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Baffr Car-T Cell","moa":"BAFF receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PeproMene Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PeproMene Bio \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"PeproMene Bio \/ City of Hope"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ALPN-303","moa":"BAFF\/APRIL","graph1":"Undisclosed","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Thunderbolt","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"IND Enabling","graph3":"Thunderbolt","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Thunderbolt \/ Aurinia Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Thunderbolt \/ Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Phase I","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aurinia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aurinia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Phase I","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aurinia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aurinia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurinia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Aurinia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"Vera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Acquisition","leadProduct":"VT-109","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Undisclosed","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Vera Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Stanford University \/ Vera Therapeutics"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"LY4152199","moa":"BAFF-R | CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"AFTX-201","moa":"BAG3","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Affinia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Affinia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Affinia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Renovacor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"REN-001","moa":"BAG3","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renovacor \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor \/ Undisclosed"},{"orgOrder":0,"company":"Renovacor","sponsor":"Rocket Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"REN-001","moa":"BAG3","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Renovacor \/ Rocket Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor \/ Rocket Pharmaceuticals"},{"orgOrder":0,"company":"Renovacor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"REN-001","moa":"BAG3","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renovacor \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor \/ Undisclosed"},{"orgOrder":0,"company":"Rocket Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"RP-A701","moa":"BAG3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rocket Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rocket Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Aravax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PVX108","moa":"Basophil","graph1":"Immunology","graph2":"Phase I","graph3":"Aravax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aravax \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aravax \/ Undisclosed"},{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"A Race Against Blindness","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Funding","leadProduct":"AXV101","moa":"BBS1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Axovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axovia Therapeutics \/ A Race Against Blindness","highestDevelopmentStatusID":"4","companyTruncated":"Axovia Therapeutics \/ A Race Against Blindness"},{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"ALSA Ventures","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Acquisition","leadProduct":"AXV-101","moa":"BBS1","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Axovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axovia Therapeutics \/ ALSA Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Axovia Therapeutics \/ ALSA Ventures"},{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"A Race Against Blindness","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Funding","leadProduct":"AXV-101","moa":"BBS1","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Axovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axovia Therapeutics \/ A Race Against Blindness","highestDevelopmentStatusID":"4","companyTruncated":"Axovia Therapeutics \/ A Race Against Blindness"},{"orgOrder":0,"company":"Viralgen","sponsor":"Axovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2025","type":"Partnership","leadProduct":"AXV-101","moa":"BBS1","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Viralgen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viralgen \/ Axovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Viralgen \/ Axovia Therapeutics"},{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"A Race Against Blindness","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Funding","leadProduct":"AXV-101","moa":"BBS1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Axovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axovia Therapeutics \/ A Race Against Blindness","highestDevelopmentStatusID":"4","companyTruncated":"Axovia Therapeutics \/ A Race Against Blindness"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Axovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Collaboration","leadProduct":"AXV-101","moa":"BBS1","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles River Laboratories, Inc \/ Axovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ Axovia Therapeutics"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Axovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Collaboration","leadProduct":"AXV-101","moa":"BBS1","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhythm Pharmaceuticals \/ Axovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Rhythm Pharmaceuticals \/ Axovia Therapeutics"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Agreement","leadProduct":"131-I Apamistamab","moa":"||BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Immedica Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Immedica Pharma"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"||BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Funding","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Actinium pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Immunology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Immunology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Immunology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Public Offering","leadProduct":"131-I Apamistamab","moa":"||BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"||BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"||BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"||BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"||BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"||BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"||BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"||BC8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Public Offering","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Collaboration","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"6","companyTruncated":"Actinium pharmaceuticals \/ Columbia University"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Funding","leadProduct":"131-I Apamistamab","moa":"||BC8","graph1":"Oncology","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Actinium pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ALN-BCAT","moa":"BCAA metabolism","graph1":"Oncology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"EO2463","moa":"B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"The Institute for Follicular Lymphoma Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Financing","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Enterome \/ The Institute for Follicular Lymphoma Innovation","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ The Institute for Follicular Lymphoma Innovation"},{"orgOrder":0,"company":"Affinivax","sponsor":"CEPI","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Vaccine","moa":"B-cell antibody","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Affinivax \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"Affinivax \/ CEPI"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Affinivax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"24-Valent Streptococcus Pneumoniae Vaccine","moa":"B-cell antibody","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Affinivax","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Affinivax"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Czech Lymphoma Study Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Czech Lymphoma Study Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Czech Lymphoma Study Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Czech Lymphoma Study Group \/ Undisclosed"},{"orgOrder":0,"company":"Fondazione Italiana Linfomi","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Fondazione Italiana Linfomi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fondazione Italiana Linfomi \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Fondazione Italiana Linfomi \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Weill Medical College of Cornell University \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Weill Medical College of Cornell University \/ Genentech"},{"orgOrder":0,"company":"University of Rochester","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Rochester \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"University of Rochester \/ Genentech"},{"orgOrder":0,"company":"UNC Lineberger Comprehensive Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"UNC Lineberger Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNC Lineberger Comprehensive Cancer Center \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"UNC Lineberger Comprehensive Cancer Center \/ Genentech"},{"orgOrder":0,"company":"University of Washington","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"University of Washington \/ Genentech"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Seagen","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Funding","leadProduct":"Polatuzumab Vedotin","moa":"B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seagen \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX001","moa":"B-cell lymphoma\/leukemia 11A (BCL11A)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ CRISPR Therapeutics"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX001","moa":"B-cell lymphoma\/leukemia 11A (BCL11A)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ CRISPR Therapeutics"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX001","moa":"B-cell lymphoma\/leukemia 11A (BCL11A)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ALLO-605","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-605","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-605","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-605","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ALLO-605","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ALLO-605","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-605","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pregene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BCMA CAR-NK Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pregene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"BCMA Prime CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CB-011","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caribou Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Financing","leadProduct":"CB-011","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Caribou Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Financing","leadProduct":"CB-011","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Caribou Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"ProMab Biotechnologies","sponsor":"Caribou Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"CB-011","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Undisclosed","graph3":"ProMab Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProMab Biotechnologies \/ Caribou Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"ProMab Biotechnologies \/ Caribou Biosciences"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Cilta-Cel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Undisclosed","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"IBI326","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ IASO Bio","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ IASO Bio"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"JNJ-4528","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Legend Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"JNJ-4528","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Legend Biotech","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Legend Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"JNJ-4528","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"JNJ-4528","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Pregene","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"PRG1801","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0.16,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"Pregene \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"TNB-585","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":2.5,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":2.5,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"TNB-585","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":2.5,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":2.5,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Loyal Valley Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Series C Financing","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Loyal Valley Capital","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Loyal Valley Capital"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hebei Yanda Ludaopei Hospital","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BCMA\/CD19 CAR-T Cell","moa":"B-cell maturation antigen\/CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Hebei Yanda Ludaopei Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Yanda Ludaopei Hospital \/ Gracell Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Hebei Yanda Ludaopei Hospital \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"iCell Gene Therapeutics","sponsor":"iCAR Bio Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BCMA-CD19 cCAR-T Cell","moa":"B-cell maturation antigen\/CD19","graph1":"Immunology","graph2":"Phase I","graph3":"iCell Gene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"iCell Gene Therapeutics \/ iCAR Bio Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"iCell Gene Therapeutics \/ iCAR Bio Therapeutics"},{"orgOrder":0,"company":"iCell Gene Therapeutics","sponsor":"iCell ImmunityX","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BCMA-CD19 cCAR-T Cell","moa":"B-cell maturation antigen\/CD19","graph1":"Hematology","graph2":"Phase I","graph3":"iCell Gene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"iCell Gene Therapeutics \/ iCell ImmunityX","highestDevelopmentStatusID":"6","companyTruncated":"iCell Gene Therapeutics \/ iCell ImmunityX"},{"orgOrder":0,"company":"Guangzhou Bio-gene Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BCMA\/GPRC5D Double CAR-T Cell","moa":"B-cell maturation antigen\/GPRC5D","graph1":"Oncology","graph2":"Undisclosed","graph3":"Guangzhou Bio-gene Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Guangzhou Bio-gene Technology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Guangzhou Bio-gene Technology \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-647","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-647","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-715","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allogene Therapeutics \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"ALLO-647","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ALLO-647","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allogene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-715","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allogene Therapeutics \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-715","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Preclinical","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SpringWorks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"SpringWorks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"BB21217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"2Seventy Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"2Seventy Bio \/ Undisclosed"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CAR-BCMA T Cell","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcellx","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"CART-ddBCMA","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":4.2300000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":4.2300000000000004,"dosageForm":"Infusion","sponsorNew":"Arcellx \/ Kite Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ Kite Pharma"},{"orgOrder":0,"company":"Arcellx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CART-ddBCMA","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcellx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ Undisclosed"},{"orgOrder":0,"company":"Arcellx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CART-ddBCMA","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcellx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ Undisclosed"},{"orgOrder":0,"company":"Arcellx","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Termination","leadProduct":"CART-ddBCMA","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.33000000000000002,"dosageForm":"Infusion","sponsorNew":"Arcellx \/ Kite Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ Kite Pharma"},{"orgOrder":0,"company":"Arcellx","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Series C Financing","leadProduct":"CART-ddBCMA","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"Arcellx \/ Samsara BioCapital","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ Samsara BioCapital"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Shanghai AbelZeta Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"C-CAR088","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peking Union Medical College Hospital \/ Shanghai AbelZeta Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Peking Union Medical College Hospital \/ Shanghai AbelZeta Ltd."},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Shanghai AbelZeta Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"C-CAR088","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Shanghai AbelZeta Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Shanghai AbelZeta Ltd."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CTX120","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Private Placement","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase III","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Cartesian Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Merger","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Selecta Biosciences \/ Cartesian Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Biosciences \/ Cartesian Therapeutics"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Private Placement","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Selecta Biosciences \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Biosciences \/ Leerink Partners"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase I","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Descartes-08","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"HPN217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"HPN217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"HPN217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"HPN217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"HPN217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"HPN217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"New Leaf","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Private Placement","leadProduct":"HPN217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ New Leaf","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ New Leaf"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"MEDI2228","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneQuantum Healthcare \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GeneQuantum Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"MEDI2228","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"PBCAR269A","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Undisclosed","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpringWorks Therapeutics \/ Precision BioSciences","highestDevelopmentStatusID":"1","companyTruncated":"SpringWorks Therapeutics \/ Precision BioSciences"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"PHE885","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"PHE885","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"PHE885","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"P-PSMA-101","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"P-PSMA-101","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"P-PSMA-101","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"REGN5458","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TeneoOne Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TNB-383B","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TeneoOne Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TeneoOne Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TeneoOne Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TNB-383B","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"TNB-383B","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TNB-383B","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AUTO3","moa":"||B-cell receptor CD22 (CD22)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AUTO3","moa":"||B-cell receptor CD22 (CD22)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AUTO3","moa":"||B-cell receptor CD22 (CD22)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"JNJ-75348780","moa":"B-cell receptor CD22 (CD22)","graph1":"Oncology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"JNJ-75348780","moa":"B-cell receptor CD22 (CD22)","graph1":"Oncology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Triphase Accelerator","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"TRPH-222","moa":"B-cell receptor CD22 (CD22)","graph1":"Oncology","graph2":"Phase I","graph3":"Triphase Accelerator","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Triphase Accelerator \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Triphase Accelerator \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Triphase Accelerator","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"TRPH-222","moa":"B-cell receptor CD22 (CD22)","graph1":"Oncology","graph2":"Phase I","graph3":"Triphase Accelerator","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Triphase Accelerator \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Triphase Accelerator \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-950","moa":"BCL-2","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BGB-21447","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BGB-21447","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DFT383","moa":"BCL-2","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ICP-248","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ICP-248","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ICP-248","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ICP-248","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ICP-248","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ICP-248","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lupeng Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LP-118","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Lupeng Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupeng Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lupeng Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Newave Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LP-118","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Newave Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Newave Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Newave Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lupeng Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LP-168","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Lupeng Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupeng Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lupeng Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lupeng Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LP-168","moa":"BCL-2","graph1":"Neurology","graph2":"Phase I","graph3":"Lupeng Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupeng Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lupeng Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lupeng Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LP-168","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Lupeng Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupeng Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lupeng Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Newave Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LP-168","moa":"BCL-2","graph1":"Oncology","graph2":"Phase II","graph3":"Newave Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Newave Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Newave Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Newave Pharmaceutical","sponsor":"Zulfa Omer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LP-168","moa":"BCL-2","graph1":"Oncology","graph2":"Phase II","graph3":"Newave Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Newave Pharmaceutical \/ Zulfa Omer","highestDevelopmentStatusID":"8","companyTruncated":"Newave Pharmaceutical \/ Zulfa Omer"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Jiaotong University School of Medicine","sponsor":"Ruijin Hospital | BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sonrotoclax","moa":"BCL2","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Jiaotong University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Jiaotong University School of Medicine \/ Ruijin Hospital | BeOne Medicines","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Jiaotong University School of Medicine \/ Ruijin Hospital | BeOne Medicines"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sonrotoclax","moa":"BCL2","graph1":"Oncology","graph2":"Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sonrotoclax","moa":"BCL2","graph1":"Oncology","graph2":"Phase I","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sonrotoclax","moa":"BCL2","graph1":"Oncology","graph2":"Phase III","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sonrotoclax","moa":"BCL2","graph1":"Oncology","graph2":"Phase III","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"German CLL Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sonrotoclax","moa":"BCL2","graph1":"Oncology","graph2":"Phase III","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ German CLL Study Group","highestDevelopmentStatusID":"10","companyTruncated":"BeOne Medicines \/ German CLL Study Group"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sonrotoclax","moa":"BCL2","graph1":"Oncology","graph2":"Phase III","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sonrotoclax","moa":"BCL2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sonrotoclax","moa":"BCL2","graph1":"Oncology","graph2":"Phase III","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sonrotoclax","moa":"BCL2","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ BeOne Medicines","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ BeOne Medicines"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sonrotoclax","moa":"Bcl-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Zentera Therapeutics HK Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ZN-d5","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Zentera Therapeutics HK Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentera Therapeutics HK Limited \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zentera Therapeutics HK Limited \/ Undisclosed"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ZN-d5","moa":"BCL-2","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ZN-d5","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ZN-d5","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ZN-d5","moa":"BCL-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zentalis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ZN-D5","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ZN-D5","moa":"BCL-2","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ZN-D5","moa":"BCL-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Zentalis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"BP1002","moa":"BCL-2 messenger RNA (BCL2 mRNA)","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BP1002","moa":"BCL-2 messenger RNA (BCL2 mRNA)","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"BP1002","moa":"||BCL-2 messenger RNA (BCL2 mRNA)","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"BP1002","moa":"||BCL-2 messenger RNA (BCL2 mRNA)","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"BP1002","moa":"||BCL-2 messenger RNA (BCL2 mRNA)","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BP1002","moa":"||BCL-2 messenger RNA (BCL2 mRNA)","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"BP1002","moa":"BCL-2 messenger RNA (BCL2 mRNA)","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pelcitoclax","moa":"Apoptosis regulator Bcl-2 (BCL-2)||Bcl-2\/Bcl-xl","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pelcitoclax","moa":"Apoptosis regulator Bcl-2 (BCL-2)||Bcl-2\/Bcl-xl","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pelcitoclax","moa":"Bcl-2\/Bcl-xl","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pelcitoclax","moa":"Bcl-2\/Bcl-xl","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Pelcitoclax","moa":"||Bcl-2\/Bcl-xl","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ Ascentage Pharma"},{"orgOrder":0,"company":"Treeline Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TLN-121","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Treeline Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treeline Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Treeline Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BMS-986458","moa":"BCL6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Treeline Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"TLN-121","moa":"BCL6","graph1":"Oncology","graph2":"Phase I","graph3":"Treeline Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treeline Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Treeline Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AMG176","moa":"BCL-XL","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Unity Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascentage Pharma \/ Unity Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage Pharma \/ Unity Biotechnology"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"||BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"||BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Alnuctamab","moa":"BCMA","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Alnuctamab","moa":"BCMA","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Arcellx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Anitocabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Phase III","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Arcellx","highestDevelopmentStatusID":"10","companyTruncated":"Kite Pharma \/ Arcellx"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Arcellx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Anitocabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Phase III","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Arcellx","highestDevelopmentStatusID":"10","companyTruncated":"Kite Pharma \/ Arcellx"},{"orgOrder":0,"company":"Arcellx","sponsor":"Kite Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Anitocabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcellx \/ Kite Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ Kite Pharma"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Yake Biotechnology Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zhejiang University \/ Yake Biotechnology Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang University \/ Yake Biotechnology Ltd."},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Precision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Precision Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chongqing Precision Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Precision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai AbelZeta Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai AbelZeta Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai AbelZeta Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai AbelZeta Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Yake Biotechnology Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zhejiang University \/ Yake Biotechnology Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang University \/ Yake Biotechnology Ltd."},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Yake Biotechnology Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zhejiang University \/ Yake Biotechnology Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang University \/ Yake Biotechnology Ltd."},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Yake Biotechnology Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang University \/ Yake Biotechnology Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang University \/ Yake Biotechnology Ltd."},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Senlang Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hebei Senlang Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Beijing Lu Daopei Hospital | Hebei Yanda Ludaopei Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Senlang Biotechnology \/ Beijing Lu Daopei Hospital | Hebei Yanda Ludaopei Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Hebei Senlang Biotechnology \/ Beijing Lu Daopei Hospital | Hebei Yanda Ludaopei Hospital"},{"orgOrder":0,"company":"Anhui Provincial Hospital","sponsor":"Leman Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Anhui Provincial Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anhui Provincial Hospital \/ Leman Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Anhui Provincial Hospital \/ Leman Biotech"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Hebei Taihe Chunyu Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"BCMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Hebei Taihe Chunyu Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Hebei Taihe Chunyu Biotechnology"},{"orgOrder":0,"company":"Tianjin Medical University Cancer Institute and Hospital","sponsor":"AlloRunning Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Tianjin Medical University Cancer Institute and Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Medical University Cancer Institute and Hospital \/ AlloRunning Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin Medical University Cancer Institute and Hospital \/ AlloRunning Therapeutics"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"Sir Run Run Shaw Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PersonGen BioTherapeutics \/ Sir Run Run Shaw Hospital","highestDevelopmentStatusID":"6","companyTruncated":"PersonGen BioTherapeutics \/ Sir Run Run Shaw Hospital"},{"orgOrder":0,"company":"Essen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"BCMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Essen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Bioray Laboratories","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BCMA CAR-T Cell","moa":"B-cell maturation antigen","graph1":"Nephrology","graph2":"Phase I","graph3":"Bioray Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioray Laboratories \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","highestDevelopmentStatusID":"6","companyTruncated":"Bioray Laboratories \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CC-98633","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Juno Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Juno Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celyad Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CYAD-211","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celyad Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Celyad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CYAD-211","moa":"||BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Descartes-11","moa":"BCMA","graph1":"Oncology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Descartes-11","moa":"BCMA","graph1":"Oncology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"Undisclosed","graph3":"Tongji Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tongji Hospital \/ IASO Bio","highestDevelopmentStatusID":"1","companyTruncated":"Tongji Hospital \/ IASO Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Sana Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Sana Biotechnology"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ IASO Bio","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ IASO Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"IASO Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ IASO Bio","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ IASO Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Shanghai Guoxin Investment & Development","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Series C Financing","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Shanghai Guoxin Investment & Development","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Shanghai Guoxin Investment & Development"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Changzheng Hospital","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Changzheng Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Shanghai Changzheng Hospital","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Changzheng Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Shanghai Changzheng Hospital","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Changzheng Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Shanghai Changzheng Hospital","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Changzheng Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Shanghai Changzheng Hospital","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Changzheng Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Changzheng Hospital \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang University \/ Gracell Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"RenJi Hospital","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Undisclosed","graph2":"Phase I","graph3":"RenJi Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"RenJi Hospital \/ Gracell Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"RenJi Hospital \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Immunology","graph2":"Phase I","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang University \/ Gracell Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang University \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Private Placement","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Vivo Capital","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Vivo Capital"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Acquisition","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":1.2,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.2,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ AstraZeneca"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Acquisition","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":1.2,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.2,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ AstraZeneca"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"RenJi Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ RenJi Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ RenJi Hospital"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Jefferies"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Series C Financing","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ OrbiMed Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"AstraZeneca | Gracell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gracell Biotechnologies \/ AstraZeneca | Gracell Biotechnologies","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ AstraZeneca | Gracell Biotechnologies"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Daishi Tian","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"GC012F","moa":"BCMA","graph1":"Immunology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Daishi Tian","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Daishi Tian"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Qiong Fu","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"GC012F","moa":"BCMA","graph1":"Immunology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Qiong Fu","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Qiong Fu"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"AstraZeneca | Daishi Tian","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"GC012F","moa":"BCMA","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ AstraZeneca | Daishi Tian","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ AstraZeneca | Daishi Tian"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2021","type":"Agreement","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Gracell Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Group \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"GC012F","moa":"BCMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Heidelberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HDP-101","moa":"BCMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Heidelberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Heidelberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Heidelberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HLX60","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HLX60","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Kelonia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"KLN-1010","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Kelonia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kelonia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kelonia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hadassah Medical Organization","sponsor":"Nexcella","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hadassah Medical Organization","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hadassah Medical Organization \/ Nexcella","highestDevelopmentStatusID":"6","companyTruncated":"Hadassah Medical Organization \/ Nexcella"},{"orgOrder":0,"company":"Nexcella","sponsor":"Immix Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Immix Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Immix Biopharma"},{"orgOrder":0,"company":"Nexcella","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Nexcella","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Immix Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Immix Biopharma \/ Titan Partners Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Immix Biopharma \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Immix Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Immix Biopharma \/ Titan Partners Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Immix Biopharma \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Nexcella","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Undisclosed"},{"orgOrder":0,"company":"Nexcella","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Undisclosed"},{"orgOrder":0,"company":"Nexcella","sponsor":"Cirm","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Funding","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Cirm","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Cirm"},{"orgOrder":0,"company":"Nexcella","sponsor":"Immix Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Licensing Agreement","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Immix Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Immix Biopharma"},{"orgOrder":0,"company":"Nexcella","sponsor":"Immix Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Immix Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Immix Biopharma"},{"orgOrder":0,"company":"Nexcella","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Undisclosed"},{"orgOrder":0,"company":"Nexcella","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Undisclosed"},{"orgOrder":0,"company":"Nexcella","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Cirm","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Funding","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Immix Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Immix Biopharma \/ Cirm","highestDevelopmentStatusID":"8","companyTruncated":"Immix Biopharma \/ Cirm"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Nexcella","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Undisclosed"},{"orgOrder":0,"company":"Nexcella","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexcella \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immix Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immix Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Goose Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Financing","leadProduct":"NXC-201","moa":"BCMA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immix Biopharma \/ Goose Capital","highestDevelopmentStatusID":"8","companyTruncated":"Immix Biopharma \/ Goose Capital"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Orvacabtagene Autoleucel","moa":"BCMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Rapcabtagene Autoleucel","moa":"BCMA","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Rapcabtagene Autoleucel","moa":"BCMA","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Rapcabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Rapcabtagene Autoleucel","moa":"BCMA","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Rapcabtagene Autoleucel","moa":"BCMA","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Rapcabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Rapcabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Neukio Biotherapeutics (Shanghai) Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"NEUK203-215","moa":"BCMA | CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Neukio Biotherapeutics (Shanghai) Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neukio Biotherapeutics (Shanghai) Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Neukio Biotherapeutics (Shanghai) Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","sponsor":"OriCell Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"OriV508","moa":"BCMA | CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology \/ OriCell Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology \/ OriCell Therapeutics"},{"orgOrder":0,"company":"Ouro Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"OM336","moa":"BCMA | CD3","graph1":"Hematology","graph2":"Phase I","graph3":"Ouro Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ouro Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ouro Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AMG340","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AMG650","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Volastra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Volastra Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Volastra Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AMG701","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AMG701","moa":"BCMA receptor","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Arlocabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Juno Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"The First Affiliated Hospital of Soochow University","sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Anti-Bcma Car-T Cell","moa":"BCMA receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"The First Affiliated Hospital of Soochow University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The First Affiliated Hospital of Soochow University \/ Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","highestDevelopmentStatusID":"8","companyTruncated":"The First Affiliated Hospital of Soochow University \/ Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd"},{"orgOrder":0,"company":"Cellistic","sponsor":"BrightPath Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2024","type":"Collaboration","leadProduct":"BP2202","moa":"BCMA receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellistic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellistic \/ BrightPath Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cellistic \/ BrightPath Biotherapeutics"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CC-95266","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Juno Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CT053PTSA","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CT053PTSA","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CT103A","moa":"BCMA receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Tongji Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tongji Hospital \/ IASO Bio","highestDevelopmentStatusID":"6","companyTruncated":"Tongji Hospital \/ IASO Bio"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CT103A","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CT103A","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CT103A","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"ESO-T01","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wuhan Union Hospital \/ Pregene","highestDevelopmentStatusID":"6","companyTruncated":"Wuhan Union Hospital \/ Pregene"},{"orgOrder":0,"company":"EsoBiotec","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2025","type":"Acquisition","leadProduct":"ESO-T01","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"EsoBiotec","amount2":1,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Infusion","sponsorNew":"EsoBiotec \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"EsoBiotec \/ AstraZeneca"},{"orgOrder":0,"company":"EsoBiotec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"ESO-T01","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"EsoBiotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EsoBiotec \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EsoBiotec \/ Undisclosed"},{"orgOrder":0,"company":"EsoBiotec","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ESO-T01","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"EsoBiotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EsoBiotec \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EsoBiotec \/ Undisclosed"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Acquisition","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":1.5,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.5,"dosageForm":"Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Acquisition","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":1.5,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.5,"dosageForm":"Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":6.2199999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":6.2199999999999998,"dosageForm":"Injection","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Xuanwu Hospital, Beijing","sponsor":"Bioray Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Universal Bcma Car-T","moa":"BCMA receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Xuanwu Hospital, Beijing","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanwu Hospital, Beijing \/ Bioray Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Xuanwu Hospital, Beijing \/ Bioray Laboratories"},{"orgOrder":0,"company":"Philogen","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Bifikafusp Alfa","moa":"BCMA receptor\/Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Philogen \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Philogen \/ Merck & Co"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Cizutamig","moa":"BCMA\/CD3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Candid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Candid Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Candid Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BMS-986453","moa":"BCMA\/GPRC5D","graph1":"Oncology","graph2":"Phase I","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Juno Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IBI3003","moa":"BCMA\/GPRC5D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Rui Therapeutics","sponsor":"AlloRunning Therapeutics | YANRU WANG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"RN1101","moa":"BCMA|CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Rui Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rui Therapeutics \/ AlloRunning Therapeutics | YANRU WANG","highestDevelopmentStatusID":"6","companyTruncated":"Rui Therapeutics \/ AlloRunning Therapeutics | YANRU WANG"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"HQP1351","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"HealthQuest Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ HealthQuest Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ HealthQuest Pharma"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"HealthQuest Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ HealthQuest Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ HealthQuest Pharma"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":1.3,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Shenzhen Second People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Shenzhen Second People's Hospital","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Shenzhen Second People's Hospital"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Ascentage Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Ascentage Pharma"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":1.3,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Tanner Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Tanner Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Tanner Pharma"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Ascentage Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Ascentage Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Ascentage Pharma"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":1.3,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0.25,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Innovent Biologics"},{"orgOrder":0,"company":"PharmaBlock Sciences","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaBlock Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PharmaBlock Sciences \/ Ascentage Pharma","highestDevelopmentStatusID":"8","companyTruncated":"PharmaBlock Sciences \/ Ascentage Pharma"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Innovent Biologics","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Innovent Biologics"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Tanner Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Tanner Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Ascentage Pharma \/ Tanner Pharma"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Ascentage Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Ascentage Pharma","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Ascentage Pharma"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ponatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ponatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ponatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ponatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ponatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ponatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ponatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase II","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ponatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Commodore Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Commodore Capital","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Commodore Capital"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Imara","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Merger","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Imara","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Imara"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Fairmount Funds Management LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Fairmount Funds Management LLC","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Fairmount Funds Management LLC"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Imara","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Merger","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Imara","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Imara"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Enliven Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Flumatinib Mesylate","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase IV","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Terns Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Terns Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Terns Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Tablet","sponsorNew":"Terns Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Tablet","sponsorNew":"Terns Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Terns Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Terns Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"TRN-000632","moa":"BCR-ABL","graph1":"Oncology","graph2":"Preclinical","graph3":"Terns Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Terns Pharmaceuticals \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Terns Pharmaceuticals \/ Hansoh Pharma"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"The First Affiliated Hospital of Soochow University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"14-C TGRX-678","moa":"BCR-ABL|BCR-ABL T315I","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ The First Affiliated Hospital of Soochow University","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen TargetRx \/ The First Affiliated Hospital of Soochow University"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NUV-868","moa":"BD2-selective BET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Undisclosed"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NUV-868","moa":"||BD2-selective BET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvation Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Immunology","graph2":"IND Enabling","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"BCD-256","moa":"BDCA2","graph1":"Immunology","graph2":"Phase I","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ General Atlantic","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ General Atlantic"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharvaris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Undisclosed"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Series C Financing","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pharvaris","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Pharvaris \/ Viking Global Investors","highestDevelopmentStatusID":"6","companyTruncated":"Pharvaris \/ Viking Global Investors"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Jefferies"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Jefferies"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Alpha Wave Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Alpha Wave Ventures"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Apeiron Investment Group"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Cerebral Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Cerebral Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Cerebral Therapeutics"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Jefferies"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Lightswitch Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series B Financing","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Lightswitch Capital","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Lightswitch Capital"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"InVivium Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series C Financing","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ InVivium Capital","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ InVivium Capital"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Wellcome Trust","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Alto Neuroscience \/ Wellcome Trust","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Wellcome Trust"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Amino Acid","year":"2025","type":"Inapplicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Amino Acid","year":"2025","type":"Inapplicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Amino Acid","year":"2025","type":"Inapplicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PCI Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PCI Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PCI Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PCI Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PCI Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PCI Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Steba Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"PrimeVigilance Ltd | Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Steba Biotech \/ PrimeVigilance Ltd | Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ PrimeVigilance Ltd | Icon Plc"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Steba Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Steba Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Undisclosed"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImPact Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ Undisclosed"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImPact Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ Undisclosed"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"ImPact Biotech \/ EIC Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ EIC Accelerator"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImPact Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ Undisclosed"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImPact Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ Undisclosed"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImPact Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImPact Biotech \/ Undisclosed"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImPact Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImPact Biotech \/ Undisclosed"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImPact Biotech \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"ImPact Biotech \/ Undisclosed"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImPact Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImPact Biotech \/ Undisclosed"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImPact Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImPact Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"OPGx-BEST1","moa":"BEST1 gene","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opus Genetics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Opus Genetics \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"14-C CC-90010","moa":"BET","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"JAB-8263","moa":"BET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"JAB-8263","moa":"BET","graph1":"Oncology","graph2":"Phase I","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobio Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jacobio Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of New Hampshire","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"JQ-1","moa":"||BET","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of New Hampshire","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of New Hampshire \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"University of New Hampshire \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"LifeSci Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.089999999999999997,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ LifeSci Capital LLC","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ LifeSci Capital LLC"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.089999999999999997,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Access Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Access Biotechnology"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Immunology","graph2":"Preclinical","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Zenith Epigenetics | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ZEN-3694","moa":"BET","graph1":"Oncology","graph2":"Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Zenith Epigenetics | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Zenith Epigenetics | National Cancer Institute"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||BET","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenith Epigenetics \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ National Cancer Institute"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||BET","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenith Epigenetics \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ Pfizer Inc"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Ipilimumab","moa":"||BET","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenith Epigenetics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"1","companyTruncated":"Zenith Epigenetics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||BET","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenith Epigenetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ Undisclosed"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||BET","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenith Epigenetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ Undisclosed"},{"orgOrder":0,"company":"Betaliq","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BTQ-1901-A","moa":"Beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Betaliq","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Betaliq \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Betaliq \/ Undisclosed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"186-Ra","moa":"Beta\/gamma-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Plus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Atenolol","moa":"||Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unichem Laboratories Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Unichem Laboratories Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sundeep Khosla, M.D.","sponsor":"Columbia University | MaineHealth | University of California, San Francisco","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Atenolol","moa":"Beta-1 adrenergic receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Sundeep Khosla, M.D.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sundeep Khosla, M.D. \/ Columbia University | MaineHealth | University of California, San Francisco","highestDevelopmentStatusID":"8","companyTruncated":"Sundeep Khosla, M.D. \/ Columbia University | MaineHealth | University of California, San Francisco"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bisoprolol Fumarate","moa":"Beta-1 adrenergic receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bisoprolol Fumarate","moa":"||Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bisoprolol Fumarate","moa":"Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cadila Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cadila Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Bisoprolol Fumarate","moa":"||Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Athena Pharmaceutiques","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Athena Pharmaceutiques \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Athena Pharmaceutiques \/ Undisclosed"},{"orgOrder":0,"company":"Apontis Pharma","sponsor":"Midas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Bisoprolol Fumarate","moa":"||Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Apontis Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Apontis Pharma \/ Midas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Apontis Pharma \/ Midas Pharma"},{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"InBrain Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Dopamine","moa":"Beta-1 adrenergic receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Lille \/ InBrain Pharma","highestDevelopmentStatusID":"7","companyTruncated":"University Hospital, Lille \/ InBrain Pharma"},{"orgOrder":0,"company":"Brepco Biopharma","sponsor":"Piramal Critical Care","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Dopamine","moa":"Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Brepco Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Brepco Biopharma \/ Piramal Critical Care","highestDevelopmentStatusID":"15","companyTruncated":"Brepco Biopharma \/ Piramal Critical Care"},{"orgOrder":0,"company":"Neutec Ar-Ge San ve Tic A.?","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TURKEY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Metoprolol Tartrate","moa":"Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Neutec Ar-Ge San ve Tic A.?","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Metoprolol Tartrate","moa":"Beta-1 adrenergic receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Madeleine Puissant","sponsor":"MaineHealth","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Metoprolol Tartrate","moa":"Beta-1 adrenergic receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Madeleine Puissant","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Madeleine Puissant \/ MaineHealth","highestDevelopmentStatusID":"11","companyTruncated":"Madeleine Puissant \/ MaineHealth"},{"orgOrder":0,"company":"Biocon","sponsor":"Eris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Metoprolol Succinate","moa":"Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Biocon","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.14999999999999999,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Biocon \/ Eris Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Eris Pharmaceuticals"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Metoprolol Succinate","moa":"Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Undisclosed"},{"orgOrder":0,"company":"New American Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Metoprolol Succinate","moa":"Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"New American Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"New American Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"New American Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Metoprolol Succinate","moa":"Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sit Laboratorio Farmaceutico","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Metoprolol Tartrate","moa":"Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Sit Laboratorio Farmaceutico","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Sit Laboratorio Farmaceutico"},{"orgOrder":0,"company":"Senores Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Metoprolol Tartrate","moa":"||Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Senores Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Senores Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Senores Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Second Xiangya Hospital, Central South University","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Beta-1 adrenergic receptor | Beta-2 adrenergic receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Second Xiangya Hospital, Central South University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Second Xiangya Hospital, Central South University \/ Innovent Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Second Xiangya Hospital, Central South University \/ Innovent Biologics"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Beta-1 adrenergic receptor | Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Beta-1 adrenergic receptor | Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"ATNAHS PHARMA UK LIMITED","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Divestment","leadProduct":"Propranolol Hydrochloride","moa":"Beta-1 adrenergic receptor | Beta-2 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0.39000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.39000000000000001,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ ATNAHS PHARMA UK LIMITED","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ ATNAHS PHARMA UK LIMITED"},{"orgOrder":0,"company":"Ottawa Hospital Research Institute","sponsor":"Hamilton Health Sciences | The Ottawa Hospital | McMaster University | Sinai Health System","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Misc